US20050014840A1 - Thiol sulfonamide metalloprotease inhibitors - Google Patents

Thiol sulfonamide metalloprotease inhibitors Download PDF

Info

Publication number
US20050014840A1
US20050014840A1 US10/838,856 US83885604A US2005014840A1 US 20050014840 A1 US20050014840 A1 US 20050014840A1 US 83885604 A US83885604 A US 83885604A US 2005014840 A1 US2005014840 A1 US 2005014840A1
Authority
US
United States
Prior art keywords
compound
group
alkyl
phenyl
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/838,856
Inventor
Zaheer Abbas
Gary DeCrescenzo
John Freskos
Daniel Getman
Robert Heintz
Joseph McDonald
Brent Mischke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to US10/838,856 priority Critical patent/US20050014840A1/en
Assigned to PHARMACIA CORPORATION reassignment PHARMACIA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABBAS, ZAHEER S., DECRESCENZO, GARY A., FRESKOS, JOHN N., GETMAN, DANIEL P., HEINTZ, ROBERT M., MCDONALD, JOSEPH J., MISCHKE, BRENT V.
Publication of US20050014840A1 publication Critical patent/US20050014840A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention is directed to proteinase (protease) inhibitors, and more particularly to thiol sulfonamide inhibitors for matrix metalloproteinases, compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the preparation of proteinase inhibitors and processes for treating pathological conditions associated with pathological matrix metalloproteinase activity.
  • protease protease
  • thiol sulfonamide inhibitors for matrix metalloproteinases compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the preparation of proteinase inhibitors and processes for treating pathological conditions associated with pathological matrix metalloproteinase activity.
  • Connective tissue, extracellular matrix constituents and basement membranes are required components of all mammals. These components are the biological materials that provide rigidity, differentiation, attachments and, in some cases, elasticity to biological systems including human beings and other mammals.
  • Connective tissues components include, for example, collagen, elastin, proteoglycans, fibronectin and laminin. These biochemicals makeup, or are components of structures, such as skin, bone, teeth, tendon, cartilage, basement membrane, blood vessels, cornea and vitreous humor.
  • Degradation of connective tissue or connective tissue components is carried out by the action of proteinase enzymes released from resident tissue cells and/or invading inflammatory or tumor cells.
  • a major class of enzymes involved in this function are the zinc metalloproteinases (metalloproteases).
  • the metalloprotease enzymes are divided into classes with some members having several different names in common use. Examples are: collagenase I (MMP-1, fibroblast collagenase; EC 3.4.24.3); collagenase II (MMP-8, neutrophil collagenase; EC 3.4.24.34), collagenase III (MMP-13), stromelysin 1 (MMP-3; EC 3.4.24.17), stromelysin 2 (MMP-10; EC 3.4.24.22), proteoglycanase, matrilysin (MMP-7), gelatinase A (MMP-2, 72 kDa gelatinase, basement membrane collagenase; EC 3.4.24.24), gelatinase B (MMP-9, 92 kDa gelatinase; EC 3.4.24.35), stromelysin 3 (MMP-11), metalloelastase (MMP-12, HME, human macrophage elastase) and membrane MMP (
  • the uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions. Examples include rheumatoid arthritis, osteoarthritis, septic arthritis; corneal, epidermal or gastric ulceration; tumor metastasis, invasion or angiogenesis; periodontal disease; proteinuria; Alzheimers Disease; coronary thrombosis and bone disease. Defective injury repair processes also occur. This can produce improper wound healing leading to weak repairs, adhesions and scarring. These latter defects can lead to disfigurement and/or permanent disabilities as with post-surgical adhesions.
  • TNF- ⁇ tumor necrosis factor
  • TNF- ⁇ is a cytokine that at present is thought to be produced initially as a 28 kD cell-associated molecule. It is released as an active, 17 kD form that can mediate a large number of deleterious effects in vitro and in vivo.
  • TNF can cause and/or contribute to the effects of inflammation, rheumatoid arthritis, autoimmune disease, multiple sclerosis, graft rejection, fibrotic disease, cancer, infectious diseases, malaria, mycobacterial infection, meningitis, fever, psoriasis, cardiovascular/pulmonary effects such as post-ischemic reperfusion injury, congestive heart failure, hemorrhage, coagulation, hyperoxic alveolar injury, radiation damage and acute phase responses like those seen with infections and sepsis and during shock such as septic shock and hemodynamic shock.
  • Chronic release of active TNF can cause cachexia and anorexia.
  • TNF can be lethal.
  • TNF- ⁇ convertase is a metalloproteinase involved in the formation of active TNF- ⁇ . Inhibition of TNF- ⁇ convertase inhibits production of active TNF- ⁇ .
  • Compounds that inhibit both MMPs activity have been disclosed in WIPO International Publication Nos. WO 94/24140, WO 94/02466 and WO 97/20824. There remains a need for effective MMP and TNF- ⁇ convertase inhibiting agents.
  • Compounds that inhibit MMPs such as collagenase, stromelysin and gelatinase have been shown to inhibit the release of TNF (Gearing et al. Nature 376, 555-557 (1994), McGeehan et al., Nature 376, 558-561 (1994)).
  • MMPs are involved in other biochemical processes in mammals as well. Included is the control of ovulation, post-partum uterine involution, possibly implantation, cleavage of APP ( ⁇ -Amyloid Precursor Protein) to the amyloid plaque and inactivation of ⁇ 1 -protease inhibitor ( ⁇ 1 -PI). Inhibition of these metalloproteases permits the control of fertility and the treatment or prevention of Alzheimers Disease. In addition, increasing and maintaining the levels of an endogenous or administered serine protease inhibitor drug or biochemical such as ⁇ 1 -PI supports the treatment and prevention of diseases such as emphysema, pulmonary diseases, inflammatory diseases and diseases of aging such as loss of skin or organ stretch and resiliency.
  • diseases such as emphysema, pulmonary diseases, inflammatory diseases and diseases of aging such as loss of skin or organ stretch and resiliency.
  • Inhibition of selected MMPs can also be desirable in other instances.
  • Treatment of cancer and/or inhibition of metastasis and/or inhibition of angiogenesis are examples of approaches to the treatment of diseases wherein the selective inhibition of stromelysin, gelatinase, or collagenase III are the relatively most important enzyme or enzymes to inhibit especially when compared with collagenase I (MMP-1).
  • a drug that does not inhibit collagenase I can have a superior therapeutic profile.
  • Osteoarthritis another prevalent disease wherein it is believed that cartilage degradation in inflamed joints is at least partially caused by MMP-13 released from cells such as stimulated chrondrocytes, may be best treated by administration of drugs one of whose modes of action is inhibition of MMP-13. See, for example, Mitchell et al., J. Clin. Invest., 97:761-768 (1996) and Reboul et al., J. Clin. Invest., 97:2011-2019 (1996).
  • Inhibitors of metalloproteases are known. Examples include natural biochemicals such as tissue inhibitor of metalloproteinase (TIMP), ⁇ 2 -macroglobulin and their analogs or derivatives. These are high molecular weight protein molecules that form inactive complexes with metalloproteases. A number of smaller peptide-like compounds that inhibit metalloproteases have been described. Mercaptoamide peptidyl derivatives have shown ACE inhibition in vitro and in vivo. Angiotensin converting enzyme (ACE) aids in the production of angiotensin II, a potent pressor substance in mammals and inhibition of this enzyme leads to the lowering of blood pressure.
  • ACE Angiotensin converting enzyme
  • Thiol group-containing amide or peptidyl amide-based metalloprotease (MMP) inhibitors are known as is shown in, for example, WO95/12389, WO96/11209 and U.S. Pat. No. 4,595,700.
  • the present invention is directed to a process for treating a mammal having a condition associated with pathological matrix metalloprotease (MMP) activity, as well as to molecules that particularly inhibit the activity of MMP-13.
  • MMP pathological matrix metalloprotease
  • one embodiment of the present invention is directed to a process for treating a mammal having a condition associated with pathological matrix metalloprotease activity that comprises administering a metalloprotease inhibitor in an effective amount to a host having such a condition.
  • the administered enzyme inhibitor corresponds in structure to one of formulae (I), (II) or (III), below where x represents 0, 1 or 2, and W is oxygen or sulfur.
  • R 9 group is an alkyl, aryl, alkoxy, cycloalkyl, aryloxy, aralkoxy, aralkyl, aminoalkyl, heteroaryl and N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxycarbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclic or heteroaryl ring.
  • R 1 group is linked to the SO 2 portion of an inhibitor and is an alkyl, cycloalkyl, heterocycloalkyl, aralkanoylalkyl, arylcarbonylalkyl, hydroxyalkyl, alkanoylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, haloalkyl, alkylthioaryl, arylthioalkyl, alkylthioaralkyl, aralkylthioalkyl, or aralkylthioaryl group, the sulfoxide or sulfone of any of those thio substituents, alkylthioalkyl, and preferably aryl and heterocyclic (heteroaryl) rings such as aralkyl, heteroaralkyl, aralkoxyalkyl, aryloxyalkyl, as well as
  • aryl (carbocyclic) and heteroaryl substituents of R 1 are themselves unsubstituted or substituted with one or two substituents independently selected from among halo, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, nitro, cyano, perfluoroalkyl, trifluoromethylalkyl, hydroxy, thiol, hydroxycarbonyl, aryloxy, arylthio, arylamino, aralkyl, arylcarboxamido, heteroarylcarboxamido, azoaryl, azoheteroaryl, aryl, heteroaryloxy, heteroarylthio, heteroarylamino, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy, cycloalkylthio, cycloalkylamino, heteroaralkoxy, heteroaralkylthio, heteroaralky
  • R 2 substituent can be hydrogen (hydrido), an alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkynylalkyl, alkenylalkyl, thioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, aralkoxyalkyl, aminoalkyl, alkoxyalkoxyalkyl, aryloxyalkyl, hydroxyalkyl, hydroxycarbonylalkyl, hydroxycarbonylaralkyl, or N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein R 2 and the nitrogen to which it is bonded and another substituent (i.e., R 2 and R 4
  • Contemplated R 3 and R 4 groups are independently selected. Those substituents can be hydrogen (hydrido), an alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, hydroxycarbonyl, alkoxycarbonyl, perfluoroalkyl, trifluoromethylalkyl, thioalkyl, alkylthioalkyl, arylthioalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, or a sulfoxide or sulfone of any of the thio substituents, aminocarbonyl, aminocarbonylalkyl, N-monosubstituted
  • R 5 and R 6 substituents are also independently selected.
  • R 5 and R 6 substituents can be a substituent that constitutes R 3 and R 4 , or R 6 and R 4 together with atoms to which they are attached form a 4- to 8-membered ring, or R 6 and R 2 together with the atoms to which they are attached form a 5- to 8-membered ring (as above), or R 6 and R 8 together with the atoms to which they are attached form a 4- to 8-membered ring, or R 5 and R 6 together with atom to which they are attached form a 3- to 8-membered ring.
  • R 7 and R 8 substituents are also independently selected.
  • R 7 and R 8 substituents can also be a substituent that constitutes R 3 and R 4 , or R 8 and R 2 together with the atoms to which they are attached form a 6- to 8-membered ring (as above), or R 7 and R 8 together with the atom to which they are attached form a 3- to 8-membered ring, or R 8 and R 4 together with the atom to which they are attached form a 5- to 8-membered ring (as above), or R 8 and R 6 together with the atoms to which they are attached form a 4- to 8-membered ring (as above).
  • the present invention is also directed to a more preferred sub-set of molecules of formulas I, II, and III, above.
  • x is zero so that the mercapto group is bonded directly to the carbon atom that bears the R 5 and R 6 substituent radicals, which are themselves both hydrido, as is R 3 .
  • R 2 is other than hydrogen (hydrido) unless R 1 is phenylazophenyl, R 1 is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group containing one 5- or 6-membered ring; i.e. R 1 is not a fused aryl ring or heteroaryl group, and a compound of formula III is a homodimer.
  • R 1 is phenylazophenyl
  • R 1 is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group containing one 5- or 6-membered ring
  • R 1 is not a fused aryl ring or heteroary
  • a contemplated inhibitor compound constitutes another sub-set of the compounds of formulas I, II and III.
  • R 3 , R 5 and R 6 are again hydrido
  • the SO 2 -linked R 1 substituent is a 4-substituted phenyl group (PhR 11 )
  • W is O.
  • Yet another aspect of the invention is directed to a matrix metalloprotease inhibitor corresponding to formula IV, below, where R 10 is hydrogen (hydrido) or —C(O)—R 9 , and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and x are as defined above, and Y represents hydrogen, halogen, alkyl, alkoxy, nitro, cyano, carboxy or amino.
  • a benefit of this invention is the provision of a compound and composition effective for inhibiting metalloproteinases, particularly MMP-13, associated with pathological conditions such as, for example, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal, epidermal or gastric ulceration, tumor metastasis, invasion or angiogenesis, periodontal disease, proteinuria, Alzheimer's Disease, coronary thrombosis and bone disease.
  • pathological conditions such as, for example, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal, epidermal or gastric ulceration, tumor metastasis, invasion or angiogenesis, periodontal disease, proteinuria, Alzheimer's Disease, coronary thrombosis and bone disease.
  • An advantage of the invention is the provision of a method for preparing such compositions. Another benefit is the provision of a method for treating a pathological condition associated with abnormal matrix metalloproteinase activity.
  • Another advantage is the provision of compounds, compositions and methods effective for treating such pathological conditions by selective inhibition of a metalloproteinase, MMP-13, associated with such conditions with minimal side effects resulting from inhibition of other proteinases whose activity is necessary or desirable for normal body function.
  • MMP-13 metalloproteinase
  • certain thiol sulfonamides are effective for inhibition of matrix metalloproteinases (“MMPs”) believed to be associated with uncontrolled or otherwise pathological breakdown of connective tissue.
  • MMPs matrix metalloproteinases
  • these certain thiol sulfonamides are effective for inhibition of collagenase III (MMP-13), which can be particularly destructive to tissue if present or generated in abnormal quantities or concentrations, and thus exhibit a pathological activity.
  • thiol sulfonamides are selective in the inhibition of MMP-13, as well as other MMPs associated with diseased conditions without excessive inhibition of other collagenases essential to normal bodily function such as tissue turnover and repair. More particularly, it has been found that particularly preferred the thiol sulfonamides of the invention are particularly active in inhibiting of MMP-13, while being selective for MMP-13, in having a limited or minimal effect on MMP-1. This point is discussed in detail hereinafter and is illustrated in several examples.
  • One embodiment of the present invention is directed to a process for treating a mammal having a condition associated with pathological matrix metalloprotease activity. That process comprises administering a metalloprotease inhibitor in an effective amount to a host having such a condition.
  • the administered enzyme inhibitor corresponds in structure to one of formulas (I), (II) or (III), below where x represents 0, 1 or 2, and W is oxygen or sulfur.
  • R 9 group is an alkyl, aryl, alkoxy, cycloalkyl, aryloxy, aralkoxy, aralkyl, aminoalkyl, heteroaryl and N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxycarbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclo or heteroaryl ring;
  • R 1 group is linked to the SO 2 portion of an inhibitor and is an alkyl, cycloalkyl, heterocycloalkyl, aralkanoylalkyl, arylcarbonylalkyl, hydroxyalkyl, alkanoylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, haloalkyl, alkylthioaryl, arylthioalkyl, alkylthioaralkyl, aralkylthioalkyl, or aralkylthioaryl group, the sulfoxide or sulfone of any of those thio substituents, alkylthioalkyl, and preferably aryl (carbocyclicaryl) and heteroaryl rings such as aralkyl, heteroaralkyl, aralkoxyalkyl, aryloxyalkyl, as well
  • the aryl and heteroaryl substituents of which R 1 can be comprised are unsubstituted or preferably substituted with one (preferably) or two substituents independently selected from among halo, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, nitro, cyano, perfluoroalkyl, trifluoromethylalkyl, hydroxy, thiol, hydroxycarbonyl, aryloxy, arylthio, arylamino, aralkyl, arylcarboxamido, heteroarylcarboxamido, azoaryl, azoheteroaryl, aryl, heteroaryloxy, heteroarylthio, heteroarylamino, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy, cycloalkylthio, cycloalkylamino, heteroaralkoxy, heteroaralkylthio, hetero
  • R 2 substituent can be hydrogen (hydrido), an alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkynylalkyl, alkenylalkyl, thioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, aralkoxyalkyl, aminoalkyl, alkoxyalkoxyalkyl, aryloxyalkyl, hydroxyalkyl, hydroxycarbonylalkyl, hydroxycarbonylaralkyl, or N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein R 2 and the nitrogen to which it is bonded and another substituent (i.e., R 2 and R 4
  • R 3 and R 4 groups are independently selected.
  • substituents can be hydrogen (hydrido), an alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, hydroxycarbonyl, alkoxycarbonyl, perfluoroalkyl, trifluoromethylalkyl, thioalkyl, alkylthioalkyl, arylthioalkyl, aralkylthioalkyl, heteroaralkyl-thioalkyl, or a sulfoxide or sulfone of any of the thio substituents, aminocarbonyl, aminocarbonylalkyl, N-monosubstituted
  • R 5 and R 6 substituents are also independently selected.
  • R 5 and R 6 substituents can be a substituent that constitutes R 3 and R 4 .
  • R 6 and R 4 together with atoms to which they are attached form a 4- to 8-membered ring, or R 6 and R 2 together with the atoms to which they are attached form a 5- to 8-membered ring (as above), or R 6 and R 8 together with the atoms to which they are attached form a 4- to 8-membered ring, or R 5 and R 6 together with atom to which they are attached form a 3- to 8-membered ring;
  • R 7 and R 8 substituents are also independently selected.
  • R 7 and R 8 substituents can also be a substituent that constitutes R 3 and R 4 .
  • R 8 and R 2 together with the atoms to which they are attached form a 6- to 8-membered ring (as above), or R 7 and R 8 together with the atom to which they are attached form a 3- to 8-membered ring, or R 8 and R 4 together with the atom to which they are attached form a 5- to 8-membered ring (as above), or R 8 and R 6 together with the atoms to which they are attached form a 4- to 8-membered ring (as above).
  • R 1 represents an aryl or heteroaryl ring C 1 -C 10 alkyl, wherein the aryl or heteroaryl ring can optionally be substituted by one or more of the following substituents: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C 1 -C 10 alkylthio, arylthio, heteroarylthio.
  • R 1 represents a single aryl or heteroaryl ring, wherein the single aryl or heteroaryl ring can optionally be substituted by one or more of the following substituents: C 1 -C 6 alkyl, C 1 -C 6 alkoxy, arylcarboxamido, heteroarylcarboxamido,arylazo, heteroarylazo, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C 1 -C 6 alkylthio, arylthio, heteroarylthio in which each ring-containing substituent itself contains a single ring.
  • R 1 represents a 6-membered aryl ring, wherein the aryl ring can optionally be substituted in the para-position (4-position) by one of the following substituents: C 1 -C 6 alkyl, C 1 -C 6 alkoxy, arylcarboxamido, heteroarylcarboxamido, arylazo, heteroarylazo, aryloxy, heteroaryloxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C 1 -C 6 alkylthio, arylthio, heteroarylthio in which each ring-containing substituent itself contains a single ring.
  • R 1 represents a 6-membered aryl ring, wherein the aryl-ring is substituted in the para-position by C 1 -C 6 alkyl, C 1 -C 6 alkoxy arylcarboxamido, arylazo, aryloxy, arylthio and aryl in which each ring-containing substituent itself contains a single ring.
  • R 1 represents phenyl, wherein the phenyl ring is substituted in the para-position by n-propyl, n-butyl, n-pentyl, n-hexyl, isobutyl, isoamyl, ethoxy, n-propyloxy, n-butoxy, n-pentyloxy, n-hexyloxy, isobutoxy, phenoxy, thiophenoxy (phenylthio), phenyl, azophenyl or benzamido, in which the para-substituted R 1 phenyl substituent can itself optionally contain a meta- or para-substituent, or both containing one atom or a chain of no more than five atoms other than hydrogen.
  • R 2 represents hydrogen, C 1 -C 6 alkyl, aralkyl, heteroaralkyl, cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms can be nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons, C 1 -C 5 alkyl substituted by hydroxycarbonyl, amino, mono-substituted amino and di-substituted amino, wherein the substituents on nitrogen are chosen from C 1 -C 4 alkyl, aralkyl, C 5 -C 8 cycloalkyl and C 1 -C 6 alkanoyl groups, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.
  • R 2 represents hydrogen, C 1 -C 6 alkyl, aralkyl, heteroaralkyl, cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms can be nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons.
  • R 2 represents hydrogen or C 1 -C 6 alkyl.
  • R 2 represents hydrogen, methyl, ethyl, n-propyl, n-butyl, isobutyl.
  • R 2 represents carbocyclic aralkyl or heteroaralkyl as discussed above.
  • R 2 represents benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl, 5-thiazolylmethyl.
  • R 2 represents cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms can be nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons.
  • R 2 represents cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl.
  • R 2 represents alkyl substituted by hydroxycarbonyl, amino, mono-substituted amino and di-substituted amino, wherein the substituents on the amino nitrogen are chosen from C 1 -C 6 alkyl, aralkyl, C 5 -C 8 cycloalkyl and C 1 -C 6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur.
  • R 2 represents C l -C 5 alkyl substituted by hydroxycarbonyl.
  • R 2 represents 5-pentanoic acid, 4-n-butanoic acid, 3-propanoic acid or 2-ethanoic acid.
  • R 2 represents hydrido, C 1 -C 6 alkyl, C 2 -C 4 alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituents on nitrogen are chosen from C 1 -C 6 alkyl, aralkyl, C 5 -C 8 cycloalkyl and C 1 -C 6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur, a C 1 -C 4 alkylaryl or C 1 -C 4 alkylheteroaryl group having a single ring.
  • R 2 represents methyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, N,N-dimethyl-2-aminoethyl, 2-(4-morpholino)ethyl, 2-(1-piperidino)ethyl, 2-(1-pyrrolidino)ethyl.
  • R 3 and R 4 independently represent hydrogen, hydroxycarbonyl, aminocarbonyl, C 1 -C 6 alkyl, aralkyl, aryl, heteroaryl, C 5 -C 8 cycloalkyl, heteroaralkyl, cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain.
  • R 3 is hydrido
  • R 4 is hydroxycarbonyl, aminocarbonyl or C 1 -C 6 alkyl.
  • R 3 and R 4 independently represents hydrogen, aminocarbonyl, methyl.
  • R 3 is hydrido and R 4 represents methyl.
  • R 3 is hydrido and R 4 represents hydroxycarbonyl or aminocarbonyl.
  • R 3 represents hydrido and R 4 represents aminocarbonyl (carbamyl) or methyl.
  • R 5 and R 6 independently represent hydrogen (hydrido), hydroxycarbonyl, aryl, heteroaryl, C 1 -C 6 alkyl.
  • R 5 and R 6 are both hydrido.
  • R 7 and R 8 independently represent hydrogen, hydroxycarbonyl, C 1 -C 6 alkyl.
  • x is preferably zero.
  • W is preferably oxygen (O).
  • R 9 represents C 1 -C 6 alkyl, aryl, C 1 -C 6 alkoxy, heteroaryl, amino C 1 -C 6 alkyl, N-monosubstituted amino C 1 -C 6 alkyl and N,N-disubstituted amino C 1 -C 6 alkyl, wherein the substituents on nitrogen are chosen from C 1 -C 6 alkyl, aralkyl, C 5 -C 8 cycloalkyl and C 1 -C 6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.
  • R 9 represents C 1 -C 6 alkyl, C 5 -C 8 cycloalkyl, aryl, C 1 -C 6 alkoxy, heteroaryl, amino C 1 -C 6 alkyl, N-monosubstituted amino C 1 -C 6 alkyl and N,N-disubstituted amino C 1 -C 6 alkyl, wherein the substituents on nitrogen are chosen from C 1 -C 6 alkyl, aralkyl, C 5 -C 8 cycloalkyl and C 1 -C 6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.
  • R 9 represents C 1 -C 6 alkyl, C 1 -C 6 alkoxy, a single-ringed aryl or heteroaryl.
  • R 9 represents methyl, ethyl, n-propyl, n-butyl, isopropyl, isobutyl
  • R 9 represents a 3- to 8-membered cycloalkyl ring.
  • R 9 represents cyclohexyl and cyclopentyl.
  • R 9 represents aryl or heteroaryl.
  • R 9 represents phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl.
  • R 9 represents C 1 -C 6 alkoxy.
  • R 9 represents methoxy and ethoxy.
  • Starred substituents, R*, and x* are preferably the same as unstarred substituents, R, and x so that a compound of formula III is homodimer.
  • an SO 2 -linked R 1 substituent is an aryl or heteroaryl group that is a 5- or 6-membered single-ring, and is itself substituted with one other single-ringed aryl or heteroaryl group or, with an alkyl or alkoxy group containing an umbranched chain of 3 to about 7 carbon atoms, a phenoxy group, a thiophenoxy [C 6 H 5 —S—] group, a phenylazido [C 6 H 5 —N 2 —] group or a benzamido [—NHC(O)C 6 H 5 ] group.
  • the SO 2 -linked single-ringed aryl or heteroaryl R 1 group is substituted at its own 4-position when a 6-membered ring and at its own 3-position when a 5-membered ring.
  • the R 1 group's substituent single-ringed aryl or heteroaryl, phenoxy, thiophenoxy, phenylazo or benzamido group is unsubstituted or can itself be substituted at the 4-position when a 6-membered ring or the 3-position when a 5-membered ring.
  • the 4- and 3-positions of rings discussed here are numbered from the sites of substituent bonding as compared to formalized ring numbering positions used in heteroaryl nomenclature.
  • single atoms such as halogen moieties or substituents that contain one to a chain of about five atoms other than hydrogen such as C 1 -C 4 alkyl, C 1 -C 4 alkoxy or carboxyethyl groups can be used.
  • Exemplary substituted SO 2 -linked R 1 substituents include biphenyl, 4-phenoxyphenyl, 4-thiophenoxyphenyl, 4-butoxyphenyl, 4-pentylphenyl, 4-(4′-dimethylaminophenyl)azophenyl, and 2-[(2-pyridyl)-5-thienyl].
  • an R 1 substituent including its own substituent When examined along its longest chain of atoms, an R 1 substituent including its own substituent has a total length of greater than a saturated chain of four carbon atoms and less than a saturated chain of about 18 and preferably about 12 carbon atoms, even though many more atoms may be present in ring structures or substituents. This length requirement is discussed further below.
  • a particularly preferred R 1 radical (group or moiety) has a length greater than that of an butyl group.
  • Such an R 1 radical also has a length that is less than that of a stearyl (octadecyl) group. That is to say that a particularly preferred R 1 is a radical having a length greater than that of a saturated four carbon chain, and shorter than that of a saturated eighteen carbon chain, and more preferably, a length greater than that of a pentyl group and less than that of a lauryl group.
  • the radical chain lengths are measured along the longest linear atom chain in the radical, and each atom in the chain, e.g. oxygen or nitrogen, is presumed to be carbon for ease in calculation.
  • Such lengths can be readily determined by using published bond angles, bond lengths and atomic radii, as needed, to draw and measure a staggered chain, or by building models using commercially available kits whose bond angles, lengths and atomic radii are in accord with accepted, published values.
  • Radical lengths can also be determined somewhat less exactly by assuming that all atoms have bond lengths saturated carbon, that unsaturated bonds have the same lengths as saturated bonds and that bond angles for unsaturated bonds are the same as those for saturated bonds, although the above-mentioned modes of measurement are preferred.
  • a particularly preferred R 1 group when rotated about an axis drawn through the SO 2 -bonded 1-position and the 4-position of a 6-membered ring or the SO 2 -bonded position and substituent-bonded 3- or 5-position of a 5-membered ring defines a three-dimensional volume whose widest dimension has the width of about one phenyl ring to about three phenyl rings in a direction transverse to that axis to rotation.
  • R 1 substituents such as 4-(phenyl)phenyl[biphenyl], 4-(4′-methoxyphenyl)phenyl, 4-(phenoxy)phenyl, 4-(thiophenyl)phenyl[4-(phenylthio)phenyl], 4-(azophenyl)phenyl and 4-(benzamido)phenyl are particularly preferred R 1 substituents.
  • R 4 -containing carbon atom is that of a naturally-occurring amino acid.
  • the substituent groups are discussed below for these compounds.
  • R 1 group represents a single aryl or heteroaryl ring, wherein the single aryl ring is unsubstituted or can optionally be substituted by one or more of the following substituents: C 1 -C 6 alkyl, C 1 -C 6 alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C 1 -C 6 alkylthio, arylthio, heteroarylthio in which each ring-containing substituent itself contains a single ring.
  • R 2 represents hydrido, C 1 -C 6 alkyl, C 2 -C 4 alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituents on nitrogen are chosen from C 1 -C 6 alkyl, aralkyl, C 5 -C 8 cycloalkyl and C 1 -C 6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur, a C 1 -C 4 alkylaryl or C 1 -C 4 alkylheteroaryl group having a single ring.
  • An R 9 group represents a C 1 -C 6 alkyl group, C 1 -C 6 alkoxy group, or a single-ringed carbocyclic aryl or heteroaryl group.
  • a most preferred MMP-13 inhibitor sub-set of compounds useful in a before-described process also preferably has the configuration of a naturally-occurring amino acid, and corresponds to the structures depicted by formulas Ib, IIb and IIIb, below.
  • R 4 group is C 1 -C 6 alkyl, and particularly methyl, or aminocarbonyl [—C(O)NH 2 ].
  • R 2 group is C 1 -C 6 alkyl and particularly methyl, a C 2 -C 3 alkyl cycloamino group having five or six atoms in the ring and zero or one additional heteroatom that is oxygen or nitrogen, and C 1 -C 4 alkyl single-ringed aryl or heteroaryl, wherein the single heteroaryl ring contains one or two nitrogen atoms.
  • Exemplary most preferred substituents in addition to methyl include 2-(4-morpholino)ethyl, 2-(1-piperidino)ethyl, 2-(1-pyrrolidino)ethyl and (3-pyridyl)methyl.
  • Hydrogen (hydrido) can also be a most preferred R 2 group as is discussed below.
  • the sulfonyl group (—SO 2 —) of a most preferred sub-set of inhibitor compounds is linked to a phenyl group (Ph), which itself is substituted at the 4-position by a substituent denominated R 11 that together with the phenyl group is referred to as PhR 11 .
  • a 4-substituted phenyl group substituent, R 11 can be C 3 -C 8 alkoxy such as butoxy, C 3 -C 8 alkyl such as pentyl, as well as phenoxy, thiophenoxy (phenylthio), benzamido, phenylazo or phenyl.
  • R 11 6-membered ring-containing substituent group can itself also be substituted in a 3-(meta) or 4-(para-) position, or both, with a halogen (fluorine, chlorine, bromine or iodine), a C 1 -C 4 alkoxy group such as methoxy or isopropoxy, a C 1 -C 4 alkyl group such as methyl, a two or three carbon-containing carboxyl group such as carboxymethyl or carboxyethyl an amine, or a mono- or di-C 1 -C 4 alkyl-substituted amine such as dimethyl amino.
  • a halogen fluorine, chlorine, bromine or iodine
  • a C 1 -C 4 alkoxy group such as methoxy or isopropoxy
  • a C 1 -C 4 alkyl group such as methyl
  • a two or three carbon-containing carboxyl group such as carboxymethyl or carboxyethyl an amine
  • a 3,4-methylenedioxy substituent is a contemplated 3,4-substituent, whereas methyl is a contemplated 3-substituent.
  • a substituent of such a R 11 ring para substituent has one atom or a longest chain of up to five atoms, excluding hydrogen.
  • R 9 represents a C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group, a single-ringed carbocyclic aryl or heteroaryl group, and more particularly, a phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl, methyl, ethyl, methoxy or ethoxy group.
  • R 10 is hydrogen (hydrido) or —C(O)—R 9 and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and x are as defined above, and Y represents hydrogen, halogen, alkyl, alkoxyl, nitro, cyano, carboxy or amino.
  • substituent “R” groups and x are as they have been previously described in regard to formulas Ia-IIIa and Ib-IIIb, respectively, except that R 3 and R 4 are both hydrido in most preferred compounds.
  • x is zero so that R 5 and R 6 and the carbon to which they are bonded are absent, Y is hydrogen, and the sulfur atom bonded to the depicted phenyl ring is linked ortho to the sulfonamide-bearing carbon atom. It is thus seen that particularly preferred and most preferred compounds of formula IV constitute compounds of formulas I and II in which x is one, and the R 6 and R 8 substituents together with the atoms to which they are attached form a 6-membered, aromatic ring.
  • a particularly or most preferred R 1 group is a radical having a length greater than that of a saturated four carbon chain, and shorter than that of a saturated eighteen carbon chain.
  • the substituent When rotated about an axis drawn through the SO 2 -bonded R 1 group 1-position and the 4-position of a 6-membered ring or the SO 2 -bonded position and substituent-bonded 3- or 5-position of a 5-membered R 1 ring, the substituent defines a three-dimensional volume whose widest dimension has the width of about one phenyl ring to about three phenyl rings in a direction transverse to that axis to rotation.
  • an SO 2 -linked R 1 substituent is an aryl or heteroaryl group that is a 5- or 6-membered single-ring, and is itself substituted with one other single-ringed aryl or heteroaryl group or, with an alkyl or alkoxy group containing an umbranched chain of 3 to about 7 carbon atoms, a phenoxy group, a thiophenoxy [C 6 H 5 —S—] group, a phenylazido [C 6 H 5 —N 2 —] group or a benzamido [—NHC(O)C 6 H 5 ] group.
  • the SO 2 -linked single-ringed aryl or heteroaryl R 1 group is substituted at its own 4-position when a 6-membered ring and at its own 3-position when a 5-membered ring
  • R 2 represents hydrido, C 1 -C 6 alkyl, C 2 -C 4 alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituents on nitrogen are chosen from C 1 -C 6 alkyl, aralkyl, C 5 -C 8 cycloalkyl and C 1 -C 6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur, a C 1 -C 4 alkylaryl or C 1 -C 4 alkylheteroaryl group having a single ring.
  • R 3 group is hydrido
  • R 4 is hydroxyxcarbonyl, aminocarbonyl or C 1 -C 6 alkyl. Again, R 3 and R 4 are both hydrido in most preferred compounds.
  • An R 9 group represents C 1 -C 6 alkyl, C 1 -C 6 alkoxy, a single-ringed carbocyclic aryl or heteroaryl, and more particularly, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl, methyl, ethyl, methoxy and ethoxy.
  • the compounds described herein are useful in a process described herein in that such compounds can inhibit the activity of MMP-13.
  • a particularly preferred compound inhibits the enzyme with an IC 50 value of about 1000 nm or less in the in vitro assay discussed hereinafter.
  • a most preferred compound exhibits an IC 50 value in that assay of about 20 nm or less, with some compounds exhibiting values of about 1 nm or less.
  • a contemplated inhibitor compound is used for treating a host mammal such as a mouse, rat, rabbit, dog, horse, primate such as a monkey, chimpanzee or human that has a condition associated with pathological matrix metalloprotease activity.
  • contemplated is use of a contemplated metalloprotease inhibitor compound in the treatment of a disease state that can be affected by the activity of metalloproteases TNF- ⁇ convertase.
  • exemplary of such disease states are the acute phase responses of shock and sepsis, coagulation responses, hemorrhage and cardiovascular effects, fever and inflammation, anorexia and cachexia.
  • a contemplated MMP inhibitor compound in the form of an amine salt derived from an inorganic or organic acid.
  • exemplary salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfon
  • a basic nitrogen-containing group can be quaternized with such agents-as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibuytl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others to provide enhanced water-solubility. Water or oil-soluble or dispersible products are thereby obtained as desired.
  • the salts are formed by combining the basic compounds with the desired acid.
  • salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases or basic quaternary ammonium salts.
  • the salts can also be used as an aid in the isolation, purification or resolution of the compounds of this invention.
  • Total daily dose administered to a host mammal in single or divided doses can be in amounts, for example, for 0.001 to 30 mg/kg body weight daily and more usually 0.01 to 10 mg.
  • Dosage unit compositions can contain such amounts or submultiples thereof to make up the daily dose.
  • a suitable dose can be administered, in multiple sub-doses per day. Multiple doses per day can also increase the total daily dose should this be desired by the person prescribing the drug.
  • the dosage regimen for treating a disease condition with a compound and/or composition of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination.
  • the dosage regimen actually employed can vary widely and therefore can deviate from the preferred dosage regimen set forth above.
  • a compound useful in the present invention can be formulated as a pharmaceutical composition. Such a composition can then be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal administration such as transdermal patches or iontophoresis devices.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa.; 1975 and Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.
  • sterile injectable preparations for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules.
  • the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration.
  • the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
  • Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
  • the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.
  • formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.
  • solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
  • the compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
  • Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
  • Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
  • the amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the mammalian host treated and the particular mode of administration.
  • Certain compounds of this invention can serve as prodrugs to other compounds of this invention.
  • Prodrugs are drugs that can be chemically converted in viva or in vitro by biological systems into an active derivative or derivatives.
  • An example from this invention are drugs of formula II (IIa or IIb) where the acyl group is hydrolyzed to a compound of formula I (or Ia or Ib).
  • An additional example is where a disulfide of this invention is reduced to its thiol product or, in some cases, converted into an active mixed disulfide.
  • Table 1 through Table 80, below, show several series of compounds useful in this invention. Each case, class or group of compounds is illustrated by a generic formula, or formulae, followed by a series of preferred moieties or groups that constitute various substituents that can be attached at the position clearly shown in the generic structure.
  • the generic symbols, e.g., R 1 , R 2 and the like, are as defined before, except that R 3 of the following tables corresponds to particularly and must preferred R 4 discussed previously.
  • This system is well known in the chemical communication arts and is widely used in scientific papers and presentations.
  • R 2 is the variable group with the structural variables that can substitute for R 2 shown in the balance of the table.
  • R 2 groups including hydrogen
  • Table 43 illustrates a compound with a generic structure containing two variable groups.
  • the groups are R 1 and R 2 .
  • this example shows a matrix of 12 R 1 groups and 10 R 2 groups (including hydrogen) that represent 120 non-limiting compounds of this invention that can be prepared.
  • molecular descriptors can be combined to produce words or phrases that describe structural groups or are combined to describe structural groups. Such descriptors are used in this document. Common illustrative examples include such terms as aralkyl (or arylalkyl), heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, aralkoxyalkoxycarbonyl and the like.
  • aralkyl or arylalkyl
  • heteroaralkyl heterocycloalkyl
  • cycloalkylalkyl aralkoxyalkoxycarbonyl and the like.
  • a specific example of a compound encompassed with the latter descriptor aralkoxyalkoxycarbonyl is C 6 H 5 —CH 2 —CH 2 —O—CH 2 —O—(C ⁇ O)— wherein C 6 H 5 — is phenyl.
  • a structural group can have more than one descriptive word or phrase in the art, for example, heteroaryloxyalkylcarbonyl can also be termed heteroaryloxyalkanoyl.
  • heteroaryloxyalkylcarbonyl can also be termed heteroaryloxyalkanoyl.
  • alkyl means a straight-chain or branched-chain alkyl radical containing 1 to about 12 carbon atoms, preferably 1 to about 10 carbon atoms, and more preferably 1 to about 6 carbon atoms.
  • examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like.
  • alkenyl means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing 2 to about 12 carbon atoms preferably 2 to about 10 carbon atoms, and more preferably, 2 to about 6 carbon atoms.
  • suitable alkenyl radicals include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, decenyl and the like.
  • alkynyl alone or in combination, means a straight-chain hydrocarbon radical having one or more triple bonds and containing 2 to about 12 carbon atoms, preferably 2 to about 10 carbon atoms, and more preferably, 2 to about 6 carbon atoms.
  • alkynyl radicals include ethynyl, 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, 3-butynyl, and the like.
  • carbonyl alone or in combination, means a —C( ⁇ O)— group wherein the remaining two bonds (valences) can be independently substituted.
  • thiol or “sulfhydryl”, alone or in combination, means a —SH group.
  • thio or “thia”, alone or in combination, means a thiaether group; i.e., an ether group wherein the ether oxygen is replaced by a sulfur atom.
  • amino alone or in combination, means an amine or —NH 2 group whereas the term mono-substituted amino, alone or in combination, means a substituted amine —N(H) (substituent) group wherein one hydrogen atom is replaced with a substituent, and disubstituted amine means a —N(substituent) 2 wherein two hydrogen atoms of the amino group are replaced with independently selected substituent groups.
  • Amines, amino groups and amides are compounds that can be designated as primary (I°), secondary (II°) or tertiary (III°) or unsubstituted, mono-substituted or di-substituted depending on the degree of substitution of the amino nitrogen.
  • Quaternary amine (ammonium) (IV°) means a nitrogen with four substituents [—N + (substituent) 4 ] that is positively charged and accompanied by a counter ion, whereas N-oxide means one substituent is oxygen and the group is represented as [—N + (substituent) 3 —O ⁇ ]; i.e., the charges are internally compensated.
  • cyano alone or in combination, means a —C-triple bond-N (—C/N) group.
  • zido alone or in combination, means a —N-triple bond-N (—N/N) group.
  • hydroxyl alone or in combination, means a —OH group.
  • nitro alone or in combination, means a —NO 2 group.
  • azo alone or in combination, means a —N ⁇ N— group wherein the bonds at the terminal positions can be independently substituted.
  • hydrazino alone or in combination, means a —NH—NH— group wherein the depicted remaining two bonds (valences) can be independently substituted.
  • the hydrogen atoms of the hydrazino group can be replaced, independently, with substituents and the nitrogen atoms can form acid addition salts or be quaternized.
  • sulfonyl alone or in combination, means a —SO 2 — group wherein the depicted remaining two bonds (valences) can be independently substituted.
  • sulfoxido alone or in combination, means a —SO— group wherein the remaining two bonds (valences) can be independently substituted.
  • sulfonylamide alone or in combination, means a —SO 2 —N ⁇ group wherein the depicted remaining three bonds (valences) can be independently substituted.
  • sulfinamido alone or in combination, means a —SON ⁇ group wherein the remaining three depicted bonds (valences) can be independently substituted.
  • sulfenamide alone or in combination, means a —S—N ⁇ group wherein the remaining three bonds (valences) can be independently substituted.
  • alkoxy alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above.
  • suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.
  • cycloalkyl alone or in combination, means a cyclic alkyl radical that contains 3 to about 8 carbon atoms.
  • cycloalkylalkyl means an alkyl radical as defined above that is substituted by a cycloalkyl radical containing 3 to about 8, preferably 3 to about 6, carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • aryl alone or in combination, means a 5- or 6-membered aromatic ring-containing moiety or a fused ring system containing two or three rings that have all carbon atoms in the ring; i.e., a carbocyclic aryl radical, or a heteroaryl radical containing one or more heteroatoms such as sulfur, oxygen and nitrogen in the ring(s).
  • exemplary carbocyclic aryl radicals include phenyl, indenyl and naphthyl radicals.
  • heterocyclic or heteroaryl groups examples include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol-4-yl, 1-benzyloxycarbonylimidazol-4-yl, and the like), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, tetrahydrofuryl, thienyl, triazolyl, oxazolyl, oxadiazoyl, thiazolyl, thiadiazoyl, indolyl (e.g., 2-indolyl, and the like), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, and the like), isoquinolinyl (e.g., 1-isoquinolin
  • An aryl ring group optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like.
  • substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like.
  • aralkyl alone or in combination, means an alkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl and the like.
  • aralkoxycarbonyl alone or in combination, means a radical of the formula —C(O)—O— aralkyl in which the term “aralkyl” has the significance given above.
  • An example of an aralkoxycarbonyl radical is benzyloxycarbonyl.
  • aryloxy means a radical of the formula aryl-O— in which the term aryl has the significance given above.
  • alkanoyl or “alkylcarbonyl”, alone or in combination, means an acyl radical derived from an alkanecarboxylic acid, examples of which include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like.
  • cycloalkylcarbonyl means an acyl group derived from a monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkanecarboxylic acid that is optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl.
  • aralkanoyl or “aralkylcarbonyl” mean an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl and the like.
  • aroyl or “arylcarbonyl” means an acyl radical derived from an aromatic carboxylic acid.
  • radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2 naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like.
  • heterocyclic (heterocyclo) or heterocycloalkyl portion of a heterocyclocarbonyl, heterocyclooxycarbonyl, heterocycloalkoxycarbonyl, or heterocycloalkyl group or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle that contains one or more hetero atoms selected from nitrogen, oxygen and sulphur.
  • Such a moiety can be optionally substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., —NH—) by alkyl, aralkoxycarbonyl, alkanoyl, aryl or arylalkyl or on a tertiary nitrogen atom (i.e. ⁇ N—) by oxido and that is attached via a carbon atom.
  • the tertiary nitrogen atom with three substituents can also attached to form a N-oxide [ ⁇ N(O)—] group.
  • cycloalkylalkoxycarbonyl means an acyl group of the formula cycloalkylalkyl-O—CO— wherein cycloalkylalkyl has the significance given above.
  • aryloxyalkanoyl means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above.
  • heterocyclooxycarbonyl means an acyl group having the formula heterocyclo-O—CO— wherein heterocyclo is as defined above.
  • heterocycloalkanoyl is an acyl radical of the formula heterocyclo-substituted alkane carboxylic acid wherein heterocyclo has the significance given above.
  • heterocycloalkoxycarbonyl means an acyl radical of the formula heterocyclo-substituted alkane-O—CO— wherein heterocyclo has the significance given above.
  • heteroaryloxycarbonyl means an acyl radical represented by the formula heteroaryl-O—CO— wherein heteroaryl has the significance given above.
  • aminocarbonyl alone or in combination, means an amino-substituted carbonyl (carbamoyl) group derived from an amino-substituted carboxylic acid (carboxamide) wherein the amino group can be a primary or secondary amino (amido nitrogen) group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like.
  • aminoalkanoyl means an acyl group derived from an amino-substituted alkanecarboxylic acid wherein the amino group can be a primary or secondary amino group containing substituents independently selected from hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like.
  • halogen means fluoride, chloride, bromide or iodide.
  • haloalkyl means an alkyl radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like.
  • perfluoroalkyl means an alkyl group wherein each hydrogen has been replaced by a fluorine atom.
  • perfluoroalkyl groups in addition to trifluoromethyl above, are perfluorobutyl, perfluoroisopropyl, perfluorododecyl and perfluorodecyl.
  • aromatic ring in combinations such as substituted-aromatic ring sulfonamide, substituted-aromatic ring sulfinamide or substituted-aromatic ring sulfenamide means aryl or heteroaryl as defined above.
  • M utilized in the reaction Schemes that follow represents a leaving group such as halogen, phosphate ester or sulfate ester.
  • Schemes 1 through 5 illustrate chemical processes and transformations that can be useful for the preparation of compounds useful in this invention; i.e., compounds of formulas I-III, Ia-IIIa and Ib-IIIb.
  • the groups R 1 through R 9 shown in the schemes are defined above.
  • reactions can be carried out under a dry inert atmosphere such a nitrogen or argon if desired.
  • Selected reactions known to those skilled in the art can be carried out under a dry atmosphere such as dry air whereas other synthetic steps, for example, aqueous acid or base ester or amide hydrolysis, can be carried out under laboratory air.
  • some processes of this invention can be carried out in a pressure apparatus at pressures above, equal to or below atmospheric pressure. The use of such an apparatus aids in the control of gaseous reagents such as hydrogen, ammonia, trimethylamine, methylamine, oxygen and the like. It can also help prevent the leakage of air or humidity into a reaction in progress.
  • This discussion is not intended to be exhaustive as it is readily noted that additional or alternative methods, conditions, reactions or systems can be identified and used by a chemist of ordinary skill.
  • Step 1 in Scheme 1 illustrates conversion of a hydroxyl group into compound 2 with an activated carbon-M bond via hydroxyl activation or replacement to provide intermediates useful as electrophilic reagents or, when M is —SH, a product of this invention of formula I is formed.
  • M usually represents leaving groups such as halides (Cl, Br, I), fluorides (aromatic) or sulfate esters such as tosylate (OTs), mesylate (OMs), triflate (OTs) and the like, or epoxides.
  • OTs tosylate
  • OMs mesylate
  • OTs triflate
  • epoxides The preparations of epoxides, sulfate esters or organic halides are well known in the art.
  • M can also represent groups such as —SH (thiol) or, following treatment of a thiol with base or with a pre-formed salt, an —S ⁇ group.
  • the non-thiols are prepared from the alcohols by standard methods such as treatment with HCl, HBr, thionyl chloride or bromide, phosphorus trihalide, phosphorus pentahalide, trifluoromethylsulfonyl chloride, tosylchloride or methanesulfonyl chloride and the like.
  • reaction are usually carried out at a temperature of about ⁇ 25° C. to solvent reflux under an inert atmosphere such as nitrogen or argon.
  • the solvent or solvent mixture can vary widely depending upon reagents and other conditions and can include polar or dipolar aprotic solvents as listed or mixtures of these solvents.
  • amines such as triethyl amine, pyridine or other non-reactive bases can serve as reagents and/or solvents and/or co-solvents.
  • protecting groups can be used to maintain or retain groups in other parts of a molecule(s) at locations that is(are) not desired reactive centers. Examples of such groups that the skilled person might want to maintain or retain include, amines, other hydroxyls, thiols, acids and the like.
  • Such protecting groups can include acyl groups, arylalkyl groups, carbamoyl groups, ethers, alkoxyalkyl ethers, cycloalkyloxy ethers, arylalkyl groups, silyl groups including trisubstituted silyl groups, ester groups and the like.
  • protecting groups include acetyl, trifluoroacetyl, tetrahydropyran (THP), Benzyl, tert-butoxy carbonyl (BOC or TBOC), benzyloxycarbonyl (Z or CBZ), tert-butyldimethylsilyl (TBDMS) or methoxyethoxymethylene (MEM) groups.
  • the second step in Scheme 1 illustrates preparation of a sulfonamide 2.
  • Sulfamidation reactions are conveniently carried out by reacting an amine with, for example, a sulfonyl chloride or sulfonic anhydride.
  • a suitable solvent or mixture of solvents includes aprotic or dipolar aprotic solvents as defined below with examples being acetone, methylene chloride DMF, THF, tert-butylmethylether (tBME) or mixtures of such solvents.
  • aprotic or dipolar aprotic solvents as defined below with examples being acetone, methylene chloride DMF, THF, tert-butylmethylether (tBME) or mixtures of such solvents.
  • tBME tert-butylmethylether
  • a base for the scavenging of acid is usually also present with non-limiting examples being triethyl amine, pyridine, DBU, N-ethyl morpholine (NEM), sodium carbonate and the like.
  • the sulfonyl chlorides are well know in the art and are commercially available or can be prepared by the reaction of a suitable organometallic reagent with sulfuryl chloride or sulfur dioxide followed by oxidation with a halogen such as chlorine.
  • Grignard and alkyl lithium reagents are desirable organometallic reagents.
  • thiols can be oxidized to sulfonyl chlorides using chlorine and/or chlorine with water.
  • Sulfonic acids are available by the oxidation of thiols, reaction of sulfur derivatives with organometallic reagents and the like and can be converted into sulfonyl chlorides by treatment with thionyl chloride, PCl 5 and the like. They are also commercially available.
  • Bases that can be used include, for example, metal hydroxides such as sodium, potassium, lithium, cesium or magnesium hydroxide, oxides such as those of sodium, potassium, lithium, calcium or magnesium, metal carbonates such as those of sodium, potassium, lithium, cesium, calcium or magnesium, metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, primary (I°), secondary (II°) or tertiary (III°) organic amines such as alkyl amines, arylalkyl amines, alkylarylalkyl amines, heterocyclic amines or heteroaryl amines, ammonium hydroxides or quaternary ammonium hydroxides.
  • metal hydroxides such as sodium, potassium, lithium, cesium or magnesium hydroxide
  • oxides such as those of sodium, potassium, lithium, calcium or magnesium
  • metal carbonates such as those of sodium, potassium, lithium, cesium, calcium or magnesium
  • metal bicarbonates such as sodium bicarbonate or potassium bicarbonate
  • such amines can include triethylamine, trimethylamine, diisopropylamine, methyldiisopropylamine, diazabicyclononane, tribenzylamine, dimethylbenzylamine, morpholine, N-methylmorpholine, N,N′-dimethylpiperazine, N-ethylpiperidine, 1,1,5,5-tetramethylpiperidine, dimethylaminopyridine, pyridine, quinoline, tetramethylethylenediamine, diazabicyclononane and the like.
  • Non-limiting examples of ammonium hydroxides can include ammonium hydroxide, triethyl ammonium hydroxide, trimethyl ammonium hydroxide, methyldiiospropyl ammonium hydroxide, tribenzyl ammonium hydroxide, dimethylbenzyl ammonium hydroxide, morpholinium hydroxide, N-methylmorpholinium hydroxide, N,N′-dimethylpiperazinium hydroxide, N-ethylpiperidinium hydroxide, and the like.
  • quaternary ammonium hydroxides can include tetraethyl ammonium hydroxide, tetramethyl ammonium hydroxide, dimethyldiiospropyl ammonium hydroxide, benzymethyldiisopropyl ammonium hydroxide, methyldiazabicyclononyl ammonium hydroxide, methyltribenzyl ammonium hydroxide, N,N-dimethylmorpholinium hydroxide, N,N,N′,N′-tetramethylpiperazenium hydroxide, and N-ethyl-N′-hexylpiperidinium hydroxide and the like.
  • Metal hydrides, amides or alcoholates such as calcium hydride, sodium hydride, potassium hydride, lithium hydride, aluminum hydride, diisobutylaluminum hydrice (DIBAL) sodium methoxide, potassium tert-butoxide, calcium ethoxide, magnesium ethoxide, sodium amide, potassium diisopropyl amide and the like can also be suitable reagents.
  • DIBAL diisobutylaluminum hydrice
  • Organometallic deprotonating agents such as alkyl or aryl lithium reagents such as methyl lithium, phenyl lithium, tert-butyl lithium, lithium acetylide or butyl lithium, Grignard reagents such as methylmagnesium bromide or methymagnesium chloride, organocadium reagents such as dimethylcadium and the like can also serve as bases for causing salt formation or catalyzing the reaction. Quaternary ammonium hydroxides or mixed salts are also useful for aiding phase transfer couplings or serving as phase transfer reagents. Pharmaceutically acceptable bases and be reacted with acids to form pharmaceutically acceptable salts of this invention. It should also be noted that optically active bases can be used to make optically active salts which can be used for optical resolutions.
  • reaction media can consist of a single solvent, mixed solvents of the same or different classes or serve as a reagent in a single or mixed solvent system.
  • the solvents can be protic, non-protic or dipolar aprotic.
  • protic solvents include water, methanol (MeOH), denatured or pure 95% or absolute ethanol, isopropanol and the like.
  • Typical non-protic solvents include acetone, tetrahydrofurane (THF), dioxane, diethylether, tert-butylmethyl ether (TBME), aromatics such as xylene, toluene, or benzene, ethyl acetate, methyl acetate, butyl acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hexane, heptane, isooctane, cyclohexane and the like.
  • THF tetrahydrofurane
  • TBME tert-butylmethyl ether
  • aromatics such as xylene, toluene, or benzene, ethyl acetate, methyl acetate, butyl acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hexane
  • Dipolar aprotic solvents include compounds such as dimethylformamide (DMF), dimethylacetamide (DMAc), acetonitrile, DMSO, hexamethylphosphorus triamide (HMPA), nitromethane, tetramethylurea, N-methylpyrrolidone and the like.
  • Non-limiting examples of reagents that might be used as solvents or as part of a mixed solvent system include organic or inorganic mono- or multi-protic acids or bases such as hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, succinic acid, triethylamine, morpholine, N-methylmorpholine, piperidine, pyrazine, piperazine, pyridine, potassium hydroxide, sodium hydroxide, alcohols or amines for making esters or amides or thiols for making the products of this invention and the like.
  • organic or inorganic mono- or multi-protic acids or bases such as hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, succinic acid, triethylamine, morpholine, N-methylmorpholine, piperidine, pyrazine, piperazine, pyridine, potassium hydroxide, sodium hydroxide, alcohol
  • Step 4 of Scheme 1 is sulfamidation of compound 1 where R 2 can be hydrogen or as otherwise defined.
  • R 2 can be hydrogen or as otherwise defined.
  • the process of sulfamidation is discussed above in reference to Step 2.
  • the product is the alcohol 4.
  • Scheme 1 shows in Step 5 the direct conversion of an alcohol such as compound 4 into a contemplated sulfur-containing compound, 5.
  • a descriptive term for this process is activated azo coupling.
  • the process can be carried out by reacting a phosphine such as triphenyl phosphine and an azo compound such as diisopropylaziodicarboxylate (DIAD) or diethylazodicarboxylate (DEAD), a starting alcohol and a thiolcarboxylic acid or dithiocarboxylic acid.
  • the reaction is usually carried out under an inert atmosphere such as nitrogen or argon at about ⁇ 40° C. to about 50° C. in an inert solvent such as methylene chloride, THF or the others listed above.
  • the thioester or dithioester [R 9 (C ⁇ S)—] 5 is a compound of Formula II.
  • Compound 5 can be hydrolyzed to form compound 8 in Scheme 1 or compounds 15 or 16 as shown in Scheme 4.
  • Compound 8 is a compound of formula I. This hydrolysis can be carried out with bases such as a metal hydroxide (LiOH, NaOH, KOH), carbonate (Na 2 CO 3 , K 2 CO 3 ) or a bicarbonate (NaHCO 3 ).
  • bases such as a metal hydroxide (LiOH, NaOH, KOH), carbonate (Na 2 CO 3 , K 2 CO 3 ) or a bicarbonate (NaHCO 3 ).
  • hydrolytic reagents suitable for this reaction include alkoxides such as sodium methoxide, potassium ethoxide and the like, a thiolate such as sodium thiophenolate, potassium methanethiolate and the like or by hydrolytic exchange with an amine or ammonia.
  • reaction can be carried out under an inert atmosphere such as helium, nitrogen or argon at temperatures of from about ⁇ 50° C. to about 100° C. Temperatures from about 0° C. to about 60° C. are preferred.
  • Solvents, pure or mixed, include water, alcohols especially for alcoholate hydrolysis or dipolar aprotic solvents such as acetonitrile, DMSO or DMF. Amine exchanges can occur under conditions as discussed above.
  • the amine can serve if desired as the solvent or a co-solvent as, for example, when diethylamine, morpholine, dimethyl amine (in a pressure system) or piperidine, are used as exchange agents.
  • the preparation of compound 8 from compound 5 can also be carried out using reductive processes if desired.
  • Useful reducing agents may include lithium aluminum hydride, aluminum hydride, DIBAL, potassium borohydride, sodium borohydride, lithium borohydride or a metal catalyzed hydrogenation with a system such as the employing a Rosenmund catalyst.
  • Reductions of the hydride type are usually carried out at between 80° C. and ⁇ 80° C. in non-polar aprotic solvents such as THF or ethers whereas hydrogenations with hydrogen gas require containers (hydrogenation bottles, Parr bombs, pressure kettles and the like) with protic or non-protic solvents or solvent mixtures at temperatures of between ⁇ 20° C. to 100° C.
  • Conversion of compound 3 in Scheme 1 into the sulfur-containing compound 5 illustrates displacement of an electrophile by a nucleophile; i.e., the conversion of a intermediate containing our activated leaving group M or a derivative into a sulfur compound of this invention.
  • This method of synthesis is commonly called bimolecular nucleophilic substitution.
  • Solvolysis or SN 1 reactions are also possible and, if desired, can be used to provide electrophilic substitutions to produce alcohols, ethers, amines, carboxylate esters and the like.
  • the reagents that provide the above compounds via SN 1 ractions are water, alcohols, amines and carboxylic acids.
  • the nucleophilic displacement (SN 2 ) reaction can be used in Step 3 wherein group M is displaced by a thiol compound or the salt of a thiol compound to produce compounds of formula I (compound 8) or formula II (compound 5) directly or a compound of formula I via conversion of II into I.
  • the diagramatically reverse procedure; i.e., synthesis of a compound of formula I followed by its conversion into a compound of formula II or formula III can also be accomplished.
  • Either compounds of formula I or of formula II can be direct or non-direct intermediates in the preparation of compounds III (e.g. compound 6).
  • thiol reagents or their salts useful for nucleophilic displacement reactions are hydrogen sulfide (H 2 S), sodium sulfide (NaSH), thiolacetic acid [HS(C ⁇ O)CH 3 ], sodium thiolacetate [NaS(C ⁇ O)CH 3 ], dithioacetic acid [HS(C ⁇ S)CH 3 ] and sodium dithiolacetate [NaS(C ⁇ S)CH 3 ].
  • a thiolate or other anion can be obtained from a preformed salt such as sodium sulfide or sodium thiolacetate or it can be formed in situ via addition of a base to an acid such as hydrogen sulfide or thiolacetic acid.
  • bases and solvents are discussed above.
  • Preferred bases are those that are hindered or tertiary such that competition with a sulfur anion as a nucleophile in a two stage reaction is minimized, e.g., triethylamine, pyridine, DBU, DMAP and the like.
  • a strong inorganic base or organometallic base can be used if desired.
  • non-protic or dipolar aprotic solvents such as acetone, acetonitrile, DMF, acetonitrile and the like are examples of a preferred class.
  • Bases can also be used as solvents as well as reagents. Mixtures of the above solvents or with a solvent and a base such as pyridine or triethylamine are also useful. These reactions are usually carried out under an inert atmosphere (nitrogen, argon) at temperatures varying from between about ⁇ 10° C. to about 80° C. In many cases, room temperature is preferred due to cost or simplicity. Again, procedures involving nucleophilic substitution reactions are well know in the art and sulfur based anions are known to be excellent nucleophiles.
  • reagents examples include thionyl chloride, oxalyl chloride, phosphorus oxychloride, HOBT (hydroxybenzotriazole), isobutylchloroformate, carbodimide, azodicarboxylate compounds an the like all of which are well known and established in the art.
  • Reduction of the disulfide to the corresponding thiol can be carried out by, for example, treatment with hydride reagents such as lithium aluminum hydride, aluminum hydride, DIBAL, metal borohydrides (Li + , Na + , K + , Ca ++ ), sodium cyanoborohydride and the like.
  • the aminoalcohol compound 7 in Scheme 2 illustrates a special case example of compound 1 wherein R 2 is hydrogen.
  • This series of reactions using, for example, compound 7, permits sulfamidation by processes discussed above wherein one skilled in the art can produce examples of compound 4 where R 2 is hydrogen.
  • This intermediate or product can then be alkylated or otherwise substituted to produce compound 4 wherein R 2 is other than hydrogen.
  • Alkylating agents include compounds that contain groups that can be displaced by a nucleophile such as a sulfamic acid salt.
  • This anion can be reacted in an SN 2 manner with an intermediate or reagent containing a group that can be displaced with such displaceable groups including such non-limiting examples as epoxide, chloride, bromide, iodide, tosylate, mesylate, triflate, mesylate and the like.
  • reagents or intermediates examples include benzyl bromide, methyl iodide, n-butyl chloride, isoamyl tosylate, N-chloroethylmorpholine, N-bromoethylpiperidine and the like.
  • the anion can also be reacted (acylated) with a carbonyl compound in an addition-elimination sequence to provide a N-carbonyl compound.
  • acylated compounds might be reduced to desired intermediates or serve as protecting groups or both.
  • the anion can be formed with the bases listed and discussed above if the affects of sulfamide structure on pKa are accommodated.
  • Sodium carbonate, potassium carbonate, potassium methoxide or DMAP represent bases sufficiently strong that they can be used to deprotonate a sulfonamide such as 4.
  • a strong base such as an organometallic base under argon in a aprotic solvent is desirable.
  • the reactions are normally carried out under an inert atmosphere at temperatures of from about 0° C. to about 100° C. using either protic or dipolar aprotic solvents or with solvent mixtures.
  • the solvent mixtures can include reagents such as amine bases that can also serve as part of a solvent mixture.
  • An alkylation or acylation reactions involving salt formation are examples of the type reaction wherein a non-participating group such as a hydroxly group hydroxyl group on compound 4 can be protected if desired by the skilled chemist.
  • a second process that can be used to place an R 2 group a sulfonamide with at least one hydrogen atom is reductive amination.
  • Treatment of compound 4 containing an active hydrogen on the nitrogen of the sulfamide with an aldehyde or ketone and a reducing agent such as LiAlH 4 , NaCNBH 4 , LiBH 4 , AlH 4 or hydrogen in the presence of controlled activity metal catalyst may provide compounds with a R 2 group.
  • An intermediate in this reductive process can be an sulfimine, sulfimine derivative or a tautomer thereof.
  • the reducing agent can be present in the initial reaction or the intermediate can be subsquently reduced, i.e., the intermdiate carbonyl-sulfamide compound can be isolatable or it may be reduced further directly.
  • a sulfamide salt can also add to a carbonyl group (acylation) of an ester, amide, anhydride, acid halide, mixed anhydride or similar compound and then be reduced.
  • Step 4 in Scheme 2 involves the hydroxyl conversion step discussed in with regards to Step 1 in Scheme 1.
  • protection of a non-reactive group can be desirable.
  • the sulfamide can be alkylated or reductively alkylated to introduce the R 2 group (Step 5) if such is desired.
  • Scheme 2 also illustrates the conversion of compound 4 into compound 5, compound 4 into compound 9 and compound 9 into compound 3.
  • the former conversion is discussed above per Scheme 1.
  • the preparation of Compound 9 illustrates the preparation of a sulfonamide compound where R 2 is hydrogen and M is a leaving group (activated intermediate).
  • hydroxyl conversion process is well discussed above under Step 1 of Scheme 1.
  • protection of groups that one does not wish to participate in a reaction or process can be useful.
  • reagents that convert hydroxyl groups into halide type leaving groups is preferred.
  • agents include hydrogen bromide, hydrogen chloride, hydrogen iodide, hydrobromic acid, hydrochloric acid or hydriodic acid.
  • Agents that can convert a sulfonamide nitrogen-hydrogen bond into a nitrogen-halogen bond such as sodium hypochlorite can serve as a method of protecting the sulfonamide from further substitution on nitrogen.
  • the halogen is removable when desired by reduction.
  • compound 9 can be alkylated or acylated by processes as discussed for Step 2 in this Scheme to provide compound 3.
  • Compound 3 can be converted into a compound of this invention of formula I or formula II (compound 5) via a nucleophilic or electrophilic substitution process as illustrated in Step 6. These processes and reactions are discussed above.
  • Amination can be a nucleophilic substitution process wherein the nucleophile is an amine, amine anion or other amine derivative. If an amine is the reagent desired, one can treat compound 10 directly with the amine at temperatures of from about ⁇ 60° C. to reflux temperature in protic, non-protic or dipolar aprotic solvents under an inert atmospheres or air.
  • Protic solvents can include water wherein the reagent is usually an amine hydroxide such as ammonium hydroxide, benzylamine hydroxide and the like. Amine hydroxides are discussed above. Solvents that can react with amines such as ethyl acetate or acetone are not to be used.
  • a pressure containment system or a low temperature system can be used for gaseous amines such as ammonia, methyl amine ethyl amine and the like.
  • gaseous amines such as ammonia, methyl amine ethyl amine and the like.
  • reactions with or in ammonia can be run in liquid ammonia at a temperature of about ⁇ 33° C.
  • the SN 2 reaction can also be carried out with an metal-amine salt such as sodium amide, calcium amide, potassium metylamide and the like.
  • Step 3 in this sequence illustrates conversion of the unprotected alcohol group into the sulfur compound 12, which can then be converted into 5, which is a sulfonamide of this invention if formula II.
  • Step 5 shows conversion of the M-substituted carbinol 10 into the sulfur compound 13 via a before-discussed activated azo procedure as in Step 3.
  • Compound 13 can then be treated in Step 6 as with Step 1 to convert the M-carbon bond in compound 13 into a carbon-nitrogen bond to produce compounds 12 or 14 wherein R 2 is either hydrogen (compound 14) or not hydrogen (compound 12).
  • R 2 is either hydrogen (compound 14) or not hydrogen (compound 12).
  • this product is compound 14 and R 2 is hydrogen, it can be converted into compound 12 by alkylation or reductive alkylation processes of Step 7 using the methods of Step 2.
  • Scheme 4 presents an alternative synthetic route to the compounds of this invention such as compounds 5, 15 or 16.
  • the amine R 2 NH 2 is reacted with a sulfonamide forming reagent such as a sulfonyl chloride under sulfamidation conditions to provide a sulfonamide.
  • the sulfonamide can have two hydrogen atoms on the nitrogen of the sulfonamide group or it can have one nitrogen-carbon bond valence be occupied by a group R 2 .
  • the sulfonamide can be alkylated (Step 3) by processes discussed above using compound 13 as the electrophile.
  • Compound 13 was prepared in Scheme 3.
  • Step three displays the same process as Step 1 except that the amine is replaced by ammonia to provide an unsubstituted sulfonamide.
  • This unsubstituted sulfonamide can be alkylated with, for example, compound 13 or compound 10, to produce sulfonamide compound 14 or sulfonamide compound 4.
  • Alkylation of compound 14 by procedures illustrated above provides compound 5.
  • Hydrolysis of compound 14 (Step 5) can produce compound 15 which is a compound of this invention of formula I.
  • Step 3 or Step 2 is provided by the procedure of Example 44.
  • the amine can be R 2 NH 2 with R 2 being methyl followed by post sulfamidation alkylation with 2-iodobenzylchloride to produce a dialkylated sulfonamide that is subsequently converted into a thiol compound of this invention of formula IV.
  • the inverse procedures can be carried out wherein the product of reaction with iodobenzylchloride or iodobenzylamine is the first sulfonamide that is then alkylated with methyl iodide. Conversion of this intermediate into the sulfur-containing product uses a cobalt complex with thiourea followed by reduction with sodium cyanoborohydride. This process is a useful alternative for the synthesis of aromatic sulfur compounds.
  • Scheme 5 presents the preparation of the product of Example 41C.
  • the carbinol amine a was treated with the sulfonyl chloride b under sulfamidation conditions to produce sulfonamide compound c.
  • the reaction was carried out under nitrogen in THF and water as co-solvents and with triethylamine as the base to act a the product hydrochloric acid scavenger.
  • the reaction temperature was about 0° C. in an ice bath.
  • the sulfonamide c in which R 2 is H was alkylated with methyl iodide to produce the product d wherein R 2 is methyl.
  • the solvent for this reaction was DMF with potassium carbonate base being suspended/dissolved therein under an atmosphere of nitrogen.
  • the reaction mixture including the methyl iodide was maintained at room temperature.
  • This alcohol was then converted via the activated azo coupling procedure into the sulfur compound f, which is a compound, useful in a process of this invention.
  • This reaction was carried out at 0° C. in THF under nitrogen.
  • the reagents triphenylphosphine and diethyldiazodicarboxylate were dissolved in the THF and thiolacetic acid was added.
  • the reaction was permitted to proceed for about one hour to yield compound f which is the product of Example 41B.
  • Hydrolysis of compound f with sodium methoxide in methanol at room temperature for about one half hour provide compound g which is also the product of Example 41C.
  • Optically active compound isomers as well as mixed or non-optically active compound isomers are specifically intended to be included in this discussion.
  • isomers are RS isomers, enantiomers, diastereomers, racemates, cis isomers, trans isomers, E isomers, Z isomers, syn-isomers, anti-isomers, tautomers and the like.
  • Aryl, heterocyclo or heteroaryl tautomers, heteroatom isomers and ortho, meta or para substitution isomers are also included as isomers.
  • Part A To a solution of (10.0 g, 133 mmol) 2R-amino-1-propanol in 120 mL of acetone and 50 mL of water, was added 35.8 mL of triethylamine. After cooling in an ice bath, 23.5 g (133 mmol) of 3-chloro propanesulfonyl chloride was slowly added over 15 minutes. After stirring at room temperature for 2 hours, the solvent was removed under reduced pressure and ethyl acetate and water was added.
  • Part B To a solution of 4.13 g (20 mmol) of product from part A in (25 mL) of anhydrous acetonitrile, was added (4.4 g, 40 mmol) of triethylamine followed by (3.3 g, 30 mmol) of benzenethiol. After stirring at room temperature for 16 hours, the reaction was diluted with (200 mL) of dichloromethane.
  • Part B To a solution of 2.0 g (6.2 mmol) of product from Part A and 1.79 g (6.8 mmol) of triphenylphosphine in 31 mL of anhydrous THF at 0 C, was added 1.35 mL (6.8 mmol) of diisopropylazodi-carboxylate, followed by 0.50 mL (6.8 mmol) of thiolacetic acid.
  • Part C To a suspension of 0.57 g (1.5 mmol) of product from Part B above in 4 mL of anhydrous methanol, was added 1.2 mL (5.4 mmol) of 25 weight % sodium methoxide in methanol. After 30 minutes, the solution was cooled in ice and 2% hydrochloric acid added. Ethyl acetate was added and the organic layer separated and washed with saturated sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and stripped to afford 0.5 g of crude material.
  • Part A To a solution of 2.0 g (8.6 mmol) of N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide from Example 1 in 20 mL of anhydrous DMF, was added 3.58 g (25.9 mmol) of powdered potassium carbonate and then 1.96 g (13 mmol) of 1-bromopentane. After 24 hours, ethyl acetate and water was added, the organic layer separated and washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 2.3 g of crude product.
  • Part A To a solution of 3.0 g (12 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzenesulfonamide from Example 3 in 40 mL of anhydrous DMF, was added 5.1 g (37 mmol) of powdered potassium carbonate, followed by 2.0 mL (2.5 g, 18 mmol) of 1-bromobutane. After 66 hours, and additional 2.5 g (18 mmol) of powdered potassium carbonate and 1.0 mL (1.3 g, 9 mmol) of 1-bromobutane were added, and the reaction heated at 40° C.
  • Part C To a solution of 2.0 g (6 mmol) of the product from Part B in 50 mL of anhydrous methanol, was added 0.5 g (21 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.6 g of crude product.
  • Part A To a solution of 10.04 g (43 mmol) of N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide from Example 1 in 85 mL of anhydrous DMF, was added 17.8 g (128 mmol) of powdered potassium carbonate and then 8.2 g (48 mmol) of benzyl bromide. After 24 hours, ethyl acetate and water was added, the oragnic layer separated and washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 14.3 g of crude product.
  • Part B To a solution of 4.0 g (12.4 mmol) of N-(2-hydroxyethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide from Part A in 6 mL of anhydrous methylene chloride and 6 mL of anhydrous dimethyl sulfoxide, was added 17.1 mL of triethylamine, the solution cooled in an ice bath and 7.9 g (50 mmol) of sulfur trioxide/pyridine complex in 38 mL of DMSO was added over 15 minutes.
  • Part C To 8.3 mL (25 mmol) of 3M methyl magnesium bromide in diethyl ether at 0 C under nitrogen, was added a solution of 4 g (12.4 mmol) of crude N-(2-propanal)-4-methoxybenzenesulfonamide from Part B in 10 mL of anhydrous tetrahydrofuran. After 1 hour at room temperature, the reaction was cooled in ice and quenched by the addition of saturated ammonium chloride solution, extracted with ethyl acetate, washed with 5% KHSO4, brine, dried and stripped to afford 4.0 g of crude material.
  • Part E To a solution of 0.43 g (1.1 mmol) of the product of Part D in 5 mL of anhydrous methanol, was added 0.9 mL (3.9 mmol) of 25 wt % sodium methoxide/methanol. After 15 hours at room temperature, an additional 0.9 mL of sodium methoxide/methanol was added.
  • Part A To a solution of 3.0 g (12.2 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzenesulfonamide from example 3, in 20 mL of anhydrous DMF, was added 5.06 g (36.7 mmol) of powdered potassium carbonate, and then 1.1 mL (17.7 mmol) of methyl iodide. After stirring at room temperature for 48 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 2.83 g of crude material.
  • Part D To a solution of 1.77 g (5.58 mmol) of product from Part C in 20 mL of anhydrous methanol, was added 4.6 mL (20 mmol) of a 25 weight % solution of sodium methoxide in methanol.
  • Part A To a solution of 5.0 g (20 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzene-sulfonamide from Example 3 in 40 mL of anhydrous DMF, was added 8.5 g (61 mmol) of powdered potassium carbonate, followed by 3.2 mL (4.5 g, 27 mmol) of benzyl bromide. After 16 hours, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed 3 ⁇ s with brine, dried with magnesium sulfate, filtered and concentrated to afford 7.1 g of crude product.
  • Part C To a solution of 4.3 g (11 mmol) of product from Part B in 100 mL of anhydrous methanol, was added 0.9 g (40 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 3.5 g of crude product.
  • Part A To a solution of 15.5 mL (15.0 g, 200 mmol) of (S)-(+)-2-amino-1-propanol in 70 mL of THF and 18 mL of water, was added 36 mL (259 mmol) of triethylamine. After cooling in an ice bath, a solution of 37.1 g (179 mmol) of 4-methoxybenzenesulfonyl chloride in 30 mL of tetrahydrofuran was slowly added over 15 minutes.
  • Part B To a solution of 5.0 g (20 mmol) of N-(2-hydroxy-1S-methylethyl)4-methoxybenzenesulfonamide from part A in 40 mL of anhydrous DMF, was added 8.5 g (61 mmol) of powdered potassium carbonate, followed by 3.2 mL (4.5 g, 27 mmol) of benzyl bromide. After 64 hours, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed 3 ⁇ s with brine, dried with magnesium sulfate, filtered and concentrated to afford 7.0 g of crude product.
  • Part D To a solution of 3.8 g (9.7 mmol) of product from Part C in 20 mL of anhydrous methanol, was added 7.9 mL (34.8 mmol) of a 25 weight % solution of sodium methoxide in methanol.
  • Part A To a solution of 3.0 g (12.2 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzene-sulfonamide from example 3, in 20 mL of anhydrous DMF, was added 5.06 g (36.7 mmol) of powdered potassium carbonate, and then 2.0 mL (18.3 mmol) of isobutyl bromide. After stirring at room temperature for 72 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 3.35 g of crude material.
  • Part C To a solution of 0.73 g (2.0 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 1.7 mL (7.3 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 10.6 g of crude product.
  • Part A To a solution of 2.69 g (9.36 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from example 4 and 2.7 g (10.3 mmol) of triphenylphosphine in 37 mL of anhydrous THF at 0° C., was added 1.6 mL (10.3 mmol) of diethylazodi-carboxylate, followed after 5 minutes by 0.75 mL (10.3 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 10%-50% ethyl acetate/hexane to yield 1.59 g of impure material, which was carried into the next step.
  • Part B To a solution of 1.59 g (4.6 mmol) of product from Part A in 18 mL of anhydrous methanol, was added 3.8 mL (16.6 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.4 g of crude product.
  • Part A To a solution of 3.52 g (12.3 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzenesulfonamide from example 4 in 25 mL of anhydrous DMF, was added 5.07 g (36.8 mmol) of powdered potassium carbonate, followed by 1.9 mL (2.7 g, 15.9 mmol) of benzyl bromide. After 63 hours, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed 3 ⁇ s with brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product.
  • Part C To a solution of 0.99 g (2.3 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 1.9 mL (8.2 mmol) of a 25 weight % solution of sodium methoxide in methanol.
  • the mixture was heated to 67° C. for 5 hours followed by cooling to 16° C. with an ice bath.
  • the reaction was quenched with water (51) at a rate that kept the temperature below 20° C. After the addition of water was complete, the mixture was stirred for 10 minutes.
  • the layers were separated and the organic layer was washed again twice with water (51).
  • the organic layer was dried with magnesium sulfate (500 g) and filtered to remove the drying agent.
  • the solvent was removed under vacuum at 50° C.
  • the resulting warm liquid was permitted to cool at which time a solid began to form. After one hour, the solid was washed with hexane (400 mL), filtered and dried to provide sulfonyl chloride (2823 g).
  • Part A To a solution of 5.4 g (72 mmol) of (R)-2-amino-1-propanol in 25 mL of tetrahydrofuran and 10 mL of water, was added 13 mL (93 mmol) of triethylamine. The solution was cooled in an ice bath and a solution of 13.3 g (60 mmol) of 1,3-benzodioxole-5-sulfonyl chloride in 20 mL of tetrahydrofuran was added over 20 minutes.
  • Part B To a solution of 2.6 g (10 mmol) of N-(2-hydroxy-1R-methylethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide from Part A, in 15 mL of anhydrous DMF, was added 4.15 g (30 mmol) of powdered potassium carbonate, and then 1.25 mL (20 mmol) of methyl iodide. After stirring at room temperature for 17 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 2.8 g of crude material.
  • Part D To a solution of 1.86 g (5.6 mmol) of product from Part C in 20 mL of anhydrous methanol, was added 4.6 mL (20 mmol) of a 25 weight % solution of sodium methoxide in methanol.
  • Part A To a solution of 5.4 g (72 mmol) of (R)-2-amino-1-propanol in 25 mL of tetrahydrofuran and 10 mL of water, was added 13 mL (93 mmol) of triethylamine. The solution was cooled in an ice bath and a solution of 13.3 g (60 mmol) of 1,3-benzodioxole-5-sulfonyl chloride in 20 mL of tetrahydrofuran was added over 20 minutes.
  • Part B To a solution of 2.5 g (9.6 mmol) of N-(2-hydroxy-1R-methylethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide from Part A, in 20 mL of anhydrous DMF, was added 3.99 g (29 mmol) of powdered potassium carbonate, and then 1.5 mL (12.5 mmol) of benzyl bromide. After stirring at room temperature for 17 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 3.15 g of crude material.
  • Part D To a solution of 0.76 g (1.86 mmol) of product from Part C in 8 mL of anhydrous methanol, was added 1.5 mL (6.7 mmol) of a 25 weight % solution of sodium methoxide in methanol.
  • Part A To a solution of 3.24 g (11 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from example 4, in 22 mL of anhydrous DMF, was added 4.98 g (36 mmol) of powdered potassium carbonate, and then 1.5 mL (24 mmol) of methyl iodide. After stirring at room temperature for 21 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 3.28 g of crude material.
  • Part C To a solution of 1.55 g (4.3 mmol) of product from Part B in 18 mL of anhydrous methanol, was added 3.6 mL (15.5 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.3 g of crude product.
  • Part A To a solution of 3.91 g (44 mmol) of (R)-2-amino-1-butanol in 20 mL of tetrahydrofuran and 5 mL of water, was added 9.5 mL (68 mmol) of triethylamine. The solution was cooled in an ice bath and a solution of 9.85 g (40 mmol) of 4-(n-butoxybenzene)sulfonyl chloride in 10 mL of tetrahydrofuran was added over 10 minutes.
  • Part B To a solution of 3.0 g (9.85 mmol) of N-(1R-hydroxymethyl)propyl-4-(n-butoxy)benzene-sulfonamide from Part A, in 12 mL of anhydrous DMF, was added 4.1 g (30 mmol) of powdered potassium carbonate, and then 1.2 mL (20 mmol) of methyl iodide. After stirring at room temperature for 21 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 2.9 g of crude material.
  • Part A To a solution of 2.0 g (7 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from example 4, in 10 mL of anhydrous DMF, was added 2.9 g (21 mmol) of powdered potassium carbonate, and then 1.6 mL of an 80 wt. % solution of propargyl bromide in toluene (15 mmol). After stirring at room temperature for 24 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 2.31 g of crude material.
  • Part B To a solution of 1.1 g (2.9 mmol) of product from Part A in 7 mL of anhydrous methanol, was added 7.4 mL of 30% aqueous ammonia. After 1 hour, the reaction was quenched with 1N HCl solution, followed by diethyl ether and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.90 g of crude product.
  • Part A To a solution of 4.5 g (52 mmol) of racemic 3-pyrrolidinol in 20 mL of tetrahydrofuran and 5 mL of water, was added 10 mL of triethylamine. The solution was cooled to 0 C, and 9.0 g (46 mmol) of 4-(methoxybenzene)sulfonyl chloride was slowly added.
  • Part C To a solution of 1.05 g (3.3 mmol) of product from Part C in 6 mL of anhydrous methanol, was added 8.6 mL of 30% aqueous ammonia. After 1 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.74 g of crude product.
  • Part A To a solution of 10.27 g (89 mmol) of D,L-proline in 100 mL of water and 60 mL of acetone, was added 40 mL (287 mmol) of triethylamine. After cooling in an ice bath, 17.6 g (85 mmol) of 4-(methoxybenzene)sulfonyl chloride was slowly added. After stirring at room temperature for 13 hours, the acetone was stripped, the aqueous layer extracted twice with toluene, then acidified with 25 mL of 6N hydrochloric acid and extracted with ethyl acetate.
  • Part B To a solution of 4.00 g (14 mmol) of 1-[(4-methoxyphenyl)sulfonyl]-2-carboxypyrrolidine from part A in 50 mL of anhydrous tetrahydrofuran at 0 C under a nitrogen atmosphere, was slowly added over 15 minutes, 20 mL (20 mmol) of a 1M solution of lithium aluminum hydride in diethyl ether. After stirring at room temperature for 2 hours, the solution was cooled in an ice bath, and quenched by the slow sequential addition of 0.8 mL of water, 0.8 mL of 10% sodium hydroxide and 2.4 mL of water.
  • Part D To a solution of 1.5 g (4.6 mmol) of product from Part C in 10 mL of anhydrous methanol, was added 3.7 mL (16.4 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.9 g of crude product.
  • Part A To a solution of 10.0 g (76.2 mmol) of D,L-leucine in 85 mL of water and 50 mL of acetone, was added 30 mL (215 mmol) of triethylamine. This solution was cooled in an ice bath, and a solution of 15.0 g (72.7 mmol) of 4-methoxybenzenesulfonyl chloride in 50 mL of acetone was slowly added over a 30 minute period.
  • Part D To a solution of 3.2 g (7.9 mmol) of the product from part C in 30 mL of anhydrous tetrahydrofuran at 0 C under a nitrogen atmosphere, was slowly added over 15 minutes, 7.9 mL (7.9 mmol) of a 1M solution of lithium aluminum hydride in diethyl ether. After stirring at room temperature for 1 hour, the solution was cooled in an ice bath, and quenched by the slow sequential addition of 0.3 mL of water, 0.3 mL of 10% sodium hydroxide and 0.9 mL of water. The resulting suspension was filtered through celite and the celite washed with ethyl acetate.
  • Part A To a solution of 20.0 g (170 mmol) of D-valine in 170 mL of water and 95 mL of acetone, was added 50 mL (360 mmol) of triethylamine. This solution was cooled in an ice bath, and a solution of 35.2 g (170 mmol) of 4-methoxybenzenesulfonyl chloride in 75 mL of acetone was slowly added over a 20 minute period.
  • Part B To a solution of 6.3 g (20mmol) of product from Part A in 60 mL of anhydrous THF at 0C under nitrogen, was added 16.1 mL (0.6 g, 16 mmol) of a 1.0 M solution of lithium aluminum hydride in diethyl ether. After 1.5 hours, the reaction mixture was cooled to 0° C.
  • Part D To a solution of 4.7 g (11 mmol) of product from Part C in 100 mL of anhydrous methanol, was added 1.0 g (41 mmol) of sodium metal. After 1 hour, the reaction was quenched using dry ice, ethyl acetate and 5% potassium hydrogen sulfate solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product.
  • Part A To a solution of 10.0 g (85 mmol) of L-valine in 85 mL of water and 50 mL of acetone, was added 25 mL (180 mmol) of triethylamine. This solution was cooled in an ice bath, and a solution of 17.6 g (85 mmol) of 4-methoxybenzenesulfonyl chloride in 35 mL of acetone was slowly added over a 20 minute period.
  • Part B To a solution of 18.9 g (65.8 mmol) of product from part A in 60 mL of anhydrous methanol at 0 C, was slowly added 6.0 mL (83 mmol) of thionyl chloride over 15 minutes. The solution was then stirred for 14 hours at room temperature, concentrated, ethyl acetate added, washed with water, saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and stripped to afford the crude material.
  • Part B To a solution of 4.88 g (12.5 mmol) of product from Part A in 50 mL of anhydrous THF at 0C under nitrogen, was added 12.5 mL (12.5 mmol) of a 1.0 M solution of lithium aluminum hydride in diethyl ether. After 0.5 hours, the reaction mixture was cooled to 0° C.
  • Part D To a solution of 2.7 g (6.4 mmol) of product from Part C in 20 mL of anhydrous methanol, was added 5.3 mL (23 mmol) of 25 weight % sodium methoxide in methanol solution. After 0.5 hour, the reaction was quenched with 1N hydrochloric acid, ethyl acetate added and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 2.05 g of crude product.
  • Part A To a solution of 15.11 g (55 mmol) of N-(2-hydroxyethyl)-4-(n-butoxy)benzenesulfonamide from Example 2 in 100 mL of anhydrous DMF, was added 22.9 g (165 mmol) of powdered potassium carbonate and then 10.3 g (60 mmol) of benzyl bromide. After 16 hours, ethyl acetate and water was added, the oragnic layer separated and washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 20.7 g of crude product.
  • Part B To a solution of 3.0 g (8.2 mmol) of N-(2-hydroxyethyl)-N-(phenylmethyl)-4-(n-butoxy)-benzenesulfonamide from Part A and 2.38 g (9.1 mmol) of triphenylphosphine in 40 mL of anhydrous THF at 0 C, was added 1.4 mL (9.1 mmol) of diisopropylazo-dicarboxylate, followed by 0.65 mL (9.1 mmol) of thiolacetic acid.
  • Part C To a suspension of 1.7 g (4.1 mmol) of product from Part B above in 20 mL of anhydrous methanol, was added 3.3 mL (14.6 mmol) of 25 weight % sodium methoxide in methanol. After 30 minutes, the solution was cooled in ice and 2% hydrochloric acid added.
  • Part A To a solution of 7.4 mL (95.1 mmol) of (R)-( ⁇ )-2-amino-1-propanol in 31 mL of THF and 9 mL of water, was added 17.2 mL (123 mmol) of triethylamine. After cooling in an ice bath, a solution of 24.4 g (86.5 mmol) of 4-(benzyloxy)-benzenesulfonyl chloride in 40 mL of tetrahydrofuran was slowly added over 15 minutes.
  • Part A To a solution of 1.50 g (6.11 mmol) of N-(2-hydroxy-1R-methylethyl)-4-hydroxybenzene-sulfonamide from example 36, in 10 mL of anhydrous DMF, was added 2.53 g (18.3 mmol) of powdered potassium carbonate, and then 0.85 mL (9.3 mmol) of bromopropane.
  • Part C To a solution of 1.02 g (2.95 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 2.4 mL (10.5 mmol) of a 25 weight % solution of sodium methoxide in methanol.
  • Part A To a solution of 1.50 g (6.11 mmol) of N-(2-hydroxy-1R-methylethyl)-4-hydroxybenzenesulfonamide from example 36, in 10 mL of anhydrous DMF, was added 2.53 g (18.3 mmol) of powdered potassium carbonate, and then 0.70 mL (9.2 mmol) of bromoethane.
  • Part A To a solution of 1.50 g (6.11 mmol) of N-(2-hydroxy-1R-methylethyl)-4-hydroxybenzenesulfonamide from example 36 in 10 mL of anhydrous DMF, was added 2.53 g (18.3 mmol) of powdered potassium carbonate, and then 1.13 mL (9.2 mmol) of 1-bromopentane.
  • Part C To a solution of 1.48 g (3.96 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 3.3 mL (14 mmol) of a 25 weight % solution of sodium methoxide in methanol.
  • Part A To a solution of 5.02 g (66.8 mmol) of (R)-( ⁇ )-2-amino-1-propanol in 28 mL of THF and 7 mL of water, was added 14.0 mL (100 mmol) of triethylamine. After cooling in an ice bath, 11.7 g (60 mmol) of 4-fluorobenzenesulfonyl chloride was slowly added over 10 minutes.
  • Part B To a solution of 5.14 g (22.0 mmol) of N-(2-hydroxy-1R-methylethyl)-4-fluorobenzene-sulfonamide from Part A in 40 mL of anhydrous DMF, was added 9.12 g (66.1 mmol) of powdered potassium carbonate, and then 4.2 mL (66 mmol) of methyl iodide.
  • Part C To a solution of 3.00 g (12.1 mmol) of the product from Part B in 25 mL of anhydrous DMF, was added 5.02 g (36.4 mmol) of powdered potassium carbonate, and then 2.3 g (24.3 mmol) of phenol. The reaction mixture was heated to 100 C for 48 hours, cooled and tert-butylmethyl ether and water added. The organic layer was separated and washed with 10% sodium hydroxide, brine, dried with sodium sulfate, filtered and stripped to afford 3.0 g of crude material.
  • Part E To a solution of 0.76 g (2.05 mmol) of product from Part D in 5 mL of anhydrous methanol, was added 1.8 mL (7.4 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product.
  • Part A To a solution of 1.72 g (6.95 mmol) of N-(2-hydroxy-1R-methylethyl)-N-methyl-4-fluorobenzenesulfonamide from Example 40, part B, in 10 mL of anhydrous DMF, was added 7.03 g (21.5 mmol) of cesium carbonate, and then 1.0 mL (1.07 g, 9.73 mmol) of thiophenol. The reaction mixture was heated to 70 C for 15 hours, cooled and ethyl acetate and water added. The organic layer was separated and washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 2.5 g of crude material.
  • Part C To a solution of 1.0 g (2.53 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 2.1 mL (9.1 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product.
  • Part A To a solution of 1.97 g (26.2 mmol) of (R)-( ⁇ )-2-amino-1-propanol in 10 mL of THF and 3.5 mL of water, was added 4.5 mL (32 mmol) of triethylamine. After cooling in an ice bath, 5.44 g (20.9 mmol) of 2-(pyrid-2-yl)thiophene-5-sulfonyl chloride was slowly added over 10 minutes.
  • Part B To a solution of 0.94 g (3.15 mmol) of product from Part A in 10 mL of anhydrous DMF, was added 1.31 g (9.45 mmol) of powdered potassium carbonate, and then 0.60 mL (9.5 mmol) of methyl iodide. After stirring at room temperature for 24 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 0.93 g of the desired N-(2-hydroxy-1R-methylethyl)-N-methyl-2-(pyrid-2-yl)thiophene-5-sulfonamide.
  • Part A To a solution of 4.47 g (50 mmol) of 2-amino-2-methyl-1-propanol in 20 mL of THF and 5 mL of water, was added 10 mL (72 mmol) of triethylamine. After cooling in an ice bath, 9.0 g (44 mmol) of 4-methoxybenzenesulfonyl chloride was slowly added over 10 minutes.
  • Part B To a solution of 3.12 g (12 mmol) of product from Part A in 25 mL of anhydrous DMF, was added 5.0 g (36 mmol) of powdered potassium carbonate, and then 2.2 mL (18 mmol) of benzyl bromide. After stirring at room temperature for 17 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 3.2 g of crude product.
  • Part D To a solution of 0.60 g (1.47 mmol) of product from Part C in 10 mL of anhydrous methanol, was added 1.2 mL (5.3 mmol) of a 25 weight percent solution of sodium methoxide in methanol.
  • Part B To a solution of 6.32 g (25.0 mmol) of 2-iodobenzyl chloride in 40 mL of anhydrous DMF, was added 5.04 g (25.0 mmol) of the product from Part A, and then 10.4 g (75.3 mmol) of powdered potassium carbonate was added. After stirring at room temperature for 5 hours, ethyl acetate and water were added, the organic layer separated and washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 10.6 g of crude product. This was recrystallized from ethyl acetate/hexane to afford 9.0 g of the desired N-[(2-iodophenyl)methyl]-N-methyl-4-methoxybenzenesulfonamide.
  • Part C To a mixture of 834 mg (2.0 mmol) of the product from Part B, 236 mg (3.1 mmol) of thiourea and 55 mg (0.10 mmol) of bis(tri-n-butylphosphine)-nickel (II) chloride under a nitrogen atmosphere at room temperature, was added 1 mL of anhydrous DMF, and then 16 mg (0.25 mmol) of sodium cyanoborohydride. The reaction was then warmed to 65 C for 15 hours, cooled to room temperature and 2.0 mL (5 mmol) of 2.5 N sodium hydroxide solution added.
  • Part A To a solution of 2.87 g (10 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from Example 4 in (10 ml) of anhydrous DMF, was added 4.14 g (30 mmol) of powdered potassium carbonate and then 2.04 g (11 mmol) of 4-(2-Chloroethyl)morpholine hydrochloride.
  • Part B To a solution of 1.5 g (3.74 mmol) of product from Part A and 983 mg (3.74 mmol) of triphenylphosphine in 15 ml of anhydrous THF at room temperature was added 0.588 mL (3.74 mmol) of diethyl azodicarboxylate,followed by 0.8 mL (11.22 mmol) of thiolacetic acid.
  • Part C To a suspension of 0.63 g (1.7 mmol) of product from Part B in 20 mL of anhydrous methanol, was added 0.5 mL (2.3 mmol) of 25 wt. % sodium methoxide in methanol.
  • Part A To a solution of 1.0 g (3.5 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)-benzene-sulfonamide from Example 4 in (30 ml) of anhydrous DMF, was added 2.16 g (15.6 mmol) of powdered potassium carbonate and then 0.96 g (5.2 mmol) of 1-(2-chloroethyl)piperidine hydrochloride.
  • Part B To a solution of 0.9 g (2.26 mmol) of product from Part A and 0.6 g (2.3 mmol) of triphenylphosphine in 20 ml of anhydrous THF at room temperature was added 0.36 mL (2.3 mmol) of diethyl azodicarboxylate, followed by 0.48 mL (6.78 mmol) of thiolacetic acid.
  • Part C To a suspension of 0.36 g (0.77 mmol) of product from Part B in 20 mL of anhydrous methanol, was added 0.3 mL (1.4 mmol) of 25 wt. % sodium methoxide in methanol.
  • Part A To a solution of 2.87 g (10 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from Example 4 in (10 ml) of anhydrous DMF, was added 4.14 g (30 mmol) of powdered potassium carbonate and then 1.88 g (11 mmol) of 1-(2-chloro-ethyl)pyrrolidine hydrochloride.
  • Part B To a solution of 1.2 g (3 mmol) of product from Part A and 0.79 g (3 mmol) of triphenylphosphine in 15 ml of anhydrous THF at room temperature was added 0.47 mL (3 mmol) of diethyl azodicarboxylate, followed by 0.7 mL (10 mmol) of thiolacetic acid.
  • Part C To a suspension of 0.39 g (0.87 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 0.3 mL (1.4 mmol) of 25 wt. % sodium methoxide in methanol.
  • Part B To a solution of 2.0 g (5.6 mmol) of product from Part A and 1.58 g (6 mmol) of triphenylphosphine in 20 ml of anhydrous THF at room temperature was added 0.94 mL (6 mmol) of diethyl azodicarboxylate, followed by 0.86 mL (12 mmol) of thiolacetic acid.
  • Part C To a suspension of 1.0 g (2.4 mmol) of product from Part B in 20 mL of anhydrous methanol, was added 1.0 mL (4.6 mmol) of 25 wt. % sodium methoxide in methanol.
  • Part A To a solution of3.69 g (15 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzene-sulfonamide from Example 3 in (25 ml) of anhydrous DMF, was added 6.3 g (45 mmol) of powdered potassium carbonate and then 2.7 g (16.5 mmol) of 3-picolyl hydrochloride.
  • Part B To a solution of 1.07 g (3.18 mmol) of product from Part A and 0.84 g (3.2 mmol) of triphenylphosphine in 25 ml of anhydrous THF at room temperature was added 0.5 mL (3.18 mmol) of diethyl azodicarboxylate, followed by 0.68 mL (9.5 mmol) of thiolacetic acid.
  • Part C To a suspension of 0.18 g (0.45 mmol) of product from Part B in 25 mL of anhydrous methanol, was added 0.2 mL (1.2 mmol) of 25 wt. % sodium methoxide in methanol.
  • Part A To a solution of 1.1 g (3.8 mmol) of N-(2-hydroxy-1R-methylethyl) (3-thiophenoxypropyl)-sulphonamide from Example 5 in (25 ml) of anhydrous DMF, was added 2.1 g (15 mmol) of powdered potassium carbonate and then 1.1 g (7.6 mmol) of methyl iodide.
  • Part B To a solution of 0.9 g (2.96 mmol) of product from Part A and 0.78 g (2.96 mmol) of triphenylphosphine in 25 ml of anhydrous THF at room temperature was added 0.47 mL (2.96 mmol) of diethyl azodicarboxylate, followed by 0.63 mL (8.8 mmol) of thiolacetic acid.
  • Part C To a suspension of 0.18 g (0.5 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 0.25 mL (1.12 mmol) of 25 wt. % sodium methoxide in methanol.
  • Part A To a solution of 0.86 g (3 mmol) of N-(2-hydroxy-1R-methylethyl)(3-thiophenoxypropyl)-sulphonamide from Example 5 in (25 ml) of anhydrous DMF, was added 1.24 g (8.9 mmol) of powdered potassium carbonate and then 0.62 g (3.6 mmol) of benzyl bromide.
  • Part B To a solution of 0.6g (1.58 mmol) of product from Part A and 0.42 g (1.6 mmol) of triphenylphosphine in 15 ml of anhydrous THF at room temperature was added 0.25 mL (1.6 mmol) of diethyl azodicarboxylate, followed by 0.34 mL (4.8 mmol) of thiolacetic acid.
  • Part C To a suspension of 0.17 g (0.39 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 0.2 mL (0.92 mmol) of 25 wt. % sodium methoxide in methanol.
  • Part A To a solution of 1.0 g (3.45 mmol) of N-(2-hydroxy-1R-methylethyl)(3-thiophenoxypropy)-sulphonamide from Example 5 in (30 ml) of anhydrous DMF, was added 2.16 g (15.6 mmol) of powdered potassium carbonate and then 0.96 g (5.2 mmol) of methyl iodide.
  • Part B To a solution of 0.83 g (2.07 mmol) of product from Part A and 0.54 g (2.07 mmol) of triphenylphosphine in 25 ml of anhydrous THF at room temperature was added 0.33 mL (2.07 mmol) of diethyl azodicarboxylate, followed by 0.44 mL (6.21 mmol) of thiolacetic acid.
  • Part C To a suspension of 0.225 g (0.5 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 0.2 mL (0.9 mmol) of 25 wt. % sodium methoxide in methanol.
  • Part A Preparation of N-(2-hydroxy-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide.
  • the organic phase was washed with saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated to a dark yellow oil.
  • the crude material was purified by silica gel chromatography using an eluant of 30 % ethyl acetate in hexane to yield 1.53 grams of a clear oil.
  • Part B Preparation of N-(2-thioacetyl-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide.
  • Part C Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide.
  • Part A Preparation of N-(2-hydroxy-1R-methylethyl)-N-[2-(4morpholino)ethyl]-4-(n-pentyl)benzenesulfonamide.
  • Part B Preparation of N-(2-thioacetyl-1R-methylethyl)-N-[2-(4-morpholino)ethyl]-4-(n-pentyl)benzenesulfonamide.
  • Part C Preparation of N-(2-mercapto-1R-methylethyl)-N-(2-(4-morpholino)ethyl]-4-(n-pentyl)-benzenesulfonamide.
  • Part A Preparation of N-(2-Hydroxy-1R-methylethyl)-4-bromo- benzenesulfonamide.
  • Part B Preparation of N-(2-Hydroxy-1R-methylethyl)-4-(phenyl)benzenesulfonamide.
  • the organic layer was washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated to a dark oil, which contained precipitated catalyst.
  • the crude oil was purified by silical gel chromatography using ethyl acetate hexane as the eluant to yield 1.0 g of purified product.
  • Part C Preparation of N-(2-Hydroxy-1R-methylethyl)-N-methyl-4-(phenyl)benzenesulfonamide.
  • Part D Preparation of N-(2-thioacetyl-1R-methylethyl)-N-methyl-4-(phenyl)benzenesulfonamide.
  • Part E Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(phenyl)benzenesulfonamide.
  • Part A To a stirred solution (10.0 g,36.6 mmol) of N-(4-methoxybenzenesulfonyl)-D,L-alanine methyl ester in dimethylformamide in 200 mL of was added (15.17 g, 109 mmol) of powdered potassium carbonate followed by (6.2 g, 36.6 mmol) of benzyl bromide and the solution stirred for 20 hours.
  • Part B To an ice cooled, stirred solution of (8.55 g, 23.5 mmol) of N-phenylmethyl-N-4-methoxybenzene-sulfonamide-D,L-alanine methyl ester in 100 mL of anhydrous tetrahydrofuran, under nitrogen atmosphere was added (23 mL, 23 mmol) of 1M lithium aluminum hydride in diethyl ether and the solution stirred at 0 C for three hours. The solution was carefully quenched at 0 C by the addition of 2 mL of 10% sodium hydroxide dropwise followed by 2 mL of water.
  • Part C To an ice cooled solution of (1.0 g, 3 mmol) of N-phenylmethyl-N-4-methoxybenzenesulfonamide-D,L-alaninol and (860 mg, 3.3 mmol) of triphenylphosphine in 20 mL of anhydrous tetrahydrofuran was added (510 mg,3.3 mmol) of diethyldiazodicarboxylate followed by (250 mg, 3.3 mmol) of thioacetic acid and the solution stirred to room temperature for 2 hours.
  • Part D To a stirred solution of ( 730 mg, 1.8 mmol) of N-(2-thioacetyl-1R,S-methylethyl)-N-phenylmethyl-4-methoxybenzenesulfonamide benzenesulfonamide in 10 mL of methanol was added 1.5 mL of 25 wt % sodium methoxide in methanol and the solution stirred for 10 minutes. The contents were diluted with 20 mL of 1 N hydrochloric acid and extracted with ethyl acetate.
  • Part A To a stirred solution (2.03 g,4.6 mmol) of N-(4-methoxybenzenesulfonyl)-D,L-phenylalanine methyl ester in dimethylformamide in 50 mL of was added (1.8 g,13 mmol) of powdered potassium carbonate followed by (789 mg,4.6 mmol) of benzyl bromide and the solution stirred for 20 hours.
  • Part B To an ice cooled, stirred solution of (1.55 g,3.5mmol ) of N-phenylmethyl-N-4-methoxybenzene-sulfonamide-D,L-phenylalanine methyl ester in 50 mL of anhydrous tetrahydrofuran, under nitrogen atmosphere was added (4.2 mL) of 1M lithium aluminum hydride in diethyl ether and the solution stirred at 0 C for three hours. The solution was carefully quenched at 0 C by the addition of 2 mL of 10% sodium hydroxide dropwise , followed by 2 mL of water.
  • Part C To an ice cooled solution of 1.24 g, 3.0 mmol) of N-phenylmethyl-N-4-methoxybenzene-sulfonamide-D,L-phenylalaninol and ( 949 mg, 3.6 mmol) of triphenylphosphine in 20 mL of anhydrous tetrahydrofuran was added (630 mg, 3.6 mmol) of diethyldiazodicarboxylate followed by (275 mg, 3.6 mmol) of thioacetic acid and the solution stirred to room temperature for 2 hours.
  • Part D To a stirred solution of (1.10 g, 2.3 mmol) of N-(2-thioacetyl-1R,S-phenylmethyl)-N-phenylmethyl-4-methoxybenzenesulfonamide benzenesulfonamide in 10 mL of methanol was added 2.0 mL of 25 wt % sodium methoxide in methanol and the solution stirred for 10 minutes. The contents were diluted with 20 mL of 1 N hydrochloric acid and extracted with ethyl acetate.
  • Part B Preparation of 2R-(N-Fluorenylmethyloxy-carbonyl)-aminopropanethiol-S-acetate
  • Part C Preparation of 2R-(N-Fluorenylmethyloxy-carbonyl)-aminopropanethiol.
  • the resin was washed with 300 mls methanol to cap any unreacted sites, followed by 4 dimethylformamide washes, 4 methylene chloride washes and 2 additional methanol washes.
  • the recovered resin was then dried to constant weight under vacuum and loading was quanitated by 1) mass balance 2) Fmoc release and/or 3) elemental analysis. Using this protocol, the desired compound was loaded on approximately 92% of the available sites, as determined by resin manufacturer's data sheet.
  • Dried resin was washed with methylene chloride (about 250 mls) followed by dimethylformamide (about 250 mls) and the Fmoc protecting group was removed by incubation in a solution of 20% piperidine in dimethylformamide for 30-60 minutes.
  • the resin was washed with dimethylformamide, methanol, dimethylformamide. This procedure was repeated one additional cycle.
  • the final wash included a methylene chloride wash followed by methanol.
  • the resin was dried to constant weight and stored at 4 degrees. Prior to any additional chemistry, the resin was always washed with methylene chloride to ensure good swelling, followed by the solvent of choice for the desired protocol.
  • Part A To a solution of 8.38 g (35.9 mmol) of N-(2-hydroxy-1R-methylethyl)-4-fluorobenzene-sulfonamide from Example 40, part A, in 70 mL of anhydrous DMF, was added 15.38 g (111 mmol) of powdered potassium carbonate, and then 5.2 mL (5.54 g, 50.3 mmol) of thiophenol. The reaction mixture was heated to 70 C for 15 hours, cooled and ethyl acetate and water added. The organic layer was separated and washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford crude material.
  • Part B To a solution of 3.0 g (9.3 mmol) of N-(2-hydroxy-1R-methylethyl)′-4-(thiophenyl)benzene-sulfonamide from part A, in 18 mL of anhydrous DMF, was added 3.85 g (27.8 mmol) of powdered potassium carbonate, and then 2.42 g (13 mmol) of 4-(2-chloroethyl)morpholine hydrochloride. The reaction mixture was stirred for 15 hours, ethyl acetate and water added. The organic layer was separated and washed 3 ⁇ s with brine, dried with sodium sulfate, filtered and stripped to afford 4.7 g of crude material.
  • Part D To a solution of 1.4 g (2.83 mmol) of product from Part C in 10 mL of anhydrous methanol, was added 2.3 mL (10.2 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched the the addition of dry ice, followed by ethyl acetate and water, the organic layer was separated and washed with brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product.
  • Part C To a solution of 2.3 g (4.67 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 3.8 mL (16.8 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched the the addition of dry ice, followed by ethyl acetate and water, the organic layer was separated and washed with brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product.
  • Rink resin (0.88 g, 0.44 mmoles) was reacted with 5 mL of: 4 piperidine/DMF for 30 min, then washed with DMF (3 ⁇ 5 mL), MeOH (3 ⁇ 5 mL), and CH 2 Cl 2 (3 ⁇ 5 mL).
  • Part B N-(4-Butoxyphenyl)sulfonyl-L-Cys(Trt)-Rink resin.
  • Fmoc-L-Cys(Trt)-Rink resin from above 50 mg, 0.022 mmol was reacted with 1 mL of: 4 piperidine/DMF for 30 min, then washed with DMF (3 ⁇ 1 mL), MeOH (3 ⁇ 1 mL), and CH 2 Cl 2 (3 ⁇ 1 mL). Then, 0.5 mL of anhydrous CH 2 Cl 2 was added to the resin followed by 27 mg of 4-butoxyphenylsulfonyl chloride (0.11 mmol), and the reaction slurry was shaken overnight at rt (20 h).
  • the resin was then drained, washed with CH 2 Cl 2 (3 ⁇ 1 mL), MeOH (3 ⁇ 1 mL), CH 2 Cl 2 (3 ⁇ 1 mL), and Et 2 O (3 ⁇ 1 mL), and dried in vacuo to yield 105 mg brown polymeric solid.
  • N-(4-Butoxyphenyl)sulfonyl-L-Cys-NH 2 N-(4-Butoxyphenyl)sulfonyl-L-Cys-NH 2 .
  • N-(4-Butoxyphenyl)-sulfonyl-L-Cys(Trt)-Rink resin from above was reacted with 1 mL of a 5:5:95 solution of TFA/triethylsilane/CH 2 Cl 2 at rt for one hour. The resin was drained and washed with CH 2 Cl 2 (3 ⁇ 1 mL). The resin was subsequently reacted with 0.5 mL of a 80:5:15 solution of TFA/triethylsilane/CH 2 Cl 2 at rt for one hour. The resin was drained, and the filtrate collected.
  • N-(4-(4 ′-isopropoxyphenyl)benzene-sulfonyl-N-(4-(morpholinoethyl))- L-cysteine amide was prepared in a manner similar to Example 131, by substitution of the sulfonyl chloride to 4-(4-isopropoxyphenyl)phenylsulfonyl chloride prepared in an analogous manner.
  • Mass spec. m/z 508.7 (M+H)
  • Part A To a solution of 12.4 grams(5.0 mmol) of 4-(4′-bromophenyl)phenol in 50 mL of dimethylformamide was added 10.1 grams of potassium carbonate followed by 10.51 grams of iodomethane and this stirred at room temperature for 48 hours. The solution was diluted with 400 mL of water and extracted with ethyl acetate. The organics were dried over magnesium sulfate filtered and concentrated to yield 14.1 grams of crude product. Purification by recrystallization from ethyl acetate hexane gave 8.2 grams of 4-(4′-bromophenyl)anisole as a white crystalline solid.
  • Part B 5.2 grams(20 mmol) of 4-(4′-bromophenyl)-anisole was dissolved in 100 mL of anhydrous tetrahydrofuran and placed under nitrogen to cool to ⁇ 78 C. to this flask was added 8.0 mL of 2.5 molar butyl lithium over 10 minutes. In an adjacent flask was added 100 mL of anhydrous tetrahydrofuran which was cooled to ⁇ 60 C and a stream of sulfur dioxide was added through a dispersion tube while the system is under nitrogen atmosphere. After the addition of approximately 10 mL of liquid sulfur dioxide the dispersion tube was removed and the cold sulfur dioxide solution was transferred by a cannula to the stirred aryl lithium solution over five minutes.
  • Part C To a solution of 2.93 grams(8.1 mmol) of S-trityl-L-cysteine amide in 50 mL of dry methylene chloride was added 2 equivalents of triethylamine followed by 2.29 grams(8.1 mmol) of 4-(4′-methoxyphenyl)phenylsulfonyl chloride. The solution was stirred at room temperature for one hour, then concentrated on a rotory evaporator. The resulting slurry was partitioned between ethyl acetate and water. The organics were washed with 5% potassium hydrogen sulfate, saturated sodium bicarbonate, and brine, dried over sodium sulfate, filtered and concentrated to give 4.2 grams of crude product.
  • Part D To 3.36 grams(5.5 mmol) of N-(4-(4′methoxy-phenyl)-benzenesulfonyl- S-trityl-L-cysteine amide in 12 mL of dry dimethylformamide was added 1.50 grams(8.3 mmol) of 4-(2-chloroethylmorpholine)hydrochloride followed by 2.5 grams(17. mmol) of powdered potassium carbonate, and the suspension was heated to 60 C in an oil bath under nitrogen atmosphere for 5 hours. The solution is cooled to room temperature and diluted with 100 mL of ethyl acetate and washed with water.
  • Part E 2.1 grams(2.9 mmol) of N-(4-(4′methoxy-phenyl)-benzenesulfonyl-N-(4-(morpholinoethyl))-S-trityl-L-cysteine amide was dissolved in 10 mL of methylene chloride and 10 mL of triisopropylsilane was added followed by 40 mL of trifluoroacetic acid and the solution is stirred for 1.5 hours. The contents were concentrated on a rotory evaporator and the resultant material is decanted three times with 50 mL of diethyl ether.
  • Part A To a cooled (10 C) solution of 19.4 grams (250 mmol) of chlorosulfonic acid under nitrogen atmosphere was added 10 grams (50.7 mmol) of benzanalide in portions over five minutes. The black solution was heated to 60 C for one hour, then cooled to room temperature and carefully poured over ice slowly. The solid organic material was filtered and dissolved in methylene chloride, washed with water and dried over sodium sulfate. The solution was concentrated on a rotory evaporator to 8.6 grams of a tan solid.
  • Part B To a solution of 4.0 grams(11.03 mmol) of S-trityl-L-cysteine amide in 50 mL of dry methylene chloride was added 2.0 mL (14.33 mmol) of triethylamine followed by 2.93 grams (9.93 mmol) of 4-benzoylamino-benzenesulfonyl chloride. The solution was stirred at room temperature for one hour, then concentrated on a rotory evaporator. The resulting slurry was partitioned between ethyl acetate and water.
  • Part C To 3.5 grams(5.74mmol) of N-(4-benzoylamino)phenylsulfonyl-S-trityl-L-cysteine amide in 12 mL of dry dimethylformamide was added 1.60 grams(8.61 mmol) of 4-(2-chloroethylmorpholine) hydrochloride followed by 2.38 grams (17.22 mmol) of powdered potassium carbonate, and the suspension was heated to 60 C in an oil bath under nitrogen atmosphere for 5 hours. The solution is cooled to room temperature and diluted with 100 mL of ethyl acetate and washed with water.
  • Part D 3.5 grams(4.8 mmol) of N-(4-benzoylamino)phenylsulfonyl-N-(4-(morpholinoethyl))-S-trityl-L-cysteine amide was dissolved in 10 mL of methylene chloride and 10 mL of triisopropylsilane was added followed by 40 mL of trifluoroacetic acid and the solution is stirred for 1.5 hours. The contents were concentrated on a rotory evaporator and the resultant material is decanted three times with 50 mL of diethyl ether.
  • MMP-13 was expressed in baculovirus as a proenzyme, and purified first over a heparin agarose column and then over a chelating zinc chloride column.
  • the proenzyme was activated by APMA for use in the assay.
  • MMP-1 expressed in transfected HT-1080 was provided by Dr. Howard Welgus of Washington University, St. Louis, Mo. The enzyme was also activated using APMA and was then purified over a hydroxamic acid column.
  • the enzyme substrate is a methoxycoumarin-containing polypeptide having the following sequence:
  • MCA-ProLeuGlyLeuDpaAlaArgNH 2 wheein MCA is methoxycoumarin and Dpa is 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl alanine.
  • This substrate is commercially available from Baychem as product M-1895.
  • the buffer used for assays contained 100 mM Tris-HCl, 100 mM NaCl, 10 mM CaCl 2 and 0.05 percent polyethyleneglycol (23) lauryl ether at a pH value of 7.5. Assays were carried out at room temperature, and dimethyl sulfoxide (DMSO) at a final concentration of 1 percent was used to dissolve inhibitor compound.
  • DMSO dimethyl sulfoxide
  • the assayed inhibitor compound in DMSO/buffer solution was compared to an equal amount of DMSO/buffer with no inhibitor as control using microfluorTM white plates (Dynatech).
  • the inhibitor or control solution was maintained in the plate for 10 minutes and the substrate was added to provide a final concentration of 4 uM.
  • a fluorogenic peptide is cleaved at the gly-leu peptide bond, separating the highly fluorogenic peptide from a 2,4-dinitrophenyl quencher, resulting in an increase of fluorescence intensity (excitation at 328 nm/emission at 415 nm).
  • Inhibition was measured as a reduction in fluorescent intensity as a function of inhibitor concentration, using a Perkin Elmer L550 plate reader. The IC 50 values were calculated from those values. The results are set forth in the Inhibition Table below, reported in terms of IC 50 to three significant figures.
  • the study of angiogenesis depends on a reliable and reproducible model for the stimulation and inhibition of a neovascular response.
  • the corneal micropocket assay provides such a model of angiogenesis in the cornea of a mouse. See, A Model of Angiogenesis in the Mouse Cornea; Kenyon, B M, et al., Investigative Ophthalmology & Visual Science, July 1996, Vol. 37, No. 8
  • the corneal pocket was made by anesthetizing a 7 week old C57B1/6 female mouse, then proptosing the eye with a jeweler's forceps. Using a dissecting microscope, a central, intrastromal linear keratotomy of approximately 0.6 mm in length was performed with a #15 surgical blade, parallel to the insertion of the lateral rectus muscle. Using a modified cataract knife, a lamellar micropocket was dissected toward the temporal limbus. The pocket was extended to within 1.0 mm of the temporal-limbus. A single pellet was placed on the corneal surface at the base of the pocket with a jeweler's forceps. The pellet was then advanced to the temporal end of the pocket. Antibiotic ointment was then applied to the eye.
  • mice were dosed on a daily basis for the duration of the assay. Dosing of the animals was based on bioavailability and overall potency of the compound. In the case of the compound of Example 218, dosing was 50 mg/kg bid, po. Neovascularization of the corneal stroma began at about day three and was permitted to continue under the influence of the assayed compound until day five. At day five, the degree of angiogenic inhibition was scored by viewing the neovascular progression with a slit lamp microscope.
  • mice were anesthetized and the studied eye was once again proptosed.
  • the maximum vessel length of neovascularization, extending from the limbal vascular plexus toward the pellet was measured.
  • the contiguous circumferential zone of neovascularization was measured as clock hours, where 30 degrees of arc equals 1 clock hour.
  • the studied mice were thereafter compared to control mice and the difference in the area of neovascularization was recorded.
  • the compound of Example 218 exhibited 37 percent inhibition, whereas the vehicle control exhibited zero percent inhibition.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to proteinase (protease) inhibitors, and more particularly to thiol sulfonamide inhibitors for matrix metalloproteinase 13(MMP-13), compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the preparation of proteinase inhibitors and processes for treating pathological conditions associated with pathological matrix metalloproteinase activity related to MMP-13.

Description

    TECHNICAL FIELD
  • This invention is directed to proteinase (protease) inhibitors, and more particularly to thiol sulfonamide inhibitors for matrix metalloproteinases, compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the preparation of proteinase inhibitors and processes for treating pathological conditions associated with pathological matrix metalloproteinase activity.
  • BACKGROUND OF THE INVENTION
  • Connective tissue, extracellular matrix constituents and basement membranes are required components of all mammals. These components are the biological materials that provide rigidity, differentiation, attachments and, in some cases, elasticity to biological systems including human beings and other mammals. Connective tissues components include, for example, collagen, elastin, proteoglycans, fibronectin and laminin. These biochemicals makeup, or are components of structures, such as skin, bone, teeth, tendon, cartilage, basement membrane, blood vessels, cornea and vitreous humor.
  • Under normal conditions, connective tissue turnover and/or repair processes are controlled and in equilibrium. The loss of this balance for whatever reason leads to a number of disease states. Inhibition of the enzymes responsible loss of equilibrium provides a control mechanism for this tissue decomposition and, therefore, a treatment for these diseases.
  • Degradation of connective tissue or connective tissue components is carried out by the action of proteinase enzymes released from resident tissue cells and/or invading inflammatory or tumor cells. A major class of enzymes involved in this function are the zinc metalloproteinases (metalloproteases).
  • The metalloprotease enzymes are divided into classes with some members having several different names in common use. Examples are: collagenase I (MMP-1, fibroblast collagenase; EC 3.4.24.3); collagenase II (MMP-8, neutrophil collagenase; EC 3.4.24.34), collagenase III (MMP-13), stromelysin 1 (MMP-3; EC 3.4.24.17), stromelysin 2 (MMP-10; EC 3.4.24.22), proteoglycanase, matrilysin (MMP-7), gelatinase A (MMP-2, 72 kDa gelatinase, basement membrane collagenase; EC 3.4.24.24), gelatinase B (MMP-9, 92 kDa gelatinase; EC 3.4.24.35), stromelysin 3 (MMP-11), metalloelastase (MMP-12, HME, human macrophage elastase) and membrane MMP (MMP-14). MMP is an abbreviation or acronym representing the term Matrix Metalloprotease with the attached numerals providing differentiation between specific members of the MMP group.
  • The uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions. Examples include rheumatoid arthritis, osteoarthritis, septic arthritis; corneal, epidermal or gastric ulceration; tumor metastasis, invasion or angiogenesis; periodontal disease; proteinuria; Alzheimers Disease; coronary thrombosis and bone disease. Defective injury repair processes also occur. This can produce improper wound healing leading to weak repairs, adhesions and scarring. These latter defects can lead to disfigurement and/or permanent disabilities as with post-surgical adhesions.
  • Matrix metalloproteases are also involved in the biosynthesis of tumor necrosis factor (TNF), and inhibition of the production or action of TNF and related compounds is an important clinical disease treatment mechanism. TNF-α, for example, is a cytokine that at present is thought to be produced initially as a 28 kD cell-associated molecule. It is released as an active, 17 kD form that can mediate a large number of deleterious effects in vitro and in vivo. For example, TNF can cause and/or contribute to the effects of inflammation, rheumatoid arthritis, autoimmune disease, multiple sclerosis, graft rejection, fibrotic disease, cancer, infectious diseases, malaria, mycobacterial infection, meningitis, fever, psoriasis, cardiovascular/pulmonary effects such as post-ischemic reperfusion injury, congestive heart failure, hemorrhage, coagulation, hyperoxic alveolar injury, radiation damage and acute phase responses like those seen with infections and sepsis and during shock such as septic shock and hemodynamic shock. Chronic release of active TNF can cause cachexia and anorexia. TNF can be lethal.
  • TNF-α convertase is a metalloproteinase involved in the formation of active TNF-α. Inhibition of TNF-α convertase inhibits production of active TNF-α. Compounds that inhibit both MMPs activity have been disclosed in WIPO International Publication Nos. WO 94/24140, WO 94/02466 and WO 97/20824. There remains a need for effective MMP and TNF-α convertase inhibiting agents. Compounds that inhibit MMPs such as collagenase, stromelysin and gelatinase have been shown to inhibit the release of TNF (Gearing et al. Nature 376, 555-557 (1994), McGeehan et al., Nature 376, 558-561 (1994)).
  • MMPs are involved in other biochemical processes in mammals as well. Included is the control of ovulation, post-partum uterine involution, possibly implantation, cleavage of APP (β-Amyloid Precursor Protein) to the amyloid plaque and inactivation of α1-protease inhibitor (α1-PI). Inhibition of these metalloproteases permits the control of fertility and the treatment or prevention of Alzheimers Disease. In addition, increasing and maintaining the levels of an endogenous or administered serine protease inhibitor drug or biochemical such as α1-PI supports the treatment and prevention of diseases such as emphysema, pulmonary diseases, inflammatory diseases and diseases of aging such as loss of skin or organ stretch and resiliency.
  • Inhibition of selected MMPs can also be desirable in other instances. Treatment of cancer and/or inhibition of metastasis and/or inhibition of angiogenesis are examples of approaches to the treatment of diseases wherein the selective inhibition of stromelysin, gelatinase, or collagenase III are the relatively most important enzyme or enzymes to inhibit especially when compared with collagenase I (MMP-1). A drug that does not inhibit collagenase I can have a superior therapeutic profile. Osteoarthritis, another prevalent disease wherein it is believed that cartilage degradation in inflamed joints is at least partially caused by MMP-13 released from cells such as stimulated chrondrocytes, may be best treated by administration of drugs one of whose modes of action is inhibition of MMP-13. See, for example, Mitchell et al., J. Clin. Invest., 97:761-768 (1996) and Reboul et al., J. Clin. Invest., 97:2011-2019 (1996).
  • Inhibitors of metalloproteases are known. Examples include natural biochemicals such as tissue inhibitor of metalloproteinase (TIMP), α2-macroglobulin and their analogs or derivatives. These are high molecular weight protein molecules that form inactive complexes with metalloproteases. A number of smaller peptide-like compounds that inhibit metalloproteases have been described. Mercaptoamide peptidyl derivatives have shown ACE inhibition in vitro and in vivo. Angiotensin converting enzyme (ACE) aids in the production of angiotensin II, a potent pressor substance in mammals and inhibition of this enzyme leads to the lowering of blood pressure. Thiol group-containing amide or peptidyl amide-based metalloprotease (MMP) inhibitors are known as is shown in, for example, WO95/12389, WO96/11209 and U.S. Pat. No. 4,595,700.
  • It is recognized that a compound that inhibits a known member of the MMP group of enzymes can inhibit members in that group and also new, yet to be discovered, enzymes. Therefore, the skilled person will presume that the novel inhibitors of this invention can be useful in the treatment of the diseases in which known and new MMP enzymes are implicated.
  • SUMMARY OF THE INVENTION
  • The present invention is directed to a process for treating a mammal having a condition associated with pathological matrix metalloprotease (MMP) activity, as well as to molecules that particularly inhibit the activity of MMP-13.
  • Briefly, therefore, one embodiment of the present invention is directed to a process for treating a mammal having a condition associated with pathological matrix metalloprotease activity that comprises administering a metalloprotease inhibitor in an effective amount to a host having such a condition. The administered enzyme inhibitor corresponds in structure to one of formulae (I), (II) or (III), below
    Figure US20050014840A1-20050120-C00001

    where x represents 0, 1 or 2, and W is oxygen or sulfur.
  • A contemplated R9 group is an alkyl, aryl, alkoxy, cycloalkyl, aryloxy, aralkoxy, aralkyl, aminoalkyl, heteroaryl and N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxycarbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclic or heteroaryl ring.
  • A contemplated R1 group is linked to the SO2 portion of an inhibitor and is an alkyl, cycloalkyl, heterocycloalkyl, aralkanoylalkyl, arylcarbonylalkyl, hydroxyalkyl, alkanoylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, haloalkyl, alkylthioaryl, arylthioalkyl, alkylthioaralkyl, aralkylthioalkyl, or aralkylthioaryl group, the sulfoxide or sulfone of any of those thio substituents, alkylthioalkyl, and preferably aryl and heterocyclic (heteroaryl) rings such as aralkyl, heteroaralkyl, aralkoxyalkyl, aryloxyalkyl, as well as a fused ring structure comprising two or three 5- or 6-membered aryl rings that can be carbocyclic or heterocyclic rings. The aryl (carbocyclic) and heteroaryl substituents of R1 are themselves unsubstituted or substituted with one or two substituents independently selected from among halo, C1-C10 alkyl, C1-C10 alkoxy, nitro, cyano, perfluoroalkyl, trifluoromethylalkyl, hydroxy, thiol, hydroxycarbonyl, aryloxy, arylthio, arylamino, aralkyl, arylcarboxamido, heteroarylcarboxamido, azoaryl, azoheteroaryl, aryl, heteroaryloxy, heteroarylthio, heteroarylamino, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy, cycloalkylthio, cycloalkylamino, heteroaralkoxy, heteroaralkylthio, heteroaralkylamino, aralkoxy, aralkylthio, aralkylamino, heterocyclic, heteroaryl, arylazo, hydroxycarbonylalkoxy, alkoxycarbonylalkoxy, alkanoyl, arylcarbonyl, aralkanoyl, alkanoyloxy, aralkanoyloxy, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkoxyalkylthio, alkoxycarbonyl, aryloxyalkoxyaryl, arylthioalkylthioaryl, aryloxyalkylthioaryl, arylthioalkoxyaryl, hydroxycarbonylalkoxy, hydroxycarbonylalkylthio, alkoxycarbonylalkoxy, alkoxycarbonylalkylthio, amino, alkanoylamino, arylcarbonylamino, aralkanoylamino, heteroarylcarbonylamino, heteroaralkanoylamino, and N-monosubstituted or N,N-disubstituted aminoalkyl wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxycarbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto together form a 5- to 8-membered heterocyclo or heteroaryl ring.
  • A contemplated R2 substituent can be hydrogen (hydrido), an alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkynylalkyl, alkenylalkyl, thioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, aralkoxyalkyl, aminoalkyl, alkoxyalkoxyalkyl, aryloxyalkyl, hydroxyalkyl, hydroxycarbonylalkyl, hydroxycarbonylaralkyl, or N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein R2 and the nitrogen to which it is bonded and another substituent (i.e., R2 and R4, or R2 and R6 or R2 and R8) together form a 4- to 8-membered heterocyclo or heteroaryl ring.
  • Contemplated R3 and R4 groups are independently selected. Those substituents can be hydrogen (hydrido), an alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, hydroxycarbonyl, alkoxycarbonyl, perfluoroalkyl, trifluoromethylalkyl, thioalkyl, alkylthioalkyl, arylthioalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, or a sulfoxide or sulfone of any of the thio substituents, aminocarbonyl, aminocarbonylalkyl, N-monosubstituted or N,N-disubstituted aminocarbonyl or aminocarbonylalkyl group wherein the substituent(s) on the nitrogen are independently selected from among alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein the nitrogen and two substituents attached thereto together form a 5- to 8-membered heterocyclo or heteroaryl ring that can contain one additional heteroatom, or R2 and R4 together with the atoms to which they are attached form a 4- to 8-membered ring (as above), or R3 and R4 together with the atom to which they are attached form a 3- to 8-membered ring or R4 and R8 together with the atoms to which they are attached form a 5- to 8-membered ring.
  • R5 and R6 substituents are also independently selected. R5 and R6 substituents can be a substituent that constitutes R3 and R4, or R6 and R4 together with atoms to which they are attached form a 4- to 8-membered ring, or R6 and R2 together with the atoms to which they are attached form a 5- to 8-membered ring (as above), or R6 and R8 together with the atoms to which they are attached form a 4- to 8-membered ring, or R5 and R6 together with atom to which they are attached form a 3- to 8-membered ring.
  • Contemplated R7 and R8 substituents are also independently selected. R7 and R8 substituents can also be a substituent that constitutes R3 and R4, or R8 and R2 together with the atoms to which they are attached form a 6- to 8-membered ring (as above), or R7 and R8 together with the atom to which they are attached form a 3- to 8-membered ring, or R8 and R4 together with the atom to which they are attached form a 5- to 8-membered ring (as above), or R8 and R6 together with the atoms to which they are attached form a 4- to 8-membered ring (as above).
  • A provision to the above definitions is that no carbon atom is geminally substituted with more than one sulfhydryl group. Additionally, a starred substituent “R” groups and “x” of formula III are the same as or different from the unstarred “R” groups and “x”.
  • The present invention is also directed to a more preferred sub-set of molecules of formulas I, II, and III, above. Here, x is zero so that the mercapto group is bonded directly to the carbon atom that bears the R5 and R6 substituent radicals, which are themselves both hydrido, as is R3. Here, also, R2 is other than hydrogen (hydrido) unless R1 is phenylazophenyl, R1 is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group containing one 5- or 6-membered ring; i.e. R1 is not a fused aryl ring or heteroaryl group, and a compound of formula III is a homodimer. These preferred compounds are depicted by formulas Ia, IIa, and IIIa, below, and the substituent “R” groups and W are as otherwise defined before.
    Figure US20050014840A1-20050120-C00002
  • In most preferred practice, a contemplated inhibitor compound constitutes another sub-set of the compounds of formulas I, II and III. Here, R3, R5 and R6 are again hydrido, the SO2-linked R1 substituent is a 4-substituted phenyl group (PhR11), and W is O. These most preferred compounds are depicted by formulas Ib, IIb and IIIb, below. Specifics of the depicted “R” groups are discussed hereinafter.
    Figure US20050014840A1-20050120-C00003
  • Yet another aspect of the invention is directed to a matrix metalloprotease inhibitor corresponding to formula IV, below,
    Figure US20050014840A1-20050120-C00004

    where R10 is hydrogen (hydrido) or —C(O)—R9, and R1, R2, R3, R4, R5, R6, R9 and x are as defined above, and Y represents hydrogen, halogen, alkyl, alkoxy, nitro, cyano, carboxy or amino.
  • Among the several benefits and advantages of the present invention are the provision of compounds and compositions effective as inhibitors of matrix metalloproteinase activity, the provision of such compounds and compositions that are effective for the inhibition of metalloproteinases implicated in diseases and disorders involving uncontrolled breakdown of connective tissue.
  • More particularly, a benefit of this invention is the provision of a compound and composition effective for inhibiting metalloproteinases, particularly MMP-13, associated with pathological conditions such as, for example, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal, epidermal or gastric ulceration, tumor metastasis, invasion or angiogenesis, periodontal disease, proteinuria, Alzheimer's Disease, coronary thrombosis and bone disease.
  • An advantage of the invention is the provision of a method for preparing such compositions. Another benefit is the provision of a method for treating a pathological condition associated with abnormal matrix metalloproteinase activity.
  • Another advantage is the provision of compounds, compositions and methods effective for treating such pathological conditions by selective inhibition of a metalloproteinase, MMP-13, associated with such conditions with minimal side effects resulting from inhibition of other proteinases whose activity is necessary or desirable for normal body function.
  • Still further benefits and advantages of the invention will be apparent to the skilled worker from the disclosure that follows.
  • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • In accordance with the present invention, it has been discovered that certain thiol sulfonamides are effective for inhibition of matrix metalloproteinases (“MMPs”) believed to be associated with uncontrolled or otherwise pathological breakdown of connective tissue. In particular, it has been found that these certain thiol sulfonamides are effective for inhibition of collagenase III (MMP-13), which can be particularly destructive to tissue if present or generated in abnormal quantities or concentrations, and thus exhibit a pathological activity.
  • Moreover, it has been discovered that many of these thiol sulfonamides are selective in the inhibition of MMP-13, as well as other MMPs associated with diseased conditions without excessive inhibition of other collagenases essential to normal bodily function such as tissue turnover and repair. More particularly, it has been found that particularly preferred the thiol sulfonamides of the invention are particularly active in inhibiting of MMP-13, while being selective for MMP-13, in having a limited or minimal effect on MMP-1. This point is discussed in detail hereinafter and is illustrated in several examples.
  • One embodiment of the present invention is directed to a process for treating a mammal having a condition associated with pathological matrix metalloprotease activity. That process comprises administering a metalloprotease inhibitor in an effective amount to a host having such a condition. The administered enzyme inhibitor corresponds in structure to one of formulas (I), (II) or (III), below
    Figure US20050014840A1-20050120-C00005

    where x represents 0, 1 or 2, and W is oxygen or sulfur.
  • A contemplated R9 group is an alkyl, aryl, alkoxy, cycloalkyl, aryloxy, aralkoxy, aralkyl, aminoalkyl, heteroaryl and N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxycarbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclo or heteroaryl ring;
  • A contemplated R1 group is linked to the SO2 portion of an inhibitor and is an alkyl, cycloalkyl, heterocycloalkyl, aralkanoylalkyl, arylcarbonylalkyl, hydroxyalkyl, alkanoylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, haloalkyl, alkylthioaryl, arylthioalkyl, alkylthioaralkyl, aralkylthioalkyl, or aralkylthioaryl group, the sulfoxide or sulfone of any of those thio substituents, alkylthioalkyl, and preferably aryl (carbocyclicaryl) and heteroaryl rings such as aralkyl, heteroaralkyl, aralkoxyalkyl, aryloxyalkyl, as well as a fused ring structure comprising two or three 5- or 6-membered aryl rings that can be carbocyclic or heterocyclic rings. The aryl and heteroaryl substituents of which R1 can be comprised are unsubstituted or preferably substituted with one (preferably) or two substituents independently selected from among halo, C1-C10 alkyl, C1-C10 alkoxy, nitro, cyano, perfluoroalkyl, trifluoromethylalkyl, hydroxy, thiol, hydroxycarbonyl, aryloxy, arylthio, arylamino, aralkyl, arylcarboxamido, heteroarylcarboxamido, azoaryl, azoheteroaryl, aryl, heteroaryloxy, heteroarylthio, heteroarylamino, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy, cycloalkylthio, cycloalkylamino, heteroaralkoxy, heteroaralkylthio, heteroaralkylamino, aralkoxy, aralkylthio, aralkylamino, heterocyclic, heteroaryl, arylazo, hydroxycarbonylalkoxy, alkoxycarbonylalkoxy, alkanoyl, arylcarbonyl, aralkanoyl, alkanoyloxy, aralkanoyloxy, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkoxyalkylthio, alkoxycarbonyl, aryloxyalkoxyaryl, arylthioalkylthioaryl, aryloxyalkylthioaryl, arylthioalkoxyaryl, hydroxycarbonylalkoxy, hydroxycarbonylalkylthio, alkoxycarbonylalkoxy, alkoxycarbonylalkylthio, amino, alkanoylamino, arylcarbonylamino, aralkanoylamino, heteroarylcarbonylamino, heteroaralkanoylamino, and N-monosubstituted or N,N-disubstituted aminoalkyl wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxycarbonyl, and alkanoyl, or wherein the nitrogen and two substituents attached thereto together form a 5- to 8-membered heterocyclo or heteroaryl ring.
  • A contemplated R2 substituent can be hydrogen (hydrido), an alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkynylalkyl, alkenylalkyl, thioalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, aralkoxyalkyl, aminoalkyl, alkoxyalkoxyalkyl, aryloxyalkyl, hydroxyalkyl, hydroxycarbonylalkyl, hydroxycarbonylaralkyl, or N-monosubstituted or N,N-disubstituted aminoalkyl group wherein the substituent(s) on the nitrogen are selected from the group consisting of alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein R2 and the nitrogen to which it is bonded and another substituent (i.e., R2 and R4, or R2 and R6, or R2 and R8) together form a 4- to 8-membered heterocyclo or heteroaryl ring.
  • Contemplated R3 and R4 groups are independently selected. Those substituents can be hydrogen (hydrido), an alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, aryloxyalkyl, aralkoxyalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, hydroxycarbonyl, alkoxycarbonyl, perfluoroalkyl, trifluoromethylalkyl, thioalkyl, alkylthioalkyl, arylthioalkyl, aralkylthioalkyl, heteroaralkyl-thioalkyl, or a sulfoxide or sulfone of any of the thio substituents, aminocarbonyl, aminocarbonylalkyl, N-monosubstituted or N,N-disubstituted aminocarbonyl or aminocarbonylalkyl group wherein the substituent(s) on the nitrogen are independently selected from among alkyl, aralkyl, cycloalkyl and alkanoyl, or wherein the nitrogen and two substituents attached thereto together form a 5- to 8-membered heterocyclo or heteroaryl ring that can contain one additional heteroatom, or R2 and R4 together with the atoms to which they are attached form a 4- to 8-membered ring (as above), or R3 and R4 together with the atom to which they are attached form a 3- to 8-membered ring, or R4 and R6 together with the atoms to which they are attached form a 4- to 8-membered ring, or R4 and R8 together with the atoms to which they are attached form a 5- to 8-membered ring.
  • R5 and R6 substituents are also independently selected. R5 and R6 substituents can be a substituent that constitutes R3 and R4. Alternatively, R6 and R4 together with atoms to which they are attached form a 4- to 8-membered ring, or R6 and R2 together with the atoms to which they are attached form a 5- to 8-membered ring (as above), or R6 and R8 together with the atoms to which they are attached form a 4- to 8-membered ring, or R5 and R6 together with atom to which they are attached form a 3- to 8-membered ring;
  • Contemplated R7 and R8 substituents are also independently selected. R7 and R8 substituents can also be a substituent that constitutes R3 and R4. Alternatively, R8 and R2 together with the atoms to which they are attached form a 6- to 8-membered ring (as above), or R7 and R8 together with the atom to which they are attached form a 3- to 8-membered ring, or R8 and R4 together with the atom to which they are attached form a 5- to 8-membered ring (as above), or R8 and R6 together with the atoms to which they are attached form a 4- to 8-membered ring (as above).
  • A provision to the above definitions is provided that no carbon atom is geminally substituted with more than one sulfhydryl group. In addition, starred substituent “R” groups and “x” of formula III are the same as or different from the unstarred “R” groups and “x”.
  • In generally increasing order of preference, the following paragraphs summarize the substituents which may most advantageously constitute each of R1 through R10, as well as W and x.
  • R1 represents an aryl or heteroaryl ring C1-C10 alkyl, wherein the aryl or heteroaryl ring can optionally be substituted by one or more of the following substituents: C1-C10 alkyl, C1-C10 alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C1-C10 alkylthio, arylthio, heteroarylthio.
  • R1 represents a single aryl or heteroaryl ring, wherein the single aryl or heteroaryl ring can optionally be substituted by one or more of the following substituents: C1-C6 alkyl, C1-C6 alkoxy, arylcarboxamido, heteroarylcarboxamido,arylazo, heteroarylazo, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C1-C6 alkylthio, arylthio, heteroarylthio in which each ring-containing substituent itself contains a single ring.
  • R1 represents a 6-membered aryl ring, wherein the aryl ring can optionally be substituted in the para-position (4-position) by one of the following substituents: C1-C6 alkyl, C1-C6 alkoxy, arylcarboxamido, heteroarylcarboxamido, arylazo, heteroarylazo, aryloxy, heteroaryloxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C1-C6 alkylthio, arylthio, heteroarylthio in which each ring-containing substituent itself contains a single ring.
  • R1 represents a 6-membered aryl ring, wherein the aryl-ring is substituted in the para-position by C1-C6 alkyl, C1-C6 alkoxy arylcarboxamido, arylazo, aryloxy, arylthio and aryl in which each ring-containing substituent itself contains a single ring.
  • R1 represents phenyl, wherein the phenyl ring is substituted in the para-position by n-propyl, n-butyl, n-pentyl, n-hexyl, isobutyl, isoamyl, ethoxy, n-propyloxy, n-butoxy, n-pentyloxy, n-hexyloxy, isobutoxy, phenoxy, thiophenoxy (phenylthio), phenyl, azophenyl or benzamido, in which the para-substituted R1 phenyl substituent can itself optionally contain a meta- or para-substituent, or both containing one atom or a chain of no more than five atoms other than hydrogen.
  • R2 Preferences:
  • R2 represents hydrogen, C1-C6 alkyl, aralkyl, heteroaralkyl, cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms can be nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons, C1-C5 alkyl substituted by hydroxycarbonyl, amino, mono-substituted amino and di-substituted amino, wherein the substituents on nitrogen are chosen from C1-C4 alkyl, aralkyl, C5-C8 cycloalkyl and C1-C6 alkanoyl groups, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.
  • R2 represents hydrogen, C1-C6 alkyl, aralkyl, heteroaralkyl, cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms can be nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons.
  • R2 represents hydrogen or C1-C6 alkyl.
  • R2 represents hydrogen, methyl, ethyl, n-propyl, n-butyl, isobutyl.
  • R2 represents carbocyclic aralkyl or heteroaralkyl as discussed above.
  • R2 represents benzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-thiazolylmethyl, 4-thiazolylmethyl, 5-thiazolylmethyl.
  • R2 represents cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain, heterocycloalkylalkyl in which 4-8 atoms are in the ring, one or two of which atoms can be nitrogen, oxygen or sulfur and in which the alkyl chain contains 1-3 carbons.
  • R2 represents cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl.
  • R2 represents alkyl substituted by hydroxycarbonyl, amino, mono-substituted amino and di-substituted amino, wherein the substituents on the amino nitrogen are chosen from C1-C6 alkyl, aralkyl, C5-C8 cycloalkyl and C1-C6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur.
  • R2 represents Cl-C5 alkyl substituted by hydroxycarbonyl.
  • R2 represents 5-pentanoic acid, 4-n-butanoic acid, 3-propanoic acid or 2-ethanoic acid.
  • R2 represents hydrido, C1-C6 alkyl, C2-C4 alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituents on nitrogen are chosen from C1-C6 alkyl, aralkyl, C5-C8 cycloalkyl and C1-C6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur, a C1-C4 alkylaryl or C1-C4 alkylheteroaryl group having a single ring.
  • R2 represents methyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, N,N-dimethyl-2-aminoethyl, 2-(4-morpholino)ethyl, 2-(1-piperidino)ethyl, 2-(1-pyrrolidino)ethyl.
  • R3 and R4 Preferences:
  • R3 and R4 independently represent hydrogen, hydroxycarbonyl, aminocarbonyl, C1-C6 alkyl, aralkyl, aryl, heteroaryl, C5-C8 cycloalkyl, heteroaralkyl, cycloalkylalkyl having 4-8 carbons in the ring and 1-3 carbons in the alkyl chain.
  • R3 is hydrido, and R4 is hydroxycarbonyl, aminocarbonyl or C1-C6 alkyl.
  • R3 and R4 independently represents hydrogen, aminocarbonyl, methyl.
  • R3 is hydrido and R4 represents methyl.
  • R3 is hydrido and R4 represents hydroxycarbonyl or aminocarbonyl.
  • R3 represents hydrido and R4 represents aminocarbonyl (carbamyl) or methyl.
  • R5 and R6 Preferences:
  • R5 and R6 independently represent hydrogen (hydrido), hydroxycarbonyl, aryl, heteroaryl, C1-C6 alkyl.
  • R5 and R6 are both hydrido.
  • R7 and R8 Preferences:
  • R7 and R8 independently represent hydrogen, hydroxycarbonyl, C1-C6 alkyl.
  • x Preferences:
  • x is preferably zero.
  • W is preferably oxygen (O).
  • R9 Preferences:
  • R9 represents C1-C6 alkyl, aryl, C1-C6 alkoxy, heteroaryl, amino C1-C6 alkyl, N-monosubstituted amino C1-C6 alkyl and N,N-disubstituted amino C1-C6 alkyl, wherein the substituents on nitrogen are chosen from C1-C6 alkyl, aralkyl, C5-C8 cycloalkyl and C1-C6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.
  • R9 represents C1-C6 alkyl, C5-C8 cycloalkyl, aryl, C1-C6 alkoxy, heteroaryl, amino C1-C6 alkyl, N-monosubstituted amino C1-C6 alkyl and N,N-disubstituted amino C1-C6 alkyl, wherein the substituents on nitrogen are chosen from C1-C6 alkyl, aralkyl, C5-C8 cycloalkyl and C1-C6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring.
  • R9 represents C1-C6 alkyl, C1-C6 alkoxy, a single-ringed aryl or heteroaryl.
  • R9 represents methyl, ethyl, n-propyl, n-butyl, isopropyl, isobutyl
  • R9 represents a 3- to 8-membered cycloalkyl ring.
  • R9 represents cyclohexyl and cyclopentyl.
  • R9 represents aryl or heteroaryl.
  • R9 represents phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl.
  • R9 represents C1-C6 alkoxy.
  • R9 represents methoxy and ethoxy.
  • Starred substituents, R*, and x* are preferably the same as unstarred substituents, R, and x so that a compound of formula III is homodimer.
  • In particularly preferred practice, an SO2-linked R1 substituent is an aryl or heteroaryl group that is a 5- or 6-membered single-ring, and is itself substituted with one other single-ringed aryl or heteroaryl group or, with an alkyl or alkoxy group containing an umbranched chain of 3 to about 7 carbon atoms, a phenoxy group, a thiophenoxy [C6H5—S—] group, a phenylazido [C6H5—N2—] group or a benzamido [—NHC(O)C6H5] group. The SO2-linked single-ringed aryl or heteroaryl R1 group is substituted at its own 4-position when a 6-membered ring and at its own 3-position when a 5-membered ring.
  • The R1 group's substituent single-ringed aryl or heteroaryl, phenoxy, thiophenoxy, phenylazo or benzamido group is unsubstituted or can itself be substituted at the 4-position when a 6-membered ring or the 3-position when a 5-membered ring. The 4- and 3-positions of rings discussed here are numbered from the sites of substituent bonding as compared to formalized ring numbering positions used in heteroaryl nomenclature. Here, single atoms such as halogen moieties or substituents that contain one to a chain of about five atoms other than hydrogen such as C1-C4 alkyl, C1-C4 alkoxy or carboxyethyl groups can be used. Exemplary substituted SO2-linked R1 substituents include biphenyl, 4-phenoxyphenyl, 4-thiophenoxyphenyl, 4-butoxyphenyl, 4-pentylphenyl, 4-(4′-dimethylaminophenyl)azophenyl, and 2-[(2-pyridyl)-5-thienyl].
  • When examined along its longest chain of atoms, an R1 substituent including its own substituent has a total length of greater than a saturated chain of four carbon atoms and less than a saturated chain of about 18 and preferably about 12 carbon atoms, even though many more atoms may be present in ring structures or substituents. This length requirement is discussed further below.
  • Looked at more generally, and aside from specific moieties from which it is constructed, a particularly preferred R1 radical (group or moiety) has a length greater than that of an butyl group. Such an R1 radical also has a length that is less than that of a stearyl (octadecyl) group. That is to say that a particularly preferred R1 is a radical having a length greater than that of a saturated four carbon chain, and shorter than that of a saturated eighteen carbon chain, and more preferably, a length greater than that of a pentyl group and less than that of a lauryl group.
  • The radical chain lengths are measured along the longest linear atom chain in the radical, and each atom in the chain, e.g. oxygen or nitrogen, is presumed to be carbon for ease in calculation. Such lengths can be readily determined by using published bond angles, bond lengths and atomic radii, as needed, to draw and measure a staggered chain, or by building models using commercially available kits whose bond angles, lengths and atomic radii are in accord with accepted, published values. Radical lengths can also be determined somewhat less exactly by assuming that all atoms have bond lengths saturated carbon, that unsaturated bonds have the same lengths as saturated bonds and that bond angles for unsaturated bonds are the same as those for saturated bonds, although the above-mentioned modes of measurement are preferred.
  • In addition, a particularly preferred R1 group when rotated about an axis drawn through the SO2-bonded 1-position and the 4-position of a 6-membered ring or the SO2-bonded position and substituent-bonded 3- or 5-position of a 5-membered ring defines a three-dimensional volume whose widest dimension has the width of about one phenyl ring to about three phenyl rings in a direction transverse to that axis to rotation.
  • As a consequence of these length and width requirements, R1 substituents such as 4-(phenyl)phenyl[biphenyl], 4-(4′-methoxyphenyl)phenyl, 4-(phenoxy)phenyl, 4-(thiophenyl)phenyl[4-(phenylthio)phenyl], 4-(azophenyl)phenyl and 4-(benzamido)phenyl are particularly preferred R1 substituents.
  • One sub-set of particularly preferred MMP-13 inhibitor compounds useful in a before-described process has structures depicted by formulas Ia, IIa and IIIa, below.
    Figure US20050014840A1-20050120-C00006
  • In a particularly preferred compound of the above structural formulas, the configuration about the
  • R4-containing carbon atom is that of a naturally-occurring amino acid. The substituent groups are discussed below for these compounds.
  • An R1 group represents a single aryl or heteroaryl ring, wherein the single aryl ring is unsubstituted or can optionally be substituted by one or more of the following substituents: C1-C6 alkyl, C1-C6 alkoxy, aryloxy, heteroaryloxy, aryl, heteroaryl, aralkoxy, heteroaralkoxy, C1-C6 alkylthio, arylthio, heteroarylthio in which each ring-containing substituent itself contains a single ring.
  • A single-ringed aryl or heteroaryl group is 5- or 6-membered, and is itself preferably substituted at its own 4-position when a 6-membered ring and at its own 3-position when a 5-membered ring with a substituent selected from the group consisting of one other single-ringed aryl or hetroaryl group, an alkyl or alkoxy group containing an umbranched chain of 3 to about 7 carbon atoms, a phenoxy group, a thiophenoxy group, a phenylazo group or a benzamido group.
  • R2 represents hydrido, C1-C6 alkyl, C2-C4 alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituents on nitrogen are chosen from C1-C6 alkyl, aralkyl, C5-C8 cycloalkyl and C1-C6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur, a C1-C4 alkylaryl or C1-C4 alkylheteroaryl group having a single ring.
  • An R4 group is hydroxyxcarbonyl, aminocarbonyl or C1-C6 alkyl.
  • W is sulfur or oxygen, but preferably oxygen (O).
  • An R9 group represents a C1-C6 alkyl group, C1-C6 alkoxy group, or a single-ringed carbocyclic aryl or heteroaryl group.
  • A most preferred MMP-13 inhibitor sub-set of compounds useful in a before-described process also preferably has the configuration of a naturally-occurring amino acid, and corresponds to the structures depicted by formulas Ib, IIb and IIIb, below.
    Figure US20050014840A1-20050120-C00007
  • The substituents of these most preferred MMP-13 inhibitor compounds are as follows:
  • An R4 group is C1-C6 alkyl, and particularly methyl, or aminocarbonyl [—C(O)NH2].
  • An R2 group is C1-C6 alkyl and particularly methyl, a C2-C3 alkyl cycloamino group having five or six atoms in the ring and zero or one additional heteroatom that is oxygen or nitrogen, and C1-C4 alkyl single-ringed aryl or heteroaryl, wherein the single heteroaryl ring contains one or two nitrogen atoms. Exemplary most preferred substituents in addition to methyl include 2-(4-morpholino)ethyl, 2-(1-piperidino)ethyl, 2-(1-pyrrolidino)ethyl and (3-pyridyl)methyl. Hydrogen (hydrido) can also be a most preferred R2 group as is discussed below.
  • The sulfonyl group (—SO2—) of a most preferred sub-set of inhibitor compounds is linked to a phenyl group (Ph), which itself is substituted at the 4-position by a substituent denominated R11 that together with the phenyl group is referred to as PhR11. A 4-substituted phenyl group substituent, R11, can be C3-C8 alkoxy such as butoxy, C3-C8 alkyl such as pentyl, as well as phenoxy, thiophenoxy (phenylthio), benzamido, phenylazo or phenyl.
  • An R11 6-membered ring-containing substituent group can itself also be substituted in a 3-(meta) or 4-(para-) position, or both, with a halogen (fluorine, chlorine, bromine or iodine), a C1-C4 alkoxy group such as methoxy or isopropoxy, a C1-C4 alkyl group such as methyl, a two or three carbon-containing carboxyl group such as carboxymethyl or carboxyethyl an amine, or a mono- or di-C1-C4 alkyl-substituted amine such as dimethyl amino. A 3,4-methylenedioxy substituent is a contemplated 3,4-substituent, whereas methyl is a contemplated 3-substituent. A substituent of such a R11 ring para substituent has one atom or a longest chain of up to five atoms, excluding hydrogen.
  • R9 represents a C1-C6 alkyl group, a C1-C6 alkoxy group, a single-ringed carbocyclic aryl or heteroaryl group, and more particularly, a phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl, methyl, ethyl, methoxy or ethoxy group.
  • With respect to compounds of the formula
    Figure US20050014840A1-20050120-C00008

    R10 is hydrogen (hydrido) or —C(O)—R9and R1, R2, R3, R4, R5, R6, R9 and x are as defined above, and Y represents hydrogen, halogen, alkyl, alkoxyl, nitro, cyano, carboxy or amino.
  • In particularly preferred and most preferred practice, the substituent “R” groups and x are as they have been previously described in regard to formulas Ia-IIIa and Ib-IIIb, respectively, except that R3 and R4 are both hydrido in most preferred compounds. Additionally, x is zero so that R5 and R6 and the carbon to which they are bonded are absent, Y is hydrogen, and the sulfur atom bonded to the depicted phenyl ring is linked ortho to the sulfonamide-bearing carbon atom. It is thus seen that particularly preferred and most preferred compounds of formula IV constitute compounds of formulas I and II in which x is one, and the R6 and R8 substituents together with the atoms to which they are attached form a 6-membered, aromatic ring.
  • A particularly or most preferred R1 group is a radical having a length greater than that of a saturated four carbon chain, and shorter than that of a saturated eighteen carbon chain. When rotated about an axis drawn through the SO2-bonded R1 group 1-position and the 4-position of a 6-membered ring or the SO2-bonded position and substituent-bonded 3- or 5-position of a 5-membered R1 ring, the substituent defines a three-dimensional volume whose widest dimension has the width of about one phenyl ring to about three phenyl rings in a direction transverse to that axis to rotation.
  • More specifically, an SO2-linked R1 substituent is an aryl or heteroaryl group that is a 5- or 6-membered single-ring, and is itself substituted with one other single-ringed aryl or heteroaryl group or, with an alkyl or alkoxy group containing an umbranched chain of 3 to about 7 carbon atoms, a phenoxy group, a thiophenoxy [C6H5—S—] group, a phenylazido [C6H5—N2—] group or a benzamido [—NHC(O)C6H5] group. The SO2-linked single-ringed aryl or heteroaryl R1 group is substituted at its own 4-position when a 6-membered ring and at its own 3-position when a 5-membered ring
  • R2 represents hydrido, C1-C6 alkyl, C2-C4 alkyl substituted by amino, mono-substituted amino or di-substituted amino, wherein the substituents on nitrogen are chosen from C1-C6 alkyl, aralkyl, C5-C8 cycloalkyl and C1-C6 alkanoyl, or wherein the two substituents and the nitrogen to which they are attached when taken together form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero or one additional hetero atoms that are nitrogen, oxygen or sulfur, a C1-C4 alkylaryl or C1-C4 alkylheteroaryl group having a single ring.
  • An R3 group is hydrido, and R4 is hydroxyxcarbonyl, aminocarbonyl or C1-C6 alkyl. Again, R3 and R4 are both hydrido in most preferred compounds.
  • An R9 group represents C1-C6 alkyl, C1-C6 alkoxy, a single-ringed carbocyclic aryl or heteroaryl, and more particularly, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiophene-2-yl, 3-thiophene-3-yl, methyl, ethyl, methoxy and ethoxy.
  • Particularly preferred and most preferred compounds correspond to formulas IVa, IVb, IVc and IVd that are shown below:
    Figure US20050014840A1-20050120-C00009
  • The compounds described herein are useful in a process described herein in that such compounds can inhibit the activity of MMP-13. A particularly preferred compound inhibits the enzyme with an IC50 value of about 1000 nm or less in the in vitro assay discussed hereinafter. A most preferred compound exhibits an IC50 value in that assay of about 20 nm or less, with some compounds exhibiting values of about 1 nm or less.
  • In addition, while being highly active against MMP-13, selectivity of inhibitory activity toward MMP-1 is also exhibited by many of these particularly preferred and most preferred compounds. That is, many compounds exhibit little or no inhibition in the in vitro assay against MMP-1 so that IC50 values are often found to be several thousand to greater than 10,000 nm toward MMP-1. Exemplary ratios of IC50 values toward MMP-1 and MMP-13 (IC50 MMP-1/IC50 MMP-13) can range from about 5 to about 20,000, with most preferred compounds exhibiting ratios of about 500 to about 20,000. Inhibition data for several exemplary compounds are provided in a table hereinafter.
  • A contemplated inhibitor compound is used for treating a host mammal such as a mouse, rat, rabbit, dog, horse, primate such as a monkey, chimpanzee or human that has a condition associated with pathological matrix metalloprotease activity.
  • Also contemplated is use of a contemplated metalloprotease inhibitor compound in the treatment of a disease state that can be affected by the activity of metalloproteases TNF-α convertase. Exemplary of such disease states are the acute phase responses of shock and sepsis, coagulation responses, hemorrhage and cardiovascular effects, fever and inflammation, anorexia and cachexia.
  • In treating a disease condition associated with pathological matrix metalloproteinase activity, a contemplated MMP inhibitor compound can be used in the form of an amine salt derived from an inorganic or organic acid. Exemplary salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate.
  • Also, a basic nitrogen-containing group can be quaternized with such agents-as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibuytl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others to provide enhanced water-solubility. Water or oil-soluble or dispersible products are thereby obtained as desired. The salts are formed by combining the basic compounds with the desired acid.
  • Other compounds useful in this invention that are acids can also form salts. Examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases or basic quaternary ammonium salts.
  • In some cases, the salts can also be used as an aid in the isolation, purification or resolution of the compounds of this invention.
  • Total daily dose administered to a host mammal in single or divided doses can be in amounts, for example, for 0.001 to 30 mg/kg body weight daily and more usually 0.01 to 10 mg. Dosage unit compositions can contain such amounts or submultiples thereof to make up the daily dose. A suitable dose can be administered, in multiple sub-doses per day. Multiple doses per day can also increase the total daily dose should this be desired by the person prescribing the drug.
  • The dosage regimen for treating a disease condition with a compound and/or composition of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed can vary widely and therefore can deviate from the preferred dosage regimen set forth above.
  • A compound useful in the present invention can be formulated as a pharmaceutical composition. Such a composition can then be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa.; 1975 and Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.
  • Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.
  • Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.
  • For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
  • The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the mammalian host treated and the particular mode of administration.
  • Certain compounds of this invention can serve as prodrugs to other compounds of this invention. Prodrugs are drugs that can be chemically converted in viva or in vitro by biological systems into an active derivative or derivatives. An example from this invention are drugs of formula II (IIa or IIb) where the acyl group is hydrolyzed to a compound of formula I (or Ia or Ib). An additional example is where a disulfide of this invention is reduced to its thiol product or, in some cases, converted into an active mixed disulfide.
  • Table 1 through Table 80, below, show several series of compounds useful in this invention. Each case, class or group of compounds is illustrated by a generic formula, or formulae, followed by a series of preferred moieties or groups that constitute various substituents that can be attached at the position clearly shown in the generic structure. The generic symbols, e.g., R1, R2 and the like, are as defined before, except that R3 of the following tables corresponds to particularly and must preferred R4 discussed previously. This system is well known in the chemical communication arts and is widely used in scientific papers and presentations. For example in Table 1, R2 is the variable group with the structural variables that can substitute for R2 shown in the balance of the table. There are 40 R2 groups (including hydrogen) shown that are used to represent, in a non-limiting manner, 40 distinct compounds. In a similar manner, Table 43 for example, illustrates a compound with a generic structure containing two variable groups. The groups are R1 and R2. Thus, this example shows a matrix of 12 R1 groups and 10 R2 groups (including hydrogen) that represent 120 non-limiting compounds of this invention that can be prepared.
    TABLE 1
    Figure US20050014840A1-20050120-C00010
    —R2
    —H —CH3
    Figure US20050014840A1-20050120-C00011
    Figure US20050014840A1-20050120-C00012
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C00013
    Figure US20050014840A1-20050120-C00014
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C00015
    Figure US20050014840A1-20050120-C00016
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C00017
    Figure US20050014840A1-20050120-C00018
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C00019
    Figure US20050014840A1-20050120-C00020
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C00021
    Figure US20050014840A1-20050120-C00022
    Figure US20050014840A1-20050120-C00023
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C00024
    Figure US20050014840A1-20050120-C00025
    Figure US20050014840A1-20050120-C00026
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C00027
    Figure US20050014840A1-20050120-C00028
    Figure US20050014840A1-20050120-C00029
    Figure US20050014840A1-20050120-C00030
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C00031
    Figure US20050014840A1-20050120-C00032
  • TABLE 2
    Figure US20050014840A1-20050120-C00033
    Figure US20050014840A1-20050120-C00034
    Figure US20050014840A1-20050120-C00035
    Figure US20050014840A1-20050120-C00036
    Figure US20050014840A1-20050120-C00037
    Figure US20050014840A1-20050120-C00038
    Figure US20050014840A1-20050120-C00039
    Figure US20050014840A1-20050120-C00040
    Figure US20050014840A1-20050120-C00041
    Figure US20050014840A1-20050120-C00042
    Figure US20050014840A1-20050120-C00043
    Figure US20050014840A1-20050120-C00044
    Figure US20050014840A1-20050120-C00045
    Figure US20050014840A1-20050120-C00046
    Figure US20050014840A1-20050120-C00047
    Figure US20050014840A1-20050120-C00048
    Figure US20050014840A1-20050120-C00049
    Figure US20050014840A1-20050120-C00050
    Figure US20050014840A1-20050120-C00051
    Figure US20050014840A1-20050120-C00052
    Figure US20050014840A1-20050120-C00053
    Figure US20050014840A1-20050120-C00054
    Figure US20050014840A1-20050120-C00055
    Figure US20050014840A1-20050120-C00056
    Figure US20050014840A1-20050120-C00057
    Figure US20050014840A1-20050120-C00058
    Figure US20050014840A1-20050120-C00059
    Figure US20050014840A1-20050120-C00060
    Figure US20050014840A1-20050120-C00061
    Figure US20050014840A1-20050120-C00062
    Figure US20050014840A1-20050120-C00063
    Figure US20050014840A1-20050120-C00064
    Figure US20050014840A1-20050120-C00065
  • TABLE 3
    Figure US20050014840A1-20050120-C00066
    Figure US20050014840A1-20050120-C00067
    Figure US20050014840A1-20050120-C00068
    Figure US20050014840A1-20050120-C00069
    Figure US20050014840A1-20050120-C00070
    Figure US20050014840A1-20050120-C00071
    Figure US20050014840A1-20050120-C00072
    Figure US20050014840A1-20050120-C00073
    Figure US20050014840A1-20050120-C00074
    Figure US20050014840A1-20050120-C00075
    Figure US20050014840A1-20050120-C00076
    Figure US20050014840A1-20050120-C00077
    Figure US20050014840A1-20050120-C00078
    Figure US20050014840A1-20050120-C00079
    Figure US20050014840A1-20050120-C00080
    Figure US20050014840A1-20050120-C00081
    Figure US20050014840A1-20050120-C00082
    Figure US20050014840A1-20050120-C00083
    Figure US20050014840A1-20050120-C00084
    Figure US20050014840A1-20050120-C00085
    Figure US20050014840A1-20050120-C00086
    Figure US20050014840A1-20050120-C00087
    Figure US20050014840A1-20050120-C00088
    Figure US20050014840A1-20050120-C00089
    Figure US20050014840A1-20050120-C00090
    Figure US20050014840A1-20050120-C00091
    Figure US20050014840A1-20050120-C00092
    Figure US20050014840A1-20050120-C00093
    Figure US20050014840A1-20050120-C00094
    Figure US20050014840A1-20050120-C00095
    Figure US20050014840A1-20050120-C00096
    Figure US20050014840A1-20050120-C00097
    Figure US20050014840A1-20050120-C00098
  • TABLE 4
    Figure US20050014840A1-20050120-C00099
    Figure US20050014840A1-20050120-C00100
    Figure US20050014840A1-20050120-C00101
    Figure US20050014840A1-20050120-C00102
    Figure US20050014840A1-20050120-C00103
    Figure US20050014840A1-20050120-C00104
    Figure US20050014840A1-20050120-C00105
    Figure US20050014840A1-20050120-C00106
    Figure US20050014840A1-20050120-C00107
    Figure US20050014840A1-20050120-C00108
    Figure US20050014840A1-20050120-C00109
    Figure US20050014840A1-20050120-C00110
    Figure US20050014840A1-20050120-C00111
    Figure US20050014840A1-20050120-C00112
    Figure US20050014840A1-20050120-C00113
    Figure US20050014840A1-20050120-C00114
    Figure US20050014840A1-20050120-C00115
    Figure US20050014840A1-20050120-C00116
    Figure US20050014840A1-20050120-C00117
  • TABLE 5
    Figure US20050014840A1-20050120-C00118
    Figure US20050014840A1-20050120-C00119
    Figure US20050014840A1-20050120-C00120
    Figure US20050014840A1-20050120-C00121
    Figure US20050014840A1-20050120-C00122
    Figure US20050014840A1-20050120-C00123
    Figure US20050014840A1-20050120-C00124
    Figure US20050014840A1-20050120-C00125
    Figure US20050014840A1-20050120-C00126
    Figure US20050014840A1-20050120-C00127
    Figure US20050014840A1-20050120-C00128
    Figure US20050014840A1-20050120-C00129
    Figure US20050014840A1-20050120-C00130
    Figure US20050014840A1-20050120-C00131
    Figure US20050014840A1-20050120-C00132
    Figure US20050014840A1-20050120-C00133
    Figure US20050014840A1-20050120-C00134
    Figure US20050014840A1-20050120-C00135
    Figure US20050014840A1-20050120-C00136
    Figure US20050014840A1-20050120-C00137
    Figure US20050014840A1-20050120-C00138
    Figure US20050014840A1-20050120-C00139
    Figure US20050014840A1-20050120-C00140
    Figure US20050014840A1-20050120-C00141
    Figure US20050014840A1-20050120-C00142
    Figure US20050014840A1-20050120-C00143
    Figure US20050014840A1-20050120-C00144
    Figure US20050014840A1-20050120-C00145
    Figure US20050014840A1-20050120-C00146
    Figure US20050014840A1-20050120-C00147
    Figure US20050014840A1-20050120-C00148
    Figure US20050014840A1-20050120-C00149
    Figure US20050014840A1-20050120-C00150
  • TABLE 6
    Figure US20050014840A1-20050120-C00151
    Figure US20050014840A1-20050120-C00152
    Figure US20050014840A1-20050120-C00153
    Figure US20050014840A1-20050120-C00154
    Figure US20050014840A1-20050120-C00155
    Figure US20050014840A1-20050120-C00156
    Figure US20050014840A1-20050120-C00157
    Figure US20050014840A1-20050120-C00158
    Figure US20050014840A1-20050120-C00159
    Figure US20050014840A1-20050120-C00160
    Figure US20050014840A1-20050120-C00161
    Figure US20050014840A1-20050120-C00162
    Figure US20050014840A1-20050120-C00163
    Figure US20050014840A1-20050120-C00164
    Figure US20050014840A1-20050120-C00165
    Figure US20050014840A1-20050120-C00166
    Figure US20050014840A1-20050120-C00167
    Figure US20050014840A1-20050120-C00168
    Figure US20050014840A1-20050120-C00169
    Figure US20050014840A1-20050120-C00170
    Figure US20050014840A1-20050120-C00171
    Figure US20050014840A1-20050120-C00172
    Figure US20050014840A1-20050120-C00173
    Figure US20050014840A1-20050120-C00174
    Figure US20050014840A1-20050120-C00175
    Figure US20050014840A1-20050120-C00176
    Figure US20050014840A1-20050120-C00177
    Figure US20050014840A1-20050120-C00178
    Figure US20050014840A1-20050120-C00179
    Figure US20050014840A1-20050120-C00180
    Figure US20050014840A1-20050120-C00181
    Figure US20050014840A1-20050120-C00182
    Figure US20050014840A1-20050120-C00183
    Figure US20050014840A1-20050120-C00184
  • TABLE 7
    Figure US20050014840A1-20050120-C00185
    Figure US20050014840A1-20050120-C00186
    Figure US20050014840A1-20050120-C00187
    Figure US20050014840A1-20050120-C00188
    Figure US20050014840A1-20050120-C00189
    Figure US20050014840A1-20050120-C00190
    Figure US20050014840A1-20050120-C00191
    Figure US20050014840A1-20050120-C00192
    Figure US20050014840A1-20050120-C00193
    Figure US20050014840A1-20050120-C00194
    Figure US20050014840A1-20050120-C00195
    Figure US20050014840A1-20050120-C00196
    Figure US20050014840A1-20050120-C00197
    Figure US20050014840A1-20050120-C00198
    Figure US20050014840A1-20050120-C00199
    Figure US20050014840A1-20050120-C00200
    Figure US20050014840A1-20050120-C00201
    Figure US20050014840A1-20050120-C00202
    Figure US20050014840A1-20050120-C00203
    Figure US20050014840A1-20050120-C00204
    Figure US20050014840A1-20050120-C00205
    Figure US20050014840A1-20050120-C00206
    Figure US20050014840A1-20050120-C00207
    Figure US20050014840A1-20050120-C00208
    Figure US20050014840A1-20050120-C00209
    Figure US20050014840A1-20050120-C00210
    Figure US20050014840A1-20050120-C00211
    Figure US20050014840A1-20050120-C00212
    Figure US20050014840A1-20050120-C00213
    Figure US20050014840A1-20050120-C00214
    Figure US20050014840A1-20050120-C00215
    Figure US20050014840A1-20050120-C00216
    Figure US20050014840A1-20050120-C00217
    Figure US20050014840A1-20050120-C00218
  • TABLE 8
    Figure US20050014840A1-20050120-C00219
    —R2
    —H —CH3
    Figure US20050014840A1-20050120-C00220
    Figure US20050014840A1-20050120-C00221
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C00222
    Figure US20050014840A1-20050120-C00223
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C00224
    Figure US20050014840A1-20050120-C00225
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C00226
    Figure US20050014840A1-20050120-C00227
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C00228
    Figure US20050014840A1-20050120-C00229
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C00230
    Figure US20050014840A1-20050120-C00231
    Figure US20050014840A1-20050120-C00232
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C00233
    Figure US20050014840A1-20050120-C00234
    Figure US20050014840A1-20050120-C00235
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C00236
    Figure US20050014840A1-20050120-C00237
    Figure US20050014840A1-20050120-C00238
    Figure US20050014840A1-20050120-C00239
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C00240
    Figure US20050014840A1-20050120-C00241
  • TABLE 9
    Figure US20050014840A1-20050120-C00242
    Figure US20050014840A1-20050120-C00243
    Figure US20050014840A1-20050120-C00244
    Figure US20050014840A1-20050120-C00245
    Figure US20050014840A1-20050120-C00246
    Figure US20050014840A1-20050120-C00247
    Figure US20050014840A1-20050120-C00248
    Figure US20050014840A1-20050120-C00249
    Figure US20050014840A1-20050120-C00250
    Figure US20050014840A1-20050120-C00251
    Figure US20050014840A1-20050120-C00252
    Figure US20050014840A1-20050120-C00253
    Figure US20050014840A1-20050120-C00254
    Figure US20050014840A1-20050120-C00255
    Figure US20050014840A1-20050120-C00256
    Figure US20050014840A1-20050120-C00257
    Figure US20050014840A1-20050120-C00258
    Figure US20050014840A1-20050120-C00259
    Figure US20050014840A1-20050120-C00260
    Figure US20050014840A1-20050120-C00261
    Figure US20050014840A1-20050120-C00262
    Figure US20050014840A1-20050120-C00263
    Figure US20050014840A1-20050120-C00264
    Figure US20050014840A1-20050120-C00265
    Figure US20050014840A1-20050120-C00266
    Figure US20050014840A1-20050120-C00267
    Figure US20050014840A1-20050120-C00268
    Figure US20050014840A1-20050120-C00269
    Figure US20050014840A1-20050120-C00270
    Figure US20050014840A1-20050120-C00271
    Figure US20050014840A1-20050120-C00272
    Figure US20050014840A1-20050120-C00273
    Figure US20050014840A1-20050120-C00274
  • TABLE 10
    Figure US20050014840A1-20050120-C00275
    Figure US20050014840A1-20050120-C00276
    Figure US20050014840A1-20050120-C00277
    Figure US20050014840A1-20050120-C00278
    Figure US20050014840A1-20050120-C00279
    Figure US20050014840A1-20050120-C00280
    Figure US20050014840A1-20050120-C00281
    Figure US20050014840A1-20050120-C00282
    Figure US20050014840A1-20050120-C00283
    Figure US20050014840A1-20050120-C00284
    Figure US20050014840A1-20050120-C00285
    Figure US20050014840A1-20050120-C00286
    Figure US20050014840A1-20050120-C00287
    Figure US20050014840A1-20050120-C00288
    Figure US20050014840A1-20050120-C00289
    Figure US20050014840A1-20050120-C00290
    Figure US20050014840A1-20050120-C00291
    Figure US20050014840A1-20050120-C00292
    Figure US20050014840A1-20050120-C00293
    Figure US20050014840A1-20050120-C00294
    Figure US20050014840A1-20050120-C00295
    Figure US20050014840A1-20050120-C00296
    Figure US20050014840A1-20050120-C00297
    Figure US20050014840A1-20050120-C00298
    Figure US20050014840A1-20050120-C00299
    Figure US20050014840A1-20050120-C00300
    Figure US20050014840A1-20050120-C00301
    Figure US20050014840A1-20050120-C00302
    Figure US20050014840A1-20050120-C00303
    Figure US20050014840A1-20050120-C00304
    Figure US20050014840A1-20050120-C00305
    Figure US20050014840A1-20050120-C00306
    Figure US20050014840A1-20050120-C00307
  • TABLE 11
    Figure US20050014840A1-20050120-C00308
    Figure US20050014840A1-20050120-C00309
    Figure US20050014840A1-20050120-C00310
    Figure US20050014840A1-20050120-C00311
    Figure US20050014840A1-20050120-C00312
    Figure US20050014840A1-20050120-C00313
    Figure US20050014840A1-20050120-C00314
    Figure US20050014840A1-20050120-C00315
    Figure US20050014840A1-20050120-C00316
    Figure US20050014840A1-20050120-C00317
    Figure US20050014840A1-20050120-C00318
    Figure US20050014840A1-20050120-C00319
    Figure US20050014840A1-20050120-C00320
    Figure US20050014840A1-20050120-C00321
    Figure US20050014840A1-20050120-C00322
    Figure US20050014840A1-20050120-C00323
    Figure US20050014840A1-20050120-C00324
    Figure US20050014840A1-20050120-C00325
    Figure US20050014840A1-20050120-C00326
    Figure US20050014840A1-20050120-C00327
    Figure US20050014840A1-20050120-C00328
    Figure US20050014840A1-20050120-C00329
    Figure US20050014840A1-20050120-C00330
    Figure US20050014840A1-20050120-C00331
    Figure US20050014840A1-20050120-C00332
    Figure US20050014840A1-20050120-C00333
    Figure US20050014840A1-20050120-C00334
    Figure US20050014840A1-20050120-C00335
    Figure US20050014840A1-20050120-C00336
    Figure US20050014840A1-20050120-C00337
    Figure US20050014840A1-20050120-C00338
    Figure US20050014840A1-20050120-C00339
    Figure US20050014840A1-20050120-C00340
  • TABLE 12
    Figure US20050014840A1-20050120-C00341
    Figure US20050014840A1-20050120-C00342
    Figure US20050014840A1-20050120-C00343
    Figure US20050014840A1-20050120-C00344
    Figure US20050014840A1-20050120-C00345
    Figure US20050014840A1-20050120-C00346
    Figure US20050014840A1-20050120-C00347
    Figure US20050014840A1-20050120-C00348
    Figure US20050014840A1-20050120-C00349
    Figure US20050014840A1-20050120-C00350
    Figure US20050014840A1-20050120-C00351
    Figure US20050014840A1-20050120-C00352
    Figure US20050014840A1-20050120-C00353
    Figure US20050014840A1-20050120-C00354
    Figure US20050014840A1-20050120-C00355
    Figure US20050014840A1-20050120-C00356
    Figure US20050014840A1-20050120-C00357
    Figure US20050014840A1-20050120-C00358
    Figure US20050014840A1-20050120-C00359
    Figure US20050014840A1-20050120-C00360
    Figure US20050014840A1-20050120-C00361
    Figure US20050014840A1-20050120-C00362
    Figure US20050014840A1-20050120-C00363
    Figure US20050014840A1-20050120-C00364
    Figure US20050014840A1-20050120-C00365
    Figure US20050014840A1-20050120-C00366
    Figure US20050014840A1-20050120-C00367
    Figure US20050014840A1-20050120-C00368
    Figure US20050014840A1-20050120-C00369
    Figure US20050014840A1-20050120-C00370
    Figure US20050014840A1-20050120-C00371
    Figure US20050014840A1-20050120-C00372
    Figure US20050014840A1-20050120-C00373
  • TABLE 13
    Figure US20050014840A1-20050120-C00374
    Figure US20050014840A1-20050120-C00375
    Figure US20050014840A1-20050120-C00376
    Figure US20050014840A1-20050120-C00377
    Figure US20050014840A1-20050120-C00378
    Figure US20050014840A1-20050120-C00379
    Figure US20050014840A1-20050120-C00380
    Figure US20050014840A1-20050120-C00381
    Figure US20050014840A1-20050120-C00382
    Figure US20050014840A1-20050120-C00383
    Figure US20050014840A1-20050120-C00384
    Figure US20050014840A1-20050120-C00385
    Figure US20050014840A1-20050120-C00386
    Figure US20050014840A1-20050120-C00387
    Figure US20050014840A1-20050120-C00388
    Figure US20050014840A1-20050120-C00389
    Figure US20050014840A1-20050120-C00390
    Figure US20050014840A1-20050120-C00391
    Figure US20050014840A1-20050120-C00392
  • TABLE 14
    Figure US20050014840A1-20050120-C00393
    Figure US20050014840A1-20050120-C00394
    Figure US20050014840A1-20050120-C00395
    Figure US20050014840A1-20050120-C00396
    Figure US20050014840A1-20050120-C00397
    Figure US20050014840A1-20050120-C00398
    Figure US20050014840A1-20050120-C00399
    Figure US20050014840A1-20050120-C00400
    Figure US20050014840A1-20050120-C00401
    Figure US20050014840A1-20050120-C00402
    Figure US20050014840A1-20050120-C00403
    Figure US20050014840A1-20050120-C00404
    Figure US20050014840A1-20050120-C00405
    Figure US20050014840A1-20050120-C00406
    Figure US20050014840A1-20050120-C00407
    Figure US20050014840A1-20050120-C00408
    Figure US20050014840A1-20050120-C00409
    Figure US20050014840A1-20050120-C00410
  • TABLE 15
    Figure US20050014840A1-20050120-C00411
    Figure US20050014840A1-20050120-C00412
    Figure US20050014840A1-20050120-C00413
    Figure US20050014840A1-20050120-C00414
    Figure US20050014840A1-20050120-C00415
    Figure US20050014840A1-20050120-C00416
    Figure US20050014840A1-20050120-C00417
    Figure US20050014840A1-20050120-C00418
    Figure US20050014840A1-20050120-C00419
    Figure US20050014840A1-20050120-C00420
    Figure US20050014840A1-20050120-C00421
    Figure US20050014840A1-20050120-C00422
    Figure US20050014840A1-20050120-C00423
    Figure US20050014840A1-20050120-C00424
    Figure US20050014840A1-20050120-C00425
    Figure US20050014840A1-20050120-C00426
    Figure US20050014840A1-20050120-C00427
    Figure US20050014840A1-20050120-C00428
  • TABLE 16
    Figure US20050014840A1-20050120-C00429
    —H —CH3
    Figure US20050014840A1-20050120-C00430
    Figure US20050014840A1-20050120-C00431
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C00432
    Figure US20050014840A1-20050120-C00433
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C00434
    Figure US20050014840A1-20050120-C00435
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C00436
    Figure US20050014840A1-20050120-C00437
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C00438
    Figure US20050014840A1-20050120-C00439
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C00440
    Figure US20050014840A1-20050120-C00441
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C00442
    Figure US20050014840A1-20050120-C00443
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C00444
    Figure US20050014840A1-20050120-C00445
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C00446
    Figure US20050014840A1-20050120-C00447
  • TABLE 17
    Figure US20050014840A1-20050120-C00448
    Figure US20050014840A1-20050120-C00449
    Figure US20050014840A1-20050120-C00450
    Figure US20050014840A1-20050120-C00451
    Figure US20050014840A1-20050120-C00452
    Figure US20050014840A1-20050120-C00453
    Figure US20050014840A1-20050120-C00454
    Figure US20050014840A1-20050120-C00455
    Figure US20050014840A1-20050120-C00456
    Figure US20050014840A1-20050120-C00457
    Figure US20050014840A1-20050120-C00458
    Figure US20050014840A1-20050120-C00459
    Figure US20050014840A1-20050120-C00460
    Figure US20050014840A1-20050120-C00461
    Figure US20050014840A1-20050120-C00462
    Figure US20050014840A1-20050120-C00463
    Figure US20050014840A1-20050120-C00464
    Figure US20050014840A1-20050120-C00465
    Figure US20050014840A1-20050120-C00466
    Figure US20050014840A1-20050120-C00467
    Figure US20050014840A1-20050120-C00468
    Figure US20050014840A1-20050120-C00469
    Figure US20050014840A1-20050120-C00470
    Figure US20050014840A1-20050120-C00471
    Figure US20050014840A1-20050120-C00472
    Figure US20050014840A1-20050120-C00473
    Figure US20050014840A1-20050120-C00474
    Figure US20050014840A1-20050120-C00475
    Figure US20050014840A1-20050120-C00476
    Figure US20050014840A1-20050120-C00477
    Figure US20050014840A1-20050120-C00478
    Figure US20050014840A1-20050120-C00479
    Figure US20050014840A1-20050120-C00480
  • TABLE 18
    Figure US20050014840A1-20050120-C00481
    Figure US20050014840A1-20050120-C00482
    Figure US20050014840A1-20050120-C00483
    Figure US20050014840A1-20050120-C00484
    Figure US20050014840A1-20050120-C00485
    Figure US20050014840A1-20050120-C00486
    Figure US20050014840A1-20050120-C00487
    Figure US20050014840A1-20050120-C00488
    Figure US20050014840A1-20050120-C00489
    Figure US20050014840A1-20050120-C00490
    Figure US20050014840A1-20050120-C00491
    Figure US20050014840A1-20050120-C00492
    Figure US20050014840A1-20050120-C00493
    Figure US20050014840A1-20050120-C00494
    Figure US20050014840A1-20050120-C00495
    Figure US20050014840A1-20050120-C00496
    Figure US20050014840A1-20050120-C00497
    Figure US20050014840A1-20050120-C00498
    Figure US20050014840A1-20050120-C00499
    Figure US20050014840A1-20050120-C00500
    Figure US20050014840A1-20050120-C00501
    Figure US20050014840A1-20050120-C00502
    Figure US20050014840A1-20050120-C00503
    Figure US20050014840A1-20050120-C00504
    Figure US20050014840A1-20050120-C00505
    Figure US20050014840A1-20050120-C00506
    Figure US20050014840A1-20050120-C00507
    Figure US20050014840A1-20050120-C00508
    Figure US20050014840A1-20050120-C00509
    Figure US20050014840A1-20050120-C00510
    Figure US20050014840A1-20050120-C00511
    Figure US20050014840A1-20050120-C00512
    Figure US20050014840A1-20050120-C00513
  • TABLE 19
    Figure US20050014840A1-20050120-C00514
    Figure US20050014840A1-20050120-C00515
    Figure US20050014840A1-20050120-C00516
    Figure US20050014840A1-20050120-C00517
    Figure US20050014840A1-20050120-C00518
    Figure US20050014840A1-20050120-C00519
    Figure US20050014840A1-20050120-C00520
    Figure US20050014840A1-20050120-C00521
    Figure US20050014840A1-20050120-C00522
    Figure US20050014840A1-20050120-C00523
    Figure US20050014840A1-20050120-C00524
    Figure US20050014840A1-20050120-C00525
    Figure US20050014840A1-20050120-C00526
    Figure US20050014840A1-20050120-C00527
    Figure US20050014840A1-20050120-C00528
    Figure US20050014840A1-20050120-C00529
    Figure US20050014840A1-20050120-C00530
    Figure US20050014840A1-20050120-C00531
    Figure US20050014840A1-20050120-C00532
    Figure US20050014840A1-20050120-C00533
    Figure US20050014840A1-20050120-C00534
    Figure US20050014840A1-20050120-C00535
    Figure US20050014840A1-20050120-C00536
    Figure US20050014840A1-20050120-C00537
    Figure US20050014840A1-20050120-C00538
    Figure US20050014840A1-20050120-C00539
    Figure US20050014840A1-20050120-C00540
    Figure US20050014840A1-20050120-C00541
    Figure US20050014840A1-20050120-C00542
    Figure US20050014840A1-20050120-C00543
    Figure US20050014840A1-20050120-C00544
    Figure US20050014840A1-20050120-C00545
    Figure US20050014840A1-20050120-C00546
  • TABLE 20
    Figure US20050014840A1-20050120-C00547
    Figure US20050014840A1-20050120-C00548
    Figure US20050014840A1-20050120-C00549
    Figure US20050014840A1-20050120-C00550
    Figure US20050014840A1-20050120-C00551
    Figure US20050014840A1-20050120-C00552
    Figure US20050014840A1-20050120-C00553
    Figure US20050014840A1-20050120-C00554
    Figure US20050014840A1-20050120-C00555
    Figure US20050014840A1-20050120-C00556
    Figure US20050014840A1-20050120-C00557
    Figure US20050014840A1-20050120-C00558
    Figure US20050014840A1-20050120-C00559
    Figure US20050014840A1-20050120-C00560
    Figure US20050014840A1-20050120-C00561
    Figure US20050014840A1-20050120-C00562
    Figure US20050014840A1-20050120-C00563
    Figure US20050014840A1-20050120-C00564
    Figure US20050014840A1-20050120-C00565
    Figure US20050014840A1-20050120-C00566
    Figure US20050014840A1-20050120-C00567
    Figure US20050014840A1-20050120-C00568
    Figure US20050014840A1-20050120-C00569
    Figure US20050014840A1-20050120-C00570
    Figure US20050014840A1-20050120-C00571
    Figure US20050014840A1-20050120-C00572
    Figure US20050014840A1-20050120-C00573
    Figure US20050014840A1-20050120-C00574
    Figure US20050014840A1-20050120-C00575
    Figure US20050014840A1-20050120-C00576
    Figure US20050014840A1-20050120-C00577
    Figure US20050014840A1-20050120-C00578
    Figure US20050014840A1-20050120-C00579
  • TABLE 21
    Figure US20050014840A1-20050120-C00580
    —H —CH3
    Figure US20050014840A1-20050120-C00581
    Figure US20050014840A1-20050120-C00582
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C00583
    Figure US20050014840A1-20050120-C00584
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C00585
    Figure US20050014840A1-20050120-C00586
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C00587
    Figure US20050014840A1-20050120-C00588
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C00589
    Figure US20050014840A1-20050120-C00590
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C00591
    Figure US20050014840A1-20050120-C00592
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C00593
    Figure US20050014840A1-20050120-C00594
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C00595
    Figure US20050014840A1-20050120-C00596
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C00597
    Figure US20050014840A1-20050120-C00598
  • TABLE 22
    Figure US20050014840A1-20050120-C00599
    Figure US20050014840A1-20050120-C00600
    Figure US20050014840A1-20050120-C00601
    Figure US20050014840A1-20050120-C00602
    Figure US20050014840A1-20050120-C00603
    Figure US20050014840A1-20050120-C00604
    Figure US20050014840A1-20050120-C00605
    Figure US20050014840A1-20050120-C00606
    Figure US20050014840A1-20050120-C00607
    Figure US20050014840A1-20050120-C00608
    Figure US20050014840A1-20050120-C00609
    Figure US20050014840A1-20050120-C00610
    Figure US20050014840A1-20050120-C00611
    Figure US20050014840A1-20050120-C00612
    Figure US20050014840A1-20050120-C00613
    Figure US20050014840A1-20050120-C00614
    Figure US20050014840A1-20050120-C00615
    Figure US20050014840A1-20050120-C00616
    Figure US20050014840A1-20050120-C00617
    Figure US20050014840A1-20050120-C00618
    Figure US20050014840A1-20050120-C00619
    Figure US20050014840A1-20050120-C00620
    Figure US20050014840A1-20050120-C00621
    Figure US20050014840A1-20050120-C00622
    Figure US20050014840A1-20050120-C00623
    Figure US20050014840A1-20050120-C00624
    Figure US20050014840A1-20050120-C00625
    Figure US20050014840A1-20050120-C00626
    Figure US20050014840A1-20050120-C00627
    Figure US20050014840A1-20050120-C00628
    Figure US20050014840A1-20050120-C00629
    Figure US20050014840A1-20050120-C00630
    Figure US20050014840A1-20050120-C00631
  • TABLE 23
    Figure US20050014840A1-20050120-C00632
    Figure US20050014840A1-20050120-C00633
    Figure US20050014840A1-20050120-C00634
    Figure US20050014840A1-20050120-C00635
    Figure US20050014840A1-20050120-C00636
    Figure US20050014840A1-20050120-C00637
    Figure US20050014840A1-20050120-C00638
    Figure US20050014840A1-20050120-C00639
    Figure US20050014840A1-20050120-C00640
    Figure US20050014840A1-20050120-C00641
    Figure US20050014840A1-20050120-C00642
    Figure US20050014840A1-20050120-C00643
    Figure US20050014840A1-20050120-C00644
    Figure US20050014840A1-20050120-C00645
    Figure US20050014840A1-20050120-C00646
    Figure US20050014840A1-20050120-C00647
    Figure US20050014840A1-20050120-C00648
    Figure US20050014840A1-20050120-C00649
    Figure US20050014840A1-20050120-C00650
    Figure US20050014840A1-20050120-C00651
    Figure US20050014840A1-20050120-C00652
    Figure US20050014840A1-20050120-C00653
    Figure US20050014840A1-20050120-C00654
    Figure US20050014840A1-20050120-C00655
    Figure US20050014840A1-20050120-C00656
    Figure US20050014840A1-20050120-C00657
    Figure US20050014840A1-20050120-C00658
    Figure US20050014840A1-20050120-C00659
    Figure US20050014840A1-20050120-C00660
    Figure US20050014840A1-20050120-C00661
    Figure US20050014840A1-20050120-C00662
    Figure US20050014840A1-20050120-C00663
    Figure US20050014840A1-20050120-C00664
  • TABLE 24
    Figure US20050014840A1-20050120-C00665
    Figure US20050014840A1-20050120-C00666
    Figure US20050014840A1-20050120-C00667
    Figure US20050014840A1-20050120-C00668
    Figure US20050014840A1-20050120-C00669
    Figure US20050014840A1-20050120-C00670
    Figure US20050014840A1-20050120-C00671
    Figure US20050014840A1-20050120-C00672
    Figure US20050014840A1-20050120-C00673
    Figure US20050014840A1-20050120-C00674
    Figure US20050014840A1-20050120-C00675
    Figure US20050014840A1-20050120-C00676
    Figure US20050014840A1-20050120-C00677
    Figure US20050014840A1-20050120-C00678
    Figure US20050014840A1-20050120-C00679
    Figure US20050014840A1-20050120-C00680
    Figure US20050014840A1-20050120-C00681
    Figure US20050014840A1-20050120-C00682
    Figure US20050014840A1-20050120-C00683
    Figure US20050014840A1-20050120-C00684
    Figure US20050014840A1-20050120-C00685
    Figure US20050014840A1-20050120-C00686
    Figure US20050014840A1-20050120-C00687
    Figure US20050014840A1-20050120-C00688
    Figure US20050014840A1-20050120-C00689
    Figure US20050014840A1-20050120-C00690
    Figure US20050014840A1-20050120-C00691
    Figure US20050014840A1-20050120-C00692
    Figure US20050014840A1-20050120-C00693
    Figure US20050014840A1-20050120-C00694
    Figure US20050014840A1-20050120-C00695
    Figure US20050014840A1-20050120-C00696
    Figure US20050014840A1-20050120-C00697
  • TABLE 25
    Figure US20050014840A1-20050120-C00698
    Figure US20050014840A1-20050120-C00699
    Figure US20050014840A1-20050120-C00700
    Figure US20050014840A1-20050120-C00701
    Figure US20050014840A1-20050120-C00702
    Figure US20050014840A1-20050120-C00703
    Figure US20050014840A1-20050120-C00704
    Figure US20050014840A1-20050120-C00705
    Figure US20050014840A1-20050120-C00706
    Figure US20050014840A1-20050120-C00707
    Figure US20050014840A1-20050120-C00708
    Figure US20050014840A1-20050120-C00709
    Figure US20050014840A1-20050120-C00710
    Figure US20050014840A1-20050120-C00711
    Figure US20050014840A1-20050120-C00712
    Figure US20050014840A1-20050120-C00713
    Figure US20050014840A1-20050120-C00714
    Figure US20050014840A1-20050120-C00715
    Figure US20050014840A1-20050120-C00716
    Figure US20050014840A1-20050120-C00717
    Figure US20050014840A1-20050120-C00718
    Figure US20050014840A1-20050120-C00719
    Figure US20050014840A1-20050120-C00720
    Figure US20050014840A1-20050120-C00721
    Figure US20050014840A1-20050120-C00722
    Figure US20050014840A1-20050120-C00723
    Figure US20050014840A1-20050120-C00724
    Figure US20050014840A1-20050120-C00725
    Figure US20050014840A1-20050120-C00726
    Figure US20050014840A1-20050120-C00727
    Figure US20050014840A1-20050120-C00728
    Figure US20050014840A1-20050120-C00729
    Figure US20050014840A1-20050120-C00730
    Figure US20050014840A1-20050120-C00731
  • TABLE 26
    Figure US20050014840A1-20050120-C00732
    Figure US20050014840A1-20050120-C00733
    Figure US20050014840A1-20050120-C00734
    Figure US20050014840A1-20050120-C00735
    Figure US20050014840A1-20050120-C00736
    Figure US20050014840A1-20050120-C00737
    Figure US20050014840A1-20050120-C00738
    Figure US20050014840A1-20050120-C00739
    Figure US20050014840A1-20050120-C00740
    Figure US20050014840A1-20050120-C00741
    Figure US20050014840A1-20050120-C00742
    Figure US20050014840A1-20050120-C00743
    Figure US20050014840A1-20050120-C00744
    Figure US20050014840A1-20050120-C00745
    Figure US20050014840A1-20050120-C00746
    Figure US20050014840A1-20050120-C00747
    Figure US20050014840A1-20050120-C00748
    Figure US20050014840A1-20050120-C00749
    Figure US20050014840A1-20050120-C00750
    Figure US20050014840A1-20050120-C00751
    Figure US20050014840A1-20050120-C00752
    Figure US20050014840A1-20050120-C00753
    Figure US20050014840A1-20050120-C00754
    Figure US20050014840A1-20050120-C00755
    Figure US20050014840A1-20050120-C00756
    Figure US20050014840A1-20050120-C00757
    Figure US20050014840A1-20050120-C00758
    Figure US20050014840A1-20050120-C00759
    Figure US20050014840A1-20050120-C00760
    Figure US20050014840A1-20050120-C00761
    Figure US20050014840A1-20050120-C00762
    Figure US20050014840A1-20050120-C00763
    Figure US20050014840A1-20050120-C00764
  • TABLE 27
    Figure US20050014840A1-20050120-C00765
    Figure US20050014840A1-20050120-C00766
    Figure US20050014840A1-20050120-C00767
    Figure US20050014840A1-20050120-C00768
    Figure US20050014840A1-20050120-C00769
    Figure US20050014840A1-20050120-C00770
    Figure US20050014840A1-20050120-C00771
    Figure US20050014840A1-20050120-C00772
    Figure US20050014840A1-20050120-C00773
    Figure US20050014840A1-20050120-C00774
    Figure US20050014840A1-20050120-C00775
    Figure US20050014840A1-20050120-C00776
    Figure US20050014840A1-20050120-C00777
    Figure US20050014840A1-20050120-C00778
    Figure US20050014840A1-20050120-C00779
    Figure US20050014840A1-20050120-C00780
    Figure US20050014840A1-20050120-C00781
    Figure US20050014840A1-20050120-C00782
    Figure US20050014840A1-20050120-C00783
    Figure US20050014840A1-20050120-C00784
    Figure US20050014840A1-20050120-C00785
    Figure US20050014840A1-20050120-C00786
    Figure US20050014840A1-20050120-C00787
    Figure US20050014840A1-20050120-C00788
    Figure US20050014840A1-20050120-C00789
    Figure US20050014840A1-20050120-C00790
    Figure US20050014840A1-20050120-C00791
    Figure US20050014840A1-20050120-C00792
    Figure US20050014840A1-20050120-C00793
    Figure US20050014840A1-20050120-C00794
    Figure US20050014840A1-20050120-C00795
  • TABLE 28
    Figure US20050014840A1-20050120-C00796
    Figure US20050014840A1-20050120-C00797
    Figure US20050014840A1-20050120-C00798
    Figure US20050014840A1-20050120-C00799
    Figure US20050014840A1-20050120-C00800
    Figure US20050014840A1-20050120-C00801
    Figure US20050014840A1-20050120-C00802
    Figure US20050014840A1-20050120-C00803
    Figure US20050014840A1-20050120-C00804
    Figure US20050014840A1-20050120-C00805
    Figure US20050014840A1-20050120-C00806
    Figure US20050014840A1-20050120-C00807
    Figure US20050014840A1-20050120-C00808
    Figure US20050014840A1-20050120-C00809
    Figure US20050014840A1-20050120-C00810
    Figure US20050014840A1-20050120-C00811
  • TABLE 29
    Figure US20050014840A1-20050120-C00812
    Figure US20050014840A1-20050120-C00813
    Figure US20050014840A1-20050120-C00814
    Figure US20050014840A1-20050120-C00815
    Figure US20050014840A1-20050120-C00816
    Figure US20050014840A1-20050120-C00817
    Figure US20050014840A1-20050120-C00818
    Figure US20050014840A1-20050120-C00819
    Figure US20050014840A1-20050120-C00820
    Figure US20050014840A1-20050120-C00821
    Figure US20050014840A1-20050120-C00822
    Figure US20050014840A1-20050120-C00823
    Figure US20050014840A1-20050120-C00824
    Figure US20050014840A1-20050120-C00825
    Figure US20050014840A1-20050120-C00826
    Figure US20050014840A1-20050120-C00827
    Figure US20050014840A1-20050120-C00828
    Figure US20050014840A1-20050120-C00829
    Figure US20050014840A1-20050120-C00830
    Figure US20050014840A1-20050120-C00831
    Figure US20050014840A1-20050120-C00832
    Figure US20050014840A1-20050120-C00833
  • TABLE 30
    Figure US20050014840A1-20050120-C00834
    Figure US20050014840A1-20050120-C00835
    Figure US20050014840A1-20050120-C00836
    Figure US20050014840A1-20050120-C00837
    Figure US20050014840A1-20050120-C00838
    Figure US20050014840A1-20050120-C00839
    Figure US20050014840A1-20050120-C00840
    Figure US20050014840A1-20050120-C00841
    Figure US20050014840A1-20050120-C00842
    Figure US20050014840A1-20050120-C00843
    Figure US20050014840A1-20050120-C00844
    Figure US20050014840A1-20050120-C00845
    Figure US20050014840A1-20050120-C00846
    Figure US20050014840A1-20050120-C00847
    Figure US20050014840A1-20050120-C00848
    Figure US20050014840A1-20050120-C00849
    Figure US20050014840A1-20050120-C00850
  • TABLE 31
    Figure US20050014840A1-20050120-C00851
    Figure US20050014840A1-20050120-C00852
    Figure US20050014840A1-20050120-C00853
    Figure US20050014840A1-20050120-C00854
    Figure US20050014840A1-20050120-C00855
    Figure US20050014840A1-20050120-C00856
    Figure US20050014840A1-20050120-C00857
    Figure US20050014840A1-20050120-C00858
    Figure US20050014840A1-20050120-C00859
    Figure US20050014840A1-20050120-C00860
    Figure US20050014840A1-20050120-C00861
    Figure US20050014840A1-20050120-C00862
    Figure US20050014840A1-20050120-C00863
    Figure US20050014840A1-20050120-C00864
    Figure US20050014840A1-20050120-C00865
    Figure US20050014840A1-20050120-C00866
    Figure US20050014840A1-20050120-C00867
  • TABLE 32
    Figure US20050014840A1-20050120-C00868
    Figure US20050014840A1-20050120-C00869
    Figure US20050014840A1-20050120-C00870
    Figure US20050014840A1-20050120-C00871
    Figure US20050014840A1-20050120-C00872
    Figure US20050014840A1-20050120-C00873
    Figure US20050014840A1-20050120-C00874
    Figure US20050014840A1-20050120-C00875
    Figure US20050014840A1-20050120-C00876
    Figure US20050014840A1-20050120-C00877
    Figure US20050014840A1-20050120-C00878
    Figure US20050014840A1-20050120-C00879
    Figure US20050014840A1-20050120-C00880
    Figure US20050014840A1-20050120-C00881
    Figure US20050014840A1-20050120-C00882
    Figure US20050014840A1-20050120-C00883
    Figure US20050014840A1-20050120-C00884
  • TABLE 33
    Figure US20050014840A1-20050120-C00885
    Figure US20050014840A1-20050120-C00886
    Figure US20050014840A1-20050120-C00887
    Figure US20050014840A1-20050120-C00888
    Figure US20050014840A1-20050120-C00889
    Figure US20050014840A1-20050120-C00890
    Figure US20050014840A1-20050120-C00891
    Figure US20050014840A1-20050120-C00892
    Figure US20050014840A1-20050120-C00893
    Figure US20050014840A1-20050120-C00894
    Figure US20050014840A1-20050120-C00895
    Figure US20050014840A1-20050120-C00896
    Figure US20050014840A1-20050120-C00897
  • TABLE 34
    Figure US20050014840A1-20050120-C00898
    Figure US20050014840A1-20050120-C00899
    Figure US20050014840A1-20050120-C00900
    Figure US20050014840A1-20050120-C00901
    Figure US20050014840A1-20050120-C00902
    Figure US20050014840A1-20050120-C00903
    Figure US20050014840A1-20050120-C00904
    Figure US20050014840A1-20050120-C00905
    Figure US20050014840A1-20050120-C00906
    Figure US20050014840A1-20050120-C00907
    Figure US20050014840A1-20050120-C00908
    Figure US20050014840A1-20050120-C00909
    Figure US20050014840A1-20050120-C00910
  • TABLE 35
    Figure US20050014840A1-20050120-C00911
    Figure US20050014840A1-20050120-C00912
    Figure US20050014840A1-20050120-C00913
    Figure US20050014840A1-20050120-C00914
    Figure US20050014840A1-20050120-C00915
    Figure US20050014840A1-20050120-C00916
    Figure US20050014840A1-20050120-C00917
    Figure US20050014840A1-20050120-C00918
    Figure US20050014840A1-20050120-C00919
    Figure US20050014840A1-20050120-C00920
    Figure US20050014840A1-20050120-C00921
    Figure US20050014840A1-20050120-C00922
    Figure US20050014840A1-20050120-C00923
  • TABLE 36
    Figure US20050014840A1-20050120-C00924
    Figure US20050014840A1-20050120-C00925
    Figure US20050014840A1-20050120-C00926
    Figure US20050014840A1-20050120-C00927
    Figure US20050014840A1-20050120-C00928
    Figure US20050014840A1-20050120-C00929
    Figure US20050014840A1-20050120-C00930
    Figure US20050014840A1-20050120-C00931
    Figure US20050014840A1-20050120-C00932
    Figure US20050014840A1-20050120-C00933
    Figure US20050014840A1-20050120-C00934
    Figure US20050014840A1-20050120-C00935
    Figure US20050014840A1-20050120-C00936
  • TABLE 37
    Figure US20050014840A1-20050120-C00937
    Figure US20050014840A1-20050120-C00938
    Figure US20050014840A1-20050120-C00939
    Figure US20050014840A1-20050120-C00940
    Figure US20050014840A1-20050120-C00941
    Figure US20050014840A1-20050120-C00942
    Figure US20050014840A1-20050120-C00943
    Figure US20050014840A1-20050120-C00944
    Figure US20050014840A1-20050120-C00945
    Figure US20050014840A1-20050120-C00946
    Figure US20050014840A1-20050120-C00947
    Figure US20050014840A1-20050120-C00948
    Figure US20050014840A1-20050120-C00949
  • TABLE 38
    Figure US20050014840A1-20050120-C00950
    Figure US20050014840A1-20050120-C00951
    Figure US20050014840A1-20050120-C00952
    Figure US20050014840A1-20050120-C00953
    Figure US20050014840A1-20050120-C00954
    Figure US20050014840A1-20050120-C00955
    Figure US20050014840A1-20050120-C00956
    Figure US20050014840A1-20050120-C00957
    Figure US20050014840A1-20050120-C00958
    Figure US20050014840A1-20050120-C00959
    Figure US20050014840A1-20050120-C00960
    Figure US20050014840A1-20050120-C00961
    Figure US20050014840A1-20050120-C00962
  • TABLE 39
    Figure US20050014840A1-20050120-C00963
    Figure US20050014840A1-20050120-C00964
    Figure US20050014840A1-20050120-C00965
    Figure US20050014840A1-20050120-C00966
    Figure US20050014840A1-20050120-C00967
    Figure US20050014840A1-20050120-C00968
    Figure US20050014840A1-20050120-C00969
    Figure US20050014840A1-20050120-C00970
    Figure US20050014840A1-20050120-C00971
    Figure US20050014840A1-20050120-C00972
    Figure US20050014840A1-20050120-C00973
    Figure US20050014840A1-20050120-C00974
    Figure US20050014840A1-20050120-C00975
    Figure US20050014840A1-20050120-C00976
    Figure US20050014840A1-20050120-C00977
    Figure US20050014840A1-20050120-C00978
    Figure US20050014840A1-20050120-C00979
    Figure US20050014840A1-20050120-C00980
    Figure US20050014840A1-20050120-C00981
    Figure US20050014840A1-20050120-C00982
    Figure US20050014840A1-20050120-C00983
    Figure US20050014840A1-20050120-C00984
    Figure US20050014840A1-20050120-C00985
    Figure US20050014840A1-20050120-C00986
  • TABLE 40
    Figure US20050014840A1-20050120-C00987
    Figure US20050014840A1-20050120-C00988
    Figure US20050014840A1-20050120-C00989
    Figure US20050014840A1-20050120-C00990
    Figure US20050014840A1-20050120-C00991
    Figure US20050014840A1-20050120-C00992
    Figure US20050014840A1-20050120-C00993
    Figure US20050014840A1-20050120-C00994
    Figure US20050014840A1-20050120-C00995
    Figure US20050014840A1-20050120-C00996
    Figure US20050014840A1-20050120-C00997
    Figure US20050014840A1-20050120-C00998
    Figure US20050014840A1-20050120-C00999
    Figure US20050014840A1-20050120-C01000
    Figure US20050014840A1-20050120-C01001
    Figure US20050014840A1-20050120-C01002
    Figure US20050014840A1-20050120-C01003
    Figure US20050014840A1-20050120-C01004
    Figure US20050014840A1-20050120-C01005
    Figure US20050014840A1-20050120-C01006
    Figure US20050014840A1-20050120-C01007
    Figure US20050014840A1-20050120-C01008
    Figure US20050014840A1-20050120-C01009
    Figure US20050014840A1-20050120-C01010
  • TABLE 41
    Figure US20050014840A1-20050120-C01011
    Figure US20050014840A1-20050120-C01012
    Figure US20050014840A1-20050120-C01013
    Figure US20050014840A1-20050120-C01014
    Figure US20050014840A1-20050120-C01015
    Figure US20050014840A1-20050120-C01016
    Figure US20050014840A1-20050120-C01017
    Figure US20050014840A1-20050120-C01018
    Figure US20050014840A1-20050120-C01019
    Figure US20050014840A1-20050120-C01020
    Figure US20050014840A1-20050120-C01021
    Figure US20050014840A1-20050120-C01022
    Figure US20050014840A1-20050120-C01023
    Figure US20050014840A1-20050120-C01024
    Figure US20050014840A1-20050120-C01025
    Figure US20050014840A1-20050120-C01026
    Figure US20050014840A1-20050120-C01027
    Figure US20050014840A1-20050120-C01028
    Figure US20050014840A1-20050120-C01029
    Figure US20050014840A1-20050120-C01030
    Figure US20050014840A1-20050120-C01031
    Figure US20050014840A1-20050120-C01032
    Figure US20050014840A1-20050120-C01033
    Figure US20050014840A1-20050120-C01034
    Figure US20050014840A1-20050120-C01035
  • TABLE 42
    Figure US20050014840A1-20050120-C01036
    Figure US20050014840A1-20050120-C01037
    Figure US20050014840A1-20050120-C01038
    Figure US20050014840A1-20050120-C01039
    Figure US20050014840A1-20050120-C01040
    Figure US20050014840A1-20050120-C01041
    Figure US20050014840A1-20050120-C01042
    Figure US20050014840A1-20050120-C01043
    Figure US20050014840A1-20050120-C01044
    Figure US20050014840A1-20050120-C01045
    Figure US20050014840A1-20050120-C01046
    Figure US20050014840A1-20050120-C01047
    Figure US20050014840A1-20050120-C01048
    Figure US20050014840A1-20050120-C01049
    Figure US20050014840A1-20050120-C01050
    Figure US20050014840A1-20050120-C01051
    Figure US20050014840A1-20050120-C01052
    Figure US20050014840A1-20050120-C01053
    Figure US20050014840A1-20050120-C01054
    Figure US20050014840A1-20050120-C01055
    Figure US20050014840A1-20050120-C01056
    Figure US20050014840A1-20050120-C01057
    Figure US20050014840A1-20050120-C01058
    Figure US20050014840A1-20050120-C01059
    Figure US20050014840A1-20050120-C01060
  • TABLE 43
    Figure US20050014840A1-20050120-C01061
    Figure US20050014840A1-20050120-C01062
    Figure US20050014840A1-20050120-C01063
    Figure US20050014840A1-20050120-C01064
    Figure US20050014840A1-20050120-C01065
    Figure US20050014840A1-20050120-C01066
    Figure US20050014840A1-20050120-C01067
    Figure US20050014840A1-20050120-C01068
    Figure US20050014840A1-20050120-C01069
    Figure US20050014840A1-20050120-C01070
    Figure US20050014840A1-20050120-C01071
    Figure US20050014840A1-20050120-C01072
    Figure US20050014840A1-20050120-C01073
    Figure US20050014840A1-20050120-C01074
    Figure US20050014840A1-20050120-C01075
    Figure US20050014840A1-20050120-C01076
    Figure US20050014840A1-20050120-C01077
    Figure US20050014840A1-20050120-C01078
    Figure US20050014840A1-20050120-C01079
    Figure US20050014840A1-20050120-C01080
    Figure US20050014840A1-20050120-C01081
    Figure US20050014840A1-20050120-C01082
    Figure US20050014840A1-20050120-C01083
    Figure US20050014840A1-20050120-C01084
    Figure US20050014840A1-20050120-C01085
  • TABLE 44
    Figure US20050014840A1-20050120-C01086
    Figure US20050014840A1-20050120-C01087
    Figure US20050014840A1-20050120-C01088
    Figure US20050014840A1-20050120-C01089
    Figure US20050014840A1-20050120-C01090
    Figure US20050014840A1-20050120-C01091
    Figure US20050014840A1-20050120-C01092
    Figure US20050014840A1-20050120-C01093
    Figure US20050014840A1-20050120-C01094
    Figure US20050014840A1-20050120-C01095
    Figure US20050014840A1-20050120-C01096
    Figure US20050014840A1-20050120-C01097
    Figure US20050014840A1-20050120-C01098
    Figure US20050014840A1-20050120-C01099
    Figure US20050014840A1-20050120-C01100
    Figure US20050014840A1-20050120-C01101
    Figure US20050014840A1-20050120-C01102
    Figure US20050014840A1-20050120-C01103
    Figure US20050014840A1-20050120-C01104
    Figure US20050014840A1-20050120-C01105
    Figure US20050014840A1-20050120-C01106
    Figure US20050014840A1-20050120-C01107
    Figure US20050014840A1-20050120-C01108
    Figure US20050014840A1-20050120-C01109
    Figure US20050014840A1-20050120-C01110
  • TABLE 45
    Figure US20050014840A1-20050120-C01111
    Figure US20050014840A1-20050120-C01112
    Figure US20050014840A1-20050120-C01113
    Figure US20050014840A1-20050120-C01114
    Figure US20050014840A1-20050120-C01115
    Figure US20050014840A1-20050120-C01116
    Figure US20050014840A1-20050120-C01117
    Figure US20050014840A1-20050120-C01118
    Figure US20050014840A1-20050120-C01119
    Figure US20050014840A1-20050120-C01120
    Figure US20050014840A1-20050120-C01121
    Figure US20050014840A1-20050120-C01122
  • TABLE 46
    Figure US20050014840A1-20050120-C01123
    Figure US20050014840A1-20050120-C01124
    Figure US20050014840A1-20050120-C01125
    Figure US20050014840A1-20050120-C01126
    Figure US20050014840A1-20050120-C01127
    Figure US20050014840A1-20050120-C01128
    Figure US20050014840A1-20050120-C01129
    Figure US20050014840A1-20050120-C01130
    Figure US20050014840A1-20050120-C01131
    Figure US20050014840A1-20050120-C01132
    Figure US20050014840A1-20050120-C01133
    Figure US20050014840A1-20050120-C01134
    Figure US20050014840A1-20050120-C01135
    Figure US20050014840A1-20050120-C01136
    Figure US20050014840A1-20050120-C01137
    Figure US20050014840A1-20050120-C01138
    Figure US20050014840A1-20050120-C01139
    Figure US20050014840A1-20050120-C01140
    Figure US20050014840A1-20050120-C01141
    Figure US20050014840A1-20050120-C01142
    Figure US20050014840A1-20050120-C01143
    Figure US20050014840A1-20050120-C01144
    Figure US20050014840A1-20050120-C01145
    Figure US20050014840A1-20050120-C01146
    Figure US20050014840A1-20050120-C01147
    Figure US20050014840A1-20050120-C01148
    Figure US20050014840A1-20050120-C01149
    Figure US20050014840A1-20050120-C01150
    Figure US20050014840A1-20050120-C01151
    Figure US20050014840A1-20050120-C01152
    Figure US20050014840A1-20050120-C01153
    Figure US20050014840A1-20050120-C01154
    Figure US20050014840A1-20050120-C01155
  • TABLE 47
    Figure US20050014840A1-20050120-C01156
    Figure US20050014840A1-20050120-C01157
    Figure US20050014840A1-20050120-C01158
    Figure US20050014840A1-20050120-C01159
    Figure US20050014840A1-20050120-C01160
    Figure US20050014840A1-20050120-C01161
    Figure US20050014840A1-20050120-C01162
    Figure US20050014840A1-20050120-C01163
    Figure US20050014840A1-20050120-C01164
    Figure US20050014840A1-20050120-C01165
    Figure US20050014840A1-20050120-C01166
    Figure US20050014840A1-20050120-C01167
    Figure US20050014840A1-20050120-C01168
    Figure US20050014840A1-20050120-C01169
    Figure US20050014840A1-20050120-C01170
    Figure US20050014840A1-20050120-C01171
    Figure US20050014840A1-20050120-C01172
    Figure US20050014840A1-20050120-C01173
    Figure US20050014840A1-20050120-C01174
    Figure US20050014840A1-20050120-C01175
    Figure US20050014840A1-20050120-C01176
    Figure US20050014840A1-20050120-C01177
    Figure US20050014840A1-20050120-C01178
    Figure US20050014840A1-20050120-C01179
    Figure US20050014840A1-20050120-C01180
    Figure US20050014840A1-20050120-C01181
    Figure US20050014840A1-20050120-C01182
    Figure US20050014840A1-20050120-C01183
    Figure US20050014840A1-20050120-C01184
    Figure US20050014840A1-20050120-C01185
    Figure US20050014840A1-20050120-C01186
    Figure US20050014840A1-20050120-C01187
    Figure US20050014840A1-20050120-C01188
    Figure US20050014840A1-20050120-C01189
  • TABLE 48
    Figure US20050014840A1-20050120-C01190
    Figure US20050014840A1-20050120-C01191
    Figure US20050014840A1-20050120-C01192
    Figure US20050014840A1-20050120-C01193
    Figure US20050014840A1-20050120-C01194
    Figure US20050014840A1-20050120-C01195
    Figure US20050014840A1-20050120-C01196
    Figure US20050014840A1-20050120-C01197
    Figure US20050014840A1-20050120-C01198
    Figure US20050014840A1-20050120-C01199
    Figure US20050014840A1-20050120-C01200
    Figure US20050014840A1-20050120-C01201
    Figure US20050014840A1-20050120-C01202
    Figure US20050014840A1-20050120-C01203
    Figure US20050014840A1-20050120-C01204
    Figure US20050014840A1-20050120-C01205
    Figure US20050014840A1-20050120-C01206
    Figure US20050014840A1-20050120-C01207
    Figure US20050014840A1-20050120-C01208
    Figure US20050014840A1-20050120-C01209
    Figure US20050014840A1-20050120-C01210
    Figure US20050014840A1-20050120-C01211
    Figure US20050014840A1-20050120-C01212
    Figure US20050014840A1-20050120-C01213
    Figure US20050014840A1-20050120-C01214
    Figure US20050014840A1-20050120-C01215
    Figure US20050014840A1-20050120-C01216
    Figure US20050014840A1-20050120-C01217
    Figure US20050014840A1-20050120-C01218
    Figure US20050014840A1-20050120-C01219
    Figure US20050014840A1-20050120-C01220
    Figure US20050014840A1-20050120-C01221
    Figure US20050014840A1-20050120-C01222
  • TABLE 49
    Figure US20050014840A1-20050120-C01223
    —R2
    —H —CH3
    Figure US20050014840A1-20050120-C01224
    Figure US20050014840A1-20050120-C01225
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C01226
    Figure US20050014840A1-20050120-C01227
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C01228
    Figure US20050014840A1-20050120-C01229
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C01230
    Figure US20050014840A1-20050120-C01231
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C01232
    Figure US20050014840A1-20050120-C01233
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C01234
    Figure US20050014840A1-20050120-C01235
    Figure US20050014840A1-20050120-C01236
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C01237
    Figure US20050014840A1-20050120-C01238
    Figure US20050014840A1-20050120-C01239
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C01240
    Figure US20050014840A1-20050120-C01241
    Figure US20050014840A1-20050120-C01242
    Figure US20050014840A1-20050120-C01243
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C01244
    Figure US20050014840A1-20050120-C01245
  • TABLE 50
    Figure US20050014840A1-20050120-C01246
    Figure US20050014840A1-20050120-C01247
    Figure US20050014840A1-20050120-C01248
    Figure US20050014840A1-20050120-C01249
    Figure US20050014840A1-20050120-C01250
    Figure US20050014840A1-20050120-C01251
    Figure US20050014840A1-20050120-C01252
    Figure US20050014840A1-20050120-C01253
    Figure US20050014840A1-20050120-C01254
    Figure US20050014840A1-20050120-C01255
    Figure US20050014840A1-20050120-C01256
    Figure US20050014840A1-20050120-C01257
    Figure US20050014840A1-20050120-C01258
    Figure US20050014840A1-20050120-C01259
    Figure US20050014840A1-20050120-C01260
    Figure US20050014840A1-20050120-C01261
    Figure US20050014840A1-20050120-C01262
    Figure US20050014840A1-20050120-C01263
    Figure US20050014840A1-20050120-C01264
    Figure US20050014840A1-20050120-C01265
    Figure US20050014840A1-20050120-C01266
    Figure US20050014840A1-20050120-C01267
    Figure US20050014840A1-20050120-C01268
    Figure US20050014840A1-20050120-C01269
    Figure US20050014840A1-20050120-C01270
    Figure US20050014840A1-20050120-C01271
  • TABLE 51
    Figure US20050014840A1-20050120-C01272
    Figure US20050014840A1-20050120-C01273
    Figure US20050014840A1-20050120-C01274
    Figure US20050014840A1-20050120-C01275
    Figure US20050014840A1-20050120-C01276
    Figure US20050014840A1-20050120-C01277
    Figure US20050014840A1-20050120-C01278
    Figure US20050014840A1-20050120-C01279
    Figure US20050014840A1-20050120-C01280
    Figure US20050014840A1-20050120-C01281
    Figure US20050014840A1-20050120-C01282
    Figure US20050014840A1-20050120-C01283
    Figure US20050014840A1-20050120-C01284
    Figure US20050014840A1-20050120-C01285
    Figure US20050014840A1-20050120-C01286
    Figure US20050014840A1-20050120-C01287
    Figure US20050014840A1-20050120-C01288
    Figure US20050014840A1-20050120-C01289
    Figure US20050014840A1-20050120-C01290
    Figure US20050014840A1-20050120-C01291
    Figure US20050014840A1-20050120-C01292
    Figure US20050014840A1-20050120-C01293
    Figure US20050014840A1-20050120-C01294
    Figure US20050014840A1-20050120-C01295
    Figure US20050014840A1-20050120-C01296
    Figure US20050014840A1-20050120-C01297
  • TABLE 52
    Figure US20050014840A1-20050120-C01298
    Figure US20050014840A1-20050120-C01299
    Figure US20050014840A1-20050120-C01300
    Figure US20050014840A1-20050120-C01301
    Figure US20050014840A1-20050120-C01302
    Figure US20050014840A1-20050120-C01303
    Figure US20050014840A1-20050120-C01304
    Figure US20050014840A1-20050120-C01305
    Figure US20050014840A1-20050120-C01306
    Figure US20050014840A1-20050120-C01307
    Figure US20050014840A1-20050120-C01308
    Figure US20050014840A1-20050120-C01309
    Figure US20050014840A1-20050120-C01310
    Figure US20050014840A1-20050120-C01311
    Figure US20050014840A1-20050120-C01312
    Figure US20050014840A1-20050120-C01313
    Figure US20050014840A1-20050120-C01314
    Figure US20050014840A1-20050120-C01315
    Figure US20050014840A1-20050120-C01316
    Figure US20050014840A1-20050120-C01317
    Figure US20050014840A1-20050120-C01318
    Figure US20050014840A1-20050120-C01319
    Figure US20050014840A1-20050120-C01320
    Figure US20050014840A1-20050120-C01321
    Figure US20050014840A1-20050120-C01322
    Figure US20050014840A1-20050120-C01323
  • TABLE 53
    Figure US20050014840A1-20050120-C01324
    Figure US20050014840A1-20050120-C01325
    Figure US20050014840A1-20050120-C01326
    Figure US20050014840A1-20050120-C01327
    Figure US20050014840A1-20050120-C01328
    Figure US20050014840A1-20050120-C01329
    Figure US20050014840A1-20050120-C01330
    Figure US20050014840A1-20050120-C01331
    Figure US20050014840A1-20050120-C01332
    Figure US20050014840A1-20050120-C01333
    Figure US20050014840A1-20050120-C01334
    Figure US20050014840A1-20050120-C01335
    Figure US20050014840A1-20050120-C01336
    Figure US20050014840A1-20050120-C01337
    Figure US20050014840A1-20050120-C01338
    Figure US20050014840A1-20050120-C01339
    Figure US20050014840A1-20050120-C01340
    Figure US20050014840A1-20050120-C01341
    Figure US20050014840A1-20050120-C01342
    Figure US20050014840A1-20050120-C01343
    Figure US20050014840A1-20050120-C01344
    Figure US20050014840A1-20050120-C01345
    Figure US20050014840A1-20050120-C01346
    Figure US20050014840A1-20050120-C01347
    Figure US20050014840A1-20050120-C01348
    Figure US20050014840A1-20050120-C01349
  • TABLE 54
    Figure US20050014840A1-20050120-C01350
    Figure US20050014840A1-20050120-C01351
    Figure US20050014840A1-20050120-C01352
    Figure US20050014840A1-20050120-C01353
    Figure US20050014840A1-20050120-C01354
    Figure US20050014840A1-20050120-C01355
    Figure US20050014840A1-20050120-C01356
    Figure US20050014840A1-20050120-C01357
    Figure US20050014840A1-20050120-C01358
    Figure US20050014840A1-20050120-C01359
    Figure US20050014840A1-20050120-C01360
    Figure US20050014840A1-20050120-C01361
    Figure US20050014840A1-20050120-C01362
    Figure US20050014840A1-20050120-C01363
    Figure US20050014840A1-20050120-C01364
    Figure US20050014840A1-20050120-C01365
    Figure US20050014840A1-20050120-C01366
    Figure US20050014840A1-20050120-C01367
    Figure US20050014840A1-20050120-C01368
    Figure US20050014840A1-20050120-C01369
    Figure US20050014840A1-20050120-C01370
    Figure US20050014840A1-20050120-C01371
    Figure US20050014840A1-20050120-C01372
    Figure US20050014840A1-20050120-C01373
    Figure US20050014840A1-20050120-C01374
    Figure US20050014840A1-20050120-C01375
  • TABLE 55
    Figure US20050014840A1-20050120-C01376
    Figure US20050014840A1-20050120-C01377
    Figure US20050014840A1-20050120-C01378
    Figure US20050014840A1-20050120-C01379
    Figure US20050014840A1-20050120-C01380
    Figure US20050014840A1-20050120-C01381
    Figure US20050014840A1-20050120-C01382
    Figure US20050014840A1-20050120-C01383
    Figure US20050014840A1-20050120-C01384
    Figure US20050014840A1-20050120-C01385
    Figure US20050014840A1-20050120-C01386
    Figure US20050014840A1-20050120-C01387
    Figure US20050014840A1-20050120-C01388
    Figure US20050014840A1-20050120-C01389
    Figure US20050014840A1-20050120-C01390
    Figure US20050014840A1-20050120-C01391
    Figure US20050014840A1-20050120-C01392
    Figure US20050014840A1-20050120-C01393
    Figure US20050014840A1-20050120-C01394
    Figure US20050014840A1-20050120-C01395
    Figure US20050014840A1-20050120-C01396
    Figure US20050014840A1-20050120-C01397
    Figure US20050014840A1-20050120-C01398
    Figure US20050014840A1-20050120-C01399
    Figure US20050014840A1-20050120-C01400
    Figure US20050014840A1-20050120-C01401
  • TABLE 56
    Figure US20050014840A1-20050120-C01402
    Figure US20050014840A1-20050120-C01403
    Figure US20050014840A1-20050120-C01404
    Figure US20050014840A1-20050120-C01405
    Figure US20050014840A1-20050120-C01406
    Figure US20050014840A1-20050120-C01407
    Figure US20050014840A1-20050120-C01408
    Figure US20050014840A1-20050120-C01409
    Figure US20050014840A1-20050120-C01410
    Figure US20050014840A1-20050120-C01411
    Figure US20050014840A1-20050120-C01412
    Figure US20050014840A1-20050120-C01413
    Figure US20050014840A1-20050120-C01414
    Figure US20050014840A1-20050120-C01415
    Figure US20050014840A1-20050120-C01416
    Figure US20050014840A1-20050120-C01417
    Figure US20050014840A1-20050120-C01418
    Figure US20050014840A1-20050120-C01419
    Figure US20050014840A1-20050120-C01420
    Figure US20050014840A1-20050120-C01421
    Figure US20050014840A1-20050120-C01422
    Figure US20050014840A1-20050120-C01423
    Figure US20050014840A1-20050120-C01424
    Figure US20050014840A1-20050120-C01425
    Figure US20050014840A1-20050120-C01426
    Figure US20050014840A1-20050120-C01427
  • TABLE 57
    Figure US20050014840A1-20050120-C01428
    Figure US20050014840A1-20050120-C01429
    Figure US20050014840A1-20050120-C01430
    Figure US20050014840A1-20050120-C01431
    Figure US20050014840A1-20050120-C01432
    Figure US20050014840A1-20050120-C01433
    Figure US20050014840A1-20050120-C01434
    Figure US20050014840A1-20050120-C01435
    Figure US20050014840A1-20050120-C01436
    Figure US20050014840A1-20050120-C01437
    Figure US20050014840A1-20050120-C01438
    Figure US20050014840A1-20050120-C01439
    Figure US20050014840A1-20050120-C01440
    Figure US20050014840A1-20050120-C01441
    Figure US20050014840A1-20050120-C01442
    Figure US20050014840A1-20050120-C01443
    Figure US20050014840A1-20050120-C01444
    Figure US20050014840A1-20050120-C01445
    Figure US20050014840A1-20050120-C01446
    Figure US20050014840A1-20050120-C01447
    Figure US20050014840A1-20050120-C01448
    Figure US20050014840A1-20050120-C01449
    Figure US20050014840A1-20050120-C01450
    Figure US20050014840A1-20050120-C01451
    Figure US20050014840A1-20050120-C01452
    Figure US20050014840A1-20050120-C01453
  • TABLE 58
    Figure US20050014840A1-20050120-C01454
    Figure US20050014840A1-20050120-C01455
    Figure US20050014840A1-20050120-C01456
    Figure US20050014840A1-20050120-C01457
    Figure US20050014840A1-20050120-C01458
    Figure US20050014840A1-20050120-C01459
    Figure US20050014840A1-20050120-C01460
    Figure US20050014840A1-20050120-C01461
    Figure US20050014840A1-20050120-C01462
    Figure US20050014840A1-20050120-C01463
    Figure US20050014840A1-20050120-C01464
    Figure US20050014840A1-20050120-C01465
    Figure US20050014840A1-20050120-C01466
    Figure US20050014840A1-20050120-C01467
    Figure US20050014840A1-20050120-C01468
    Figure US20050014840A1-20050120-C01469
    Figure US20050014840A1-20050120-C01470
    Figure US20050014840A1-20050120-C01471
    Figure US20050014840A1-20050120-C01472
    Figure US20050014840A1-20050120-C01473
    Figure US20050014840A1-20050120-C01474
    Figure US20050014840A1-20050120-C01475
    Figure US20050014840A1-20050120-C01476
    Figure US20050014840A1-20050120-C01477
    Figure US20050014840A1-20050120-C01478
    Figure US20050014840A1-20050120-C01479
  • TABLE 59
    Figure US20050014840A1-20050120-C01480
    Figure US20050014840A1-20050120-C01481
    Figure US20050014840A1-20050120-C01482
    Figure US20050014840A1-20050120-C01483
    Figure US20050014840A1-20050120-C01484
    Figure US20050014840A1-20050120-C01485
    Figure US20050014840A1-20050120-C01486
    Figure US20050014840A1-20050120-C01487
    Figure US20050014840A1-20050120-C01488
    Figure US20050014840A1-20050120-C01489
    Figure US20050014840A1-20050120-C01490
    Figure US20050014840A1-20050120-C01491
    Figure US20050014840A1-20050120-C01492
    Figure US20050014840A1-20050120-C01493
    Figure US20050014840A1-20050120-C01494
    Figure US20050014840A1-20050120-C01495
    Figure US20050014840A1-20050120-C01496
    Figure US20050014840A1-20050120-C01497
    Figure US20050014840A1-20050120-C01498
    Figure US20050014840A1-20050120-C01499
    Figure US20050014840A1-20050120-C01500
    Figure US20050014840A1-20050120-C01501
    Figure US20050014840A1-20050120-C01502
    Figure US20050014840A1-20050120-C01503
    Figure US20050014840A1-20050120-C01504
    Figure US20050014840A1-20050120-C01505
  • TABLE 60
    Figure US20050014840A1-20050120-C01506
    Figure US20050014840A1-20050120-C01507
    Figure US20050014840A1-20050120-C01508
    Figure US20050014840A1-20050120-C01509
    Figure US20050014840A1-20050120-C01510
    Figure US20050014840A1-20050120-C01511
    Figure US20050014840A1-20050120-C01512
    Figure US20050014840A1-20050120-C01513
    Figure US20050014840A1-20050120-C01514
    Figure US20050014840A1-20050120-C01515
    Figure US20050014840A1-20050120-C01516
    Figure US20050014840A1-20050120-C01517
    Figure US20050014840A1-20050120-C01518
    Figure US20050014840A1-20050120-C01519
    Figure US20050014840A1-20050120-C01520
    Figure US20050014840A1-20050120-C01521
    Figure US20050014840A1-20050120-C01522
    Figure US20050014840A1-20050120-C01523
    Figure US20050014840A1-20050120-C01524
    Figure US20050014840A1-20050120-C01525
    Figure US20050014840A1-20050120-C01526
    Figure US20050014840A1-20050120-C01527
    Figure US20050014840A1-20050120-C01528
    Figure US20050014840A1-20050120-C01529
    Figure US20050014840A1-20050120-C01530
    Figure US20050014840A1-20050120-C01531
  • TABLE 61
    Figure US20050014840A1-20050120-C01532
    Figure US20050014840A1-20050120-C01533
    Figure US20050014840A1-20050120-C01534
    Figure US20050014840A1-20050120-C01535
    Figure US20050014840A1-20050120-C01536
    Figure US20050014840A1-20050120-C01537
    Figure US20050014840A1-20050120-C01538
    Figure US20050014840A1-20050120-C01539
    Figure US20050014840A1-20050120-C01540
    Figure US20050014840A1-20050120-C01541
    Figure US20050014840A1-20050120-C01542
    Figure US20050014840A1-20050120-C01543
    Figure US20050014840A1-20050120-C01544
    Figure US20050014840A1-20050120-C01545
    Figure US20050014840A1-20050120-C01546
    Figure US20050014840A1-20050120-C01547
    Figure US20050014840A1-20050120-C01548
    Figure US20050014840A1-20050120-C01549
    Figure US20050014840A1-20050120-C01550
    Figure US20050014840A1-20050120-C01551
    Figure US20050014840A1-20050120-C01552
    Figure US20050014840A1-20050120-C01553
    Figure US20050014840A1-20050120-C01554
    Figure US20050014840A1-20050120-C01555
    Figure US20050014840A1-20050120-C01556
    Figure US20050014840A1-20050120-C01557
  • TABLE 62
    Figure US20050014840A1-20050120-C01558
    Figure US20050014840A1-20050120-C01559
    Figure US20050014840A1-20050120-C01560
    Figure US20050014840A1-20050120-C01561
    Figure US20050014840A1-20050120-C01562
    Figure US20050014840A1-20050120-C01563
    Figure US20050014840A1-20050120-C01564
    Figure US20050014840A1-20050120-C01565
    Figure US20050014840A1-20050120-C01566
    Figure US20050014840A1-20050120-C01567
    Figure US20050014840A1-20050120-C01568
    Figure US20050014840A1-20050120-C01569
    Figure US20050014840A1-20050120-C01570
    Figure US20050014840A1-20050120-C01571
    Figure US20050014840A1-20050120-C01572
    Figure US20050014840A1-20050120-C01573
    Figure US20050014840A1-20050120-C01574
    Figure US20050014840A1-20050120-C01575
    Figure US20050014840A1-20050120-C01576
    Figure US20050014840A1-20050120-C01577
    Figure US20050014840A1-20050120-C01578
    Figure US20050014840A1-20050120-C01579
    Figure US20050014840A1-20050120-C01580
    Figure US20050014840A1-20050120-C01581
    Figure US20050014840A1-20050120-C01582
    Figure US20050014840A1-20050120-C01583
  • TABLE 63
    Figure US20050014840A1-20050120-C01584
    Figure US20050014840A1-20050120-C01585
    Figure US20050014840A1-20050120-C01586
    Figure US20050014840A1-20050120-C01587
    Figure US20050014840A1-20050120-C01588
    Figure US20050014840A1-20050120-C01589
    Figure US20050014840A1-20050120-C01590
    Figure US20050014840A1-20050120-C01591
    Figure US20050014840A1-20050120-C01592
    Figure US20050014840A1-20050120-C01593
    Figure US20050014840A1-20050120-C01594
    Figure US20050014840A1-20050120-C01595
    Figure US20050014840A1-20050120-C01596
    Figure US20050014840A1-20050120-C01597
    Figure US20050014840A1-20050120-C01598
    Figure US20050014840A1-20050120-C01599
    Figure US20050014840A1-20050120-C01600
    Figure US20050014840A1-20050120-C01601
    Figure US20050014840A1-20050120-C01602
    Figure US20050014840A1-20050120-C01603
    Figure US20050014840A1-20050120-C01604
    Figure US20050014840A1-20050120-C01605
    Figure US20050014840A1-20050120-C01606
    Figure US20050014840A1-20050120-C01607
    Figure US20050014840A1-20050120-C01608
    Figure US20050014840A1-20050120-C01609
  • TABLE 64
    Figure US20050014840A1-20050120-C01610
    Figure US20050014840A1-20050120-C01611
    Figure US20050014840A1-20050120-C01612
    Figure US20050014840A1-20050120-C01613
    Figure US20050014840A1-20050120-C01614
    Figure US20050014840A1-20050120-C01615
    Figure US20050014840A1-20050120-C01616
    Figure US20050014840A1-20050120-C01617
    Figure US20050014840A1-20050120-C01618
    Figure US20050014840A1-20050120-C01619
    Figure US20050014840A1-20050120-C01620
    Figure US20050014840A1-20050120-C01621
    Figure US20050014840A1-20050120-C01622
    Figure US20050014840A1-20050120-C01623
    Figure US20050014840A1-20050120-C01624
    Figure US20050014840A1-20050120-C01625
    Figure US20050014840A1-20050120-C01626
    Figure US20050014840A1-20050120-C01627
    Figure US20050014840A1-20050120-C01628
    Figure US20050014840A1-20050120-C01629
    Figure US20050014840A1-20050120-C01630
    Figure US20050014840A1-20050120-C01631
    Figure US20050014840A1-20050120-C01632
    Figure US20050014840A1-20050120-C01633
    Figure US20050014840A1-20050120-C01634
    Figure US20050014840A1-20050120-C01635
  • TABLE 65
    Figure US20050014840A1-20050120-C01636
    Figure US20050014840A1-20050120-C01637
    Figure US20050014840A1-20050120-C01638
    Figure US20050014840A1-20050120-C01639
    Figure US20050014840A1-20050120-C01640
    Figure US20050014840A1-20050120-C01641
    Figure US20050014840A1-20050120-C01642
    Figure US20050014840A1-20050120-C01643
    Figure US20050014840A1-20050120-C01644
    Figure US20050014840A1-20050120-C01645
    Figure US20050014840A1-20050120-C01646
    Figure US20050014840A1-20050120-C01647
    Figure US20050014840A1-20050120-C01648
    Figure US20050014840A1-20050120-C01649
    Figure US20050014840A1-20050120-C01650
    Figure US20050014840A1-20050120-C01651
    Figure US20050014840A1-20050120-C01652
    Figure US20050014840A1-20050120-C01653
    Figure US20050014840A1-20050120-C01654
    Figure US20050014840A1-20050120-C01655
    Figure US20050014840A1-20050120-C01656
    Figure US20050014840A1-20050120-C01657
    Figure US20050014840A1-20050120-C01658
    Figure US20050014840A1-20050120-C01659
    Figure US20050014840A1-20050120-C01660
    Figure US20050014840A1-20050120-C01661
  • TABLE 66
    Figure US20050014840A1-20050120-C01662
    Figure US20050014840A1-20050120-C01663
    Figure US20050014840A1-20050120-C01664
    Figure US20050014840A1-20050120-C01665
    Figure US20050014840A1-20050120-C01666
    Figure US20050014840A1-20050120-C01667
    Figure US20050014840A1-20050120-C01668
    Figure US20050014840A1-20050120-C01669
    Figure US20050014840A1-20050120-C01670
    Figure US20050014840A1-20050120-C01671
    Figure US20050014840A1-20050120-C01672
    Figure US20050014840A1-20050120-C01673
    Figure US20050014840A1-20050120-C01674
    Figure US20050014840A1-20050120-C01675
    Figure US20050014840A1-20050120-C01676
    Figure US20050014840A1-20050120-C01677
    Figure US20050014840A1-20050120-C01678
    Figure US20050014840A1-20050120-C01679
    Figure US20050014840A1-20050120-C01680
    Figure US20050014840A1-20050120-C01681
    Figure US20050014840A1-20050120-C01682
    Figure US20050014840A1-20050120-C01683
    Figure US20050014840A1-20050120-C01684
    Figure US20050014840A1-20050120-C01685
    Figure US20050014840A1-20050120-C01686
    Figure US20050014840A1-20050120-C01687
  • TABLE 67
    Figure US20050014840A1-20050120-C01688
    Figure US20050014840A1-20050120-C01689
    Figure US20050014840A1-20050120-C01690
    Figure US20050014840A1-20050120-C01691
    Figure US20050014840A1-20050120-C01692
    Figure US20050014840A1-20050120-C01693
    Figure US20050014840A1-20050120-C01694
    Figure US20050014840A1-20050120-C01695
    Figure US20050014840A1-20050120-C01696
    Figure US20050014840A1-20050120-C01697
    Figure US20050014840A1-20050120-C01698
    Figure US20050014840A1-20050120-C01699
    Figure US20050014840A1-20050120-C01700
    Figure US20050014840A1-20050120-C01701
    Figure US20050014840A1-20050120-C01702
    Figure US20050014840A1-20050120-C01703
    Figure US20050014840A1-20050120-C01704
    Figure US20050014840A1-20050120-C01705
    Figure US20050014840A1-20050120-C01706
    Figure US20050014840A1-20050120-C01707
    Figure US20050014840A1-20050120-C01708
    Figure US20050014840A1-20050120-C01709
    Figure US20050014840A1-20050120-C01710
    Figure US20050014840A1-20050120-C01711
    Figure US20050014840A1-20050120-C01712
    Figure US20050014840A1-20050120-C01713
  • TABLE 68
    Figure US20050014840A1-20050120-C01714
    Figure US20050014840A1-20050120-C01715
    Figure US20050014840A1-20050120-C01716
    Figure US20050014840A1-20050120-C01717
    Figure US20050014840A1-20050120-C01718
    Figure US20050014840A1-20050120-C01719
    Figure US20050014840A1-20050120-C01720
    Figure US20050014840A1-20050120-C01721
    Figure US20050014840A1-20050120-C01722
    Figure US20050014840A1-20050120-C01723
    Figure US20050014840A1-20050120-C01724
    Figure US20050014840A1-20050120-C01725
    Figure US20050014840A1-20050120-C01726
    Figure US20050014840A1-20050120-C01727
    Figure US20050014840A1-20050120-C01728
    Figure US20050014840A1-20050120-C01729
    Figure US20050014840A1-20050120-C01730
    Figure US20050014840A1-20050120-C01731
    Figure US20050014840A1-20050120-C01732
    Figure US20050014840A1-20050120-C01733
    Figure US20050014840A1-20050120-C01734
    Figure US20050014840A1-20050120-C01735
    Figure US20050014840A1-20050120-C01736
    Figure US20050014840A1-20050120-C01737
    Figure US20050014840A1-20050120-C01738
    Figure US20050014840A1-20050120-C01739
  • TABLE 69
    Figure US20050014840A1-20050120-C01740
    Figure US20050014840A1-20050120-C01741
    Figure US20050014840A1-20050120-C01742
    Figure US20050014840A1-20050120-C01743
    Figure US20050014840A1-20050120-C01744
    Figure US20050014840A1-20050120-C01745
    Figure US20050014840A1-20050120-C01746
    Figure US20050014840A1-20050120-C01747
    Figure US20050014840A1-20050120-C01748
    Figure US20050014840A1-20050120-C01749
    Figure US20050014840A1-20050120-C01750
    Figure US20050014840A1-20050120-C01751
    Figure US20050014840A1-20050120-C01752
    Figure US20050014840A1-20050120-C01753
    Figure US20050014840A1-20050120-C01754
    Figure US20050014840A1-20050120-C01755
    Figure US20050014840A1-20050120-C01756
    Figure US20050014840A1-20050120-C01757
    Figure US20050014840A1-20050120-C01758
    Figure US20050014840A1-20050120-C01759
    Figure US20050014840A1-20050120-C01760
    Figure US20050014840A1-20050120-C01761
    Figure US20050014840A1-20050120-C01762
    Figure US20050014840A1-20050120-C01763
    Figure US20050014840A1-20050120-C01764
    Figure US20050014840A1-20050120-C01765
  • TABLE 70
    Figure US20050014840A1-20050120-C01766
    Figure US20050014840A1-20050120-C01767
    Figure US20050014840A1-20050120-C01768
    Figure US20050014840A1-20050120-C01769
    Figure US20050014840A1-20050120-C01770
    Figure US20050014840A1-20050120-C01771
    Figure US20050014840A1-20050120-C01772
    Figure US20050014840A1-20050120-C01773
    Figure US20050014840A1-20050120-C01774
    Figure US20050014840A1-20050120-C01775
    Figure US20050014840A1-20050120-C01776
    Figure US20050014840A1-20050120-C01777
    Figure US20050014840A1-20050120-C01778
    Figure US20050014840A1-20050120-C01779
    Figure US20050014840A1-20050120-C01780
    Figure US20050014840A1-20050120-C01781
    Figure US20050014840A1-20050120-C01782
    Figure US20050014840A1-20050120-C01783
    Figure US20050014840A1-20050120-C01784
    Figure US20050014840A1-20050120-C01785
    Figure US20050014840A1-20050120-C01786
    Figure US20050014840A1-20050120-C01787
    Figure US20050014840A1-20050120-C01788
    Figure US20050014840A1-20050120-C01789
    Figure US20050014840A1-20050120-C01790
    Figure US20050014840A1-20050120-C01791
    Figure US20050014840A1-20050120-C01792
    Figure US20050014840A1-20050120-C01793
    Figure US20050014840A1-20050120-C01794
    Figure US20050014840A1-20050120-C01795
    Figure US20050014840A1-20050120-C01796
    Figure US20050014840A1-20050120-C01797
    Figure US20050014840A1-20050120-C01798
  • TABLE 71
    Figure US20050014840A1-20050120-C01799
    —H —CH3
    Figure US20050014840A1-20050120-C01800
    Figure US20050014840A1-20050120-C01801
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C01802
    Figure US20050014840A1-20050120-C01803
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C01804
    Figure US20050014840A1-20050120-C01805
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C01806
    Figure US20050014840A1-20050120-C01807
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C01808
    Figure US20050014840A1-20050120-C01809
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C01810
    Figure US20050014840A1-20050120-C01811
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C01812
    Figure US20050014840A1-20050120-C01813
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C01814
    Figure US20050014840A1-20050120-C01815
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C01816
    Figure US20050014840A1-20050120-C01817
  • TABLE 72
    Figure US20050014840A1-20050120-C01818
    Figure US20050014840A1-20050120-C01819
    Figure US20050014840A1-20050120-C01820
    Figure US20050014840A1-20050120-C01821
    Figure US20050014840A1-20050120-C01822
    Figure US20050014840A1-20050120-C01823
    Figure US20050014840A1-20050120-C01824
    Figure US20050014840A1-20050120-C01825
    Figure US20050014840A1-20050120-C01826
    Figure US20050014840A1-20050120-C01827
    Figure US20050014840A1-20050120-C01828
    Figure US20050014840A1-20050120-C01829
    Figure US20050014840A1-20050120-C01830
    Figure US20050014840A1-20050120-C01831
    Figure US20050014840A1-20050120-C01832
    Figure US20050014840A1-20050120-C01833
    Figure US20050014840A1-20050120-C01834
    Figure US20050014840A1-20050120-C01835
    Figure US20050014840A1-20050120-C01836
    Figure US20050014840A1-20050120-C01837
    Figure US20050014840A1-20050120-C01838
    Figure US20050014840A1-20050120-C01839
    Figure US20050014840A1-20050120-C01840
    Figure US20050014840A1-20050120-C01841
    Figure US20050014840A1-20050120-C01842
    Figure US20050014840A1-20050120-C01843
    Figure US20050014840A1-20050120-C01844
    Figure US20050014840A1-20050120-C01845
    Figure US20050014840A1-20050120-C01846
    Figure US20050014840A1-20050120-C01847
    Figure US20050014840A1-20050120-C01848
    Figure US20050014840A1-20050120-C01849
    Figure US20050014840A1-20050120-C01850
  • TABLE 73
    Figure US20050014840A1-20050120-C01851
    Figure US20050014840A1-20050120-C01852
    Figure US20050014840A1-20050120-C01853
    Figure US20050014840A1-20050120-C01854
    Figure US20050014840A1-20050120-C01855
    Figure US20050014840A1-20050120-C01856
    Figure US20050014840A1-20050120-C01857
    Figure US20050014840A1-20050120-C01858
    Figure US20050014840A1-20050120-C01859
    Figure US20050014840A1-20050120-C01860
    Figure US20050014840A1-20050120-C01861
    Figure US20050014840A1-20050120-C01862
    Figure US20050014840A1-20050120-C01863
    Figure US20050014840A1-20050120-C01864
    Figure US20050014840A1-20050120-C01865
    Figure US20050014840A1-20050120-C01866
    Figure US20050014840A1-20050120-C01867
    Figure US20050014840A1-20050120-C01868
    Figure US20050014840A1-20050120-C01869
    Figure US20050014840A1-20050120-C01870
    Figure US20050014840A1-20050120-C01871
    Figure US20050014840A1-20050120-C01872
    Figure US20050014840A1-20050120-C01873
    Figure US20050014840A1-20050120-C01874
    Figure US20050014840A1-20050120-C01875
    Figure US20050014840A1-20050120-C01876
    Figure US20050014840A1-20050120-C01877
    Figure US20050014840A1-20050120-C01878
    Figure US20050014840A1-20050120-C01879
    Figure US20050014840A1-20050120-C01880
    Figure US20050014840A1-20050120-C01881
    Figure US20050014840A1-20050120-C01882
    Figure US20050014840A1-20050120-C01883
  • TABLE 74
    Figure US20050014840A1-20050120-C01884
    Figure US20050014840A1-20050120-C01885
    Figure US20050014840A1-20050120-C01886
    Figure US20050014840A1-20050120-C01887
    Figure US20050014840A1-20050120-C01888
    Figure US20050014840A1-20050120-C01889
    Figure US20050014840A1-20050120-C01890
    Figure US20050014840A1-20050120-C01891
    Figure US20050014840A1-20050120-C01892
    Figure US20050014840A1-20050120-C01893
    Figure US20050014840A1-20050120-C01894
    Figure US20050014840A1-20050120-C01895
    Figure US20050014840A1-20050120-C01896
    Figure US20050014840A1-20050120-C01897
    Figure US20050014840A1-20050120-C01898
    Figure US20050014840A1-20050120-C01899
    Figure US20050014840A1-20050120-C01900
    Figure US20050014840A1-20050120-C01901
    Figure US20050014840A1-20050120-C01902
    Figure US20050014840A1-20050120-C01903
    Figure US20050014840A1-20050120-C01904
    Figure US20050014840A1-20050120-C01905
    Figure US20050014840A1-20050120-C01906
    Figure US20050014840A1-20050120-C01907
    Figure US20050014840A1-20050120-C01908
    Figure US20050014840A1-20050120-C01909
    Figure US20050014840A1-20050120-C01910
    Figure US20050014840A1-20050120-C01911
    Figure US20050014840A1-20050120-C01912
    Figure US20050014840A1-20050120-C01913
    Figure US20050014840A1-20050120-C01914
    Figure US20050014840A1-20050120-C01915
    Figure US20050014840A1-20050120-C01916
  • TABLE 75
    Figure US20050014840A1-20050120-C01917
    Figure US20050014840A1-20050120-C01918
    Figure US20050014840A1-20050120-C01919
    Figure US20050014840A1-20050120-C01920
    Figure US20050014840A1-20050120-C01921
    Figure US20050014840A1-20050120-C01922
    Figure US20050014840A1-20050120-C01923
    Figure US20050014840A1-20050120-C01924
    Figure US20050014840A1-20050120-C01925
    Figure US20050014840A1-20050120-C01926
    Figure US20050014840A1-20050120-C01927
    Figure US20050014840A1-20050120-C01928
    Figure US20050014840A1-20050120-C01929
    Figure US20050014840A1-20050120-C01930
    Figure US20050014840A1-20050120-C01931
    Figure US20050014840A1-20050120-C01932
    Figure US20050014840A1-20050120-C01933
    Figure US20050014840A1-20050120-C01934
    Figure US20050014840A1-20050120-C01935
    Figure US20050014840A1-20050120-C01936
    Figure US20050014840A1-20050120-C01937
  • TABLE 76
    Figure US20050014840A1-20050120-C01938
    Figure US20050014840A1-20050120-C01939
    Figure US20050014840A1-20050120-C01940
    Figure US20050014840A1-20050120-C01941
    Figure US20050014840A1-20050120-C01942
    Figure US20050014840A1-20050120-C01943
    Figure US20050014840A1-20050120-C01944
    Figure US20050014840A1-20050120-C01945
    Figure US20050014840A1-20050120-C01946
    Figure US20050014840A1-20050120-C01947
    Figure US20050014840A1-20050120-C01948
    Figure US20050014840A1-20050120-C01949
    Figure US20050014840A1-20050120-C01950
    Figure US20050014840A1-20050120-C01951
    Figure US20050014840A1-20050120-C01952
    Figure US20050014840A1-20050120-C01953
    Figure US20050014840A1-20050120-C01954
    Figure US20050014840A1-20050120-C01955
    Figure US20050014840A1-20050120-C01956
    Figure US20050014840A1-20050120-C01957
    Figure US20050014840A1-20050120-C01958
  • TABLE 77
    Figure US20050014840A1-20050120-C01959
    Figure US20050014840A1-20050120-C01960
    Figure US20050014840A1-20050120-C01961
    Figure US20050014840A1-20050120-C01962
    Figure US20050014840A1-20050120-C01963
    Figure US20050014840A1-20050120-C01964
    Figure US20050014840A1-20050120-C01965
    Figure US20050014840A1-20050120-C01966
    Figure US20050014840A1-20050120-C01967
    Figure US20050014840A1-20050120-C01968
    Figure US20050014840A1-20050120-C01969
    Figure US20050014840A1-20050120-C01970
    Figure US20050014840A1-20050120-C01971
    Figure US20050014840A1-20050120-C01972
    Figure US20050014840A1-20050120-C01973
    Figure US20050014840A1-20050120-C01974
    Figure US20050014840A1-20050120-C01975
    Figure US20050014840A1-20050120-C01976
    Figure US20050014840A1-20050120-C01977
    Figure US20050014840A1-20050120-C01978
    Figure US20050014840A1-20050120-C01979
  • TABLE 78
    Figure US20050014840A1-20050120-C01980
    —H —CH3
    Figure US20050014840A1-20050120-C01981
    Figure US20050014840A1-20050120-C01982
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C01983
    Figure US20050014840A1-20050120-C01984
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C01985
    Figure US20050014840A1-20050120-C01986
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C01987
    Figure US20050014840A1-20050120-C01988
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C01989
    Figure US20050014840A1-20050120-C01990
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C01991
    Figure US20050014840A1-20050120-C01992
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C01993
    Figure US20050014840A1-20050120-C01994
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C01995
    Figure US20050014840A1-20050120-C01996
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C01997
    Figure US20050014840A1-20050120-C01998
  • TABLE 79
    Figure US20050014840A1-20050120-C01999
    —H —CH3
    Figure US20050014840A1-20050120-C02000
    Figure US20050014840A1-20050120-C02001
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C02002
    Figure US20050014840A1-20050120-C02003
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C02004
    Figure US20050014840A1-20050120-C02005
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C02006
    Figure US20050014840A1-20050120-C02007
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C02008
    Figure US20050014840A1-20050120-C02009
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C02010
    Figure US20050014840A1-20050120-C02011
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C02012
    Figure US20050014840A1-20050120-C02013
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C02014
    Figure US20050014840A1-20050120-C02015
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C02016
    Figure US20050014840A1-20050120-C02017
  • TABLE 80
    Figure US20050014840A1-20050120-C02018
    —H —CH3
    Figure US20050014840A1-20050120-C02019
    Figure US20050014840A1-20050120-C02020
    —CH2CH3—CH2CH2CH3
    Figure US20050014840A1-20050120-C02021
    Figure US20050014840A1-20050120-C02022
    —CH2CH2CH2CH3—CH2CH2CH2CH2CH3
    Figure US20050014840A1-20050120-C02023
    Figure US20050014840A1-20050120-C02024
    —CH2CH2CH2CH2CH2CH3—CH2Ph
    Figure US20050014840A1-20050120-C02025
    Figure US20050014840A1-20050120-C02026
    —CH2CH2Ph —CH2CH(CH3)2
    Figure US20050014840A1-20050120-C02027
    Figure US20050014840A1-20050120-C02028
    —CH2CF3—CH2CH2OCH3
    Figure US20050014840A1-20050120-C02029
    Figure US20050014840A1-20050120-C02030
    —CH2CH2OH —CH2CO2H
    Figure US20050014840A1-20050120-C02031
    Figure US20050014840A1-20050120-C02032
    —CH2CH2CO2H —CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C02033
    Figure US20050014840A1-20050120-C02034
    —CH2CH2CH2CH2CO2H —CH2CH2CH2CH2CH2CO2H
    Figure US20050014840A1-20050120-C02035
    Figure US20050014840A1-20050120-C02036
  • In the written descriptions of molecules and groups, molecular descriptors can be combined to produce words or phrases that describe structural groups or are combined to describe structural groups. Such descriptors are used in this document. Common illustrative examples include such terms as aralkyl (or arylalkyl), heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, aralkoxyalkoxycarbonyl and the like. A specific example of a compound encompassed with the latter descriptor aralkoxyalkoxycarbonyl is C6H5—CH2—CH2—O—CH2—O—(C═O)— wherein C6H5— is phenyl. It is also to be noted that a structural group can have more than one descriptive word or phrase in the art, for example, heteroaryloxyalkylcarbonyl can also be termed heteroaryloxyalkanoyl. Such combinations are used above in the description of the compounds and compositions of this invention and further examples are described below. The following list is not intended to be exhaustive or drawn out but provide further illustrative examples of such words or phrases.
  • As utilized herein, the term “alkyl”, alone or in combination, means a straight-chain or branched-chain alkyl radical containing 1 to about 12 carbon atoms, preferably 1 to about 10 carbon atoms, and more preferably 1 to about 6 carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like.
  • The term “alkenyl”, alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing 2 to about 12 carbon atoms preferably 2 to about 10 carbon atoms, and more preferably, 2 to about 6 carbon atoms. Examples of suitable alkenyl radicals include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, decenyl and the like.
  • The term “alkynyl”, alone or in combination, means a straight-chain hydrocarbon radical having one or more triple bonds and containing 2 to about 12 carbon atoms, preferably 2 to about 10 carbon atoms, and more preferably, 2 to about 6 carbon atoms. Examples of alkynyl radicals include ethynyl, 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, 3-butynyl, and the like.
  • The term “carbonyl”, alone or in combination, means a —C(═O)— group wherein the remaining two bonds (valences) can be independently substituted. The term “thiol” or “sulfhydryl”, alone or in combination, means a —SH group. The term “thio” or “thia”, alone or in combination, means a thiaether group; i.e., an ether group wherein the ether oxygen is replaced by a sulfur atom.
  • The term “amino”, alone or in combination, means an amine or —NH2 group whereas the term mono-substituted amino, alone or in combination, means a substituted amine —N(H) (substituent) group wherein one hydrogen atom is replaced with a substituent, and disubstituted amine means a —N(substituent)2 wherein two hydrogen atoms of the amino group are replaced with independently selected substituent groups.
  • Amines, amino groups and amides are compounds that can be designated as primary (I°), secondary (II°) or tertiary (III°) or unsubstituted, mono-substituted or di-substituted depending on the degree of substitution of the amino nitrogen. Quaternary amine (ammonium) (IV°) means a nitrogen with four substituents [—N+ (substituent)4] that is positively charged and accompanied by a counter ion, whereas N-oxide means one substituent is oxygen and the group is represented as [—N+ (substituent)3—O−]; i.e., the charges are internally compensated.
  • The term “cyano”, alone or in combination, means a —C-triple bond-N (—C/N) group. The term “azido”, alone or in combination, means a —N-triple bond-N (—N/N) group. The term “hydroxyl”, alone or in combination, means a —OH group. The term “nitro”, alone or in combination, means a —NO2 group. The term “azo”, alone or in combination, means a —N═N— group wherein the bonds at the terminal positions can be independently substituted.
  • The term “hydrazino”, alone or in combination, means a —NH—NH— group wherein the depicted remaining two bonds (valences) can be independently substituted. The hydrogen atoms of the hydrazino group can be replaced, independently, with substituents and the nitrogen atoms can form acid addition salts or be quaternized.
  • The term “sulfonyl”, alone or in combination, means a —SO2— group wherein the depicted remaining two bonds (valences) can be independently substituted. The term “sulfoxido”, alone or in combination, means a —SO— group wherein the remaining two bonds (valences) can be independently substituted.
  • The term “sulfonylamide”, alone or in combination, means a —SO2—N═ group wherein the depicted remaining three bonds (valences) can be independently substituted. The term “sulfinamido”, alone or in combination, means a —SON═ group wherein the remaining three depicted bonds (valences) can be independently substituted. The term “sulfenamide”, alone or in combination, means a —S—N═ group wherein the remaining three bonds (valences) can be independently substituted.
  • The term “alkoxy”, alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.
  • The term “cycloalkyl”, alone or in combination, means a cyclic alkyl radical that contains 3 to about 8 carbon atoms. The term “cycloalkylalkyl” means an alkyl radical as defined above that is substituted by a cycloalkyl radical containing 3 to about 8, preferably 3 to about 6, carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • The term “aryl”, alone or in combination, means a 5- or 6-membered aromatic ring-containing moiety or a fused ring system containing two or three rings that have all carbon atoms in the ring; i.e., a carbocyclic aryl radical, or a heteroaryl radical containing one or more heteroatoms such as sulfur, oxygen and nitrogen in the ring(s). Exemplary carbocyclic aryl radicals include phenyl, indenyl and naphthyl radicals. Examples of such heterocyclic or heteroaryl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol-4-yl, 1-benzyloxycarbonylimidazol-4-yl, and the like), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, tetrahydrofuryl, thienyl, triazolyl, oxazolyl, oxadiazoyl, thiazolyl, thiadiazoyl, indolyl (e.g., 2-indolyl, and the like), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, and the like), isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, and the like), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl, and the like), 1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, and the like), quinoxalinyl, β-carbolinyl, 2-benzofurancarbonyl, benzothiophenyl, 1-, 2-, 4- or 5-benzimidazolyl, and the like.
  • An aryl ring group optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like.
  • The term “aralkyl”, alone or in combination, means an alkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl and the like.
  • The term “aralkoxycarbonyl”, alone or in combination, means a radical of the formula —C(O)—O— aralkyl in which the term “aralkyl” has the significance given above. An example of an aralkoxycarbonyl radical is benzyloxycarbonyl.
  • The term “aryloxy” means a radical of the formula aryl-O— in which the term aryl has the significance given above.
  • The terms “alkanoyl” or “alkylcarbonyl”, alone or in combination, means an acyl radical derived from an alkanecarboxylic acid, examples of which include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like.
  • The term “cycloalkylcarbonyl” means an acyl group derived from a monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkanecarboxylic acid that is optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl.
  • The terms “aralkanoyl” or “aralkylcarbonyl” mean an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl and the like.
  • The terms “aroyl” or “arylcarbonyl” means an acyl radical derived from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2 naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like.
  • The heterocyclic (heterocyclo) or heterocycloalkyl portion of a heterocyclocarbonyl, heterocyclooxycarbonyl, heterocycloalkoxycarbonyl, or heterocycloalkyl group or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle that contains one or more hetero atoms selected from nitrogen, oxygen and sulphur. Such a moiety can be optionally substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., —NH—) by alkyl, aralkoxycarbonyl, alkanoyl, aryl or arylalkyl or on a tertiary nitrogen atom (i.e. ═N—) by oxido and that is attached via a carbon atom. The tertiary nitrogen atom with three substituents can also attached to form a N-oxide [═N(O)—] group.
  • The term “cycloalkylalkoxycarbonyl” means an acyl group of the formula cycloalkylalkyl-O—CO— wherein cycloalkylalkyl has the significance given above. The term “aryloxyalkanoyl” means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The term “heterocyclooxycarbonyl” means an acyl group having the formula heterocyclo-O—CO— wherein heterocyclo is as defined above. The term “heterocycloalkanoyl” is an acyl radical of the formula heterocyclo-substituted alkane carboxylic acid wherein heterocyclo has the significance given above. The term “heterocycloalkoxycarbonyl” means an acyl radical of the formula heterocyclo-substituted alkane-O—CO— wherein heterocyclo has the significance given above. The term “heteroaryloxycarbonyl” means an acyl radical represented by the formula heteroaryl-O—CO— wherein heteroaryl has the significance given above.
  • The term “aminocarbonyl” alone or in combination, means an amino-substituted carbonyl (carbamoyl) group derived from an amino-substituted carboxylic acid (carboxamide) wherein the amino group can be a primary or secondary amino (amido nitrogen) group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like.
  • The term “aminoalkanoyl” means an acyl group derived from an amino-substituted alkanecarboxylic acid wherein the amino group can be a primary or secondary amino group containing substituents independently selected from hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like.
  • The term “halogen” means fluoride, chloride, bromide or iodide. The term “haloalkyl” means an alkyl radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like.
  • The term perfluoroalkyl means an alkyl group wherein each hydrogen has been replaced by a fluorine atom. Examples of such perfluoroalkyl groups, in addition to trifluoromethyl above, are perfluorobutyl, perfluoroisopropyl, perfluorododecyl and perfluorodecyl.
  • The term “aromatic ring” in combinations such as substituted-aromatic ring sulfonamide, substituted-aromatic ring sulfinamide or substituted-aromatic ring sulfenamide means aryl or heteroaryl as defined above.
  • M utilized in the reaction Schemes that follow represents a leaving group such as halogen, phosphate ester or sulfate ester.
  • Preparation of Useful Compounds
  • Schemes 1 through 5 illustrate chemical processes and transformations that can be useful for the preparation of compounds useful in this invention; i.e., compounds of formulas I-III, Ia-IIIa and Ib-IIIb. The groups R1 through R9 shown in the schemes are defined above.
  • These reactions can be carried out under a dry inert atmosphere such a nitrogen or argon if desired. Selected reactions known to those skilled in the art, can be carried out under a dry atmosphere such as dry air whereas other synthetic steps, for example, aqueous acid or base ester or amide hydrolysis, can be carried out under laboratory air. In addition, some processes of this invention can be carried out in a pressure apparatus at pressures above, equal to or below atmospheric pressure. The use of such an apparatus aids in the control of gaseous reagents such as hydrogen, ammonia, trimethylamine, methylamine, oxygen and the like. It can also help prevent the leakage of air or humidity into a reaction in progress. This discussion is not intended to be exhaustive as it is readily noted that additional or alternative methods, conditions, reactions or systems can be identified and used by a chemist of ordinary skill.
  • Step 1 in Scheme 1 illustrates conversion of a hydroxyl group into compound 2 with an activated carbon-M bond via hydroxyl activation or replacement to provide intermediates useful as electrophilic reagents or, when M is —SH, a product of this invention of formula I is formed. M usually represents leaving groups such as halides (Cl, Br, I), fluorides (aromatic) or sulfate esters such as tosylate (OTs), mesylate (OMs), triflate (OTs) and the like, or epoxides. The preparations of epoxides, sulfate esters or organic halides are well known in the art. M can also represent groups such as —SH (thiol) or, following treatment of a thiol with base or with a pre-formed salt, an —S− group. The non-thiols are prepared from the alcohols by standard methods such as treatment with HCl, HBr, thionyl chloride or bromide, phosphorus trihalide, phosphorus pentahalide, trifluoromethylsulfonyl chloride, tosylchloride or methanesulfonyl chloride and the like.
  • These reactions are usually carried out at a temperature of about −25° C. to solvent reflux under an inert atmosphere such as nitrogen or argon. The solvent or solvent mixture can vary widely depending upon reagents and other conditions and can include polar or dipolar aprotic solvents as listed or mixtures of these solvents.
  • In some cases, amines such as triethyl amine, pyridine or other non-reactive bases can serve as reagents and/or solvents and/or co-solvents. In some instances, in these reactions and other reactions in these Schemes, protecting groups can be used to maintain or retain groups in other parts of a molecule(s) at locations that is(are) not desired reactive centers. Examples of such groups that the skilled person might want to maintain or retain include, amines, other hydroxyls, thiols, acids and the like. Such protecting groups can include acyl groups, arylalkyl groups, carbamoyl groups, ethers, alkoxyalkyl ethers, cycloalkyloxy ethers, arylalkyl groups, silyl groups including trisubstituted silyl groups, ester groups and the like. Examples of such protecting groups include acetyl, trifluoroacetyl, tetrahydropyran (THP), Benzyl, tert-butoxy carbonyl (BOC or TBOC), benzyloxycarbonyl (Z or CBZ), tert-butyldimethylsilyl (TBDMS) or methoxyethoxymethylene (MEM) groups. The preparation of such protected compounds as well as their removal is well known in the art.
  • The second step in Scheme 1 illustrates preparation of a sulfonamide 2. Sulfamidation reactions are conveniently carried out by reacting an amine with, for example, a sulfonyl chloride or sulfonic anhydride. A suitable solvent or mixture of solvents includes aprotic or dipolar aprotic solvents as defined below with examples being acetone, methylene chloride DMF, THF, tert-butylmethylether (tBME) or mixtures of such solvents. Usually such reactions are carried out under and inert or dry atmosphere at a temperature of from about −25° C. to 40° C. preferably at about 0° C. A base for the scavenging of acid is usually also present with non-limiting examples being triethyl amine, pyridine, DBU, N-ethyl morpholine (NEM), sodium carbonate and the like. The sulfonyl chlorides are well know in the art and are commercially available or can be prepared by the reaction of a suitable organometallic reagent with sulfuryl chloride or sulfur dioxide followed by oxidation with a halogen such as chlorine. Grignard and alkyl lithium reagents are desirable organometallic reagents.
  • In addition, thiols can be oxidized to sulfonyl chlorides using chlorine and/or chlorine with water. Sulfonic acids are available by the oxidation of thiols, reaction of sulfur derivatives with organometallic reagents and the like and can be converted into sulfonyl chlorides by treatment with thionyl chloride, PCl5 and the like. They are also commercially available.
  • Many reactions or processes involve bases that can act as reactants, reagents, deprotonating agents, acid scavengers, salt forming reagents, solvents, co-solvents and the like. Bases that can be used include, for example, metal hydroxides such as sodium, potassium, lithium, cesium or magnesium hydroxide, oxides such as those of sodium, potassium, lithium, calcium or magnesium, metal carbonates such as those of sodium, potassium, lithium, cesium, calcium or magnesium, metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, primary (I°), secondary (II°) or tertiary (III°) organic amines such as alkyl amines, arylalkyl amines, alkylarylalkyl amines, heterocyclic amines or heteroaryl amines, ammonium hydroxides or quaternary ammonium hydroxides. As non-limiting examples, such amines can include triethylamine, trimethylamine, diisopropylamine, methyldiisopropylamine, diazabicyclononane, tribenzylamine, dimethylbenzylamine, morpholine, N-methylmorpholine, N,N′-dimethylpiperazine, N-ethylpiperidine, 1,1,5,5-tetramethylpiperidine, dimethylaminopyridine, pyridine, quinoline, tetramethylethylenediamine, diazabicyclononane and the like. Non-limiting examples of ammonium hydroxides, usually made from amines and water, can include ammonium hydroxide, triethyl ammonium hydroxide, trimethyl ammonium hydroxide, methyldiiospropyl ammonium hydroxide, tribenzyl ammonium hydroxide, dimethylbenzyl ammonium hydroxide, morpholinium hydroxide, N-methylmorpholinium hydroxide, N,N′-dimethylpiperazinium hydroxide, N-ethylpiperidinium hydroxide, and the like. As non-limiting examples, quaternary ammonium hydroxides can include tetraethyl ammonium hydroxide, tetramethyl ammonium hydroxide, dimethyldiiospropyl ammonium hydroxide, benzymethyldiisopropyl ammonium hydroxide, methyldiazabicyclononyl ammonium hydroxide, methyltribenzyl ammonium hydroxide, N,N-dimethylmorpholinium hydroxide, N,N,N′,N′-tetramethylpiperazenium hydroxide, and N-ethyl-N′-hexylpiperidinium hydroxide and the like.
  • Metal hydrides, amides or alcoholates such as calcium hydride, sodium hydride, potassium hydride, lithium hydride, aluminum hydride, diisobutylaluminum hydrice (DIBAL) sodium methoxide, potassium tert-butoxide, calcium ethoxide, magnesium ethoxide, sodium amide, potassium diisopropyl amide and the like can also be suitable reagents. Organometallic deprotonating agents such as alkyl or aryl lithium reagents such as methyl lithium, phenyl lithium, tert-butyl lithium, lithium acetylide or butyl lithium, Grignard reagents such as methylmagnesium bromide or methymagnesium chloride, organocadium reagents such as dimethylcadium and the like can also serve as bases for causing salt formation or catalyzing the reaction. Quaternary ammonium hydroxides or mixed salts are also useful for aiding phase transfer couplings or serving as phase transfer reagents. Pharmaceutically acceptable bases and be reacted with acids to form pharmaceutically acceptable salts of this invention. It should also be noted that optically active bases can be used to make optically active salts which can be used for optical resolutions.
  • Generally, reaction media can consist of a single solvent, mixed solvents of the same or different classes or serve as a reagent in a single or mixed solvent system. The solvents can be protic, non-protic or dipolar aprotic. Non-limiting examples of protic solvents include water, methanol (MeOH), denatured or pure 95% or absolute ethanol, isopropanol and the like. Typical non-protic solvents include acetone, tetrahydrofurane (THF), dioxane, diethylether, tert-butylmethyl ether (TBME), aromatics such as xylene, toluene, or benzene, ethyl acetate, methyl acetate, butyl acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hexane, heptane, isooctane, cyclohexane and the like. Dipolar aprotic solvents include compounds such as dimethylformamide (DMF), dimethylacetamide (DMAc), acetonitrile, DMSO, hexamethylphosphorus triamide (HMPA), nitromethane, tetramethylurea, N-methylpyrrolidone and the like. Non-limiting examples of reagents that might be used as solvents or as part of a mixed solvent system include organic or inorganic mono- or multi-protic acids or bases such as hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, succinic acid, triethylamine, morpholine, N-methylmorpholine, piperidine, pyrazine, piperazine, pyridine, potassium hydroxide, sodium hydroxide, alcohols or amines for making esters or amides or thiols for making the products of this invention and the like.
  • Step 4 of Scheme 1 is sulfamidation of compound 1 where R2 can be hydrogen or as otherwise defined. The process of sulfamidation is discussed above in reference to Step 2. The product is the alcohol 4.
  • Scheme 1 shows in Step 5 the direct conversion of an alcohol such as compound 4 into a contemplated sulfur-containing compound, 5. A descriptive term for this process is activated azo coupling. The process can be carried out by reacting a phosphine such as triphenyl phosphine and an azo compound such as diisopropylaziodicarboxylate (DIAD) or diethylazodicarboxylate (DEAD), a starting alcohol and a thiolcarboxylic acid or dithiocarboxylic acid. The reaction is usually carried out under an inert atmosphere such as nitrogen or argon at about −40° C. to about 50° C. in an inert solvent such as methylene chloride, THF or the others listed above.
  • The thioester or dithioester [R9(C═S)—] 5 is a compound of Formula II. Compound 5 can be hydrolyzed to form compound 8 in Scheme 1 or compounds 15 or 16 as shown in Scheme 4. Compound 8 is a compound of formula I. This hydrolysis can be carried out with bases such as a metal hydroxide (LiOH, NaOH, KOH), carbonate (Na2CO3, K2CO3) or a bicarbonate (NaHCO3). Examples of other hydrolytic reagents suitable for this reaction include alkoxides such as sodium methoxide, potassium ethoxide and the like, a thiolate such as sodium thiophenolate, potassium methanethiolate and the like or by hydrolytic exchange with an amine or ammonia.
  • These reactions can be carried out under an inert atmosphere such as helium, nitrogen or argon at temperatures of from about −50° C. to about 100° C. Temperatures from about 0° C. to about 60° C. are preferred. Solvents, pure or mixed, include water, alcohols especially for alcoholate hydrolysis or dipolar aprotic solvents such as acetonitrile, DMSO or DMF. Amine exchanges can occur under conditions as discussed above. In addition, the amine can serve if desired as the solvent or a co-solvent as, for example, when diethylamine, morpholine, dimethyl amine (in a pressure system) or piperidine, are used as exchange agents.
  • The preparation of compound 8 from compound 5 can also be carried out using reductive processes if desired. Useful reducing agents may include lithium aluminum hydride, aluminum hydride, DIBAL, potassium borohydride, sodium borohydride, lithium borohydride or a metal catalyzed hydrogenation with a system such as the employing a Rosenmund catalyst. Reductions of the hydride type are usually carried out at between 80° C. and −80° C. in non-polar aprotic solvents such as THF or ethers whereas hydrogenations with hydrogen gas require containers (hydrogenation bottles, Parr bombs, pressure kettles and the like) with protic or non-protic solvents or solvent mixtures at temperatures of between −20° C. to 100° C.
  • Conversion of compound 3 in Scheme 1 into the sulfur-containing compound 5 illustrates displacement of an electrophile by a nucleophile; i.e., the conversion of a intermediate containing our activated leaving group M or a derivative into a sulfur compound of this invention. This method of synthesis is commonly called bimolecular nucleophilic substitution. Solvolysis or SN1 reactions are also possible and, if desired, can be used to provide electrophilic substitutions to produce alcohols, ethers, amines, carboxylate esters and the like. The reagents that provide the above compounds via SN1 ractions are water, alcohols, amines and carboxylic acids.
  • The nucleophilic displacement (SN2) reaction can be used in Step 3 wherein group M is displaced by a thiol compound or the salt of a thiol compound to produce compounds of formula I (compound 8) or formula II (compound 5) directly or a compound of formula I via conversion of II into I. The diagramatically reverse procedure; i.e., synthesis of a compound of formula I followed by its conversion into a compound of formula II or formula III can also be accomplished. Either compounds of formula I or of formula II can be direct or non-direct intermediates in the preparation of compounds III (e.g. compound 6).
  • Compounds of formula III can be converted into a compound of either of formulas I or II with a thiol reagent. Non-limiting examples of thiol reagents or their salts useful for nucleophilic displacement reactions are hydrogen sulfide (H2S), sodium sulfide (NaSH), thiolacetic acid [HS(C═O)CH3], sodium thiolacetate [NaS(C═O)CH3], dithioacetic acid [HS(C═S)CH3] and sodium dithiolacetate [NaS(C═S)CH3]. A thiolate or other anion can be obtained from a preformed salt such as sodium sulfide or sodium thiolacetate or it can be formed in situ via addition of a base to an acid such as hydrogen sulfide or thiolacetic acid. The bases and solvents are discussed above. Preferred bases are those that are hindered or tertiary such that competition with a sulfur anion as a nucleophile in a two stage reaction is minimized, e.g., triethylamine, pyridine, DBU, DMAP and the like. A strong inorganic base or organometallic base can be used if desired.
  • The solvents, solvent mixtures or solvent/reagent mixtures discussed above are satisfactory but non-protic or dipolar aprotic solvents such as acetone, acetonitrile, DMF, acetonitrile and the like are examples of a preferred class. Bases can also be used as solvents as well as reagents. Mixtures of the above solvents or with a solvent and a base such as pyridine or triethylamine are also useful. These reactions are usually carried out under an inert atmosphere (nitrogen, argon) at temperatures varying from between about −10° C. to about 80° C. In many cases, room temperature is preferred due to cost or simplicity. Again, procedures involving nucleophilic substitution reactions are well know in the art and sulfur based anions are known to be excellent nucleophiles.
  • The oxidation/reduction sequence illustrated in Scheme 1 Step 6 and Step 7 is also well known in the art. In addition, in situ hydrolysis of compound 5 by base, preferably protic, reaction of the C═W group with a organometallic reagent or its reductive removal can provide an —SH compound 8. The thiol compound preformed or formed in the reaction, can then be oxidized if desired using, for example, air, oxygen, ozone, hypohalide reagents, sodium plumbite, or other likely oxidation agents. Non-oxidizable solvents and a basic or slightly basic pH value are preferred but not required and the atmosphere of the reaction can be air or another inert gas mentioned above. Preferred temperature is 0° C. to 40° C., but lower or higher temperatures can be used.
  • Mixed disulfides (heterodimers) can be made if the starting materials have different structures or by reaction of compound 6 (when R2 is H) with different alkylating agents as is discussed below. Reversal of the process ex vivo requires reduction of the disulfide bond to the thiol of formula I (compound 8). Compound 5 is formed by acylation of compound 8 with a reagent such as a derivative of HO(C═W)R9. Such a derivative can be an activated carbonyl compounds prepared using reagents well know in the art including the peptide and protein synthesis and amino acid coupling or conjugation art. Examples of such reagents are thionyl chloride, oxalyl chloride, phosphorus oxychloride, HOBT (hydroxybenzotriazole), isobutylchloroformate, carbodimide, azodicarboxylate compounds an the like all of which are well known and established in the art. Reduction of the disulfide to the corresponding thiol can be carried out by, for example, treatment with hydride reagents such as lithium aluminum hydride, aluminum hydride, DIBAL, metal borohydrides (Li+, Na+, K+, Ca++), sodium cyanoborohydride and the like.
  • The aminoalcohol compound 7 in Scheme 2 illustrates a special case example of compound 1 wherein R2 is hydrogen. This series of reactions using, for example, compound 7, permits sulfamidation by processes discussed above wherein one skilled in the art can produce examples of compound 4 where R2 is hydrogen. This intermediate or product can then be alkylated or otherwise substituted to produce compound 4 wherein R2 is other than hydrogen. Alkylating agents include compounds that contain groups that can be displaced by a nucleophile such as a sulfamic acid salt.
  • Compound 4 with R2=hydrogen is a sulfamic acid and, as such, can be treated with a base to form an anion. This anion can be reacted in an SN2 manner with an intermediate or reagent containing a group that can be displaced with such displaceable groups including such non-limiting examples as epoxide, chloride, bromide, iodide, tosylate, mesylate, triflate, mesylate and the like. Examples of such reagents or intermediates include benzyl bromide, methyl iodide, n-butyl chloride, isoamyl tosylate, N-chloroethylmorpholine, N-bromoethylpiperidine and the like.
  • The anion can also be reacted (acylated) with a carbonyl compound in an addition-elimination sequence to provide a N-carbonyl compound. Such acylated compounds might be reduced to desired intermediates or serve as protecting groups or both. The anion can be formed with the bases listed and discussed above if the affects of sulfamide structure on pKa are accommodated. Sodium carbonate, potassium carbonate, potassium methoxide or DMAP represent bases sufficiently strong that they can be used to deprotonate a sulfonamide such as 4. In some cases, the use of a strong base such as an organometallic base under argon in a aprotic solvent is desirable.
  • The reactions are normally carried out under an inert atmosphere at temperatures of from about 0° C. to about 100° C. using either protic or dipolar aprotic solvents or with solvent mixtures. The solvent mixtures can include reagents such as amine bases that can also serve as part of a solvent mixture. An alkylation or acylation reactions involving salt formation are examples of the type reaction wherein a non-participating group such as a hydroxly group hydroxyl group on compound 4 can be protected if desired by the skilled chemist.
  • A second process that can be used to place an R2 group a sulfonamide with at least one hydrogen atom is reductive amination. Treatment of compound 4 containing an active hydrogen on the nitrogen of the sulfamide with an aldehyde or ketone and a reducing agent such as LiAlH4, NaCNBH4, LiBH4, AlH4 or hydrogen in the presence of controlled activity metal catalyst may provide compounds with a R2 group. An intermediate in this reductive process can be an sulfimine, sulfimine derivative or a tautomer thereof. The reducing agent can be present in the initial reaction or the intermediate can be subsquently reduced, i.e., the intermdiate carbonyl-sulfamide compound can be isolatable or it may be reduced further directly. A sulfamide salt can also add to a carbonyl group (acylation) of an ester, amide, anhydride, acid halide, mixed anhydride or similar compound and then be reduced.
  • Step 4 in Scheme 2 involves the hydroxyl conversion step discussed in with regards to Step 1 in Scheme 1. Here again, protection of a non-reactive group can be desirable. Once the hydroxyl is converted into, for example, a halide or sulfate ester, the sulfamide can be alkylated or reductively alkylated to introduce the R2 group (Step 5) if such is desired. This produces compound 3 which can be treated with a nucleophile including —SH to produce compounds 5 or 8. Note, these are the same compounds as can be produced via the methods of Scheme 1.
  • Scheme 2 also illustrates the conversion of compound 4 into compound 5, compound 4 into compound 9 and compound 9 into compound 3. The former conversion is discussed above per Scheme 1. The preparation of Compound 9 illustrates the preparation of a sulfonamide compound where R2 is hydrogen and M is a leaving group (activated intermediate).
  • The hydroxyl conversion process is well discussed above under Step 1 of Scheme 1. In this case, protection of groups that one does not wish to participate in a reaction or process can be useful. The use of reagents that convert hydroxyl groups into halide type leaving groups is preferred. Examples of such agents include hydrogen bromide, hydrogen chloride, hydrogen iodide, hydrobromic acid, hydrochloric acid or hydriodic acid. Agents that can convert a sulfonamide nitrogen-hydrogen bond into a nitrogen-halogen bond such as sodium hypochlorite can serve as a method of protecting the sulfonamide from further substitution on nitrogen. The halogen is removable when desired by reduction.
  • Once formed, compound 9 can be alkylated or acylated by processes as discussed for Step 2 in this Scheme to provide compound 3. Compound 3 can be converted into a compound of this invention of formula I or formula II (compound 5) via a nucleophilic or electrophilic substitution process as illustrated in Step 6. These processes and reactions are discussed above.
  • An alternative synthetic process strategy wherein one starts with an alcohol or protected alcohol intermediate substituted with an M leaving group is illustrated in Scheme 3. Conversion of compound 10 into compound 7 or compound 11 or a protected derivative is accomplished by amination at the carbon-M bond with a ammonia or a I° amine or derivative.
  • Amination can be a nucleophilic substitution process wherein the nucleophile is an amine, amine anion or other amine derivative. If an amine is the reagent desired, one can treat compound 10 directly with the amine at temperatures of from about −60° C. to reflux temperature in protic, non-protic or dipolar aprotic solvents under an inert atmospheres or air. Protic solvents can include water wherein the reagent is usually an amine hydroxide such as ammonium hydroxide, benzylamine hydroxide and the like. Amine hydroxides are discussed above. Solvents that can react with amines such as ethyl acetate or acetone are not to be used. A pressure containment system or a low temperature system can be used for gaseous amines such as ammonia, methyl amine ethyl amine and the like. For example, reactions with or in ammonia can be run in liquid ammonia at a temperature of about −33° C. The SN2 reaction can also be carried out with an metal-amine salt such as sodium amide, calcium amide, potassium metylamide and the like.
  • Following synthesis of the alcohol-amine compound 7 or 11 or a protected derivative thereof, one can add the N-substituent R2 by reductive amination or alkylation processes as discussed above. Compound 7 represents compounds where R2 is hydrogen whereas compound 11 represents compounds wherein R2 is any other group described earlier in this specification.
  • Step 3 in this sequence illustrates conversion of the unprotected alcohol group into the sulfur compound 12, which can then be converted into 5, which is a sulfonamide of this invention if formula II. Step 5 shows conversion of the M-substituted carbinol 10 into the sulfur compound 13 via a before-discussed activated azo procedure as in Step 3. Compound 13 can then be treated in Step 6 as with Step 1 to convert the M-carbon bond in compound 13 into a carbon-nitrogen bond to produce compounds 12 or 14 wherein R2 is either hydrogen (compound 14) or not hydrogen (compound 12). When this product is compound 14 and R2 is hydrogen, it can be converted into compound 12 by alkylation or reductive alkylation processes of Step 7 using the methods of Step 2.
  • Scheme 4 presents an alternative synthetic route to the compounds of this invention such as compounds 5, 15 or 16. The amine R2NH2 is reacted with a sulfonamide forming reagent such as a sulfonyl chloride under sulfamidation conditions to provide a sulfonamide. The sulfonamide can have two hydrogen atoms on the nitrogen of the sulfonamide group or it can have one nitrogen-carbon bond valence be occupied by a group R2. In the latter case, the sulfonamide can be alkylated (Step 3) by processes discussed above using compound 13 as the electrophile. Compound 13 was prepared in Scheme 3.
  • The product of this alkylation is compound 5, which is a sulfur compound of formula II of this invention. Hydrolysis of compound 5 can provide compund 16, which is a compound of formula I discussed above.
  • Step three displays the same process as Step 1 except that the amine is replaced by ammonia to provide an unsubstituted sulfonamide. This unsubstituted sulfonamide can be alkylated with, for example, compound 13 or compound 10, to produce sulfonamide compound 14 or sulfonamide compound 4. Alkylation of compound 14 by procedures illustrated above provides compound 5. Hydrolysis of compound 14 (Step 5) can produce compound 15 which is a compound of this invention of formula I.
  • An extended example Step 3 or Step 2 is provided by the procedure of Example 44. In this case, the amine can be R2NH2 with R2 being methyl followed by post sulfamidation alkylation with 2-iodobenzylchloride to produce a dialkylated sulfonamide that is subsequently converted into a thiol compound of this invention of formula IV. The inverse procedures can be carried out wherein the product of reaction with iodobenzylchloride or iodobenzylamine is the first sulfonamide that is then alkylated with methyl iodide. Conversion of this intermediate into the sulfur-containing product uses a cobalt complex with thiourea followed by reduction with sodium cyanoborohydride. This process is a useful alternative for the synthesis of aromatic sulfur compounds.
  • To further illustrate some of the general principles of synthesis of the compounds of this invention, Scheme 5 presents the preparation of the product of Example 41C. The carbinol amine a was treated with the sulfonyl chloride b under sulfamidation conditions to produce sulfonamide compound c. The reaction was carried out under nitrogen in THF and water as co-solvents and with triethylamine as the base to act a the product hydrochloric acid scavenger. The reaction temperature was about 0° C. in an ice bath.
  • The sulfonamide c in which R2 is H was alkylated with methyl iodide to produce the product d wherein R2 is methyl. The solvent for this reaction was DMF with potassium carbonate base being suspended/dissolved therein under an atmosphere of nitrogen. The reaction mixture including the methyl iodide was maintained at room temperature.
  • Nucleophilic displacement of fluoride with an (ArS—)− anion from the substituted aryl group on the sulfonamide was the next step carried out to produce compound e. Here, compound d was dissolved in DMF solvent followed by cesium carbonate and thiophenol. The reaction mixture was stirred for about 15 hours at about 70° C. under nitrogen to produce the ArS-substituted aromatic N-methyl sulfonamide compound e.
  • This alcohol was then converted via the activated azo coupling procedure into the sulfur compound f, which is a compound, useful in a process of this invention. This reaction was carried out at 0° C. in THF under nitrogen. The reagents triphenylphosphine and diethyldiazodicarboxylate were dissolved in the THF and thiolacetic acid was added. The reaction was permitted to proceed for about one hour to yield compound f which is the product of Example 41B. Hydrolysis of compound f with sodium methoxide in methanol at room temperature for about one half hour provide compound g which is also the product of Example 41C. This product of this invention is a potent MMP-13 inhibitor with an IC50=0.002 μM (2 nM).
  • Optically active compound isomers as well as mixed or non-optically active compound isomers are specifically intended to be included in this discussion. Examples of isomers are RS isomers, enantiomers, diastereomers, racemates, cis isomers, trans isomers, E isomers, Z isomers, syn-isomers, anti-isomers, tautomers and the like. Aryl, heterocyclo or heteroaryl tautomers, heteroatom isomers and ortho, meta or para substitution isomers are also included as isomers.
  • The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds useful in this invention. Occasionally, the reactions may not be applicable as described to a particular compound included within the disclosed scope or can be unsafe in a particular instance. In addition, some preparations can be more desirable than the alternatives due to cost or other economic considerations. The compounds for which this occurs are readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials.
    Figure US20050014840A1-20050120-C02037
    Figure US20050014840A1-20050120-C02038
    Figure US20050014840A1-20050120-C02039
    Figure US20050014840A1-20050120-C02040
    Figure US20050014840A1-20050120-C02041

    Best Mode for Carrying Out the Invention
  • Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
  • EXAMPLE 1 Preparation of N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02042
  • To a solution of 3.5 mL (3.54 g, 58 mmol) of ethanolamine in 20 mL of THF and 5 mL of water, was added 10.7 mL of triethylamine. After cooling in an ice bath, 10.53 g (51 mmol) of para-methoxybenzenesulfonyl chloride was slowly added over ten minutes. After stirring at room temperature for 1 hour, the solvent was removed under reduced pressure and ethyl acetate and water added. The organic layer was separated, washed with 5% KHSO4 and brine, dried over sodium sulfate, filtered and stripped to afford 10.3 g of the desired N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide, m/e=238 (M+Li).
  • EXAMPLE 2 Preparation of N-(2-hydroxyethyl)-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02043
  • To a solution of 4.0 mL (66 mmol) of ethanolamine in 20 mL of tetrahydrofuran and 5 mL of water, was added 11.3 mL (81 mmol) of triethylamine. The solution was cooled to 0 C, and a solution of 15.0 g (54 mmol) of p-(n-butoxybenzene)sulfonyl chloride in 10 mL of tetrahydrofuran was slowly added. After 2 hours at room temperature, the solution was stripped, ethyl acetate added, washed with 5% KHSO4, saturated sodium bicarbonate, brine and dried over sodium sulfate, filtered and stripped to afford 15.3 g of crude material. This was crystallized from ethyl acetate/hexane to afford 13.4 g of pure N-(2-hydroxyethyl)-4-(n-butoxy)benzenesulfonamide.
  • EXAMPLE 3 Preparation of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02044
  • To a solution of 15.5 mL (15.0 g, 200 mmol) of (R)-(−)-2-amino-1-propanol in 140 mL of THF and 47 mL of water, was added 32.9 mL (23.9 g, 236 mmole) of triethylamine. After cooling in an ice bath, 37.5 g (182 mmol) of 4-methoxybenzenesulfonyl chloride was slowly added over 1 hour. After stirring at room temperature for 2 hour, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to afford 44 g of the desired N-(2-hydroxy-1R-methylethyl)-4-methoxybenzenesulfonamide, m/e=252 (M+Li).
  • EXAMPLE 4 Preparation of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02045
  • To a solution of 4.83 g (64.3 mmol) of (R)-(−)-2-amino-1-propanol in 22 mL of THF and 6 mL of water, was added 12 mL (83.6 mmol) of triethylamine. After cooling in an ice bath, a solution of 14.4 g (57.9 mmol) of 4-(n-butoxy)benzenesulfonyl chloride in 20 mL of tetrahydrofuran was slowly added over 0.5 hour. After stirring at room temperature for 2 hour, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate soution, saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to afford 16.0 g of the desired N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide, m/e=288 (M+H).
  • EXAMPLE 5 Preparation of N-(2-hydroxy-1R-methylethyl) (3-thiophenylpropyl)sulphonamide
  • Figure US20050014840A1-20050120-C02046
  • Part A: To a solution of (10.0 g, 133 mmol) 2R-amino-1-propanol in 120 mL of acetone and 50 mL of water, was added 35.8 mL of triethylamine. After cooling in an ice bath, 23.5 g (133 mmol) of 3-chloro propanesulfonyl chloride was slowly added over 15 minutes. After stirring at room temperature for 2 hours, the solvent was removed under reduced pressure and ethyl acetate and water was added. The organic layer was separated, washed with 5% KHSO4 and brine, dried over sodium sulfate, filtered and stripped to afford 8.5 g of the desired N-(2-hydroxy-1R-methylethyl) (3-chloropropyl)sulphonamide, m/e=222 (M+Li).
  • Part B: To a solution of 4.13 g (20 mmol) of product from part A in (25 mL) of anhydrous acetonitrile, was added (4.4 g, 40 mmol) of triethylamine followed by (3.3 g, 30 mmol) of benzenethiol. After stirring at room temperature for 16 hours, the reaction was diluted with (200 mL) of dichloromethane. Washed with 2×60 mL saturated aqueous sodium bicarbonate and 2×50 mL brine, dried over sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 2:1 ethyl acetate:hexane to afford 2.1 g of the desired N-(2-hydroxy-1R-methylethyl) (3-thiophenylpropyl)sulphonamide, m/e=296 (M+Li).
  • EXAMPLE 6 Preparation of N-(2-Hydroxy-1R-methylethyl)-4-(n-pentyl)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02047
  • To a ice cooled solution of (2.5 g, 30 mmol) of (R)-(−)-2-amino-1-propanol in 50 mL of acetone, 25 mL of water, and 10 grams of triethylamine was added 7.7 g, 30 mmol) of 4-(n-pentyl)benzenesulfonyl chloride slowly over 10 minutes. After stirring for 3 hours at room temperature, the solution was concentrated by rotory evaporation and the contents were partitioned between 200 mL of ethyl acetate and 200 mL of water. The organic layer was washed with 100 mL of 5% potassium hydrogen sulfate, followed by saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated to yield 8.0 grams of a clear oil, identified as N-(2-hydroxy-1R-methylethyl)-4-(n-pentyl)benzenesulfonamide.
  • EXAMPLE 7 Preparation of N-(2-mercaptoethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02048
  • Part A: To a solution of 10.04 g (43 mmol) of N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide from Example 1 in 85 mL of anhydrous DMF, was added 17.8 g (128 mmol) of powdered potassium carbonate and then 8.2 g (48 mmol) of benzyl bromide. After 24 hours, ethyl acetate and water was added, the organic layer separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 14.3 g of crude product. This was recrystallized from tert-butylmethyl ether/hexane to afford 9.0 g of the desired N-(hydroxyethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide.
  • Part B: To a solution of 2.0 g (6.2 mmol) of product from Part A and 1.79 g (6.8 mmol) of triphenylphosphine in 31 mL of anhydrous THF at 0 C, was added 1.35 mL (6.8 mmol) of diisopropylazodi-carboxylate, followed by 0.50 mL (6.8 mmol) of thiolacetic acid. After stirring at room temperature for 15 hours, the reaction was concentrated and the residue chromatographed on 150 g of silica gel using 20-30% ethyl acetate/hexane to afford 1.48 g of the desired product, which was recrystallized from ethyl acetate/hexane to afford 1.0 g of pure product, identified as the desired product, m/e=380 (M+H).
  • Part C: To a suspension of 0.57 g (1.5 mmol) of product from Part B above in 4 mL of anhydrous methanol, was added 1.2 mL (5.4 mmol) of 25 weight % sodium methoxide in methanol. After 30 minutes, the solution was cooled in ice and 2% hydrochloric acid added. Ethyl acetate was added and the organic layer separated and washed with saturated sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and stripped to afford 0.5 g of crude material. This was chromatographed on 50 g of silica gel using 20%-40% ethyl acetate/hexane to yield 0.3 g of pure N-(mercaptoethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide.
  • EXAMPLE 8 Preparation of N-(2-mercaptoethyl)-N-pentyl-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02049
  • Part A: To a solution of 2.0 g (8.6 mmol) of N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide from Example 1 in 20 mL of anhydrous DMF, was added 3.58 g (25.9 mmol) of powdered potassium carbonate and then 1.96 g (13 mmol) of 1-bromopentane. After 24 hours, ethyl acetate and water was added, the organic layer separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 2.3 g of crude product. This was chromatographed on 150 g of silica gel using 20%-50% ethyl acetate/hexane to afford 2.12 g of the desired N-(hydroxyethyl)-N-pentyl-4-methoxybenzenesulfonamide, m/e=302 (M+H).
  • Part B: To a solution of 2.1 g (7.0 mmol) of product from Part A and 2.03 g (7.7 mmol) of triphenylphosphine in 28 mL of anhydrous THF at 0 C, was added 1.2 mL (7.74 mmol) of diethylazodicarboxylate, followed by 0.56 mL (7.7 mmol) of thiolacetic acid. After stirring at room temperature for 15 minutes, the reaction was concentrated and the residue chromatographed on 150 g of silica gel using 10-50% ethyl acetate/hexane to afford 2.06 g of the desired product, m/e=360 (M+H).
  • Part C: To a solution of 2.06 g (6.3 mmol) of product from Part B above in 13 mL of anhydrous methanol, was added 5.2 mL (22.6 mmol) of 25 weight % sodium methoxide in methanol. After 30 minutes, the solution was cooled in ice and 2% hydrochloric acid added. Ethyl acetate was added and the organic layuer separated and washed with saturated sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and stripped to afford 1.26 g of pure N-(2-mercaptoethyl)-N-pentyl-4-methoxybenzenesulfonamide., m/e=324 (M+Li).
  • EXAMPLE 9 Preparation of N-(2-mercapto-1R-methylethyl)-N-butyl-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02050
  • Part A: To a solution of 3.0 g (12 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzenesulfonamide from Example 3 in 40 mL of anhydrous DMF, was added 5.1 g (37 mmol) of powdered potassium carbonate, followed by 2.0 mL (2.5 g, 18 mmol) of 1-bromobutane. After 66 hours, and additional 2.5 g (18 mmol) of powdered potassium carbonate and 1.0 mL (1.3 g, 9 mmol) of 1-bromobutane were added, and the reaction heated at 40° C. After 48 hours at 40° C., the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed 3×s with brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on silica gel using 30%-40% ethyl acetate/hexane to yield 2.8 g of pure N-(2-hydroxy-1R-methylethyl)-N-butyl-4-methoxybenzenesulfonamide, m/e=302 (M+H).
  • Part B: To a solution of 2.8 g (9 mmol) of N-(2-hydroxy-1R-methylethyl)-N-butyl-4-methoxybenzenesulfonamide from Part A and 2.7 g (10 mmol) of triphenylphosphine in 50 mL of anhydrous THF at 0° C., was added 1.6 mL (1.8 g, 10 mmol) of diethylazodicarboxylate, followed after 5 min. by 0.7 mL (0.8 g, 10 mM) of thiolacetic acid. After 17 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 2.0 g of the desired product, m/e=366 (M+Li).
  • Part C: To a solution of 2.0 g (6 mmol) of the product from Part B in 50 mL of anhydrous methanol, was added 0.5 g (21 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.6 g of crude product. This was chromatographed on silica gel using 5%-15% ethyl acetate/hexane to yield 0.9 g of pure N-(2-mercapto-1R-methylethyl)-N-butyl-4-methoxybenzenesulfonamide, m/e=324 (M+Li).
  • EXAMPLE 10 Preparation of N-(2-mercaptopropyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02051
  • Part A: To a solution of 10.04 g (43 mmol) of N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide from Example 1 in 85 mL of anhydrous DMF, was added 17.8 g (128 mmol) of powdered potassium carbonate and then 8.2 g (48 mmol) of benzyl bromide. After 24 hours, ethyl acetate and water was added, the oragnic layer separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 14.3 g of crude product. This was recrystallized from tert-butylmethyl ether/hexane to afford 9.0 g of the desired N-(hydroxyethyl)-N-(phenylmethyl)-4-methoxybenzene-sulfonamide.
  • Part B: To a solution of 4.0 g (12.4 mmol) of N-(2-hydroxyethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide from Part A in 6 mL of anhydrous methylene chloride and 6 mL of anhydrous dimethyl sulfoxide, was added 17.1 mL of triethylamine, the solution cooled in an ice bath and 7.9 g (50 mmol) of sulfur trioxide/pyridine complex in 38 mL of DMSO was added over 15 minutes. After 1 hour, the reaction mixture was poured into ice, extracted with ethyl acetate, washed with 5% KHSO4, brine, dried over magnesium sulfate, filtered and stripped to afford 4.0 g of N-(2-propanal)-4-methoxybenzenesulfonamide suitable for the next reaction.
  • Part C: To 8.3 mL (25 mmol) of 3M methyl magnesium bromide in diethyl ether at 0 C under nitrogen, was added a solution of 4 g (12.4 mmol) of crude N-(2-propanal)-4-methoxybenzenesulfonamide from Part B in 10 mL of anhydrous tetrahydrofuran. After 1 hour at room temperature, the reaction was cooled in ice and quenched by the addition of saturated ammonium chloride solution, extracted with ethyl acetate, washed with 5% KHSO4, brine, dried and stripped to afford 4.0 g of crude material. This was chromatographed on silica gel using 20%-40% ethyl acetate/hexane to afford 3.25 g of the desired N-(2-hydroxypropyl)-4-methoxybenzenesulfonamide, m/e=336 (M+H).
  • Part D: To a solution of 2.0 g (5.9 mmol) of alcohol from Part C and 1.71 g (6.5 mmol) of triphenylphosphine in 30 mL of anhydrous tetrahydrofuran at 0 C, was added 1.28 mL (1.32 g, 6.5 mmol) of diisopropylazodicarboxylate, then 0.47 mL (6.5 mmol) if thiolacetic acid. After 15 hours at room temperature, the solution was stripped and chormatographed on 150 g of silica gel using 20%-50% ethyl acetate/hexane to afford 0.43 g of the desired product, m/e=400 (M+Li).
  • Part E: To a solution of 0.43 g (1.1 mmol) of the product of Part D in 5 mL of anhydrous methanol, was added 0.9 mL (3.9 mmol) of 25 wt % sodium methoxide/methanol. After 15 hours at room temperature, an additional 0.9 mL of sodium methoxide/methanol was added. After 2 hours, the solution was cooled, 1N hydrochloric acid added, extracted with ethyl acetate, washed with saturated sodium bicarbonate, brine, dried and stripped to afford crude product, which was chromatographed over 50 g of silica ge using 100% methylene chloride to afford 117 mg of the desired N-(2-mercaptopropyl)-4-methoxybenzenesulfonamide, m/e=358 (M+Li).
  • EXAMPLE 11 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02052
  • Part A: To a solution of 3.0 g (12.2 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzenesulfonamide from example 3, in 20 mL of anhydrous DMF, was added 5.06 g (36.7 mmol) of powdered potassium carbonate, and then 1.1 mL (17.7 mmol) of methyl iodide. After stirring at room temperature for 48 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 2.83 g of crude material. This was chromatographed on 200 g of silica gel using 50%-80% ethyl acetate/hexane to afford 2.1 g of pure N-(2-hydroxy-1R-methylethyl)-N-methyl-4-methoxybenzenesulfonamide, m/e=266(M+Li).
  • Part B: To a solution of 2.09 g (8.06 mmol) of product from Part A and 2.32 g (8.86 mmol) of triphenylphosphine in 32 mL of anhydrous THF at 0° C., was added 1.4 mL (8.86 mmol) of diethylazodicarboxylate, followed after 5 min. by 0.64 mL (8.86 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 200 g of silica gel using 10%-50% ethyl acetate/hexane to yield 1.77 g of the desired product, m/e=324 (M+Li).
  • Part D: To a solution of 1.77 g (5.58 mmol) of product from Part C in 20 mL of anhydrous methanol, was added 4.6 mL (20 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.2 g of pure product, identified as N-(2-mercapto-1R-methylethyl)-4-methoxy-N-methyl-4-methoxybenzenesulfonamide, m/e=282 (M+Li).
  • EXAMPLE 12 Preparation of N-(2-mercapto-1R-methylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02053
  • Part A: To a solution of 5.0 g (20 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzene-sulfonamide from Example 3 in 40 mL of anhydrous DMF, was added 8.5 g (61 mmol) of powdered potassium carbonate, followed by 3.2 mL (4.5 g, 27 mmol) of benzyl bromide. After 16 hours, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed 3×s with brine, dried with magnesium sulfate, filtered and concentrated to afford 7.1 g of crude product. This was chromatographed on silica gel using 30%-50% ethyl acetate/hexane to yield 4.1 g of pure N-(2-hydroxy-1R-methylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=342 (M+Li).
  • Part B: To a solution of 4.1 g (12 mmol) of N-(2-hydroxy-1R-methylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide from Part A and 3.6 g (14 mmole) of triphenylphosphine in 80 mL of anhydrous THF at 0° C., was added 2.1 mL (2.4 g, 14 mmol) of diethylazodicarboxylate, followed after 5 min. by 1.0 mL (1.0 g, 14 mM) of thiolacetic acid. After 1 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-40% ethyl acetate/hexane to yield 4.3 g of the desired product, m/e=400 (M+Li).
  • Part C: To a solution of 4.3 g (11 mmol) of product from Part B in 100 mL of anhydrous methanol, was added 0.9 g (40 mmol) of sodium metal. After 1 hour, the reaction was cooled, 1N HCl solution was added, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 3.5 g of crude product. This was chromatographed on silica gel using 15%-25% ethyl acetate/hexane to yield 1.9 g of pure N-(2-mercapto-1R-methylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=358 (M+Li).
  • EXAMPLE 13 Preparation of N-(2-mercapto-1S-methylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02054
  • Part A: To a solution of 15.5 mL (15.0 g, 200 mmol) of (S)-(+)-2-amino-1-propanol in 70 mL of THF and 18 mL of water, was added 36 mL (259 mmol) of triethylamine. After cooling in an ice bath, a solution of 37.1 g (179 mmol) of 4-methoxybenzenesulfonyl chloride in 30 mL of tetrahydrofuran was slowly added over 15 minutes. After stirring at room temperature for 2 hour, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate soution, saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to afford 43.3 g of the desired N-(2-hydroxy-1S-methylethyl)-4-methoxybenzenesulfonamide, m/e=246 (M+H).
  • Part B: To a solution of 5.0 g (20 mmol) of N-(2-hydroxy-1S-methylethyl)4-methoxybenzenesulfonamide from part A in 40 mL of anhydrous DMF, was added 8.5 g (61 mmol) of powdered potassium carbonate, followed by 3.2 mL (4.5 g, 27 mmol) of benzyl bromide. After 64 hours, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed 3×s with brine, dried with magnesium sulfate, filtered and concentrated to afford 7.0 g of crude product. This was chromatographed on silica gel using 20%-50% ethyl acetate/hexane to yield 4.2 g of pure N-(2-hydroxy-1S-methylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=342 (M+Li).
  • Part C: To a solution of 4.2 g (12.5 mmol) of N-(2-hydroxy-1S-methylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide from Part B and 3.6 g (14 mmole) of triphenylphosphine in 50 mL of anhydrous THF at 0° C., was added 2.2 mL (13.8 mmol) of diethylazodicarboxylate, followed after 5 min. by 1.0 mL (13.8 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-40% ethyl acetate/hexane to yield 3.9 g of the desired product, m/e=394 (M+H).
  • Part D: To a solution of 3.8 g (9.7 mmol) of product from Part C in 20 mL of anhydrous methanol, was added 7.9 mL (34.8 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 2.78 g of pure product, identified as N-(2-mercapto-1R-methylethyl)-N-(phenylmethyl)-4-methoxy-benzenesulfonamide, m/e=352 (M+H).
  • EXAMPLE 14 Preparation of N-(2-mercapto-1R-methylethyl)-N-(2-methylpropyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02055
  • Part A: To a solution of 3.0 g (12.2 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzene-sulfonamide from example 3, in 20 mL of anhydrous DMF, was added 5.06 g (36.7 mmol) of powdered potassium carbonate, and then 2.0 mL (18.3 mmol) of isobutyl bromide. After stirring at room temperature for 72 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 3.35 g of crude material. This was chromatographed on 150 g of silica gel using 30%-70% ethyl acetate/hexane to afford 2.1 g of pure N-(2-hydroxy-1R-methylethyl)-N-(2-methylpropyl)-4-methoxybenzenesulfonamide, m/e=308(M+Li).
  • Part B: To a solution of 1.3 g (4.3 mmol) of product from Part A and 1.24 g (4.7 mmol) of triphenylphosphine in 17 mL of anhydrous THF at 0° C., was added 0.75 mL (4.7 mmol) of diethylazo-dicarboxylate, followed after 5 min. by 0.34 mL (4.7 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 100 g of silica gel using 10%-30% ethyl acetate/hexane to yield 0.73 g of the desired product, m/e=366 (M+Li).
  • Part C: To a solution of 0.73 g (2.0 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 1.7 mL (7.3 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 10.6 g of crude product. This was chromatographed on 100 g of silica gel to afford 182 mg of pure product, identified as N-(2-mercapto-1R-methylethyl)-N-(2-methylpropyl)-4-methoxybenzenesulfonamide, m/e=324 (M+Li).
  • EXAMPLE 15 Preparation of N-(2-mercapto-1R-methylethyl)-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02056
  • Part A: To a solution of 2.69 g (9.36 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from example 4 and 2.7 g (10.3 mmol) of triphenylphosphine in 37 mL of anhydrous THF at 0° C., was added 1.6 mL (10.3 mmol) of diethylazodi-carboxylate, followed after 5 minutes by 0.75 mL (10.3 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 10%-50% ethyl acetate/hexane to yield 1.59 g of impure material, which was carried into the next step.
  • Part B: To a solution of 1.59 g (4.6 mmol) of product from Part A in 18 mL of anhydrous methanol, was added 3.8 mL (16.6 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.4 g of crude product. This was chromatographed on 150 g of silica gel using 1%-20% methanol/methylene chloride to afford 230 mg of pure product, identified as N-(2-mercapto-1R-methylethyl)-4-(n-butoxy)benzenesulfonamide, m/e=304 (M+H).
  • EXAMPLE 16 Preparation of N-(2-mercapto-1R-methylethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02057
  • Part A: To a solution of 2.58 g (10.5 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzene-sulfonamide from example 3 and 3.03 g (11.6 mmol) of triphenylphosphine in 40 mL of anhydrous THF at 0° C., was added 1.8 mL (11.6 mmol) of diethylazodi-carboxylate, followed after 5 minutes by 0.83 mL (11.6 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-30% ethyl acetate/hexane to yield 1.5 g of pure material, m/e=304 (M+H).
  • Part B: To a solution of 1.5 g (4.9 mmol) of product from Part A in 20 mL of anhydrous methanol, was added 4.0 mL (17.8 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.23 g of pure product, identified as N-(2-mercapto-1R-methylethyl)-4-methoxybenzenesulfonamide, m/e=262 (M+H).
  • Example 17 Preparation of N-(2-mercapto-1R-methylethyl)-N-phenylmethyl)-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02058
  • Part A: To a solution of 3.52 g (12.3 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzenesulfonamide from example 4 in 25 mL of anhydrous DMF, was added 5.07 g (36.8 mmol) of powdered potassium carbonate, followed by 1.9 mL (2.7 g, 15.9 mmol) of benzyl bromide. After 63 hours, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed 3×s with brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on 200 g of silica gel using 20%-50% ethyl acetate/hexane to yield 3.64 g of pure N-(2-hydroxy-1R-methylethyl)-N-phenylmethyl)-4-(n-butoxy)benzenesulfonamide, m/e=384 (M+Li).
  • Part B: To a solution of 3.6 g (9.5 mmol) of product from Part A and 2.74 g (10.5 mmol) of triphenylphosphine in 40 mL of anhydrous THF at 0° C., was added 1.7 mL (10.5 mmol) of diethylazo-dicarboxylate, followed after 5 min. by 0.75 mL (10.5 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 200 g of silica gel using 10%-15% ethyl acetate/hexane to yield 0.99 g of the desired product, m/e=442 (M+Li).
  • Part C: To a solution of 0.99 g (2.3 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 1.9 mL (8.2 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.75 g of pure product, identified as N-(2-mercapto-1R-methylethyl)-N-phenylmethyl)-4-(nbutoxy)benzenesulfonamide., m/e=400 (M+Li).
  • EXAMPLE 18 Preparation of N-(2-mercapto-1R-methylethyl)-N-phenylmethyl)-4-(n-butoxy)benzenesulfonamide disulfide
  • Figure US20050014840A1-20050120-C02059
  • To a solution of 0.42 g (1.32 mmol) of N-(2-mercapto-1R-methylethyl)-N-phenylmethyl)-4-(n-butoxy)benzenesulfonamide in 25 mL of methanol at 0 C, was added 174 mg (0.69 mmol) of iodine crystals. After stirring for 30 minutes, aqueous sodium thiosulfate was added to remove any unreacted iodine and ethyl acetate was added. The organic layer was separated and washed with saturated sodium bicarbonate, brine, dried with magnesium sulfate and stripped to afford 0.40 g of crude product. This was chromatographed on 100 g of silica gel using 20%-50% ethyl acetate/hexane to afford 154 mg of pure N-(2-mercapto-1R-methylethyl)-N-phenylmethyl)-4-(n-butoxy)benzenesulfonamide disulfide, m/e=633 (M+H).
  • EXAMPLE 19 Preparation of 1,3-benzodioxole-5-sulfonyl chloride
  • Figure US20050014840A1-20050120-C02060
  • To a 22 liter round bottom flask fitted with a mechanical stirrer, a cooling condenser, a heating mantle and a pressure equalizing dropping funnel was added sulfur trioxide DMF complex (2778 g, 18.1 moles). Dichloroethane (4 liters) was then added and stirring initiated. 1,2-Benzodioxole (1905 g, 15.6 moles) as then added through the dropping funnel over a five minute period. The temperature was then raised to 75° C. and held for 22 hours (NMR indicated that the reaction was done after 9 hours.) The reaction was cooled to 26° and oxalyl chloride (2290 g, 18.1 moles) was added at a rate so as to maintain the temperature below 40° C. (1.5 hours). The mixture was heated to 67° C. for 5 hours followed by cooling to 16° C. with an ice bath. The reaction was quenched with water (51) at a rate that kept the temperature below 20° C. After the addition of water was complete, the mixture was stirred for 10 minutes. The layers were separated and the organic layer was washed again twice with water (51). The organic layer was dried with magnesium sulfate (500 g) and filtered to remove the drying agent. The solvent was removed under vacuum at 50° C. The resulting warm liquid was permitted to cool at which time a solid began to form. After one hour, the solid was washed with hexane (400 mL), filtered and dried to provide sulfonyl chloride (2823 g). The hexane wash was concentrated and the resulting solid washed with 400 mL hexane to provide additional sulfonyl chloride (464 g). The total yield was 3287 g (95.5% based upon 1,3-benzodioxole).
  • EXAMPLE 20 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-5-(1,3-benzodioxol-5-yl)sulfonamide
  • Figure US20050014840A1-20050120-C02061
  • Part A: To a solution of 5.4 g (72 mmol) of (R)-2-amino-1-propanol in 25 mL of tetrahydrofuran and 10 mL of water, was added 13 mL (93 mmol) of triethylamine. The solution was cooled in an ice bath and a solution of 13.3 g (60 mmol) of 1,3-benzodioxole-5-sulfonyl chloride in 20 mL of tetrahydrofuran was added over 20 minutes. The reaction was stirred at room temperature for 21 hours, stripped, ethyl acetate added, washed with 5% KHSO4 and brine, dried with sodium sulfate, filtered and stripped to afford 12 g of crude material. This was triturated with warm methylene chloride, hexane added and the resulting solids collected, washed with hexane and air dried to yield 7.7 g of pure N-(2-hydroxy-1R-methylethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide, m/e=266(M+Li).
  • Part B: To a solution of 2.6 g (10 mmol) of N-(2-hydroxy-1R-methylethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide from Part A, in 15 mL of anhydrous DMF, was added 4.15 g (30 mmol) of powdered potassium carbonate, and then 1.25 mL (20 mmol) of methyl iodide. After stirring at room temperature for 17 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 2.8 g of crude material. This was chromatographed on 150 g of silica gel using 50%-80% ethyl acetate/hexane to afford 2.0 g of pure N-(2-hydroxy-1R-methylethyl)-Nmethyl-5-(1,3-benzodioxol-5-yl)sulfonamide, m/e=280(M+Li).
  • Part C: To a solution of 2.0 g (7.3 mmol) of product from Part B and 2.11 g (8.05 mmol) of triphenylphosphine in 30 mL of anhydrous THF at 0° C., was added 1.3 mL (8.05 mmol) of diethylazo-dicarboxylate, followed after 5 minutes by 0.58 mL (8.05 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 20%-50% ethyl acetate/hexane to yield 1.86 g of the desired product, m/e=332(M+H).
  • Part D: To a solution of 1.86 g (5.6 mmol) of product from Part C in 20 mL of anhydrous methanol, was added 4.6 mL (20 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.53 mg of pure product, identified as N-(2-mercapto-1R-methylethyl)-N-methyl-5-(1,3-benzodioxol-5-yl)sulfonamide, m/e=290 (M+H).
  • EXAMPLE 21 Preparation of N-(2-mercapto-1R-methylethyl)-N-(phenylmethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide
  • Figure US20050014840A1-20050120-C02062
  • Part A: To a solution of 5.4 g (72 mmol) of (R)-2-amino-1-propanol in 25 mL of tetrahydrofuran and 10 mL of water, was added 13 mL (93 mmol) of triethylamine. The solution was cooled in an ice bath and a solution of 13.3 g (60 mmol) of 1,3-benzodioxole-5-sulfonyl chloride in 20 mL of tetrahydrofuran was added over 20 minutes. The reaction was stirred at room temperature for 21 hours, stripped, ethyl acetate added, washed with 5% KHSO4 and brine, dried with sodium sulfate, filtered and stripped to afford 12 g of crude material. This was triturated with warm methylene chloride, hexane added and the resulting solids collected, washed with hexane and air dried to yield 7.7 g of pure N-(2-hydroxy-1R-methylethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide, m/e=266(M+Li).
  • Part B: To a solution of 2.5 g (9.6 mmol) of N-(2-hydroxy-1R-methylethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide from Part A, in 20 mL of anhydrous DMF, was added 3.99 g (29 mmol) of powdered potassium carbonate, and then 1.5 mL (12.5 mmol) of benzyl bromide. After stirring at room temperature for 17 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 3.15 g of crude material. This was chromatographed on 150 g of silica gel using 20%-75% ethyl acetate/hexane to afford 1.0 g of pure N-(2-hydroxy-1R-methylethyl)-N-(phenylmethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide, m/e=356(M+Li).
  • Part C: To a solution of 0.96 g (2.7 mmol) of product from Part B and 0.79 g (3.0 mmol) of triphenylphosphine in 10 mL of anhydrous THF at 0° C., was added 0.47 mL (3.0 mmol) of diethylazodicarboxylate, followed after 5 minutes by 0.22 mL (3.0 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 100 g of silica gel using 20%-50% ethyl acetate/hexane to yield 0.76 g of the desired product, m/e=414 (M+Li).
  • Part D: To a solution of 0.76 g (1.86 mmol) of product from Part C in 8 mL of anhydrous methanol, was added 1.5 mL (6.7 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 465 mg of pure product, identified as N-(2-mercapto-1R-methylethyl)-N-(phenylmethyl)-5-(1,3-benzodioxol-5-yl)sulfonamide, m/e=372 (M+Li).
  • EXAMPLE 22 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-butoxybenzene)sulfonamide
  • Figure US20050014840A1-20050120-C02063
  • Part A: To a solution of 3.24 g (11 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from example 4, in 22 mL of anhydrous DMF, was added 4.98 g (36 mmol) of powdered potassium carbonate, and then 1.5 mL (24 mmol) of methyl iodide. After stirring at room temperature for 21 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 3.28 g of crude material. This was chromatographed on 150 g of silica gel using 20%-80% ethyl acetate/hexane to afford 2.7 g of pureN-(2-hydroxy-1R-methylethyl)-N-methyl-4-(n-butoxy)benzenesulfonamide, m/e=308(M+Li).
  • Part B: To a solution of 2.7 g (8.96 mmol) of product from Part A and 2.58 g (9.85 mmol) of triphenylphosphine in 36 mL of anhydrous THF at 0° C., was added 1.6 mL (9.85 mmol) of diethylazo-dicarboxylate, followed after 5 minutes by 0.71 mL (9.85 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 20%-50% ethyl acetate/hexane to yield 1.55 g of the desired product, m/e=366 (M+Li).
  • Part C: To a solution of 1.55 g (4.3 mmol) of product from Part B in 18 mL of anhydrous methanol, was added 3.6 mL (15.5 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.3 g of crude product. This was chromatographed on 100 g of silica gel using 1% methanol/methylene chloride to afford 460 mg of pure product, identified as N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-butoxybenzene)sulfonamide, m/e=324 (M+Li).
  • EXAMPLE 23 Preparation of N-(1R-mercaptomethyl)propyl-N-methyl-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02064
  • Part A: To a solution of 3.91 g (44 mmol) of (R)-2-amino-1-butanol in 20 mL of tetrahydrofuran and 5 mL of water, was added 9.5 mL (68 mmol) of triethylamine. The solution was cooled in an ice bath and a solution of 9.85 g (40 mmol) of 4-(n-butoxybenzene)sulfonyl chloride in 10 mL of tetrahydrofuran was added over 10 minutes. The reaction was stirred at room temperature for 5 hours, stripped, ethyl acetate added, washed with 5% KHSO4 and brine, dried with sodium sulfate, filtered and stripped to afford 12.1 g of crude material, which was identified as N-(1R-hydroxymethyl)propyl-4-(n-butoxy)benzenesulfonamide, m/e=308 (M+Li).
  • Part B: To a solution of 3.0 g (9.85 mmol) of N-(1R-hydroxymethyl)propyl-4-(n-butoxy)benzene-sulfonamide from Part A, in 12 mL of anhydrous DMF, was added 4.1 g (30 mmol) of powdered potassium carbonate, and then 1.2 mL (20 mmol) of methyl iodide. After stirring at room temperature for 21 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 2.9 g of crude material. This was chromatographed on 150 g of silica gel using 20%-80% ethyl acetate/hexane to afford 2.0 g of pure N-(1R-hydroxymethyl)propyl-N-methyl-4-(n-butoxy)benzenesulfonamide, m/e=322(M+Li).
  • Part C: To a solution of 2.4 g (7.6 mmol) of product from Part B and 2.19 g (8.37 mmol) of triphenylphosphine in 30 mL of anhydrous THF at 0° C., was added 1.3 mL (8.37 mmol) of diethylazo-dicarboxylate, followed after 5 minutes by 0.60 mL (8.37 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-30% ethyl acetate/hexane to yield 2.12 g of pure material, m/e=374 (M+H).
  • Part D: To a solution of 2.12 g (5.7 mmol) of product from Part C in 23 mL of anhydrous methanol, was added 4.7 mL (20.4 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.32 g of pure product, identified as N-(1R-mercaptomethyl)propyl-N-methyl-4-(n-butoxy)benzenesulfonamide, m/e=332 (M+H).
  • EXAMPLE 24 Preparation of N-(2-hydroxy-1R-methylethyl)-N-(propyn-3yl)-4-(n-butoxybenzene)sulfonamide
  • Figure US20050014840A1-20050120-C02065
  • Part A: To a solution of 2.0 g (7 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from example 4, in 10 mL of anhydrous DMF, was added 2.9 g (21 mmol) of powdered potassium carbonate, and then 1.6 mL of an 80 wt. % solution of propargyl bromide in toluene (15 mmol). After stirring at room temperature for 24 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 2.31 g of crude material. This was chromatographed on 100 g of silica gel using 20%-50% ethyl acetate/hexane to afford 2.1 g of pure N-(2-hydroxy-1R-methylethyl)-(N-propyn-3-yl)-4-(n-butoxy)benzenesulfonamide, m/e=326(M+H).
  • EXAMPLE 25 Preparation of N-(mercapto-1R-methylethyl)-N-(propyn-3-yl)-4-(n-butoxybenzene)sulfonamide disulfide
  • Figure US20050014840A1-20050120-C02066
  • Part A: To a solution of 4.11 g (12.6 mmol) of N-(2-hydroxy-1R-methylethyl)-N-(propyn-3-yl)-4-(n-butoxybenzene)sulfonamide and 3.64 g (13.9 mmol) of triphenylphosphine in 50 mL of anhydrous THF at 0° C., was added 2.2 mL (13.9 mmol) of diethylazodicarboxylate, followed after 5 minutes by 1.0 mL (13.9 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 3.68 g of pure material, m/e=390 (M+Li).
  • Part B: To a solution of 1.1 g (2.9 mmol) of product from Part A in 7 mL of anhydrous methanol, was added 7.4 mL of 30% aqueous ammonia. After 1 hour, the reaction was quenched with 1N HCl solution, followed by diethyl ether and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.90 g of crude product. This was chromatographed on silica gel using 10%-15% ethyl acetate/hexane to afford 200 mg of pure product, identified as N-(mercapto-1R-methylethyl)-N-(propyn-3-yl)-4-(n-butoxybenzene)sulfonamide disulfide, m/e=687 (M+Li).
  • EXAMPLE 26 Preparation of 1-((4-methoxyphenyl)sulfonyl]-3-mercaptopyrrolidine
  • Figure US20050014840A1-20050120-C02067
  • Part A: To a solution of 4.5 g (52 mmol) of racemic 3-pyrrolidinol in 20 mL of tetrahydrofuran and 5 mL of water, was added 10 mL of triethylamine. The solution was cooled to 0 C, and 9.0 g (46 mmol) of 4-(methoxybenzene)sulfonyl chloride was slowly added. After 18 hours at room temperature, the solution was stripped, ethyl acetate added, washed with 5% KHSO4, saturated sodium bicarbonate, brineand dried over sodium sulfate, filtered and stripped to afford the crude material., which was recrystrallized from warm ethyl acetate/hexane to afford 7.0 g of pure 1-[(4-methoxyphenyl)sulfonyl)-3-hydroxypyrrolidine, m/e=258 (M+H).
  • Part B: To a solution of 2.0 g (7.77 mmol) of product from Part B and 2.24 g (8.54 mmol) of triphenylphosphine in 35 mL of anhydrous THF at 0° C., was added 1.35 mL (8.54 mmol) of diethylazo-dicarboxylate, followed after 5 minutes by 0.62 mL (8.54 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-30% ethyl acetate/hexane to yield 1.05 g of pure material, m/e=316 (M+H).
  • Part C: To a solution of 1.05 g (3.3 mmol) of product from Part C in 6 mL of anhydrous methanol, was added 8.6 mL of 30% aqueous ammonia. After 1 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.74 g of crude product. This was crystallyzed from diethyl ether/hexane to afford 220 mg of pure product, identified as 1-[(4-methoxyphenyl)sulfonyl]-3-mercaptopyrrolidine, m/e=274 (M+H).
  • EXAMPLE 27 Preparation of 1-((4-methoxyphenyl)sulfonyl]-3-hydroxypiperidine
  • Figure US20050014840A1-20050120-C02068
  • To a solution of 3.44 g (25 mmol) of racemic 3-hydroxypiperidine hydrochloride in 10 mL of tetrahydrofuran and 5 mL of water, was added 14 mL (100 mmol) of triethylamine. The solution was cooled to 0 C, and 4.64 g (22 mmol) of 4-(methoxybenzene)sulfonyl chloride was slowly added. After 21 hours at room temperature, the solution was stripped, ethyl acetate added, washed with 5% KHSO4, saturated sodium bicarbonate, brineand dried over sodium sulfate, filtered and stripped to afford the crude material., which was triturated with hexane to afford 5.39 g of pure 1-[(4-methoxyphenyl)sulfonyl]-3-hydroxypiperidine, m/e=272 (M+H).
  • EXAMPLE 28 Preparation of 1-[(4-methoxyphenyl)sulfonyl]pyrrolidine-2-methanethiol
  • Figure US20050014840A1-20050120-C02069
  • Part A: To a solution of 10.27 g (89 mmol) of D,L-proline in 100 mL of water and 60 mL of acetone, was added 40 mL (287 mmol) of triethylamine. After cooling in an ice bath, 17.6 g (85 mmol) of 4-(methoxybenzene)sulfonyl chloride was slowly added. After stirring at room temperature for 13 hours, the acetone was stripped, the aqueous layer extracted twice with toluene, then acidified with 25 mL of 6N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with 5% KHSO4, brine, dried with sodium sulfate, filtered and stripped to afford 23.5 g of racemic 1-[(4-methoxyphenyl)sulfonyl]-2-carboxypyrrolidine, m/e=292(M+Li).
  • Part B: To a solution of 4.00 g (14 mmol) of 1-[(4-methoxyphenyl)sulfonyl]-2-carboxypyrrolidine from part A in 50 mL of anhydrous tetrahydrofuran at 0 C under a nitrogen atmosphere, was slowly added over 15 minutes, 20 mL (20 mmol) of a 1M solution of lithium aluminum hydride in diethyl ether. After stirring at room temperature for 2 hours, the solution was cooled in an ice bath, and quenched by the slow sequential addition of 0.8 mL of water, 0.8 mL of 10% sodium hydroxide and 2.4 mL of water. The resulting suspension was filtered through celite and the celite washed with ethyl acetate. The combined organic filtrates were stripped, the residue disolved in ethyl acetate, which was washed with 5% KHSO4, saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and stripped to afford 3.66 g of crude material. This was chromatographed on 200 g of silica gel using 40%-75% ethyl acetate/hexane to yield pure 1-[(4-methoxyphenyl)sulfonyl)-2-(hydroxymethyl)-pyrrolidine, m/e=278(M+Li).
  • Part C: To a solution of 1.78 g (6.6 mmol) of product from Part B and 1.9 g (7.2 mmol) of triphenylphosphine in 26 mL of anhydrous THF at 0° C., was added 1.14 mL (7.2 mmol) of diethylazodicarboxylate, followed after 5 min. by 0.52 mL (7.2 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 200 g of silica gel using 50%-80% ethyl acetate/hexane to yield 1.5 g of the desired product, m/e=336 (M+Li).
  • Part D: To a solution of 1.5 g (4.6 mmol) of product from Part C in 10 mL of anhydrous methanol, was added 3.7 mL (16.4 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.9 g of crude product. This was dissolved in methylene chloride and passed down a short column of silica gel using methylene chloride to afford 0.55 g of pure product, identified as 1-((4-methoxyphenyl)sulfonyl]pyrrolidine-2-methanethiol, m/e=294 (M+Li).
  • EXAMPLE 29 Preparation of Racemic N-[1-(mercaptomethyl)-3-methylbutyl]-N-(phenylmethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02070
  • Part A: To a solution of 10.0 g (76.2 mmol) of D,L-leucine in 85 mL of water and 50 mL of acetone, was added 30 mL (215 mmol) of triethylamine. This solution was cooled in an ice bath, and a solution of 15.0 g (72.7 mmol) of 4-methoxybenzenesulfonyl chloride in 50 mL of acetone was slowly added over a 30 minute period. The reaction was stirred at room temperature for 15 hours, concentrated, the remaining aqueous layer extracted twice with toluene, then acidified with 20 mL of 6N hydrochloric acid, extracted with ethyl acetate, which was washed with 5% KHSO4, brine, dried over sodium sulfate, filtered and stripped to afford 19.2 g of crude material, which was triturated with warm hexane to afford 17.5 g of pure material, m/e=308 (M+Li), suitable for use in the next step.
  • Part B: To a solution of 17.5 g of product from part A in 45 mL of anhydrous methanol at 0 C, was slowly added 5.5 mL (75 mmol) of thionyl chloride over 15 minutes. The solution was then stirred for 15 hours at room temperature, concentrated, ethyl acetate added, washed with water, saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and stripped to afford 18.6 g of crude material. This was crystallized from ethyl acetate/hexane to afford 13.3 g of the desired product, m/e=322 (M+Li).
  • Part C: To a solution of 3.00 g (9.5 mmol) of the product from Part B, in 20 mL of anhydrous DMF, was added 4.0 g (29 mmol) of powdered potassium carbonate, and then 1.5 mL (12.6 mmol) of benzyl bromide. After stirring at room temperature for 16 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 4.2 g of crude material. This was recrystallized from ethyl acetate/hexane to afford 3.41 g of pure product, m/e=412(M+Li).
  • Part D: To a solution of 3.2 g (7.9 mmol) of the product from part C in 30 mL of anhydrous tetrahydrofuran at 0 C under a nitrogen atmosphere, was slowly added over 15 minutes, 7.9 mL (7.9 mmol) of a 1M solution of lithium aluminum hydride in diethyl ether. After stirring at room temperature for 1 hour, the solution was cooled in an ice bath, and quenched by the slow sequential addition of 0.3 mL of water, 0.3 mL of 10% sodium hydroxide and 0.9 mL of water. The resulting suspension was filtered through celite and the celite washed with ethyl acetate. The combined organic filtrates were stripped, the residue disolved in ethyl acetate, which was washed with 5% KHSO4, saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and stripped to afford 2.71 g ofcrude product identified as racemic N-[1-(hydroxymethyl)-3-methylbutyl]-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=384 (M+Li).
  • Part E: To a solution of 2.7 g (7.2 mmol) of product from Part D and 2.07 g (7.9 mmol) of triphenylphosphine in 30 mL of anhydrous THF at 0° C., was added 1.13 mL (7.2 mmol) of diethylazo-dicarboxylate, followed after 5 min. by 0.52 mL (7.2 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 200 g of silica gel using 20%-50% ethyl acetate/hexane to yield 2.0 g of pure product, m/e=442 (M+Li).
  • Part F: To a solution of 2.0 g (4.6 mmol) of product from Part E in 10 mL of anhydrous methanol, was added 3.7 mL (16.4 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.8 g of pure product, identified as racemic N-[1-(mercaptomethyl)-3-methylbutyl]-N-(phenylmethyl)-4-methoxybenzene-sulfonamide. m/e=400 (M+Li).
  • EXAMPLE 30 Preparation of N-(4-methoxybenzene-sulfonamide)-D-valine methyl ester
  • Figure US20050014840A1-20050120-C02071
  • Part A: To a solution of 20.0 g (170 mmol) of D-valine in 170 mL of water and 95 mL of acetone, was added 50 mL (360 mmol) of triethylamine. This solution was cooled in an ice bath, and a solution of 35.2 g (170 mmol) of 4-methoxybenzenesulfonyl chloride in 75 mL of acetone was slowly added over a 20 minute period. The reaction was stirred at room temperature for 21 hours, concentrated, the remaining aqueous layer extracted twice with toluene, then acidified with 25 mL of 6N hydrochloric acid, extracted with ethyl acetate, which was washed with 5% KHSO4, brine, dried over sodium sulfate, filtered and stripped to afford 39.4 g of crude material, m/e=294 (M+Li), suitable for use in the next step.
  • Part B: To a solution of 35.04 g (122 mmol) of product from part A in 125 mL of anhydrous methanol at 0 C, was slowly added 10.0 mL (137 mmol) of thionyl chloride over 15 minutes. The solution was then stirred for 14 hours at room temperature, concentrated, ethyl acetate added, washed with water, saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and stripped to afford 37.1 g of crude material. This was triturated with hexane to afford 32.9 g of the desired product, N-(4-methoxybenzenesulfonamide)-D-valine methyl ester, m/e=308 (M+Li).
  • EXAMPLE 31 Preparation of N-[(1R-mercaptomethyl)-2-methylpropyl]-4-methoxy-N-(phenylmethyl)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02072
  • Part A: To a solution of 5.0 g (17 mmol) of product from Example 30 in 40 mL of anhydrous DMF, was added 6.9 g (50 mmol) of powdered potassium carbonate, followed by 2.2 mL (3.1 g, 18 mmol) of benzyl bromide. After 66 hours, ethyl acetate and water were added to the reaction, the organic layer was separated and washed 3×s with brine, dried with magnesium sulfate, filtered and concentrated to afford 7.4 g of crude product. This was chromatographed on silica gel using 15%-20% ethyl acetate/hexane to yield 6.3 g of pure product, m/e=392 (M+H).
  • Part B: To a solution of 6.3 g (20mmol) of product from Part A in 60 mL of anhydrous THF at 0C under nitrogen, was added 16.1 mL (0.6 g, 16 mmol) of a 1.0 M solution of lithium aluminum hydride in diethyl ether. After 1.5 hours, the reaction mixture was cooled to 0° C. and 0.7 mL of water was added, followed by 0.7 mL of 2.5 N sodium hydroxide solution and 2.1 mL of water, the reaction was filtered, the filtrate concentrated in vacuo, ethyl acetate and 5% citric acid solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 5.6 g of pure N-[(1R-hydroxymethyl)-2-methylpropyl]-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=364 (M+H).
  • Part C: To a solution of 5.6 g (15 mmol) of N-[(1R-hydroxymethyl)-2-methylpropyl]-N-(phenylmethyl)-4-methoxybenzenesulfonamide from Part B and 4.5 g (17 mmole) of triphenylphosphine in 100 mL of anhydrous THF at 0° C., was added 2.7 mL (3.0 g, 17 mmol) of diethylazodicarboxylate, followed after 5 min. by 1.2 mL (1.3 g, 17 mM) of thiolacetic acid. After 16 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 10%-25% ethyl acetate/hexane to yield 4.7 g of pure product, m/e=428 (M+Li).
  • Part D: To a solution of 4.7 g (11 mmol) of product from Part C in 100 mL of anhydrous methanol, was added 1.0 g (41 mmol) of sodium metal. After 1 hour, the reaction was quenched using dry ice, ethyl acetate and 5% potassium hydrogen sulfate solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on silica gel using 10%-20% ethyl acetate/hexane to yield 1.6 g of pure N-[(1R-mercaptomethyl)-2-methylpropyl]-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=386 (M+Li).
  • EXAMPLE 32 Preparation of N-(4-methoxybenzenesulfonamide)-L-valine methyl ester
  • Figure US20050014840A1-20050120-C02073
  • Part A: To a solution of 10.0 g (85 mmol) of L-valine in 85 mL of water and 50 mL of acetone, was added 25 mL (180 mmol) of triethylamine. This solution was cooled in an ice bath, and a solution of 17.6 g (85 mmol) of 4-methoxybenzenesulfonyl chloride in 35 mL of acetone was slowly added over a 20 minute period. The reaction was stirred at room temperature for 21 hours, concentrated, the remaining aqueous layer extracted twice with toluene, then acidified with 25 mL of 6N hydrochloric acid, extracted with ethyl acetate, which was washed with 5% KHSO4, brine, dried over sodium sulfate, filtered and stripped to afford 22 g of crude material, m/e=288 (M+H), suitable for use in the next step.
  • Part B: To a solution of 18.9 g (65.8 mmol) of product from part A in 60 mL of anhydrous methanol at 0 C, was slowly added 6.0 mL (83 mmol) of thionyl chloride over 15 minutes. The solution was then stirred for 14 hours at room temperature, concentrated, ethyl acetate added, washed with water, saturated sodium bicarbonate, brine, dried with sodium sulfate, filtered and stripped to afford the crude material. This was recrystallized from ethyl acetate/hexane to afford 16.5 g of the desired product, N-(4-methoxy-benzenesulfonamide)-L-valine methyl ester, m/e=302 (M+H).
  • EXAMPLE 33 Preparation of N-[(1S-mercaptomethyl)-2-methylpropyl]-4-methoxy-N-(phenylmethyl)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02074
  • Part A: To a solution of 4.07 g (13.5 mmol) of the product from example 32 in 25 mL of anhydrous DMF, was added 5.6 g (40.5 mmol) of powdered potassium carbonate, followed by 2.0 mL (2.9 g, 17 mmol) of benzyl bromide. After 42 hours, ethyl acetate and water were added to the reaction, the organic layer was separated and washed 3×s with brine, dried with magnesium sulfate, filtered and concentrated to afford 5.85 g of crude product. This was chromatographed on silica gel using 20%-40% ethyl acetate/hexane to yield 4.88 g of pure product, m/e=392 (M+H).
  • Part B: To a solution of 4.88 g (12.5 mmol) of product from Part A in 50 mL of anhydrous THF at 0C under nitrogen, was added 12.5 mL (12.5 mmol) of a 1.0 M solution of lithium aluminum hydride in diethyl ether. After 0.5 hours, the reaction mixture was cooled to 0° C. and 0.5 mL of water was added, followed by 0.5 mL of 2.5 N sodium hydroxide solution and 1.5 mL of water, the reaction was filtered, the filtrate concentrated in vacuo, ethyl acetate and 5% citric acid solution were added, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 4.0 g of pure N-[(1S-hydroxymethyl)-2-methylpropyl]-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=364 (M+H).
  • Part C: To a solution of 3.94 g (10.8 mmol) of N-[(1S-hydroxymethyl)-2-methylpropyl]-N-(phenylmethyl)-4-methoxybenzenesulfonamide from Part B and 3.12 g (11.9 mmole) of triphenylphosphine in 50 mL of anhydrous THF at 0° C., was added 1.9 mL (2.1 g, 11.9 mmol) of diethylazodicarboxylate, followed after 5 min. by 0.86 mL (0.91 g, 11.9 mmoles) of thiolacetic acid. After 2 hours, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-40% ethyl acetate/hexane to yield 2.7 g of pure product, m/e=422 (M+H).
  • Part D: To a solution of 2.7 g (6.4 mmol) of product from Part C in 20 mL of anhydrous methanol, was added 5.3 mL (23 mmol) of 25 weight % sodium methoxide in methanol solution. After 0.5 hour, the reaction was quenched with 1N hydrochloric acid, ethyl acetate added and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 2.05 g of crude product. This was chromatographed on 100 g of silica gel using 20%-50% ethyl acetate/hexane to yield 1.5 g of pure N-[(1S-mercaptomethyl)-2-methylpropyl]-4-methoxy-N-(phenylmethyl)benzenesulfonamide, m/e=386 (M+Li).
  • EXAMPLE 34 Preparation of N-(2-mercaptoethyl)-N-(phenylmethyl)-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02075
  • Part A: To a solution of 15.11 g (55 mmol) of N-(2-hydroxyethyl)-4-(n-butoxy)benzenesulfonamide from Example 2 in 100 mL of anhydrous DMF, was added 22.9 g (165 mmol) of powdered potassium carbonate and then 10.3 g (60 mmol) of benzyl bromide. After 16 hours, ethyl acetate and water was added, the oragnic layer separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 20.7 g of crude product. This was recrystallized from ethyl acetate/hexane to afford 13.8 g of the desired N-(hydroxyethyl)-N-(phenylmethyl)-4-(n-butoxy)-benzenesulfonamide.
  • Part B: To a solution of 3.0 g (8.2 mmol) of N-(2-hydroxyethyl)-N-(phenylmethyl)-4-(n-butoxy)-benzenesulfonamide from Part A and 2.38 g (9.1 mmol) of triphenylphosphine in 40 mL of anhydrous THF at 0 C, was added 1.4 mL (9.1 mmol) of diisopropylazo-dicarboxylate, followed by 0.65 mL (9.1 mmol) of thiolacetic acid. After stirring at room temperature for 15 hours, the reaction was concentrated and the residue chromatographed on 150 g of silica gel using 20-50% ethyl acetate/hexane to afford 2.4 g of the desired product, which was recrystallized from ethyl acetate/hexane to afford 1.7 g of pure product, m/e=428 (M+Li).
  • Part C: To a suspension of 1.7 g (4.1 mmol) of product from Part B above in 20 mL of anhydrous methanol, was added 3.3 mL (14.6 mmol) of 25 weight % sodium methoxide in methanol. After 30 minutes, the solution was cooled in ice and 2% hydrochloric acid added. Ethyl acetate was added and the organic layer separated and washed with saturated sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and stripped to afford 1.42 g of pure material, identified as N-(2-mercaptoethyl)-N-(phenylmethyl)-4-(n-butoxy)benzenesulfonamide, m/e=386 (M+Li).
  • EXAMPLE 35 Preparation of 4-(Benzyloxy)benzenesulfonyl chloride
  • Figure US20050014840A1-20050120-C02076
  • To a suspension of 22.4 g (146 mmol) of sulfur trioxide/DMF complex in 60 mL of anhydrous 1,2-dichloroethane at room temperature, was added a solution of 30 g (162 mmol) of benzylphenyl ether in 30 mL of anhydrous 1,2-dichloroethane. The resulting mixture was warmed to reflux and maintained there for 1 hour, cooled to room temperature and 10.8 mL (146 mmol) of thionyl chloride added. The reaction was then warmed to 75 C for 1 hour, cooled in an ice bath, 50 mL of water slowly added, then ethyl acetate. The layers were separated, washed with saturated sodium bicarbonate, brine, dried with magnesium sulfate, filtered and stripped. The resulting solids were triturated with hexane to afford 24.5 g of pure 4-(Benzyloxy)benzenesulfonyl chloride.
  • EXAMPLE 36 Preparation of N-(2-hydroxy-1R-methylethyl)-N-methyl-4-hydroxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02077
  • Part A: To a solution of 7.4 mL (95.1 mmol) of (R)-(−)-2-amino-1-propanol in 31 mL of THF and 9 mL of water, was added 17.2 mL (123 mmol) of triethylamine. After cooling in an ice bath, a solution of 24.4 g (86.5 mmol) of 4-(benzyloxy)-benzenesulfonyl chloride in 40 mL of tetrahydrofuran was slowly added over 15 minutes. After stirring at room temperature for 16 hours, the reaction was concentrated in vacuo, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to afford a solid, which was triturated with hexane to afford 23.4 g of the desired N-(2-hydroxy-1R-methylethyl)-4-(benzyloxy)benzenesulfonamide, m/e=322 (M+H).
  • Part B: To a solution of 18.25 g (56.8 mmol) of the product from Part A in 100 mL of anhydrous DMF, was added 23.5 g (170 mmol) of powdered potassium carbonate and then 24.2 g (170 mmol) of methyl iodide. After 22 hours, ethyl acetate and water was added, the oragnic layer separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 18.2 g of crude product, suitable for the next step and identified as the desired N-(2-hydroxy-1R-methylethyl)-N-methyl-4-(benzyloxy)benzenesulfonamide, m/e=333 (M+H).
  • Part C: A solution of 18.2 g (54 mmol) of the product from Part B in 150 mL of tetrahydrofuran was hydrogenated in the presence of 6.0 g of 4% palladium-on-carbon catalyst under 50 psig of hydrogen at room temperature for 2 hours. The catalyst was removed by filtering through celite and concentrated. The resulting solids were triturated with methylene chloride and hexane, collected and air dried to afford 8.6 g of the desired N-(2-hydroxy-1R-methylethyl)-N-methyl-4-hydroxybenzenesulfonamide, m/e=246 (M+H).
  • EXAMPLE 37 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-propyloxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02078
  • Part A: To a solution of 1.50 g (6.11 mmol) of N-(2-hydroxy-1R-methylethyl)-4-hydroxybenzene-sulfonamide from example 36, in 10 mL of anhydrous DMF, was added 2.53 g (18.3 mmol) of powdered potassium carbonate, and then 0.85 mL (9.3 mmol) of bromopropane. After stirring at room temperature for 14 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 1.70 g of crude material, suitable for use in the next step and identified as N-(2-hydroxy-1R-methylethyl)-N-methyl-4-(n-propyloxy)benzenesulfonamide, m/e=288 (M+H).
  • Part B: To a solution of 1.70 g (5.9 mmol) of product from Part A and 1.70 g (6.5 mmol) of triphenylphosphine in 23 mL of anhydrous THF at 0° C., was added 1.0 mL (6.5 mmol) of diethylazodicarboxylate, followed after 5 minutes by 0.47 mL (6.5 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 20%-50% ethyl acetate/hexane to yield 1.02 g of pure product, m/e=352 (M+Li).
  • Part C: To a solution of 1.02 g (2.95 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 2.4 mL (10.5 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.90 g of the desired product, identified as N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-propyloxy)benzene-sulfonamide, m/e=304 (M+H).
  • EXAMPLE 38 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-ethoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02079
  • Part A: To a solution of 1.50 g (6.11 mmol) of N-(2-hydroxy-1R-methylethyl)-4-hydroxybenzenesulfonamide from example 36, in 10 mL of anhydrous DMF, was added 2.53 g (18.3 mmol) of powdered potassium carbonate, and then 0.70 mL (9.2 mmol) of bromoethane. After stirring at room temperature for 15 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 1.53 g of crude material, suitable for use in the next step and identified as N-(2-hydroxy-1R-methylethyl)-N-methyl-4-ethoxybenzenesulfonamide, m/e=274 (M+H).
  • Part B: To a solution of 1.53 g (5.6 mmol) of product from Part A and 1.61 g (6.15 mmol) of triphenylphosphine in 20 mL of anhydrous THF at 0° C., was added 0.97 mL (6.15 mmol) of diethylazo-dicarboxylate, followed after 5 minutes by 0.44 mL (6.15 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 20%-50% ethyl acetate/hexane to yield 1.59 g of pure product, m/e=332 (M+H).
  • Part C: To a solution of 1.53 g (4.62 mmol) of product from Part B in 20 mL of anhydrous methanol, was added 3.8 mL (16.6 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.90 g of the desired product, identified as N-(2-mercapto-1R-methylethyl)-N-methyl-4-ethoxybenzenesulfonamide, m/e=290 (M+H).
  • EXAMPLE 39 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-pentyloxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02080
  • Part A: To a solution of 1.50 g (6.11 mmol) of N-(2-hydroxy-1R-methylethyl)-4-hydroxybenzenesulfonamide from example 36 in 10 mL of anhydrous DMF, was added 2.53 g (18.3 mmol) of powdered potassium carbonate, and then 1.13 mL (9.2 mmol) of 1-bromopentane. After stirring at room temperature for 30 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 1.78 g of crude material, suitable for use in the next step and identified as N-(2-hydroxy-1R-methylethyl)-N-methyl-4-(n-pentyloxyoxy)benzene-sulfonamide, m/e=316 (M+H).
  • Part B: To a solution of 1.78 g (5.64 mmol) of product from Part A and 1.63 g (6.20 mmol) of triphenylphosphine in 20 mL of anhydrous THF at 0° C., was added 1.0 mL (6.2 mmol) of diethylazodicarboxylate, followed after 5 minutes by 0.45 mL (6.2 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 20%-50% ethyl acetate/hexane to yield 1.48 g of pure product, m/e=374 (M+H).
  • Part C: To a solution of 1.48 g (3.96 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 3.3 mL (14 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 1.14 g of the desired product, identified as N-(2-mercapto-1R-methylethyl)-N-methyl-4-ethoxybenzenesulfonamide, m/e=332 (M+H).
  • EXAMPLE 40 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(phenoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02081
  • Part A: To a solution of 5.02 g (66.8 mmol) of (R)-(−)-2-amino-1-propanol in 28 mL of THF and 7 mL of water, was added 14.0 mL (100 mmol) of triethylamine. After cooling in an ice bath, 11.7 g (60 mmol) of 4-fluorobenzenesulfonyl chloride was slowly added over 10 minutes. After stirring at room temperature for 2 hour, the reaction was concentrated, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate solution, saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to afford 14.5 g of the desired N-(2-hydroxy-1R-methylethyl)-4-fluorobenzene-sulfonamide, m/e=234 (M+H).
  • Part B: To a solution of 5.14 g (22.0 mmol) of N-(2-hydroxy-1R-methylethyl)-4-fluorobenzene-sulfonamide from Part A in 40 mL of anhydrous DMF, was added 9.12 g (66.1 mmol) of powdered potassium carbonate, and then 4.2 mL (66 mmol) of methyl iodide. After stirring at room temperature for 4 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 4.64 g of the desired N-(2-hydroxy-1R-methylethyl)-N-methyl-4-fluorobenzenesulfonamide, m/e=247 (M+H).
  • Part C: To a solution of 3.00 g (12.1 mmol) of the product from Part B in 25 mL of anhydrous DMF, was added 5.02 g (36.4 mmol) of powdered potassium carbonate, and then 2.3 g (24.3 mmol) of phenol. The reaction mixture was heated to 100 C for 48 hours, cooled and tert-butylmethyl ether and water added. The organic layer was separated and washed with 10% sodium hydroxide, brine, dried with sodium sulfate, filtered and stripped to afford 3.0 g of crude material. This was chromatographed on 150 g of silica gel using 20%-30% ethyl acetate/hexane to provide 0.92 g of pure N-(2-hydroxy-1R-methylethyl)-N-methyl-4-(phenoxy)-benzenesulfonamide, m/e=328 (M+Li).
  • Part D: To a solution of 742 mg (2.3 mmol) of product from Part C and 0.67 g (2.54 mmol) of triphenylphosphine in 10 mL of anhydrous THF at 0° C., was added 0.40 mL (2.54 mmol) of diethylazo-dicarboxylate, followed after 5 min. by 0.18 mL (2.54 mmol) of thiolacetic acid. After 0.5 hour, the reaction was concentrated and the residue was chromatographed on 100 g of silica gel using 10%-20% ethyl acetate/hexane to yield 0.77 g of the desired product, m/e=380 (M+H).
  • Part E: To a solution of 0.76 g (2.05 mmol) of product from Part D in 5 mL of anhydrous methanol, was added 1.8 mL (7.4 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on 100 g of silica gel using 100% methylene chloride to provide the pure N-(2-mercapto-1R-methylethyl)-N-methyl-4-(phenoxy)-benzenesulfonamide, m/e=338 (M+H).
  • EXAMPLE 41 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(thiophenyl)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02082
  • Part A: To a solution of 1.72 g (6.95 mmol) of N-(2-hydroxy-1R-methylethyl)-N-methyl-4-fluorobenzenesulfonamide from Example 40, part B, in 10 mL of anhydrous DMF, was added 7.03 g (21.5 mmol) of cesium carbonate, and then 1.0 mL (1.07 g, 9.73 mmol) of thiophenol. The reaction mixture was heated to 70 C for 15 hours, cooled and ethyl acetate and water added. The organic layer was separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 2.5 g of crude material. This was chromatographed on 100 g of silica gel using 20%-60% ethyl acetate/hexane to provide 1.37 g of pure N-(2-hydroxy-1Rmethylethyl)-N-methyl-4-(thiophenyl)-benzenesulfonamide, m/e=338 (M+H).
  • Part B: To a solution of 1.29 g (3.82 mmol) of product from Part A and 1.10 g (4.20 mmol) of triphenylphosphine in 19 mL of anhydrous THF at 0° C., was added 0.60 mL (4.20 mmol) of diethylazo-dicarboxylate, followed after 5 min. by 0.30 mL (4.20 mmol) of thiolacetic acid. After 1 hour, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 100% methylene chloride to yield 1.0 g of the desired product, m/e=402 (M+Li).
  • Part C: To a solution of 1.0 g (2.53 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 2.1 mL (9.1 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on 50 g of silica gel using 100% methylene chloride to provide pure N-(2-mercapto-1R-methylethyl)-N-methyl-4-(thiophenyl)benzene-sulfonamide, m/e=354 (M+H).
  • EXAMPLE 42 Preparation of N-(2-hydroxy-1R-methylethyl)-N-methyl-2-(pyrid-2-yl)thiophene-5-sulfonamide
  • Figure US20050014840A1-20050120-C02083
  • Part A: To a solution of 1.97 g (26.2 mmol) of (R)-(−)-2-amino-1-propanol in 10 mL of THF and 3.5 mL of water, was added 4.5 mL (32 mmol) of triethylamine. After cooling in an ice bath, 5.44 g (20.9 mmol) of 2-(pyrid-2-yl)thiophene-5-sulfonyl chloride was slowly added over 10 minutes. After stirring at room temperature for 3.5 hours, the reaction was concentrated, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate soution, saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to afford 4.1 g crude product. This was crystallized from acetone/diethyl ether to afford 0.96 of pure N-(2-hydroxy-1R-methylethyl)-2-(pyrid-2-yl)thiophene-5-sulfonamide.
  • Part B: To a solution of 0.94 g (3.15 mmol) of product from Part A in 10 mL of anhydrous DMF, was added 1.31 g (9.45 mmol) of powdered potassium carbonate, and then 0.60 mL (9.5 mmol) of methyl iodide. After stirring at room temperature for 24 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 0.93 g of the desired N-(2-hydroxy-1R-methylethyl)-N-methyl-2-(pyrid-2-yl)thiophene-5-sulfonamide.
  • EXAMPLE 43 Preparation of N-(2-mercapto-1,1-dimethylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02084
  • Part A: To a solution of 4.47 g (50 mmol) of 2-amino-2-methyl-1-propanol in 20 mL of THF and 5 mL of water, was added 10 mL (72 mmol) of triethylamine. After cooling in an ice bath, 9.0 g (44 mmol) of 4-methoxybenzenesulfonyl chloride was slowly added over 10 minutes. After stirring at room temperature for 12 hours, the reaction was concentrated, ethyl acetate and water were added, the organic layer was separated and washed with 5% potassium hydrogen sulfate soution, saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to afford 9.1 g of the desired N-(2-hydroxy-1,1-dimethylethyl)-4-methoxybenzenesulfonamide.
  • Part B: To a solution of 3.12 g (12 mmol) of product from Part A in 25 mL of anhydrous DMF, was added 5.0 g (36 mmol) of powdered potassium carbonate, and then 2.2 mL (18 mmol) of benzyl bromide. After stirring at room temperature for 17 hours, ethyl acetate and water was added, the layers separated and the organic layer washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 3.2 g of crude product. This was recrystallized from methylene chloride/hexane to afford 1.51 g of the desired N-(2-hydroxy-1,1-dimethylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=356 (M+Li).
  • Part C: To a solution of 1.43 g (4.1 mmol) of product from Part B and 1.18 g (4.5 mmol) of triphenylphosphine in 16 mL of anhydrous THF at zero ° C., was added 0.70 mL (4.5 mmol) of diethylazo-dicarboxylate, followed after 5 min. by 0.32 mL (4.5 mmol) of thiolacetic acid. After 3 hours, the reaction was concentrated and the residue was chromatographed on 150 g of silica gel using 20%-50% ethyl acetate/hexane to yield 0.62 g of the desired product, m/e=414 (M+Li).
  • Part D: To a solution of 0.60 g (1.47 mmol) of product from Part C in 10 mL of anhydrous methanol, was added 1.2 mL (5.3 mmol) of a 25 weight percent solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched with 1N HCl solution, followed by ethyl acetate and water, the organic layer was separated and washed with saturated sodium bicarbonate solution and brine, dried with magnesium sulfate, filtered and concentrated to afford 0.38 g of pure N-(2-mercapto-1,1-dimethylethyl)-N-(phenylmethyl)-4-methoxybenzenesulfonamide, m/e=366 (M+H).
  • EXAMPLE 44 Preparation of N-[(2-mercaptophenyl)methyl]-N-methyl-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02085
  • Part A: To a mixture of 50 mL of tetrahydrofuran, 15 mL (108 mmol) of trtiethylamine and 10 mL (116 mmol) of a 40% aqueous methylamine solution at 0 C, was added 15.0 g (72.6 mmol) of 4-methoxy-benzenesulfonyl chloride over a 15 minutes. After 1 hour, the solvents were removed in vacuo, 5% aqueous KHSO4 and ethyl acetate added, the organic layer separted, washed with saturated aqueous sodium bicarbonate, brine, dried with sodium sulfate, filtered and stripped to afford a white solid. This was recrystallized from hot ethyl acetate/hexane to afford 13.4 g of N-methyl-4-methoxybenzenesulfonamide, m/e=202 (M+H).
  • Part B: To a solution of 6.32 g (25.0 mmol) of 2-iodobenzyl chloride in 40 mL of anhydrous DMF, was added 5.04 g (25.0 mmol) of the product from Part A, and then 10.4 g (75.3 mmol) of powdered potassium carbonate was added. After stirring at room temperature for 5 hours, ethyl acetate and water were added, the organic layer separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 10.6 g of crude product. This was recrystallized from ethyl acetate/hexane to afford 9.0 g of the desired N-[(2-iodophenyl)methyl]-N-methyl-4-methoxybenzenesulfonamide.
  • Part C: To a mixture of 834 mg (2.0 mmol) of the product from Part B, 236 mg (3.1 mmol) of thiourea and 55 mg (0.10 mmol) of bis(tri-n-butylphosphine)-nickel (II) chloride under a nitrogen atmosphere at room temperature, was added 1 mL of anhydrous DMF, and then 16 mg (0.25 mmol) of sodium cyanoborohydride. The reaction was then warmed to 65 C for 15 hours, cooled to room temperature and 2.0 mL (5 mmol) of 2.5 N sodium hydroxide solution added. After stirring for 15 minutes, 1N hydrochloric acid and ethyl acetate were added, the organic layers separated, washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 650 mg of crude product. This was chromatographed on 50 g of silica gel using 20%-30% ethyl acetate/hexane to afford 520 mg of purified product, which was then recrystallized from methylene chloride/hexane to afford 167 mg of the desired N-[(2-mercaptophenyl)methyl]-N-methyl-4-methoxybenzene-sulfonamide.
  • EXAMPLE 45 Preparation of N-(2-mercapto-1R-methylethyl)-N-[2-(4-morpholino)ethyl]-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02086
  • Part A: To a solution of 2.87 g (10 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from Example 4 in (10 ml) of anhydrous DMF,was added 4.14 g (30 mmol) of powdered potassium carbonate and then 2.04 g (11 mmol) of 4-(2-Chloroethyl)morpholine hydrochloride. After 12 hours another batch of (2.0 g, mmol) of powdered potassium carbonate and 1.0 g (5.5 mmol) of 4-(2-chloroethyl)-morpholine hydrochloride was added and the reaction mixture stirred at room temperature for an additional 12 hours, ethyl acetate and water was added, the organic layer separated and washed 3x50 mL with brine, dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 3:1 mixture of ethyl acetate:hexane to afford 2.1 g of the desired N-(2-hydroxy-1R-methylethyl)-N-[2-(4-morpholino)-ethyl]-4-(n-butoxy)benzenesulfonamide, m/e=407 (M+Li).
  • Part B: To a solution of 1.5 g (3.74 mmol) of product from Part A and 983 mg (3.74 mmol) of triphenylphosphine in 15 ml of anhydrous THF at room temperature was added 0.588 mL (3.74 mmol) of diethyl azodicarboxylate,followed by 0.8 mL (11.22 mmol) of thiolacetic acid. After stirring at room temperature for 1.5 hours, the reaction was concentrated and the residue chromatographed on 100 g of silica gel using a 1:1 mixture of ethyl acetate:hexane to afford 718 mg of the desired N-[2-(S-acetyl)mercapto-1R-methylethyl]-N-[2-(4-morpholino)ethyl]-4-(n-butoxy)benzenesulfonamide, m/e=459 (M+H).
  • Part C: To a suspension of 0.63 g (1.7 mmol) of product from Part B in 20 mL of anhydrous methanol, was added 0.5 mL (2.3 mmol) of 25 wt. % sodium methoxide in methanol. After 30 minutes at room temperature, ethyl acetate and water was added, the organic layer separated and washed 3×50 ml with water and with brine and dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 3% methanol/dichloromethane to afford 0.38 g of N-(2-mercapto-1R-methylethyl)-N-[2-(4-morpholino)ethyl)-4-(n-butoxy)benzenesulfonamide, m/e=417 (M+H).
  • EXAMPLE 46 Preparation of N-(2-mercapto-1R-methylethyl)-N-[2-(1-piperidino)ethyl]-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02087
  • Part A: To a solution of 1.0 g (3.5 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)-benzene-sulfonamide from Example 4 in (30 ml) of anhydrous DMF,was added 2.16 g (15.6 mmol) of powdered potassium carbonate and then 0.96 g (5.2 mmol) of 1-(2-chloroethyl)piperidine hydrochloride. After 20 hours, ethyl acetate and water was added, the organic layer separated and washed 2×50 mL with saturated sodium bicarbonate and 2×50 mL with brine, dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 200 g of silica gel using 3:1 mixture of ethyl acetate:hexane to afford 0.98 g of the desired N-(2-hydroxy-1R-methylethyl)-N-[2-(1-piperidino)ethyl]-4-(n-butoxy)-benzenesulfonamide, m/e=399 (M+H).
  • Part B: To a solution of 0.9 g (2.26 mmol) of product from Part A and 0.6 g (2.3 mmol) of triphenylphosphine in 20 ml of anhydrous THF at room temperature was added 0.36 mL (2.3 mmol) of diethyl azodicarboxylate, followed by 0.48 mL (6.78 mmol) of thiolacetic acid. After stirring at room temperature for 6 hours, the reaction was concentrated and the residue chromatographed on 60 g of silica gel using a 3:1:0.25 mixture of ethyl acetate:hexane:methanol to afford 0.36 g of the desired N-[2-(S-acetyl)mercapto-1R-methylethyl]-N-[2-(1-piperidino)ethyl]-4-(n-butoxy)benzenesulfonamide, m/e=457 (M+H).
  • Part C: To a suspension of 0.36 g (0.77 mmol) of product from Part B in 20 mL of anhydrous methanol, was added 0.3 mL (1.4 mmol) of 25 wt. % sodium methoxide in methanol. After 30 minutes at room temperature, ethyl acetate and water was added, the organic layer separated and washed 3×50 ml with water and with brine and dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 20 g of silica gel using 5% methanol/dichloromethane to afford 0.17 g of N-(2-mercapto-1R-methylethyl)-N-[2-(1-piperidino)ethyl)-4-(n-butoxy)benzenesulfonamide, m/e=415 (M+H).
  • EXAMPLE 47 Preparation of N-(2-mercapto-1R-methylethyl)-N-[2-(1-pyrrolidino)ethyl]-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02088
  • Part A: To a solution of 2.87 g (10 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzene-sulfonamide from Example 4 in (10 ml) of anhydrous DMF, was added 4.14 g (30 mmol) of powdered potassium carbonate and then 1.88 g (11 mmol) of 1-(2-chloro-ethyl)pyrrolidine hydrochloride. After 12 hours, ethyl acetate and water was added, the organic layer separated and washed 3×50 mL with brine, dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 3:1:0.5 mixture of ethyl acetate:hexane:methanol to afford 1.6 g of the desired N-(2-hydroxy-1R-methylethyl)-N-[2-(1-pyrrolidino)-ethyl]-4-(n-butoxy)benzenesulfonamide, m/e=391 (M+Li).
  • Part B: To a solution of 1.2 g (3 mmol) of product from Part A and 0.79 g (3 mmol) of triphenylphosphine in 15 ml of anhydrous THF at room temperature was added 0.47 mL (3 mmol) of diethyl azodicarboxylate, followed by 0.7 mL (10 mmol) of thiolacetic acid. After stirring at room temperature for 2 hours, the reaction was concentrated and the residue chromatographed on 100 g of silica gel using a 3:1:1 mixture of ethyl acetate:hexane:methanol to afford 0.4 g of the desired N-[2-(S-acetyl)mercapto-1R-methylethyl]-N-[2-(1-pyrrolidino)ethyl]-4-(n-butoxy)benzenesulfonamide, m/e=443 (M+H).
  • Part C: To a suspension of 0.39 g (0.87 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 0.3 mL (1.4 mmol) of 25 wt. % sodium methoxide in methanol. After 30 minutes at room temperature, ethyl acetate and water was added, the organic layer separated and washed 3×50 ml with water and with brine and dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 50 g of silica gel using 5% methanol/dichloromethane to afford 0.18 g of the desired N-(2-mercapto-1R-methylethyl)-N-[2-(1-pyrrolidino)ethyl)-4-(n-butoxy)benzenesulfonamide, m/e=401 (M+H).
  • EXAMPLE 48 Preparation of N-(2-mercapto-1R-methylethyl)-N-pentyl-4-(n-butoxy)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02089
  • Part A:To a solution of 2.87 g (10 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(n-butoxy)benzenesulfonamide from Example 4 in (20 ml) of anhydrous DMF, was added 4.2 g (30 mmol) of powdered potassium carbonate and then 2.3 g (15 mmol) of 1-Bromopentane. The reaction mixture was stirred at 60° C. for 13 hours, ethyl acetate and water was added, the organic layer separated and washed with water and with brine, dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 2:1 mixture of ethyl acetate:hexane to afford 2.63 g of the desired N-(2-hydroxy-1R-methylethyl)-N-pentyl-4-(n-butoxy)benzenesulphonamide, m/e=364 (M+Li).
  • Part B: To a solution of 2.0 g (5.6 mmol) of product from Part A and 1.58 g (6 mmol) of triphenylphosphine in 20 ml of anhydrous THF at room temperature was added 0.94 mL (6 mmol) of diethyl azodicarboxylate, followed by 0.86 mL (12 mmol) of thiolacetic acid. After stirring at room temperature for 1 hour, the reaction was concentrated and the residue chromatographed on 100 g of silica gel using a 4:1 mixture of hexane:ethyl acetate to afford 1.2 g of the desired N-[2-(S-acetyl)mercapto-1Rmethylethyl]-N-pentyl-4-(n-butoxy)benzenesulfonamide, m/e=416 (M+H)
  • Part C: To a suspension of 1.0 g (2.4 mmol) of product from Part B in 20 mL of anhydrous methanol, was added 1.0 mL (4.6 mmol) of 25 wt. % sodium methoxide in methanol. After 30 minutes at room temperature, ethyl acetate and water was added, the organic layer separated and washed 3×50 ml with water and with brine and dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 50 g of silica gel using dichloromethane to afford g of the desired N-(2-mercapto-1R-methylethyl)-N-pentyl-4-(n-butoxy)benzenesulfonamide, m/e=380 (M+Li).
  • EXAMPLE 49 N-(2-mercapto-1-R-methylethyl)-N-(3-pyridylmethyl)-4-methoxybenzenesulfonamide
  • Figure US20050014840A1-20050120-C02090
  • Part A: To a solution of3.69 g (15 mmol) of N-(2-hydroxy-1R-methylethyl)-4-methoxybenzene-sulfonamide from Example 3 in (25 ml) of anhydrous DMF, was added 6.3 g (45 mmol) of powdered potassium carbonate and then 2.7 g (16.5 mmol) of 3-picolyl hydrochloride. The reaction mixture was stirred for 12 hours, ethyl acetate and water was added, the organic layer separated and washed with saturated sodium bicarbonate and with brine, dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 2:1 ethyl acetate:hexane to afford 1.12 g of the desired N-(2-hydroxy-1R-methylethyl)-N-(3-pyridylmethyl)-4-methoxybenzenesulphonamide, m/e=343 (M+Li).
  • Part B: To a solution of 1.07 g (3.18 mmol) of product from Part A and 0.84 g (3.2 mmol) of triphenylphosphine in 25 ml of anhydrous THF at room temperature was added 0.5 mL (3.18 mmol) of diethyl azodicarboxylate, followed by 0.68 mL (9.5 mmol) of thiolacetic acid. After stirring at room temperature for 1.5 hour, the reaction was concentrated and the residue chromatographed on 80 g of silica gel using 1:2 hexane:ethyl acetate to afford 0.21 g of the desired N-[2-(S-acetyl)mercapto-1R-methylethyl]-N-(3-pyridylmethyl)-4-methoxybenzenesulfonamide, m/e=395 (M+H).
  • Part C: To a suspension of 0.18 g (0.45 mmol) of product from Part B in 25 mL of anhydrous methanol, was added 0.2 mL (1.2 mmol) of 25 wt. % sodium methoxide in methanol. After 30 minutes at room temperature, ethyl acetate and water was added, the organic layer separated and washed 2×50 ml with water and with brine and dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 50 g of silica gel using 1% methanol/dichloromethane to afford 0.1 g of the desired N-(2-mercapto-1R-methylethyl)-N-(3-pyridylmethyl)-4-methoxybenzenesulfonamide, m/e=353 (M+H).
  • EXAMPLE 50 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl(3-thiophenylpropyl)sulphonamide
  • Figure US20050014840A1-20050120-C02091
  • Part A: To a solution of 1.1 g (3.8 mmol) of N-(2-hydroxy-1R-methylethyl) (3-thiophenoxypropyl)-sulphonamide from Example 5 in (25 ml) of anhydrous DMF, was added 2.1 g (15 mmol) of powdered potassium carbonate and then 1.1 g (7.6 mmol) of methyl iodide. The reaction mixture was stirred at room temperature for 14 hours, ethyl acetate and water was added, the organic layer separated and washed with saturated sodium bicarbonate and with brine, dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 2:1 ethyl acetate:hexane to afford 0.93 g of the desired N-(2-hydroxy-1R-methylethyl)-N-methyl(3-thiophenylpropyl)sulphonamide, m/e=326 (M+Na).
  • Part B: To a solution of 0.9 g (2.96 mmol) of product from Part A and 0.78 g (2.96 mmol) of triphenylphosphine in 25 ml of anhydrous THF at room temperature was added 0.47 mL (2.96 mmol) of diethyl azodicarboxylate, followed by 0.63 mL (8.8 mmol) of thiolacetic acid. After stirring at room temperature for 1.5 hour, the reaction was concentrated and the residue chromatographed on 80 g of silica gel using 3:1 hexane:ethyl acetate to afford 0.85 g of the desired N-[2-(S-acetyl)mercapto-1R-methylethyl]-N-methyl(3-thiophenylpropyl)sulfonamide, m/e=368 (M+Li).
  • Part C: To a suspension of 0.18 g (0.5 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 0.25 mL (1.12 mmol) of 25 wt. % sodium methoxide in methanol. After 25 minutes at room temperature, neutralized with 0.2N hydrochloric acid, ethyl acetate was added, the organic layer separated and washed 2×50 ml with water and with brine and dried over sodium sulfate,filtered and solvent removed under reduced pressure and the residue chromatographed on 50 g of silica gel using dichloromethane to afford 72 mg of the desired N-(2-mercapto-1R-methylethyl)-N-methyl-(3-thiophenylpropyl)sulfonamide, m/e=320 (M+H)
  • EXAMPLE 51 N-(2-mercapto-1R-methylethyl)-N-benzyl(3-thiophenylpropyl)sulphonamide
  • Figure US20050014840A1-20050120-C02092
  • Part A: To a solution of 0.86 g (3 mmol) of N-(2-hydroxy-1R-methylethyl)(3-thiophenoxypropyl)-sulphonamide from Example 5 in (25 ml) of anhydrous DMF, was added 1.24 g (8.9 mmol) of powdered potassium carbonate and then 0.62 g (3.6 mmol) of benzyl bromide. The reaction mixture was stirred at room temperature for 14 hours, ethyl acetate and water was added, the organic layer separated and washed with saturated sodium bicarbonate and with brine, dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 1:2 ethyl acetate:hexane to afford 0.64 g of the desired N-(2-hydroxy-1R-methylethyl)-N-benzyl) (3-thiophenylpropyl)sulphonamide, m/e=380 (M+H).
  • Part B: To a solution of 0.6g (1.58 mmol) of product from Part A and 0.42 g (1.6 mmol) of triphenylphosphine in 15 ml of anhydrous THF at room temperature was added 0.25 mL (1.6 mmol) of diethyl azodicarboxylate, followed by 0.34 mL (4.8 mmol) of thiolacetic acid. After stirring at room temperature for 1 hour, the reaction was concentrated and the residue chromatographed on 80 g of silica gel using 2:1 hexane:ethyl acetate to afford 0.465 g of the desired N-[2-(S-acetyl)mercapto-1R-methylethyl]-N-benzyl(3-thiophenylpropyl)sulfonamide, m/e=444 (M+Li).
  • Part C: To a suspension of 0.17 g (0.39 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 0.2 mL (0.92 mmol) of 25 wt. % sodium methoxide in methanol. After 25 minutes at room temperature, neutralized with 0.2N hydrochloric acid, ethyl acetate was added, the organic layer separated and washed 2×50 ml with water and with brine and dried over sodium sulfate,filtered and solvent removed under removed under reduced pressure to afford 72 mg of the desired N-(2-mercapto-1R-methylethyl)-N-benzyl(3-thiophenylpropyl)sulfonamide, m/e=396 (M+H).
  • EXAMPLE 52 N-(2-mercapto-1R-methylethyl)-N-[2-(1-piperidino)ethyl](3-thiophenylpropyl)sulphonamide
  • Figure US20050014840A1-20050120-C02093
  • Part A: To a solution of 1.0 g (3.45 mmol) of N-(2-hydroxy-1R-methylethyl)(3-thiophenoxypropy)-sulphonamide from Example 5 in (30 ml) of anhydrous DMF, was added 2.16 g (15.6 mmol) of powdered potassium carbonate and then 0.96 g (5.2 mmol) of methyl iodide. The reaction mixture was stirred at room temperature for 10 hours, ethyl acetate and water was added, the organic layer separated and washed with saturated sodium bicarbonate and with brine, dried with sodium sulfate, filtered and solvent removed under reduced pressure and the residue chromatographed on 100 g of silica gel using 3:1:0.5 mixture of ethyl acetate:hexane:methanol to afford 0.9 g of the desired N-(2-hydroxy-1R-methylethyl)-N-[2-(1-piperidino)ethyl]-(3thiophenylpropyl)sulphonamide, m/e=401 (M+H).
  • Part B: To a solution of 0.83 g (2.07 mmol) of product from Part A and 0.54 g (2.07 mmol) of triphenylphosphine in 25 ml of anhydrous THF at room temperature was added 0.33 mL (2.07 mmol) of diethyl azodicarboxylate, followed by 0.44 mL (6.21 mmol) of thiolacetic acid. After stirring at room temperature for 1.5 hour, the reaction was concentrated and the residue chromatographed on 100 g of silica gel using a 3:1:0.25 mixture of ethyl acetate:hexane:methanol to afford 0.45 g of the desired N-[2-(S-acetyl)mercapto-1R-methylethyl]-N-[2-(1-piperidino)ethyl](3-thiophenylpropyl)sulfonamide, m/e=465 (M+Li).
  • Part C: To a suspension of 0.225 g (0.5 mmol) of product from Part B in 15 mL of anhydrous methanol, was added 0.2 mL (0.9 mmol) of 25 wt. % sodium methoxide in methanol. After 25 minutes at room temperature, ethyl acetate and water was added, the organic layer separated and washed 2×50 ml with water and with brine and dried over sodium sulfate,filtered and solvent removed under reduced pressure and the residue chromatographed on 50 g of silica gel using dichloromethane to afford 112 mg of the desired N-(2-mercapto-1R-methylethyl)-N-[2-(1-piperidino)ethyl](3-thiophenylpropyl)sulfonamide, m/e=417 (M+H).
  • EXAMPLE 53 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02094
  • Part A: Preparation of N-(2-hydroxy-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide.
  • To a stirred solution of ( 2.85 g, 10 mmol) of N-(2-Hydroxy-1R-methylethyl)-4-(n-pentyl)benzenesulfonamide from example 6, in 30 mL of dry dimethylfomamide was added ( 4.05 g, 30 mmol) of powdered potassium carbonate followed by ( 4.23 g, 30 mmol) of methyl iodide and the suspension stirred for 16 hours. The contents were concentrated by rotory evaporation and the residue was partitioned between 200 mL of ethyl acetate and 400 mL of water. The organic phase was washed with saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated to a dark yellow oil. The crude material was purified by silica gel chromatography using an eluant of 30 % ethyl acetate in hexane to yield 1.53 grams of a clear oil.
  • Part B: Preparation of N-(2-thioacetyl-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide.
  • To an ice cooled, stirred solution of (1.53 g, 5.1 mmol) of N-(2-hydroxy-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide and ( 1.46 g, 5.6 mmol) of triphenylphosphine in 20 mL of anhydrous tetrahydrofuran was added ( 946 mg, 5.6 mmol) of diethylazodicarbocylate, followed by (425 mg, 5.6 mmol) of thioacetic acid. After stirring for 1.5 hours at room temperature the contents were concentrated by rotory evaporation and purified by silica gel chromatography using an eluant of 25% ethyl acetate in hexanes to yield 1.078 grams of a clear oil. N-(2-thioacetyl-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide.
  • Part C: Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide.
  • To a stirred solution of ( 1.07 g, 3 mmol) of N-(2-thioacetyl-1R-methylethyl)-N-methyl-4-(n-pentyl)-benzenesulfonamide in 25 mL of dry methanol was added 4.0 mL of 25% sodium methoxide in methanol and the solution stirred for 15 minutes. To the clear solution was added 50 mL of 1 N hydrochloric acid and the milky suspension was extracted with 100 mL of ethyl acetate, dried over magnesium sulfate, filtered and conc. to yield 700 mg of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(n-pentyl)benzenesulfonamide of purified product. m/e=322 (M+Li)
  • EXAMPLE 54 Preparation of N-(2-mercapto-1R-methylethyl)-N-[2-(4-morpholino)ethyl]-4-(n-pentyl)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02095
  • Part A: Preparation of N-(2-hydroxy-1R-methylethyl)-N-[2-(4morpholino)ethyl]-4-(n-pentyl)benzenesulfonamide.
  • To a stirred solution of ( 2.85 g, 10 mmol) of N-(2-Hydroxy-1R-methylethyl)-4-(n-pentyl)benzenesulfonamide from example 6, in 30 mL of dry dimethylformamide was added ( 5.40 g, 40mmol) of powdered potassium carbonate followed by ( 2.23 g, 12 mmol) of 4-(2-chloroethyl)-morpholine hydrochloride and the suspension stirred for 16 hours. Thin layer chromatography, and H-NMR showed approximately 50% conversion, another 2.23 g of 4-(2-chloroethyl)morpholine hydrochloride was added and the reaction mixture stirred another 16 hours. The contents were concentrated by rotory evaporation and the residue was partitioned between 200 mL of ethyl acetate and 400 mL of water. The organic phase was washed with saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated to a yellow oil. The crude material was purified by silica gel chromatography using an eluant of 30% ethyl acetate in hexane to yield 940 mg of a clear oil.
  • Part B: Preparation of N-(2-thioacetyl-1R-methylethyl)-N-[2-(4-morpholino)ethyl]-4-(n-pentyl)benzenesulfonamide.
  • To a stirred, ice cooled solution of (940mg, 2.3 mmol) of N-(2-hydroxy-1R-methylethyl)-N-[(4-morpholino)-ethyl]-4-(n-pentyl)benzenesulfonamide and (740 mg, 2.8 mmol) of triphenylphosphine in 30 mL of anhydrous tetrahydrofuran under nitrogen was added (487 mg, 2.8 mmol) of diethylazodicarboxylate, followed by (210 mg, 2.8 mmol) of thioacetic acid. After warming to room temperature over two hours the solution was concentrated by rotory evaporation and subjected to silica gel column chromatography using an eluant of 3:1:0.1 hexane:ethyl acetate: methanol to yield 560 mg of purified product.
  • Part C: Preparation of N-(2-mercapto-1R-methylethyl)-N-(2-(4-morpholino)ethyl]-4-(n-pentyl)-benzenesulfonamide.
  • To a stirred solution of ( 560 mg, 1.2 mmol) of N-(2-thioacetyl-1R-methylethyl)-N[2-(4-morpholino)ethyl]-4-(n-pentyl)benzenesulfonamide in 25 mL of dry methanol was added 4.0 mL of 25% sodium methoxide in methanol and the solution stirred for 15 minutes. To the clear solution was added 1 N hydrochloric acid until pH=7 and the milky suspension was extracted with 100 mL of ethyl acetate, dried over magnesium sulfate, filtered and conc. to yield 480 mg of N-(2-thioacetyl-1R-methylethyl)-N[2-(4-morpholino)ethyl]-4-(n-pentyl)benzenesulfonamide of purified product; m/e=415 (M+H)
  • EXAMPLE 55 Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(phenyl)benzenesulfonamide
  • Figure US20050014840A1-20050120-C02096
  • Part A: Preparation of N-(2-Hydroxy-1R-methylethyl)-4-bromo- benzenesulfonamide.
  • To a ice cooled solution of (5.0 g, 60 mmol) of 2(R)-methyl-ethanolamine in 25 mL of tetrahydrofuran, 10 mL of water, and 8.7 grams of triethylamine was added (15.3 g, 54 mmol) of 4-bromobenzenesulfonyl chloride slowly over 10 minutes. After stirring for 3 hours at room temperature, the solution was concentrated by rotory evaporation and the contents were partitioned between 200 mL of ethyl acetate and 200 mL of water. The organic layer was washed with 100 mL of 5% potassium hydrogen sulfate, followed by saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated to yield 17.5 grams of a clear oil. The crude material was crystallized from ethyl acetate and hexane to yield 13.45 g of purified material.
  • Part B: Preparation of N-(2-Hydroxy-1R-methylethyl)-4-(phenyl)benzenesulfonamide.
  • To a stirred solution of ( 2.54 g, 8.6 mmol) of N-(2-Hydroxy-1R-methylethyl)-4-bromo- benzenesulfonamide in 60 mL of toluene was added 40 mL of ethanol, followed by (1.15 g, 9.0 mmol) of phenylboronic acid, 25 mL of 2M sodium carbonate, and (1.0 g, 0.8 mmol) of tetrakis-(triphenylphosphine)palladium. The subsequent heterogeneous solution was heated to reflux overnight. The solution was cooled and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated to a dark oil, which contained precipitated catalyst. The crude oil was purified by silical gel chromatography using ethyl acetate hexane as the eluant to yield 1.0 g of purified product.
  • Part C: Preparation of N-(2-Hydroxy-1R-methylethyl)-N-methyl-4-(phenyl)benzenesulfonamide.
  • To a solution of (1.0 g, 3.4 mmol) of N-(2-Hydroxy-1R-methylethyl)-4-(phenyl)benzenesulfonamide in 10 mL of dimethylformamide was added ( 1.35 g, 10 mmol) of potassium carbonate and (1.41 g, 10 mmol) of methyl iodide and the suspension was stirred overnight under nitrogen atmosphere. The contents were concentrated by rotory evaporation and the residue was crystallized from ether hexane to yield 535 mg of purified product.
  • Part D: Preparation of N-(2-thioacetyl-1R-methylethyl)-N-methyl-4-(phenyl)benzenesulfonamide.
  • To an ice cooled solution of (535 mg, 1.8 mmol) of N-(2-Hydroxy-1R-methylethyl)-N-methyl-4-(phenyl)-benzenesulfonamide and (524 mg, 2 mmol) of triphenylphosphine in 15 mL of anhydrous tetrahydrofuran was added (348 mg, 2 mmol) of diethyldiazodicarboxylate followed by (152 mg, 2 mmol) of thioacetic acid. The resulting solution was stirred for 1.5 hours to room temperature and then concentrated by rotory evaporation to yield a crude oil which was purified by column chromatography to yield 328 mg of desired product.
  • Part E: Preparation of N-(2-mercapto-1R-methylethyl)-N-methyl-4-(phenyl)benzenesulfonamide.
  • To a stirred solution of (328 mg, 0.9mmol) of N-(2-thioacetyl-1R-methylethyl)-N-methyl-4-(phenyl)benzene-sulfonamide in 5 mL of dry methanol was added 1 mL of 25 wt % sodium methoxide in methanol. After 10 minutes the solution was diluted with 10 mL of 1 N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried and concentrated to yield N- (2-mercapto-1R-methylethyl)-N-methyl-4-(phenyl)-benzenesulfonamide; m/e=328 (M+Li)
  • EXAMPLE 56 Preparation of N-(2-mercapto-1R,S-methylethyl)-N-phenylmethyl-4-methoxybenzenesulfonamide benzenesulfonamide
  • Figure US20050014840A1-20050120-C02097
  • Part A: To a stirred solution (10.0 g,36.6 mmol) of N-(4-methoxybenzenesulfonyl)-D,L-alanine methyl ester in dimethylformamide in 200 mL of was added (15.17 g, 109 mmol) of powdered potassium carbonate followed by (6.2 g, 36.6 mmol) of benzyl bromide and the solution stirred for 20 hours. The contents were concentrated by rotory evaporation and the residue was partition between 250 mL of ethyl acetate and 250 ml of water.e organic layer was washed with 100 mL 5% aqueous potassium hydrogen sulfate, 100 mL of saturated sodium bicarbonate,and 100 mL of saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated to an oil, which was crystallized from ethyl acetate and hexanes to yield 10.16 g of purified N-phenylmethyl-N-4-methoxybenzene-sulfonamide-D,L-alanine methyl ester.
  • Part B: To an ice cooled, stirred solution of (8.55 g, 23.5 mmol) of N-phenylmethyl-N-4-methoxybenzene-sulfonamide-D,L-alanine methyl ester in 100 mL of anhydrous tetrahydrofuran, under nitrogen atmosphere was added (23 mL, 23 mmol) of 1M lithium aluminum hydride in diethyl ether and the solution stirred at 0 C for three hours. The solution was carefully quenched at 0 C by the addition of 2 mL of 10% sodium hydroxide dropwise followed by 2 mL of water. The suspension was filtered through celite and the filtrate was dried over magnesium sulfate, filtered and concentrated to yield 5.67 g of crude N-phenylmethyl-N-4-methoxybenzenesulfonamide-D,L-alaninol which was used without purification.
  • Part C: To an ice cooled solution of (1.0 g, 3 mmol) of N-phenylmethyl-N-4-methoxybenzenesulfonamide-D,L-alaninol and (860 mg, 3.3 mmol) of triphenylphosphine in 20 mL of anhydrous tetrahydrofuran was added (510 mg,3.3 mmol) of diethyldiazodicarboxylate followed by (250 mg, 3.3 mmol) of thioacetic acid and the solution stirred to room temperature for 2 hours. The contents were concentrated by rotory evaporation and the crude oil was subjected to silica gel chromatography to yield 730 mg of N-(2-thioacetyl-1R,S-methylethyl)-N-phenylmethyl-4-methoxybenzenesulfonamide benzenesulfonamide.
  • Part D: To a stirred solution of ( 730 mg, 1.8 mmol) of N-(2-thioacetyl-1R,S-methylethyl)-N-phenylmethyl-4-methoxybenzenesulfonamide benzenesulfonamide in 10 mL of methanol was added 1.5 mL of 25 wt % sodium methoxide in methanol and the solution stirred for 10 minutes. The contents were diluted with 20 mL of 1 N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered and concentrated to yield an oil which was crystallized form ether/ethyl acetate/hexane to yield 300 mg of N-(2-mercapto-1R,S-methylethyl)-N-phenylmethyl-4-methoxybenzenesulfonamide benzenesulfonamide. m/e=358 (M+Li)
  • EXAMPLE 57 Preparation of N-(2-mercapto-1R,S-phenylmethyl)-N-phenylmethyl-4-methoxybenzene-sulfonamide
  • Figure US20050014840A1-20050120-C02098
  • Part A: To a stirred solution (2.03 g,4.6 mmol) of N-(4-methoxybenzenesulfonyl)-D,L-phenylalanine methyl ester in dimethylformamide in 50 mL of was added (1.8 g,13 mmol) of powdered potassium carbonate followed by (789 mg,4.6 mmol) of benzyl bromide and the solution stirred for 20 hours. The contents were concentrated by rotory evaporation and the residue was partition between 50 mL of ethyl acetate and 50 ml of water.e organic layer was washed with 100 mL 5% aqueous potassium hydrogen sulfate, 100 mL of saturated sodium bicarbonate,and 100 mL of saturated sodium chloride, dried over magnesium 20 sulfate, filtered and concentrated to an oil, which was crystallized from ethyl acetate and hexanes to yield 1.55 g of purified N-phenylmethyl-N-4-methoxybenzenesulfonamide-D,L-phenylalanine methyl ester.
  • Part B: To an ice cooled, stirred solution of (1.55 g,3.5mmol ) of N-phenylmethyl-N-4-methoxybenzene-sulfonamide-D,L-phenylalanine methyl ester in 50 mL of anhydrous tetrahydrofuran, under nitrogen atmosphere was added (4.2 mL) of 1M lithium aluminum hydride in diethyl ether and the solution stirred at 0 C for three hours. The solution was carefully quenched at 0 C by the addition of 2 mL of 10% sodium hydroxide dropwise , followed by 2 mL of water. The suspension was filtered through celite and the filtrate was dried over magnesium sulfate, filtered and concentrated to yield 1.40 g of crude N-phenylmethyl-N-4-methoxy-benzenesulfonamide-D,L-phenylalaninol which was used without purification.
  • Part C: To an ice cooled solution of 1.24 g, 3.0 mmol) of N-phenylmethyl-N-4-methoxybenzene-sulfonamide-D,L-phenylalaninol and ( 949 mg, 3.6 mmol) of triphenylphosphine in 20 mL of anhydrous tetrahydrofuran was added (630 mg, 3.6 mmol) of diethyldiazodicarboxylate followed by (275 mg, 3.6 mmol) of thioacetic acid and the solution stirred to room temperature for 2 hours. The contents were concentrated by rotory evaporation and the crude oil was subjected to silica gel chromatography to yield 1.10 mg of N-(2-thioacetyl-1R,S-phenylmethyl)-N-phenylmethyl-4-methoxybenzenesulfonamide benzenesulfonamide.
  • Part D: To a stirred solution of (1.10 g, 2.3 mmol) of N-(2-thioacetyl-1R,S-phenylmethyl)-N-phenylmethyl-4-methoxybenzenesulfonamide benzenesulfonamide in 10 mL of methanol was added 2.0 mL of 25 wt % sodium methoxide in methanol and the solution stirred for 10 minutes. The contents were diluted with 20 mL of 1 N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered and concentrated to yield an oil which was crystallized form ether/ethyl acetate/hexane to yield 521 mg of N-(2-mercapto-1R,S-phenylmethyl)-N-phenylmethyl-4-methoxybenzene-sulfonamide; m/e=434 (M+Li)
  • EXAMPLE 58 Preparation of N-N′-Bis-(4-methoxybenzenesulfonyl)-L-cystine
  • Figure US20050014840A1-20050120-C02099
  • To an ice cooled suspension of (3.41 g, 10 mmol) of L-cystine methyl ester hydrochloride in tetrahydrofuran was added 50 mL of saturated sodium bicarbonate followed by (4.12 g, 20 mmol) of 4-methoxybenzenesulfonyl chloride in 20 mL of tetrahydrofuran and the suspension stirred to room temperature overnight. The contents were acidified with 1N hydrochloric acid and extracted with ethyl acetate to yield 4.13 grams of product. m/e=615 (M+Li)
  • EXAMPLE 59 Preparation of N-N′-Bis-(4-methoxybenzenesulfonyl)-N,N′-dimethyl-L-cystine
  • Figure US20050014840A1-20050120-C02100
  • To a stirred solution of (1.3 g, 2.1 mmol) of N-N′-Bis-(4-methoxybenzenesulfonyl)-L-cystine in dimethylformamide was added (635 mg, 4.6 mmol) of potassium carbonate followed by (655mg, 4.6 mmol) of methyl iodide and the suspension stirred overnight. The contents were concentrated by rotory evaporation and the residue subjected to silica gel chromatography to yield 890 mg of N-N′-Bis-(4-mthoxybenzenesulfonyl)-N,N′-dimethyl-L-cystine as an oil. m/e=643 (M+Li)
  • EXAMPLE 60 2R-(N-Fluorenylmethyloxycarbonyl)amino-propanethiol
  • Figure US20050014840A1-20050120-C02101
  • Part A: Preparation of 2R-(N-Fluorenylmethyloxy-carbonyl)aminopropanol
  • To a stirred solution of (750 mg, 10 mmol ) of 2-R-amino propanol in 15 mL dioxane containing 27 mL of 10% aqueous potassium carbonate was added (2.58 g, 10 mmol) of fluorenylmethyl chloroformate and the solution was stirred vigorously for several hours. The contents were diluted with ethyl acetate and the organic layer was washed with 1N hydrochloric acid, dried over magnesium sulfate, filtered and concentrated to yield 2.97 g of crude product which was crystallized from ethyl acetate/hexanes to yield 2.61 g of purified 2R-(N-fluorenylmethyloxycarbonyl)aminopropanol.
  • Part B: Preparation of 2R-(N-Fluorenylmethyloxy-carbonyl)-aminopropanethiol-S-acetate
  • To a ice cooled stirred solution of (13.9 g, 47 mmol) of 2R-(N-fluorenylmethyloxycarbonyl)- aminopropanol in 200 mL of anhydrous tetrahydrofuran was added (13.5 g, 51 mmol) of triphenylphosphine, followed by (8.99 g, 51 mmol) of diethylazodicarboxylate, and the (3.92 g, 51 mmol) of thioacetic acid and the reaction stirred overnight to room temperature. The contents were concentrated by rotory evaporation and the residue was chromatographed on silica gel using ethyl acetate/hexane as the eluant. The desired product was crystallized to afford 7.8 g of purified 2R-(N-fluorenylmethyloxycarbonyl)-aminopropanethiol-S-acetate.
  • Part C: Preparation of 2R-(N-Fluorenylmethyloxy-carbonyl)-aminopropanethiol.
  • To an ice cooled, stirred solution of (355 mg,1.0 mmol) of 2R-(N-fluorenylmethyloxycarbonyl)-aminopropanethiol-S-acetate in 10 mL of anhydrous methanol was added 1.2 equivalents of 25% sodium hydroxide in methanol and the solution stirred for 30 minutes. The reaction mixture was diluted with 1N hydrochloric acid and concentrated. The residue was partitioned between ethyl acetate and water, and the organic layer was dried over magnesium sulfate, filtered and concentrated to yield 300 mg of mercaptan.
  • EXAMPLE 61 Preparation of 2R-(N-Fluorenylmethyl-carbamoyl)amino-propanethiol-conjugated-chlorotrityl-polystyrene Resin with 1 or 2% Cross-Linking
  • A solution of 5% trifluorocacetic acid (40 ml) in methylene chloride was added to dry 2-chlorotrityl-chloride resin (5.84 g, 7 mmoles) and swirled. To this thick slurry was immediately added 14 mmoles (4.4 g) of N-Fmoc-1-methyl-ethyl-2-mercaptan. The suspension was swirled periodically and incubated at RT under nitrogen for 1 hour. Nine volumes methylene chloride were added and incubation continued 30 minutes. Non-bound compound was then removed by vacuum filtration through a centered glass disk funnel and reserved for drying and quantitation. The resin was washed with 300 mls methanol to cap any unreacted sites, followed by 4 dimethylformamide washes, 4 methylene chloride washes and 2 additional methanol washes. The recovered resin was then dried to constant weight under vacuum and loading was quanitated by 1) mass balance 2) Fmoc release and/or 3) elemental analysis. Using this protocol, the desired compound was loaded on approximately 92% of the available sites, as determined by resin manufacturer's data sheet.
  • Dried resin was washed with methylene chloride (about 250 mls) followed by dimethylformamide (about 250 mls) and the Fmoc protecting group was removed by incubation in a solution of 20% piperidine in dimethylformamide for 30-60 minutes. The resin was washed with dimethylformamide, methanol, dimethylformamide. This procedure was repeated one additional cycle. The final wash included a methylene chloride wash followed by methanol. The resin was dried to constant weight and stored at 4 degrees. Prior to any additional chemistry, the resin was always washed with methylene chloride to ensure good swelling, followed by the solvent of choice for the desired protocol.
  • Alternatively, instead of loading the resin with two equivalents of mercaptan for each equivalent of resin sites, only 0.9 equivalents of available (monomeric) compound was added. This resulted in loading approximately 90-95% of the target compound, and the excess sites were capped as above. This loading procedure had the advantage that less initial compound had to be synthesized.
  • EXAMPLE 62 Preparation of N-(2-mercapto-1R methylethyl)-4-methoxybenzenesulfonamide
  • To a slurry of 0.12 g (0.14 mmoles) deprotected resin (Example 1) in 6ml 50% pyridine: CH2Cl2 under nitrogen was added 0.152 g (0.74 mmoles) 4-methoxybenzene-sulfonylchloride. The reaction was agitated at room temperature for 20 hr. The resin was then filtered and washed four times with 100 ml dimethylformamide and four times with 100 ml CH2Cl2 The resin was treated with 80% trifluoroacetic acid in CH2Cl2 for 1 hour. It was then filtered and the eluant stripped. The residue was extracted with ethyl acetate, washed with 1N HCl and dried with Na2SO4. The extract was stripped to dryness to afford 20 mg of the desired N-(2-mercapto-1R methylethyl)-4-methoxybenzenesulfonamide.
  • EXAMPLE 63-90 By Procedures Analogous to Example 62, the Following Compounds were Prepared EXAMPLE 63 N-(2-mercapto-1R-methylethyl)-4-fluorobenzenesulfonamide; m/e=256.3 (M+Li) EXAMPLE 64 N-(2-mercapto-1R-methylethyl)-4-chlorobenzenesulfonamide; m/e=272.7 (M+Li) EXAMPLE 65 N-(2-mercapto-1R-methylethyl)-4-bromobenzenesulfonamide; m/e=317.2 (M+Li) EXAMPLE 66 N-(2-mercapto-1R-methylethyl)-4-iodobenzenesulfonamide; m/e=364.2 (M+Li) EXAMPLE 67 N-(2-mercapto-1R-methylethyl)-4-ethylbenzenesulfonamide; m/e=266.4 (M+Li) EXAMPLE 68 N-(2-mercapto-1R-methylethyl)-4-methylbenzenesulfonamide; m/e=254.4 (M+Li) EXAMPLE 69 N-(2-mercapto-1R-methylethyl)-4-(n-butyl)benzenesulfonamide; m/e=292.4 (M+Li) EXAMPLE 70 N-(2-mercapto-1R-methylethyl)-4-n-propyl)benzenesulfonamide; m/e=280.4 (M+Li) EXAMPLE 71 N-(2-mercapto-1R-methylethyl)-4-n-pentyl)benzenesulfonamide; m/e=304.4 (M+Li) EXAMPLE 72 N-(2-mercapto-1R-methylethyl)-4-isopropylbenzenesulfonamide; m/e=280.4 (M+Li) EXAMPLE 73 N-(2-mercapto-1R-methylethyl)-4-(trifluoromethyl)-benzenesulfonamide; m/e=306.3 (M+Li) EXAMPLE 74 N-(2-mercapto-1R-methylethyl)-4-(t-butyl)benzenesulfonamide; m/e=294.4 (M+Li) EXAMPLE 75 N-(2-mercapto-1R-methylethyl)-4-(trifluoromethoxy)-benzenesulfonamide; m/e=322.3 (M+Li) EXAMPLE 76 N-(2-mercapto-1R-methylethyl)-4-cyanobenzenesulfonamide; m/e=263.3 (M+Li) EXAMPLE 77 N-(2-mercapto-1R-methylethyl)-2-(trifluoromethyoxy)-benzenesulfonamide; m/e=322.3 (M+Li) EXAMPLE 78 N-(2-mercapto-1R-methylethyl)-2,4-bis(trifluoromethyoxy)-benzenesulfonamide; m/e=434.4 (M+Li) EXAMPLE 79 N-(2-mercapto-1R-methylethyl)-2,4,6-trimethyl-benzenesulfonamide; m/e=280.4 (M+Li) EXAMPLE 80 N-(2-mercapto-1R-methylethyl)-2,4,6-triisopropyl-benzenesulfonamide; m/e=364.6 (M+Li) EXAMPLE 81 N-(2-mercapto-1R-methylethyl)-3,4-difluoro-benzenesulfonamide; m/e=274.3 (M+Li) EXAMPLE 82 N-(2-mercapto-1R-methylethyl)-benzenesulfonamide EXAMPLE 83 N-(2-mercapto-1R-methylethyl)-2-napthylenesulfonamide; m/e=288.4 (M+Li) EXAMPLE 84 N-(2-mercapto-1R-methylethyl)-4-N-acetylsulfanilamide; m/e=295.4 (M+Li) EXAMPLE 85 N-(2-mercapto-1R-methylethyl)-5-bromo-2-thiophenesulfonamide; m/e=323.3 (M+Li) EXAMPLE 86 N-(2-mercapto-1R-methylethyl)-5-chloro-2-thiophenesulfonamide EXAMPLE 87 N-(2-mercapto-1R-methylethyl)-3,5-dibromo-2-thiophenesulfonamide; m/e=403.3 (M+Li) EXAMPLE 88 N-(2-mercapto-1R-methylethyl)-5-(isoxazol-3-yl)-2-thiophenesulfonamide; m/e=311.4 (M+Li) EXAMPLE 89 N-(2-mercapto-1R-methylethyl)-4-phenylazobenzenesulfonamide; m/e=342.4 (M+Li) EXAMPLE 90 N-(2-mercapto-1R-methylethyl)-2-dibenzofuransulfonamide; m/e=328.4 (M+Li) EXAMPLE 91 Preparation of N-(2-mercapto-1R-methylethyl)-N-[2-(4-morpholino)ethyl]-4-(thiophenyl)benzenesulfonamide hydrochloride
  • Figure US20050014840A1-20050120-C02102
  • Part A: To a solution of 8.38 g (35.9 mmol) of N-(2-hydroxy-1R-methylethyl)-4-fluorobenzene-sulfonamide from Example 40, part A, in 70 mL of anhydrous DMF, was added 15.38 g (111 mmol) of powdered potassium carbonate, and then 5.2 mL (5.54 g, 50.3 mmol) of thiophenol. The reaction mixture was heated to 70 C for 15 hours, cooled and ethyl acetate and water added. The organic layer was separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford crude material. This was chromatographed on a Waters Prep 2000 chromatograph over silica gel using 40%-60% ethyl acetate/hexane to provide 9.0 g of pure N-(2-hydroxy-1R-methylethyl)-4-(thiophenyl)benzenesulfonamide, m/e=330 (M+Li).
  • Part B: To a solution of 3.0 g (9.3 mmol) of N-(2-hydroxy-1R-methylethyl)′-4-(thiophenyl)benzene-sulfonamide from part A, in 18 mL of anhydrous DMF, was added 3.85 g (27.8 mmol) of powdered potassium carbonate, and then 2.42 g (13 mmol) of 4-(2-chloroethyl)morpholine hydrochloride. The reaction mixture was stirred for 15 hours, ethyl acetate and water added. The organic layer was separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford 4.7 g of crude material. This was chromatographed on a Waters Prep 2000 chromatogram over silica gel using 50%-100% ethyl acetate/hexane, then 5% methanol/ethyl acetate, to provide 3.8 g of pure N-(2-hydroxy-1R-methylethyl)-N-[2-(4-morpholino)ethyl]-4-(thiophenyl)benzene-sulfonamide, m/e=437 (M+H).
  • Part C: To a solution of 3.4 g (7.8 mmol) of product from Part B and 2.25 g (8.6 mmol) of triphenylphosphine in 30 mL of anhydrous THF at 0° C., was added 1.4 mL (8.6 mmol) of diethylazodicarboxylate, followed after 5 min. by 0.62 mL (8.6 mmol) of thiolacetic acid. After 1 hour, the reaction was concentrated and the residue was chromatographed on silica gel using 20%-80% ethyl acetate/hexane to yield 1.4 g of the desired product, m/e=495 (M+H).
  • Part D: To a solution of 1.4 g (2.83 mmol) of product from Part C in 10 mL of anhydrous methanol, was added 2.3 mL (10.2 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched the the addition of dry ice, followed by ethyl acetate and water, the organic layer was separated and washed with brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on 75 g of silica gel using 50% ethyl acetate/hexane to provide 0.86 g of pure N-(2-mercapto-1R-methylethyl)-N-(2-(4-morpholino)ethyl]-4-(thiophenyl)benzenesulfonamide, m/e=453 (M+H).
  • Part D: To a solution of 0.66 g (1.45 mmol) of the product of Part C in 10 mL of acetonitrile was added 0.24 ml (2.88 mmol) of 12N aqueous hydrochloric acid. After 10 minutes, the solvent was removed in vacuo, acetonitrile added and removed 3×s to afford 0.66 g of the desired N-(2-mercapto-1R-methylethyl)-N-[2-(4-morpholino)ethyl]-4-(thiophenyl)benzene-sulfonamide hydrochloride, m/e=453 (M+H).
  • EXAMPLE 92 Preparation of N-(2-mercapto-1R-methylethyl)-N-[2-(1-piperidino)ethyl]-4-(thiophenyl)benzenesulfonamide hydrochloride
  • Figure US20050014840A1-20050120-C02103
  • Part A: To a solution of 4.62 g (14.2 mmol) of N-(2-hydroxy-1R-methylethyl)-4-(thiophenyl)benzene-sulfonamide from example 91 part A in 28 mL of anhydrous DMF, was added 5.92 g (42.8 mmol) of powdered potassium carbonate, and then 3.94 g (21.4 mmol) of 1-(2-chloroethyl)piperidine hydrochloride. The reaction mixture was stirred for 17 hours at 50 C, then cooled and ethyl acetate and water added. The organic layer was separated and washed 3×s with brine, dried with sodium sulfate, filtered and stripped to afford crude material. This was chromatographed on 300 g of silica gel using 100% tetrahydrofuran to provide 4.3 g of pure N-(2-hydroxy-1R-methylethyl)-N-[2-(1-piperidinyl)-ethyl]-4-(thiophenyl)benzenesulfonamide, m/e=435 (M+H).
  • Part B: To a solution of 3.7 g (8.5 mmol) of product from Part A and 2.45 g (9.3 mmol) of triphenylphosphine in 33 mL of anhydrous THF at 0° C., was added 1.47 mL (9.3 mmol) of diethylazo-dicarboxylate, followed after 5 min. by 0.67 mL (9.3 mmol) of thiolacetic acid-. After 1 hour, the reaction was concentrated and the residue was chromatographed on basic alumina using 10%-50% ethyl acetate(5% methanol)/hexane to yield 2.3 g of the desired product, m/e=493 (M+H).
  • Part C: To a solution of 2.3 g (4.67 mmol) of product from Part B in 10 mL of anhydrous methanol, was added 3.8 mL (16.8 mmol) of a 25 weight % solution of sodium methoxide in methanol. After 0.5 hour, the reaction was quenched the the addition of dry ice, followed by ethyl acetate and water, the organic layer was separated and washed with brine, dried with magnesium sulfate, filtered and concentrated to afford the crude product. This was chromatographed on 150 g of silica gel using 50% ethyl acetate(5% methanol)/methylene chloride to provide 1.5 g of pure N-(2-mercapto-1R-methylethyl)-N-(2-(1-piperidino)-ethyl]-4-(thiophenyl)benzenesulfonamide, m/e=451 (M+H).
  • Part D: To a solution of 1.1 g (2.44 mmol) of the product of Part C in 15 mL of acetonitrile was added 0.40 ml (4.88 mmol) of 12N aqueous hydrochloric acid. After 10 minutes, the solvent was removed in vacuo, acetonitrile added and removed 3×s to afford 1.12 g of the desired N-(2-mercapto-1R-methylethyl)-N-[2-(1-piperidino)ethyl]-4-(thiophenyl)benzenesulfonamide hydrochloride, m/e=451 (M+H).
  • EXAMPLE 93 Preparation of N-(4-butoxyphenyl)-L-cysteine-NH2
  • Figure US20050014840A1-20050120-C02104
  • Fmoc-L-Cys(Trt)-Rink resin. Rink resin (0.88 g, 0.44 mmoles) was reacted with 5 mL of: 4 piperidine/DMF for 30 min, then washed with DMF (3×5 mL), MeOH (3×5 mL), and CH2Cl2 (3×5 mL). In a separate flask, Fmoc-L-Cys(Trt)OH (0.77 g, 1.3 mmol) in 5 mL anhydrous dimethylacetamide (DMA) was reacted with diisopropylcarbodiimide (0.21 mL, 1.3 mmol) and N-hydroxysuccinimide (0.15 g, 1.3 mmol) for 15 min at rt. Then, this solution was added to the flask containing Rink resin from above. The reaction slurry was agitated using a tabletop shaker overnight (16 h). The resin was then drained, washed with DMF (3×5 mL), MeOH (3×5 mL), CH2Cl2 (3×5 mL), and Et2O (3×5 mL), and dried in vacuo to yield 1.09 g of tan polymeric solid. Theoretical loading of polymer=0.43 mmol/g.
  • Part B: N-(4-Butoxyphenyl)sulfonyl-L-Cys(Trt)-Rink resin. Fmoc-L-Cys(Trt)-Rink resin from above (50 mg, 0.022 mmol) was reacted with 1 mL of: 4 piperidine/DMF for 30 min, then washed with DMF (3×1 mL), MeOH (3×1 mL), and CH2Cl2 (3×1 mL). Then, 0.5 mL of anhydrous CH2Cl2 was added to the resin followed by 27 mg of 4-butoxyphenylsulfonyl chloride (0.11 mmol), and the reaction slurry was shaken overnight at rt (20 h). The resin was then drained, washed with CH2Cl2 (3×1 mL), MeOH (3×1 mL), CH2Cl2 (3×1 mL), and Et2O (3×1 mL), and dried in vacuo to yield 105 mg brown polymeric solid.
    Figure US20050014840A1-20050120-C02105
  • N(4-Butoxyphenyl)sulfonyl-L-Cys-NH2. N-(4-Butoxyphenyl)-sulfonyl-L-Cys(Trt)-Rink resin from above was reacted with 1 mL of a 5:5:95 solution of TFA/triethylsilane/CH2Cl2 at rt for one hour. The resin was drained and washed with CH2Cl2 (3×1 mL). The resin was subsequently reacted with 0.5 mL of a 80:5:15 solution of TFA/triethylsilane/CH2Cl2 at rt for one hour. The resin was drained, and the filtrate collected. The resin was further washed with 1:1 TFA/CH2Cl2 (3×0.5 mL) and CH2Cl2 (3×0.5 mL), again collecting the filtrates. The combined filtrates were concentrated to yield 6.7 mg white solid (92% crude yield). MS (FAB) 333.2 (M+H).
  • Using procedures analogous to those used in Example 93, Examples 94, 95 and 96 were prepared.
  • EXAMPLE 94 N-(4-methoxyphenyl)sulfonyl-L-cysteine-NH2 EXAMPLE 95 N-(4-iodophenyl)sulfonyl-L-cysteine-NH2 EXAMPLE 96 N-[4-(n-pentyl)-phenyl]sulfonyl-L-cysteine-NH2
  • Compounds of Example 97 to Example 223, tabulated below, were prepared by the procedures presented above. Exemplary additional specific syntheses are also provided thereafter.
    EXAMPLE TABLE I
    Figure US20050014840A1-20050120-C02106
    Figure US20050014840A1-20050120-C02107
    Figure US20050014840A1-20050120-C02108
    Figure US20050014840A1-20050120-C02109
    Figure US20050014840A1-20050120-C02110
    Figure US20050014840A1-20050120-C02111
    Figure US20050014840A1-20050120-C02112
    Figure US20050014840A1-20050120-C02113
    Figure US20050014840A1-20050120-C02114
    Figure US20050014840A1-20050120-C02115
    Figure US20050014840A1-20050120-C02116
    Figure US20050014840A1-20050120-C02117
  • EXAMPLE TABLE II
    Figure US20050014840A1-20050120-C02118
    Figure US20050014840A1-20050120-C02119
    Figure US20050014840A1-20050120-C02120
    Figure US20050014840A1-20050120-C02121
    Figure US20050014840A1-20050120-C02122
    Figure US20050014840A1-20050120-C02123
    Figure US20050014840A1-20050120-C02124
    Figure US20050014840A1-20050120-C02125
    Figure US20050014840A1-20050120-C02126
  • EXAMPLE TABLE III
    Figure US20050014840A1-20050120-C02127
    Figure US20050014840A1-20050120-C02128
    Figure US20050014840A1-20050120-C02129
    Figure US20050014840A1-20050120-C02130
    Figure US20050014840A1-20050120-C02131
    Figure US20050014840A1-20050120-C02132
    Figure US20050014840A1-20050120-C02133
    Figure US20050014840A1-20050120-C02134
  • EXAMPLE TABLE IV
    Figure US20050014840A1-20050120-C02135
    Figure US20050014840A1-20050120-C02136
    Figure US20050014840A1-20050120-C02137
    Figure US20050014840A1-20050120-C02138
    Figure US20050014840A1-20050120-C02139
    Figure US20050014840A1-20050120-C02140
    Figure US20050014840A1-20050120-C02141
    Figure US20050014840A1-20050120-C02142
  • EXAMPLE TABLE V
    Figure US20050014840A1-20050120-C02143
    EXAMPLE Z R2
    134
    Figure US20050014840A1-20050120-C02144
    Figure US20050014840A1-20050120-C02145
    135
    Figure US20050014840A1-20050120-C02146
    Figure US20050014840A1-20050120-C02147
    136
    Figure US20050014840A1-20050120-C02148
    Figure US20050014840A1-20050120-C02149
    137
    Figure US20050014840A1-20050120-C02150
    Figure US20050014840A1-20050120-C02151
    138
    Figure US20050014840A1-20050120-C02152
    Figure US20050014840A1-20050120-C02153
    139
    Figure US20050014840A1-20050120-C02154
    Figure US20050014840A1-20050120-C02155
    140
    Figure US20050014840A1-20050120-C02156
    Figure US20050014840A1-20050120-C02157
  • EXAMPLE TABLE VI
    Figure US20050014840A1-20050120-C02158
    EXAMPLE Z R2
    141
    Figure US20050014840A1-20050120-C02159
    Figure US20050014840A1-20050120-C02160
    142
    Figure US20050014840A1-20050120-C02161
    Figure US20050014840A1-20050120-C02162
    144 H—
    Figure US20050014840A1-20050120-C02163
    145
    Figure US20050014840A1-20050120-C02164
    Figure US20050014840A1-20050120-C02165
  • EXAMPLE TABLE VII
    Figure US20050014840A1-20050120-C02166
    EX-
    AMPLE R1 R2 R4
    146
    Figure US20050014840A1-20050120-C02167
    H CH3
    147
    Figure US20050014840A1-20050120-C02168
    H CH3
    148
    Figure US20050014840A1-20050120-C02169
    H CH3
    149
    Figure US20050014840A1-20050120-C02170
    H CH3
    150
    Figure US20050014840A1-20050120-C02171
    H CH3
    151
    Figure US20050014840A1-20050120-C02172
    H CH3
    152
    Figure US20050014840A1-20050120-C02173
    H CH3
    153
    Figure US20050014840A1-20050120-C02174
    H CH3
  • EXAMPLE TABLE VIII
    Figure US20050014840A1-20050120-C02175
    EXAMPLE R1 R2 R4
    154
    Figure US20050014840A1-20050120-C02176
    H CH3
    155
    Figure US20050014840A1-20050120-C02177
    H CH3
    156
    Figure US20050014840A1-20050120-C02178
    CH3 CH3
  • EXAMPLE TABLE IX
    Figure US20050014840A1-20050120-C02179
    EXAMPLE R1 R2 R4
    160
    Figure US20050014840A1-20050120-C02180
    H
    Figure US20050014840A1-20050120-C02181
    161
    Figure US20050014840A1-20050120-C02182
    —(CH2)2CH(CH3)2
    Figure US20050014840A1-20050120-C02183
    162
    Figure US20050014840A1-20050120-C02184
    H
    Figure US20050014840A1-20050120-C02185
    163
    Figure US20050014840A1-20050120-C02186
    —CH3
    Figure US20050014840A1-20050120-C02187
    164
    Figure US20050014840A1-20050120-C02188
    —(CH2)C(C═O)OH
    Figure US20050014840A1-20050120-C02189
    165
    Figure US20050014840A1-20050120-C02190
    Figure US20050014840A1-20050120-C02191
    Figure US20050014840A1-20050120-C02192
    166
    Figure US20050014840A1-20050120-C02193
    H
    Figure US20050014840A1-20050120-C02194
  • EXAMPLE TABLE X
    Figure US20050014840A1-20050120-C02195
    EXAMPLE R1 R2 R4
    167
    Figure US20050014840A1-20050120-C02196
    Figure US20050014840A1-20050120-C02197
    Figure US20050014840A1-20050120-C02198
    168
    Figure US20050014840A1-20050120-C02199
    Figure US20050014840A1-20050120-C02200
    Figure US20050014840A1-20050120-C02201
    169
    Figure US20050014840A1-20050120-C02202
    Figure US20050014840A1-20050120-C02203
    Figure US20050014840A1-20050120-C02204
    170
    Figure US20050014840A1-20050120-C02205
    Figure US20050014840A1-20050120-C02206
    Figure US20050014840A1-20050120-C02207
    171
    Figure US20050014840A1-20050120-C02208
    H
    Figure US20050014840A1-20050120-C02209
    172
    Figure US20050014840A1-20050120-C02210
    H
    Figure US20050014840A1-20050120-C02211
    173
    Figure US20050014840A1-20050120-C02212
    H
    Figure US20050014840A1-20050120-C02213
  • EXAMPLE TABLE XI
    Figure US20050014840A1-20050120-C02214
    EXAMPLE R1 R2 R4
    174
    Figure US20050014840A1-20050120-C02215
    Figure US20050014840A1-20050120-C02216
    Figure US20050014840A1-20050120-C02217
    175
    Figure US20050014840A1-20050120-C02218
    Figure US20050014840A1-20050120-C02219
    Figure US20050014840A1-20050120-C02220
    176
    Figure US20050014840A1-20050120-C02221
    Figure US20050014840A1-20050120-C02222
    Figure US20050014840A1-20050120-C02223
    177
    Figure US20050014840A1-20050120-C02224
    Figure US20050014840A1-20050120-C02225
    Figure US20050014840A1-20050120-C02226
    178
    Figure US20050014840A1-20050120-C02227
    H
    Figure US20050014840A1-20050120-C02228
    179
    Figure US20050014840A1-20050120-C02229
    H
    Figure US20050014840A1-20050120-C02230
    180
    Figure US20050014840A1-20050120-C02231
    H
    Figure US20050014840A1-20050120-C02232
  • EXAMPLE TABLE XII
    Figure US20050014840A1-20050120-C02233
    EXAMPLE R1 R2 R4
    181
    Figure US20050014840A1-20050120-C02234
    H
    Figure US20050014840A1-20050120-C02235
    182
    Figure US20050014840A1-20050120-C02236
    Figure US20050014840A1-20050120-C02237
    Figure US20050014840A1-20050120-C02238
    183
    Figure US20050014840A1-20050120-C02239
    Figure US20050014840A1-20050120-C02240
    Figure US20050014840A1-20050120-C02241
    184
    Figure US20050014840A1-20050120-C02242
    Figure US20050014840A1-20050120-C02243
    Figure US20050014840A1-20050120-C02244
    185
    Figure US20050014840A1-20050120-C02245
    Figure US20050014840A1-20050120-C02246
    Figure US20050014840A1-20050120-C02247
    186
    Figure US20050014840A1-20050120-C02248
    H
    Figure US20050014840A1-20050120-C02249
  • EXAMPLE TABLE XIII
    Figure US20050014840A1-20050120-C02250
    EXAMPLE R1 R2 R4
    187
    Figure US20050014840A1-20050120-C02251
    H
    Figure US20050014840A1-20050120-C02252
    Figure US20050014840A1-20050120-C02253
    EXAMPLE R1 R2 R4
    188
    Figure US20050014840A1-20050120-C02254
    H CH3
    189
    Figure US20050014840A1-20050120-C02255
    H CH3
    190
    Figure US20050014840A1-20050120-C02256
    H CH3
    191
    Figure US20050014840A1-20050120-C02257
    H CH3
  • EXAMPLE TABLE XIV
    Figure US20050014840A1-20050120-C02258
    EXAMPLE R1 R2 R4
    192
    Figure US20050014840A1-20050120-C02259
    H CH3
    193
    Figure US20050014840A1-20050120-C02260
    H CH3
    194
    Figure US20050014840A1-20050120-C02261
    H
    Figure US20050014840A1-20050120-C02262
    195
    Figure US20050014840A1-20050120-C02263
    H CH3
    196
    Figure US20050014840A1-20050120-C02264
    H CH3
    197
    Figure US20050014840A1-20050120-C02265
    H
    Figure US20050014840A1-20050120-C02266
    198
    Figure US20050014840A1-20050120-C02267
    H CH3
  • EXAMPLE TABLE XV
    Figure US20050014840A1-20050120-C02268
    EXAMPLE R1 R2 R4
    199
    Figure US20050014840A1-20050120-C02269
    H
    Figure US20050014840A1-20050120-C02270
    200
    Figure US20050014840A1-20050120-C02271
    Figure US20050014840A1-20050120-C02272
    Figure US20050014840A1-20050120-C02273
    201
    Figure US20050014840A1-20050120-C02274
    H
    Figure US20050014840A1-20050120-C02275
    202
    Figure US20050014840A1-20050120-C02276
    Figure US20050014840A1-20050120-C02277
    Figure US20050014840A1-20050120-C02278
    203
    Figure US20050014840A1-20050120-C02279
    CH3
    Figure US20050014840A1-20050120-C02280
    204
    Figure US20050014840A1-20050120-C02281
    H CH3
  • EXAMPLE TABLE XVI
    Figure US20050014840A1-20050120-C02282
    EXAMPLE R1 R2 R4
    206
    Figure US20050014840A1-20050120-C02283
    H CH3
    207
    Figure US20050014840A1-20050120-C02284
    H CH3
    208
    Figure US20050014840A1-20050120-C02285
    —(CH2)2CH(CH3)2
    Figure US20050014840A1-20050120-C02286
    209
    Figure US20050014840A1-20050120-C02287
    H
    Figure US20050014840A1-20050120-C02288
    210
    Figure US20050014840A1-20050120-C02289
    H
    Figure US20050014840A1-20050120-C02290
    211
    Figure US20050014840A1-20050120-C02291
    Figure US20050014840A1-20050120-C02292
    CH3
    212
    Figure US20050014840A1-20050120-C02293
    H CH3
  • EXAMPLE TABLE XVII
    Figure US20050014840A1-20050120-C02294
    213
    Figure US20050014840A1-20050120-C02295
    214
    Figure US20050014840A1-20050120-C02296
    215
    Figure US20050014840A1-20050120-C02297
    216
    Figure US20050014840A1-20050120-C02298
    217
    Figure US20050014840A1-20050120-C02299
    218
    Figure US20050014840A1-20050120-C02300
    219
  • EXAMPLE TABLE XVIII
    Figure US20050014840A1-20050120-C02301
    220
    Figure US20050014840A1-20050120-C02302
    221
    Figure US20050014840A1-20050120-C02303
    222
    Figure US20050014840A1-20050120-C02304
    223
  • EXAMPLE 126
  • N-(4-(4 ′-isopropoxyphenyl)benzene-sulfonyl-N-(4-(morpholinoethyl))- L-cysteine amide. Was prepared in a manner similar to Example 131, by substitution of the sulfonyl chloride to 4-(4-isopropoxyphenyl)phenylsulfonyl chloride prepared in an analogous manner. Mass spec. m/z=508.7 (M+H)
  • EXAMPLE 131 Preparation of N-(4-(4′methoxyphenyl)-benzenesulfonyl-N-(4-(morpholinoethyl))-L-cysteine amide
  • Figure US20050014840A1-20050120-C02305
  • Part A: To a solution of 12.4 grams(5.0 mmol) of 4-(4′-bromophenyl)phenol in 50 mL of dimethylformamide was added 10.1 grams of potassium carbonate followed by 10.51 grams of iodomethane and this stirred at room temperature for 48 hours. The solution was diluted with 400 mL of water and extracted with ethyl acetate. The organics were dried over magnesium sulfate filtered and concentrated to yield 14.1 grams of crude product. Purification by recrystallization from ethyl acetate hexane gave 8.2 grams of 4-(4′-bromophenyl)anisole as a white crystalline solid.
  • Part B: 5.2 grams(20 mmol) of 4-(4′-bromophenyl)-anisole was dissolved in 100 mL of anhydrous tetrahydrofuran and placed under nitrogen to cool to −78 C. to this flask was added 8.0 mL of 2.5 molar butyl lithium over 10 minutes. In an adjacent flask was added 100 mL of anhydrous tetrahydrofuran which was cooled to −60 C and a stream of sulfur dioxide was added through a dispersion tube while the system is under nitrogen atmosphere. After the addition of approximately 10 mL of liquid sulfur dioxide the dispersion tube was removed and the cold sulfur dioxide solution was transferred by a cannula to the stirred aryl lithium solution over five minutes. After one hour at −70 C the contents were warmed to room temperature and the solution ws concentrated to dryness to yield a crude lithium sulfinate. The crude lithium 4-(4′-methoxyphenyl)phenylsulfinic acid was slurried in 100 mL of dry hexanes under nitrogen atmosphere and cooled to 0 C. To this cooled suspension was added 2.45 grams(18.1 mmol) of sulfuryl chloride and the suspension was allowed to warm to room temperature. The contents were concentrated by rotory evaporation to yield 5.1 grams of crude 4-(4′-methoxy-phenyl)phenyl-sulfonyl chloride which ws purified by recrystalli-zation from chloroform.
  • Part C: To a solution of 2.93 grams(8.1 mmol) of S-trityl-L-cysteine amide in 50 mL of dry methylene chloride was added 2 equivalents of triethylamine followed by 2.29 grams(8.1 mmol) of 4-(4′-methoxyphenyl)phenylsulfonyl chloride. The solution was stirred at room temperature for one hour, then concentrated on a rotory evaporator. The resulting slurry was partitioned between ethyl acetate and water. The organics were washed with 5% potassium hydrogen sulfate, saturated sodium bicarbonate, and brine, dried over sodium sulfate, filtered and concentrated to give 4.2 grams of crude product. The crude material was purified by silica gel chromatography using 1:1 ethyl acetate:hexane as the eluent to yield 3.36 grams of pure N-(4-(4′methoxyphenyl)-benzenesulfonyl- S-trityl-L-cysteine amide as a white solid.
  • Part D: To 3.36 grams(5.5 mmol) of N-(4-(4′methoxy-phenyl)-benzenesulfonyl- S-trityl-L-cysteine amide in 12 mL of dry dimethylformamide was added 1.50 grams(8.3 mmol) of 4-(2-chloroethylmorpholine)hydrochloride followed by 2.5 grams(17. mmol) of powdered potassium carbonate, and the suspension was heated to 60 C in an oil bath under nitrogen atmosphere for 5 hours. The solution is cooled to room temperature and diluted with 100 mL of ethyl acetate and washed with water. The organic layer was washed saturated brine and dried over sodium sulfate, filtered and concentrated to yield 4.5 grams of crude material. Purification by flash chromatography using ethyl acetate as the eluent gave 2.1 grams of purified N-(4-(4′methoxyphenyl)-benzenesulfonyl-N-(4-(morpholinoethyl))-S-trityl-L-cysteine amide.
  • Part E: 2.1 grams(2.9 mmol) of N-(4-(4′methoxy-phenyl)-benzenesulfonyl-N-(4-(morpholinoethyl))-S-trityl-L-cysteine amide was dissolved in 10 mL of methylene chloride and 10 mL of triisopropylsilane was added followed by 40 mL of trifluoroacetic acid and the solution is stirred for 1.5 hours. The contents were concentrated on a rotory evaporator and the resultant material is decanted three times with 50 mL of diethyl ether. The resulting solid is slurried with a mixture of ethyl acetate and sodium bicarbonate until the solids dissolve. The organic layer is washed with saturated sodium bicarbonate, dried over sodium sulfate, filtered and concentrated to yield 1.87 grams of N-(4-(4′methoxyphenyl)-benzenesulfonyl-N-(4-(morpholinoethyl))-L-cysteine amide as a white solid. Mass spec. m/z=480 (M+H)
  • EXAMPLE 218 Preparation of N-(4-benzoylamino)-phenylsulfonyl-N-(4-(morpholinoethyl))-S-trityl-L-cysteine amide hydrochloride
  • Figure US20050014840A1-20050120-C02306
  • Part A: To a cooled (10 C) solution of 19.4 grams (250 mmol) of chlorosulfonic acid under nitrogen atmosphere was added 10 grams (50.7 mmol) of benzanalide in portions over five minutes. The black solution was heated to 60 C for one hour, then cooled to room temperature and carefully poured over ice slowly. The solid organic material was filtered and dissolved in methylene chloride, washed with water and dried over sodium sulfate. The solution was concentrated on a rotory evaporator to 8.6 grams of a tan solid.
  • Part B: To a solution of 4.0 grams(11.03 mmol) of S-trityl-L-cysteine amide in 50 mL of dry methylene chloride was added 2.0 mL (14.33 mmol) of triethylamine followed by 2.93 grams (9.93 mmol) of 4-benzoylamino-benzenesulfonyl chloride. The solution was stirred at room temperature for one hour, then concentrated on a rotory evaporator. The resulting slurry was partitioned between ethyl acetate and water. The organics were washed with 5% potassium hydrogen sulfate, saturated sodium bicarbonate, and brine, dried over sodium sulfate, filtered and concentrated to give 7.0 grams of crude product. The crude material was purified by silica gel chromatography using 1:1 ethyl acetate : hexane as the eluent to yield 3.5 grams of pure N-(4-benzoylamino)-phenylsulfonyl-S-trityl-L-cysteine as a white solid.
  • Part C: To 3.5 grams(5.74mmol) of N-(4-benzoylamino)phenylsulfonyl-S-trityl-L-cysteine amide in 12 mL of dry dimethylformamide was added 1.60 grams(8.61 mmol) of 4-(2-chloroethylmorpholine) hydrochloride followed by 2.38 grams (17.22 mmol) of powdered potassium carbonate, and the suspension was heated to 60 C in an oil bath under nitrogen atmosphere for 5 hours. The solution is cooled to room temperature and diluted with 100 mL of ethyl acetate and washed with water. The organic layer was washed saturated brine and dried over sodium sulfate, filtered and concentrated to yield 4.4 grams of crude material. Purification by flash chromatography using ethyl acetate as the eluent gave 3.5 grams of purified N-(4-benzoylamino)-phenylsulfonyl-N-(4-(morpholinoethyl))-S-trityl-L-cysteine amide.
  • Part D: 3.5 grams(4.8 mmol) of N-(4-benzoylamino)phenylsulfonyl-N-(4-(morpholinoethyl))-S-trityl-L-cysteine amide was dissolved in 10 mL of methylene chloride and 10 mL of triisopropylsilane was added followed by 40 mL of trifluoroacetic acid and the solution is stirred for 1.5 hours. The contents were concentrated on a rotory evaporator and the resultant material is decanted three times with 50 mL of diethyl ether. The resulting solid is slurried with a mixture of ethyl acetate and sodium bicarbonate until the solids dissolve. The organic layer is washed with saturated sodium bicarbonate, dried over sodium sulfate, filtered and concentrated to yield 1.87 grams of N-(4-benzoylamino)phenylsulfonyl-N-(4-(morpholino-ethyl))-L-cysteine amide as a white solid. Mass spec. m/z=493 (M+H)
  • EXAMPLE 219
  • 1.87 grams of N-(4-benzoylamino)-phenylsulfonyl-N-(4-(morpholinoethyl))-S-trityl-L-cysteine amide was dissolved in 20 mL of dry acetonitrile and to this was added 630 uL of concentrated HCl and the resulting solution was concentrated to give a white foam solid which was dried extensively under vacuum to obtain N-(4-benzoylamino)-phenylsulfonyl-N-(4-(morpholinoethyl))-L-cysteine amide hydrochloride.
  • EXAMPLE 220
  • N-(4-(4′-chlorobenzoyl)amino)-phenylsulfonyl-N-(4-(morpholinoethyl))-L-cysteine amide. Preparation similar to Example 218, by substitution of chlorobenzanalide in part a.
  • EXAMPLE 221
  • N-(4-(4′-chlorobenzoyl)amino)-phenylsulfonyl-N-(4-(morpholinoethyl))-L-cysteine amide. Preparation similar to Example 219.
  • EXAMPLE 222
  • N-(4-(4′-bromobenzoyl)amino)phenyl-sulfonyl-N-(4-(morpholinoethyl))-L-cysteine amide. Prepared in a similar manner as Example 218, by substitution of bromobenzanalide in part a.
  • EXAMPLE 223
  • N-(4-(4′-bromobenzoyl)amino)phenyl-sulfonyl-N-(4-(morpholinoethyl))-L-cysteine amide hydrochloride. Prepared in a similar manner as Example 219.
  • EXAMPLE 224 In vitro Metalloprotease Inhibition
  • Certain of the compounds prepared in the manner described in Examples 1 to 223 were tested for activity by an in vitro assay. Following the procedures of Knight et al., FEBS Lett. 296(3):263 (1992). Briefly, 4-aminophenylmercuric acetate (APMA) or trypsin activated MMPs were incubated with various concentrations of the inhibitor compound at room temperature for 5 minutes (0.02% 2-mercapto-ethanol added to buffer for thiol compounds with 5 minutes or overnight incubation). More specifically, recombinant human MMP-13 and MMP-1 enzymes were prepared in laboratories of the inventors' employer. MMP-13 was expressed in baculovirus as a proenzyme, and purified first over a heparin agarose column and then over a chelating zinc chloride column. The proenzyme was activated by APMA for use in the assay. MMP-1 expressed in transfected HT-1080 was provided by Dr. Howard Welgus of Washington University, St. Louis, Mo. The enzyme was also activated using APMA and was then purified over a hydroxamic acid column.
  • The enzyme substrate is a methoxycoumarin-containing polypeptide having the following sequence:
  • MCA-ProLeuGlyLeuDpaAlaArgNH2, wheein MCA is methoxycoumarin and Dpa is 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl alanine. This substrate is commercially available from Baychem as product M-1895.
  • The buffer used for assays contained 100 mM Tris-HCl, 100 mM NaCl, 10 mM CaCl2 and 0.05 percent polyethyleneglycol (23) lauryl ether at a pH value of 7.5. Assays were carried out at room temperature, and dimethyl sulfoxide (DMSO) at a final concentration of 1 percent was used to dissolve inhibitor compound.
  • The assayed inhibitor compound in DMSO/buffer solution was compared to an equal amount of DMSO/buffer with no inhibitor as control using microfluor™ white plates (Dynatech). The inhibitor or control solution was maintained in the plate for 10 minutes and the substrate was added to provide a final concentration of 4 uM.
  • In the absence of inhibitor activity, a fluorogenic peptide is cleaved at the gly-leu peptide bond, separating the highly fluorogenic peptide from a 2,4-dinitrophenyl quencher, resulting in an increase of fluorescence intensity (excitation at 328 nm/emission at 415 nm). Inhibition was measured as a reduction in fluorescent intensity as a function of inhibitor concentration, using a Perkin Elmer L550 plate reader. The IC50 values were calculated from those values. The results are set forth in the Inhibition Table below, reported in terms of IC50 to three significant figures.
    Inhibition Table
    Example MMP-1 MMP-13
    Number IC50 (nanomolar) IC50 (nanomolar)
     7B >10000 >10000
     7C 4000 300
     8 4200 65
     10 550
     11D 300 32.5
     12C 1300 38.5
     13C >10000 2000
     14C 1060 46
     15 >10000 75
     16B 7000 245
     17C >10000 260
     18 >10000 390
     20C 3000 110
     21C 7000 200
     22C 3400 13
     23C 4000 150
     26 >10000 250
     28 >10000 800
     29F 8000 1800
     31D 2500 600
     33C >10000 345
     33D >10000 >10000
     37C 1500 5.0
     38C 2500 31.0
     39C >10000 21.5
     40E 309 0.61
     41C >10000 1.8
     42D >10000 1800
     44 >10000 400
     45C 3200 3.0
     46 3500 4.0
     47C 4830 4.47
     48C >10000 45.0
     49 300 17.5
     51 >10000 340
     52 >10000 45
     53 >10000 11.0
     54 9000 7.0
     55 313 0.71
     56 2000 67.5
     57 >10000 5000
     58 6000 200
     59 1000 13
     63 300 2500
     64 900
     65 1000 445
     66 38
     67 570
     68 >10000 1720
     69 175
     70 >10000 440
     71 >10000 40
     72 2300
     73 2100
     74 >10000
     75 5000 1000
     76 3500 8800
     77 >10000
     79 >10000
     80 >10000
     81 6500
     82 >10000 1200
     83 1150
     84 >10000 >10000
     85 9000
     86 1700
     87 8500
     88 365
     89 >10000 90
     90 600
     91C >10000 0.6
     91D >10000 0.7
     91E need need
     92C need need
     92D 6000 0.7
     94 4400 34.0
     95 800 20
     96 >10000 17
     97 4000
     98 >10000
     99 900 31.3
    100 >10000 >10000
    101 >10000 30
    103 >10000 17
    104 >10000
    105 3500
    107 4000 2.7
    108 500
    109 >10000
    110 >10000 1600
    111 2000 40.0
    112 4000 150
    113 125 0.25
    114 >10000 45
    115 >10000 220
    117 8000 15.0
    118 7000 14.0
    122 >10000 4250
    123 >10000 115
    124 2100 <0.5
    125 >10000 770
    126 >100 3.5
    128 5000 1.1
    130 >10000 3300
    131 70 <0.1
    132 >10000 47.0
    133 >10000 4200
    141 >10000
    142 >10000
    146 >10000
    147 >10000 >10000
    148 >10000
    149 >10000
    150 9000
    151 >10000
    152 3000
    153 >10000
    154 9000
    155 >10000 >10000
    156 1070 7.3
    163 500 0.3
    164 >10000 40
    165 1100 0.15
    166 >10000 880
    168 540 0.45
    170 30 0.2
    171 >10000 30
    172 >10000 250
    174 1700 2.5
    175 400 0.7
    176 2900 2.5
    177 10000 20
    178 >10000 300
    179 2000 23.5
    180 >10000 700
    181 >10000 3000
    184 210 1.4
    185 300 2.2
    186 >10000 1100
    187 >10000 1000
    188 >10000
    189 >10000
    190 6500
    191 >10000 >10000
    192 >10000 >10000
    193 >10000 >10000
    195 464
    196 >10000
    197 4600 100
    198 2300
    199 >10000 350
    200 2060 <0.1
    201 7000 3.3
    203 >10000 170
    204 >10000
    206 >10000
    207 >10000
    208 >10000 190
    209 >10000 50
    210 >10000 1320
    213 >10000 1.5
    214 >10000
    216 >10000 200
    217 >10000 1.5
    218 >10000 1.1
    219
    220 7000 1.4
    221
    222 5300 1.1
    223

    In vivo Angiogenesis Assay
  • The study of angiogenesis depends on a reliable and reproducible model for the stimulation and inhibition of a neovascular response. The corneal micropocket assay provides such a model of angiogenesis in the cornea of a mouse. See, A Model of Angiogenesis in the Mouse Cornea; Kenyon, B M, et al., Investigative Ophthalmology & Visual Science, July 1996, Vol. 37, No. 8
  • In this assay, uniformly sized Hydron™ pellets containing bFGF and sucralfate were prepared and surgically implanted into the stroma mouse cornea adjacent to the temporal limbus. The pellets were formed by making a suspension of 20 μl sterile saline containing 10 μg recombinant bFGF, 10 mg of sucralfate and 10 μl of 12 percent Hydron™ in ethanol. The slurry was then deposited on a 10×10 mm piece of sterile nylon mesh. After drying, the nylon fibers of the mesh was separated to release the pellets.
  • The corneal pocket was made by anesthetizing a 7 week old C57B1/6 female mouse, then proptosing the eye with a jeweler's forceps. Using a dissecting microscope, a central, intrastromal linear keratotomy of approximately 0.6 mm in length was performed with a #15 surgical blade, parallel to the insertion of the lateral rectus muscle. Using a modified cataract knife, a lamellar micropocket was dissected toward the temporal limbus. The pocket was extended to within 1.0 mm of the temporal-limbus. A single pellet was placed on the corneal surface at the base of the pocket with a jeweler's forceps. The pellet was then advanced to the temporal end of the pocket. Antibiotic ointment was then applied to the eye.
  • Mice were dosed on a daily basis for the duration of the assay. Dosing of the animals was based on bioavailability and overall potency of the compound. In the case of the compound of Example 218, dosing was 50 mg/kg bid, po. Neovascularization of the corneal stroma began at about day three and was permitted to continue under the influence of the assayed compound until day five. At day five, the degree of angiogenic inhibition was scored by viewing the neovascular progression with a slit lamp microscope.
  • The mice were anesthetized and the studied eye was once again proptosed. The maximum vessel length of neovascularization, extending from the limbal vascular plexus toward the pellet was measured. In addition, the contiguous circumferential zone of neovascularization was measured as clock hours, where 30 degrees of arc equals 1 clock hour. The area of angiogenesis was calculated as area = ( 0.4 × clock ⁢   ⁢ hours × 3.14 × vessel ⁢   ⁢ length ⁢   ⁢ ( in ⁢   ⁢ mm ) ) 2
    where the vessel length is measured in millimeters.
  • The studied mice were thereafter compared to control mice and the difference in the area of neovascularization was recorded. The compound of Example 218 exhibited 37 percent inhibition, whereas the vehicle control exhibited zero percent inhibition.
  • From the foregoing, it will be observed that numerous modifications and variations can be effectuated without departing from the true spirit and scope of the novel concepts of the present invention. It is to be understood that no limitation with respect to the specific example presented is intended or should be inferred. The disclosure is intended to cover by the appended claims all such modifications as fall within the scope of the claims.

Claims (35)

1. A compound or a pharmaceutically acceptable salt thereof, wherein:
the compound corresponds in structure to formula Ia, IIa, or IIIa:
Figure US20050014840A1-20050120-C02307
R1 is a substituted phenyl
R1 has a length greater than that of a saturated four carbon chain and shorter than that of a saturated eighteen carbon chains;
when rotated about an axis drawn through the SO2-bonded 1-position and the 4-position of the phenyl, R1 defines a three-dimensional volume whose widest dimension has the width of about one phenyl ring to about three phenyl rings in a direction transverse to the axis of rotation;
R1 comprises no heterocyclyl substituent;
R2 is selected from the group consisting of hydrido, C1-C6-alkyl, phenyl-C1-C4-alkyl, C2-C4-alkyl substituted by amino, C2-C4-alkyl substituted by mono-substituted amino, and C2-C4-alkyl substituted by di-substituted amino, wherein:
the substituent(s) on the mono-substituted or di-substituted amino nitrogen is/are independently selected from the group consisting of C1-C6-alkyl, aralkyl, C5-C8-cycloalkyl, and C1-C6:alkanoyl;
R2 can be hydrido only when R1 is 4-(phenylazo)phenyl;
R4 is selected from the group consisting of hydroxycarbonyl, aminocarbonyl, and C1-C6-alkyl;
W is selected from the group consisting of oxygen and sulfur; and
R9 is selected from the group consisting of C1-C6-alkyl, C1-C6-alkoxy, and phenyl.
2. The compound or salt according to claim 1, wherein R1 has a length greater than that of a pentyl group and less than the length of a lauryl group.
3. The compound or salt according to claim 1, wherein R1 is phenyl substituted at its 4-position with a substituent selected from the group consisting of phenyl, alkyl comprising an unbranched chain of 3 to about 7 carbon atoms, alkoxy comprising an unbranched chain of 3 to about 7 carbon atoms, phenoxy, phenylthioxy, phenylazo, and benzamido.
4. A compound or a pharmaceutically acceptable salt thereof, wherein:
the compound corresponds in structure to formula Ib, IIb, or IIIb:
Figure US20050014840A1-20050120-C02308
PhR11 is phenyl substituted with R11 at the 4-position;
R11 is selected from the group consisting of C3-C8-alkoxy, C3-C8-alkyl, phenoxy, phenylthioxy, benzamido, phenylazo, and phenyl;
R2 is selected from the group consisting of hydrido and C1-C6-alkyl;
R2 can be hydrido only when R11 is phenylazo;
R4 is selected from the group consisting of C1-C6-alkyl and carbamido; and
R9 is selected from the group consisting of C1-C6-alkyl, C1-C6-alkoxy, and phenyl.
5. The compound or salt according to claim 4, wherein R9 is selected from the group consisting of phenyl, methyl, ethyl, methoxy, and ethoxy.
6. The compound or salt according to claim 4, wherein R11 is selected from the group consisting of phenoxy, phenylthioxy, benzamido, phenylazo, and phenyl, wherein:
the phenoxy, phenylthioxy, benzamido, phenylazo, or phenyl is substituted at the 3- or 4-position, or both, with a single atom or a non-heterocyclyl substituent comprising a longest chain of up to five atoms, excluding hydrogen.
7. The compound or salt according to claim 6, wherein R11 is selected from the group consisting of phenoxy, phenylthioxy, benzamido, phenylazo, or phenyl, wherein:
the phenoxy, phenylthioxy, benzamido, phenylazo, or phenyl is substituted at the 4-position with a substituent selected from the group consisting of halogen, C1-C4-alkoxy, C1-C4-alkyl, dimethylamino, and carboxy-C1-C2-alkyl.
8-19. (canceled)
20. The compound or salt according to claim 1, wherein the compound corresponds in structure to formula (Ia):
Figure US20050014840A1-20050120-C02309
21. The compound or salt according to claim 20, wherein R4 is selected from the group consisting of aminocarbonyl and methyl.
22. The compound or salt according to claim 20, wherein R2 is phenylmethyl.
23. The compound or salt according to claim 20, wherein R2 is selected from the group consisting of methyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, and N,N-dimethyl-2-aminoethyl.
24. The compound or salt according to claim 1, wherein the compound corresponds in structure to formula (IIa):
Figure US20050014840A1-20050120-C02310
25. The compound or salt according to claim 24, W is oxygen.
26. The compound or salt according to claim 1, wherein the compound corresponds in structure to formula (IIIa):
Figure US20050014840A1-20050120-C02311
27. The compound or salt according to claim 1, wherein the compound corresponds in structure to a formula selected from the group consisting of:
Figure US20050014840A1-20050120-C02312
Figure US20050014840A1-20050120-C02313
Figure US20050014840A1-20050120-C02314
Figure US20050014840A1-20050120-C02315
Figure US20050014840A1-20050120-C02316
Figure US20050014840A1-20050120-C02317
28. The compound or salt according to claim 27, wherein the compound corresponds in structure to a formula selected from the group consisting of:
Figure US20050014840A1-20050120-C02318
Figure US20050014840A1-20050120-C02319
Figure US20050014840A1-20050120-C02320
Figure US20050014840A1-20050120-C02321
Figure US20050014840A1-20050120-C02322
Figure US20050014840A1-20050120-C02323
29. The compound or salt according to claim 28, wherein the compound corresponds in structure to the following formula:
Figure US20050014840A1-20050120-C02324
30. The compound or salt according to claim 4, wherein the compound corresponds in structure to formula (Ib):
Figure US20050014840A1-20050120-C02325
31. The compound or salt according to claim 30, wherein R4 is selected from the group consisting of aminocarbonyl and methyl.
32. The compound or salt according to claim 30, wherein R2 is phenylmethyl.
33. The compound or salt according to claim 30, wherein R2 is selected from the group consisting of methyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, and N,N-dimethyl-2-aminoethyl.
34. The compound or salt according to claim 4, wherein the compound corresponds in structure to formula (IIb):
Figure US20050014840A1-20050120-C02326
35. The compound or salt according to claim 34, wherein W is oxygen.
36. The compound or salt according to claim 4, wherein the compound corresponds in structure to formula (IIIb):
Figure US20050014840A1-20050120-C02327
37. A method for treating a mammal having a condition associated with pathological matrix metalloprotease activity, wherein the process comprises administering to the mammal an effective amount of the compound or salt of claim 1.
38. A method for treating a mammal having a condition associated with pathological matrix metalloprotease activity, wherein the process comprises administering to the mammal an effective amount of the compound or salt of claim 4.
39. A method for treating a mammal having a condition associated with pathological matrix metalloprotease activity, wherein the process comprises administering to the mammal an effective amount of the compound or salt of claim 20.
40. A method for treating a mammal having a condition associated with pathological matrix metalloprotease activity, wherein the process comprises administering to the mammal an effective amount of the compound or salt of claim 28.
41. A method for treating a mammal having a condition associated with pathological matrix metalloprotease activity, wherein the process comprises administering to the mammal an effective amount of the compound or salt of claim 30.
42. A pharmaceutical composition, wherein the composition comprises a compound according to claim 1 (or a pharmaceutically acceptable salt thereof) dissolved or dispersed in a pharmaceutically acceptable carrier.
43. A pharmaceutical composition, wherein the composition comprises a compound according to claim 4 (or a pharmaceutically acceptable salt thereof) dissolved or dispersed in a pharmaceutically acceptable carrier.
44. A pharmaceutical composition, wherein the composition comprises a compound according to claim 20 (or a pharmaceutically acceptable salt thereof) dissolved or dispersed in a pharmaceutically acceptable carrier.
45. A pharmaceutical composition, wherein the composition comprises a compound according to claim 28 (or a pharmaceutically acceptable salt thereof) dissolved or dispersed in a pharmaceutically acceptable carrier.
46. A pharmaceutical composition, wherein the composition comprises a compound according to claim 30 (or a pharmaceutically acceptable salt thereof) dissolved or dispersed in a pharmaceutically acceptable carrier.
US10/838,856 1996-07-22 2004-05-04 Thiol sulfonamide metalloprotease inhibitors Abandoned US20050014840A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/838,856 US20050014840A1 (en) 1996-07-22 2004-05-04 Thiol sulfonamide metalloprotease inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2204096P 1996-07-22 1996-07-22
US08/898,175 US6747027B1 (en) 1996-07-22 1997-07-22 Thiol sulfonamide metalloprotease inhibitors
US10/838,856 US20050014840A1 (en) 1996-07-22 2004-05-04 Thiol sulfonamide metalloprotease inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/898,175 Division US6747027B1 (en) 1996-07-22 1997-07-22 Thiol sulfonamide metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
US20050014840A1 true US20050014840A1 (en) 2005-01-20

Family

ID=32328503

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/898,175 Expired - Fee Related US6747027B1 (en) 1996-07-22 1997-07-22 Thiol sulfonamide metalloprotease inhibitors
US10/838,856 Abandoned US20050014840A1 (en) 1996-07-22 2004-05-04 Thiol sulfonamide metalloprotease inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/898,175 Expired - Fee Related US6747027B1 (en) 1996-07-22 1997-07-22 Thiol sulfonamide metalloprotease inhibitors

Country Status (1)

Country Link
US (2) US6747027B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2510807C (en) * 2002-12-19 2011-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of tace
US8404866B2 (en) * 2008-09-03 2013-03-26 Florida State University Research Foundation Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US5451676A (en) * 1990-08-15 1995-09-19 British Biotech Pharmaceuticals Limited Biphenyl ether heterobicyclic platelet activating factor antagonists
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5475138A (en) * 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
US6013649A (en) * 1996-07-22 2000-01-11 Monsanto Company Thiol sulfone metalloprotease inhibitors
US6297247B1 (en) * 1995-11-17 2001-10-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5525629A (en) 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
US5376664A (en) 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
GB9307956D0 (en) 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
PL181782B1 (en) 1993-08-10 2001-09-28 Black James Foundation Ligands of gastrin and cck receptors
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
JPH09504793A (en) 1993-11-04 1997-05-13 ザ リポソーム カンパニー、インコーポレーテッド Multilamellar liposomal arachidonic acid metabolite formulation
GB9323162D0 (en) 1993-11-10 1994-01-05 British Bio Technology 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
JP3787605B2 (en) 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
EP0845987A4 (en) 1995-08-08 2000-05-24 Fibrogen Inc C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen
EA003294B1 (en) 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Metalloproteinase inhibitors, pharmaceutical compositions, their constituents, and their pharmaceutical use
WO1997024117A1 (en) 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
EP0994104A4 (en) 1996-06-27 2001-09-12 Ono Pharmaceutical Co Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
IL131493A (en) 1997-03-04 2004-05-12 Monsanto Co Aromatic sulfonyl alphahydroxy hydroxamic acid compounds and their use in the production of medicaments for treating a condition associated with pathological matrix metalloprotease activity
EP0983267B1 (en) 1997-03-04 2005-01-26 Pharmacia Corporation Amidoaromatic ring sulfonamide hydroxamic acid compounds
HRP980443A2 (en) 1997-08-18 1999-10-31 Carl P. Decicco Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2001523662A (en) 1997-11-14 2001-11-27 ジー・ディー・サール・アンド・カンパニー Aromatic sulfone hydroxamic acid metalloprotease inhibitors
AU775701B2 (en) 1999-02-08 2004-08-12 G.D. Searle & Co. Sulfamato hydroxamic acid metalloprotease inhibitor
EP1165500A1 (en) 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
WO2000069819A1 (en) 1999-05-12 2000-11-23 G.D. Searle & Co. Hydroxamic acid derivatives as matrix metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US5451676A (en) * 1990-08-15 1995-09-19 British Biotech Pharmaceuticals Limited Biphenyl ether heterobicyclic platelet activating factor antagonists
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5475138A (en) * 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
US5599994A (en) * 1994-07-07 1997-02-04 Pharm-Eco Laboratories, Inc. Amino acid-derived diaminopropanols
US6297247B1 (en) * 1995-11-17 2001-10-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
US6013649A (en) * 1996-07-22 2000-01-11 Monsanto Company Thiol sulfone metalloprotease inhibitors

Also Published As

Publication number Publication date
US6747027B1 (en) 2004-06-08

Similar Documents

Publication Publication Date Title
AU740263C (en) Thiol sulfonamide metalloprotease inhibitors
EP0977745B1 (en) Thioaryl sulfonamide hydroxamic acid compounds
AU750303B2 (en) N-hydroxy 4-sulfonyl butanamide compounds
AU714687B2 (en) Thiol sulfone metalloprotease inhibitors
US6638952B1 (en) Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6476027B1 (en) N-hydroxy 4-sulfonyl butanamide compounds
WO1998039313A1 (en) Thioaryl sulfonamide hydroxamic acid compounds
US6362183B1 (en) Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6747027B1 (en) Thiol sulfonamide metalloprotease inhibitors
US6087359A (en) Thioaryl sulfonamide hydroxamic acid compounds
US20040034071A1 (en) Thioaryl sulfonamide hydroxamic acid compounds
NZ506464A (en) Salts of thiol sulfonamide inhibitors for matrix metalloproteinase 13 (MMP-13)
AU6712001A (en) Thiol sulfonamide metalloprotease inhibitors
AU9135501A (en) Salts of aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHARMACIA CORPORATION, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ABBAS, ZAHEER S.;DECRESCENZO, GARY A.;FRESKOS, JOHN N.;AND OTHERS;REEL/FRAME:015062/0475;SIGNING DATES FROM 20040603 TO 20040608

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION